46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

1313 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05756179 (ClinicalTrials.gov)	July 2023	21/2/2023	Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis	Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Diosmin and Hesperidin Combination	Alexandria University	NULL	Not yet recruiting	19 Years	65 Years	All	80	Phase 3	NULL
2	NCT05306353 (ClinicalTrials.gov)	May 15, 2023	23/3/2022	CD40L Antagonism in Rheumatoid Arthritis (RA)	Combining a CD40L-Binding Protein (VIB4920) With a TNF-alpha Inhibitor for the Treatment of Inadequately Controlled Rheumatoid Arthritis (ITN092AI)	Rheumatoid Arthritis	Drug: Placebo for VIB4920;Drug: VIB4920 with TNFi;Drug: VIB4920 without TNFi	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Not yet recruiting	18 Years	70 Years	All	104	Phase 2	United States
3	NCT04585711 (ClinicalTrials.gov)	May 2023	7/10/2020	Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis	Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis	Juvenile Idiopathic Arthritis;Rheumatoid Arthritis;Obesity	Drug: Etanercept Optimal dosing	Duke University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Not yet recruiting	2 Years	65 Years	All	30	Phase 1	United States
4	NCT05622175 (ClinicalTrials.gov)	March 31, 2023	3/11/2022	Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment	A Dose-finding Phase I Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: F8IL10	Philogen S.p.A.	NULL	Not yet recruiting	18 Years	80 Years	All	32	Phase 1	NULL
5	NCT05540938 (ClinicalTrials.gov)	February 15, 2023	10/9/2022	Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis	Reevaluation of Original Research Results of Integrated Traditional Chinese and Western Medicine and Transformation of Hospital Preparations: Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Wangbi granules;Drug: Wangbi granules simulant	China-Japan Friendship Hospital	Peking Union Medical College Hospital;The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine;The 980th Hospital of PLA Joint Logistics Support Force;The Second Affiliated Hospital of Zhejiang Chinese Medical University;Southwest Hospital, China	Not yet recruiting	18 Years	75 Years	All	340	Phase 4	NULL
6	NCT05305066 (ClinicalTrials.gov)	February 1, 2023	26/2/2022	Stand UP to Rheumatoid Arthritis (SUPRA)	Innovative Trial Designs, Multi-omics and Advanced Computational Prediction to Transform Clinical Care in RA	Rheumatoid Arthritis	Drug: TNFi;Drug: Anti-IL6;Drug: JAKi	Marie Hudson, MD	McGill University Health Centre/Research Institute of the McGill University Health Centre;Montreal General Hospital;Lady Davis Institute	Recruiting	18 Years	N/A	All	75	N/A	Canada
7	NCT03938701 (ClinicalTrials.gov)	January 2023	25/2/2019	Fluorescence Imaging of Disease Activity in IBD and Rheumatoid Arthritis Using OTL38	Fluorescence Imaging for the Evaluation of Disease Activity in IBD and Rheumatoid Arthritis Using the Fluorescent Tracer OTL38 Targeting the Folate ß Receptor: a Single-center Pilot Study	IBD;Rheumatoid Arthritis	Drug: OTL38;Device: Fluorescence Imaging	University Medical Center Groningen	GlaxoSmithKline;On Target Laboratories, LLC;Amsterdam UMC, location VUmc	Not yet recruiting	18 Years	N/A	All	30	Phase 1	Netherlands
8	NCT05545020 (ClinicalTrials.gov)	December 25, 2022	9/9/2022	Trivalent Chromium Treatment for Rheumatoid Arthritis	Trivalent Chromium as a Treatment for Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Trivalent chromium versus synthetic and/ or biological DMARDs	Alexandria University	NULL	Recruiting	18 Years	80 Years	All	60	Phase 2/Phase 3	Egypt
9	NCT05480878 (ClinicalTrials.gov)	December 2, 2022	23/7/2022	Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis	Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo;Drug: Nitazoxanide 500Mg Oral Tablet;Drug: Escitalopram 10mg	Tanta University	NULL	Not yet recruiting	18 Years	75 Years	All	90	Phase 3	NULL
10	NCT05604885 (ClinicalTrials.gov)	November 30, 2022	31/10/2022	A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	A Two-part, Randomized, Double-blind, Multi-center, Placebo-controlled Study of the Dose-range, Safety and Efficacy of 4 and 12 Weeks of Treatment With AP1189 in Adult Rheumatoid Arthritis (RA) Patients With an Inadequate Response to Methotrexate (MTX) Alone - (RESOLVE)	Rheumatoid Arthritis	Drug: AP1189, 60 mg;Drug: AP1189, 80 mg;Drug: AP1189, 100 mg;Drug: Placebo	SynAct Pharma Aps	NBCD A/S	Recruiting	18 Years	85 Years	All	420	Phase 2	Moldova, Republic of
11	NCT05428488 (ClinicalTrials.gov)	November 28, 2022	16/6/2022	Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis	Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis. A Randomized Controlled Trial With an Independent Efficacy Assessor.	Rheumatoid Arthritis	Drug: Abatacept (M3-M12);Drug: TNF Inhibitor (M3-M12);Drug: TNF Inhibitor (M0-M3)	University Hospital, Montpellier	NULL	Recruiting	18 Years	85 Years	All	220	Phase 3	France
12	NCT05375942 (ClinicalTrials.gov)	November 11, 2022	11/5/2022	This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry	Characteristics and 6-month Outcomes Among Real-World Rheumatoid Arthritis Patients Initiating Inflectra	Arthritis, Rheumatoid	Drug: Inflectra	Pfizer	NULL	Completed	18 Years	N/A	All	255		United States
13	NCT05594680 (ClinicalTrials.gov)	November 1, 2022	18/10/2022	Cilostazol and Methotrexate in Rheumatoid Arthritis	The Phosphodiesterase 3 Inhibitor Cilostazol as Adjunct to Methotrexate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Cilostazol;Drug: Methotrexate;Drug: Placebo	Tanta University	NULL	Not yet recruiting	18 Years	60 Years	All	70	Phase 3	NULL
14	NCT05671497 (ClinicalTrials.gov)	November 1, 2022	14/12/2022	The Effect of Cilostazol on Rheumatoid Arthritis Patients	Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Cilostazol 100 MG;Drug: conventional synthetic antirheumatic drugs	Ain Shams University	Misr International University;Al-Azhar University	Recruiting	19 Years	N/A	All	70	Phase 2/Phase 3	Egypt
15	NCT05533372 (ClinicalTrials.gov)	October 10, 2022	5/9/2022	MAD Study of IA-14069	Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IA-14069 in Healthy Subjects, With an Extension to Explore Any Drug-Drug Interaction Potential With Methotrexate (Part 1), and in Patients With Rheumatoid Arthritis, With Preliminary Assessment of Efficacy in Patients (Part 2)	Healthy;Rheumatoid Arthritis	Drug: IA-14069;Drug: Placebo;Drug: Methotrexate	ILAb Co., Ltd.	NULL	Recruiting	18 Years	70 Years	All	75	Phase 1	United States
16	NCT05451615 (ClinicalTrials.gov)	September 30, 2022	17/6/2022	Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis	Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Receiving Abatacept in Combination With a Janus Kinase (JAK) Inhibitor	Abatacept;Treatment Compliance;Rheumatoid Arthritis	Drug: Janus Kinase Inhibitor;Drug: Abatacept	Zhejiang Provincial People's Hospital	NULL	Recruiting	N/A	N/A	All	90	Phase 3	China
17	NCT05516979 (ClinicalTrials.gov)	September 26, 2022	24/8/2022	A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment	A Double-blind, Multi-center, Randomized, Placebo-controlled Study of the Safety and Efficacy of 12 Weeks Extended Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients naïve to DMARD Treatment	Rheumatoid Arthritis	Drug: 100 mg AP1189;Drug: Placebo	SynAct Pharma Aps	NBCD A/S	Recruiting	18 Years	85 Years	All	120	Phase 2	Moldova, Republic of
18	NCT05660655 (ClinicalTrials.gov)	September 1, 2022	13/12/2022	Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis	Efficacy and Safety of Baricitinib in Different Doses for the Treatment of Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Baricitinib 4 MG;Drug: Baricitinib 2 MG	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	NULL	Recruiting	18 Years	N/A	All	94	Phase 4	Bangladesh
19	NCT05516758 (ClinicalTrials.gov)	August 31, 2022	24/8/2022	A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis	A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis;Arthritis;Joint Diseases;Musculoskeletal Diseases;Rheumatic Diseases;Connective Tissue Diseases;Autoimmune Diseases;Immune System Diseases	Drug: Peresolimab;Drug: Placebo	Eli Lilly and Company	NULL	Recruiting	18 Years	N/A	All	420	Phase 2	United States;Argentina;Canada;China;Greece;Hungary;Italy;Japan;Mexico;Poland;Puerto Rico;Spain
20	NCT05460832 (ClinicalTrials.gov)	August 29, 2022	12/7/2022	Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA	A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Study to Investigate the Efficacy & Safety of MBS2320 in Participants With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response to Methotrexate Alone	Rheumatoid Arthritis	Drug: MBS2320 5 mg;Drug: MBS2320 20 mg;Drug: MBS2320 40 mg;Drug: Placebo	Modern Biosciences Ltd	NULL	Recruiting	18 Years	75 Years	All	224	Phase 2	Bosnia and Herzegovina;Bulgaria;Chile;Czechia;Guatemala;Mexico;Poland;Serbia
21	NCT05576597 (ClinicalTrials.gov)	August 23, 2022	7/10/2022	Effect of Butyrate Supplement on Rheumatoid Arthritis	A Pilot Study to Evaluate Efficacy and Safety of Butyrate Supplement in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Sodium Butyrate	Peking University People's Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	China
22	NCT05437419 (ClinicalTrials.gov)	August 10, 2022	23/6/2022	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis	A Phase 1, Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TCK-276;Drug: TCK-276 Placebo	Teijin America, Inc.	Parexel	Recruiting	18 Years	64 Years	All	32	Phase 1	United States
23	NCT05274243 (ClinicalTrials.gov)	August 9, 2022	1/3/2022	2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis	2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 2-HOBA;Other: Placebo	Vanderbilt University Medical Center	NULL	Recruiting	18 Years	N/A	All	32	Phase 2	United States
24	NCT05447520 (ClinicalTrials.gov)	July 15, 2022	1/7/2022	Montelukast Use in Rheumatoid Arthritis	Clinical Study Evaluating the Efficacy and Safety of Adjunctive Use of Montelukast in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Montelukast;Drug: Placebo;Drug: Conventional DMARDs	Noha Mansour	NULL	Recruiting	18 Years	80 Years	All	50	Phase 2	Egypt
25	NCT05392127 (ClinicalTrials.gov)	July 15, 2022	23/5/2022	A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers	A Single-center, Open-label, Single-arm, Fixed-sequence Study to Evaluate the Pharmacokinetic Effects of SHR0302 Tablets on Substrates of CYP3A4, CYP2C8, CYP2C9, CYP2C19 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302 Tablets;Drug: Midazolam Maleate Tablets;Drug: Warfarin Sodium Tablets;Drug: Omeprazole Enteric Capsules;Drug: Vitamin K1 Tablets;Drug: Repaglinide Tablets	Jiangsu HengRui Medicine Co., Ltd.	NULL	Completed	18 Years	45 Years	Male	24	Phase 1	China
26	NCT05379322 (ClinicalTrials.gov)	July 2022	12/5/2022	The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients	The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Anti-TNF;Drug: JAK inhibitor	Abu Dhabi Stem Cells Center	NULL	Withdrawn	18 Years	N/A	All	0	Phase 3	United Arab Emirates
27	NCT05165771 (ClinicalTrials.gov)	July 2022	8/12/2021	Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 on Background Therapy With Conventional Synthetic Disease-modifying Antirheumatic Drug(s) (csDMARDs) in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Rheumatoid Arthritis	Drug: GS-5718;Drug: Placebo to match GS-5718;Drug: Tofacitinib 5 mg;Drug: Placebo to match Tofacitinib	Gilead Sciences	NULL	Withdrawn	18 Years	75 Years	All	0	Phase 2	NULL
28	NCT05404724 (ClinicalTrials.gov)	June 25, 2022	31/5/2022	Study on the Pharmacokinetic Effect of Itraconazole on SHR0302 Tablets in Healthy Subjects	Study on the Pharmacokinetic Effects of Single-centered, Open, Single-arm, Fixed-sequence Itraconazole on SHR0302 Tablets in Healthy Subjects	Rheumatoid Arthritis	Drug: itraconazole ? SHR0302 tablets	Jiangsu HengRui Medicine Co., Ltd.	NULL	Completed	18 Years	45 Years	Male	14	Phase 1	China
29	NCT05092984 (ClinicalTrials.gov)	June 22, 2022	28/9/2021	Evaluation of Spironolactone Efficacy in Patient With Rheumatoid Arthritis (RA)	Evaluation of Spironolactone Efficacy in Patient With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Spironolactone;Drug: Placebo	University Hospital, Strasbourg, France	NULL	Recruiting	18 Years	N/A	All	154	Phase 3	France
30	NCT05363917 (ClinicalTrials.gov)	June 15, 2022	2/5/2022	Natrunix Versus Methotrexate in Rheumatoid Arthritis	Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix Versus Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Natrunix with MTX placebo (+folate);Drug: Natrunix placebo with MTX (+folate)	XBiotech, Inc.	NULL	Not yet recruiting	18 Years	N/A	All	150	Phase 2	NULL
31	NCT05363891 (ClinicalTrials.gov)	June 15, 2022	2/5/2022	Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis	Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Natrunix;Drug: Placebo	XBiotech, Inc.	NULL	Not yet recruiting	18 Years	N/A	All	150	Phase 2	NULL
32	NCT05427942 (ClinicalTrials.gov)	June 3, 2022	17/6/2022	Yuflyma® (Adalimumab), Patient Experience After Switching	YUflyma® (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma®) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study	Rheumatoid Arthritis;Ankylosing Spondylarthritis;Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis;Psoriatic Arthritis;Crohn Disease;Ulcerative Colitis	Drug: Adalimumab	Celltrion HealthCare France	NULL	Recruiting	18 Years	N/A	All	300		France
33	NCT05264025 (ClinicalTrials.gov)	June 1, 2022	10/1/2022	Fexofenadine in Patients With Active Rheumatoid Arthritis	Fexofenadine as Adjunct to Standard Rheumatoid Therapy in Patients With Active Rheumatoid	Rheumatoid Arthritis	Drug: Fexofenadine;Drug: Placebo	October 6 University	NULL	Recruiting	18 Years	60 Years	All	80	Phase 1/Phase 2	Egypt
34	NCT05267431 (ClinicalTrials.gov)	June 2022	14/2/2022	Outcomes of Biological Therapy on Rheumatoid Arthritis	Outcomes of Different Biological Therapy on Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Biological Drug	Sohag University	NULL	Not yet recruiting	18 Years	N/A	All	200		Egypt
35	NCT05606107 (ClinicalTrials.gov)	May 20, 2022	1/11/2022	To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks	To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: Glucocorticoid	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jiaxing Hospital of T.C.M;Jinhua Municipal Central Hospital;SAHZU.CHANGXING CAMPUS;Zhuji People's hospital;Shaoxing People's Hospital	Recruiting	18 Years	70 Years	All	230	Phase 4	China
36	NCT04269993 (ClinicalTrials.gov)	May 18, 2022	12/2/2020	Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis	Impact of Acute Cannabis Administration on Pain Symptomology and Inflammatory Markers Among Patients With Rheumatoid or Psoriatic Arthritis	Rheumatoid Arthritis;Psoriatic Arthritis	Drug: Cannabis: placebo and medium THC/medium CBD	Brown University	NULL	Recruiting	18 Years	65 Years	All	76	Phase 2	United States
37	NCT05323591 (ClinicalTrials.gov)	May 3, 2022	5/4/2022	Prospective Observational Study of Filgotinib in Female Participants With Rheumatoid Arthritis in France	A Prospective, Non-interventional Study in Female Patients With Moderate to Severe Active Rheumatoid Arthritis in France Receiving Filgotinib for 2 Years	Rheumatoid Arthritis	Drug: Filgotinib	Galapagos NV	NULL	Recruiting	18 Years	N/A	Female	150		France
38	NCT05374785 (ClinicalTrials.gov)	May 1, 2022	4/5/2022	Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis	A 12-week, Phase II, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing CPL409116 to Placebo, in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to MTX	Rheumatoid Arthritis	Drug: CPL409116;Other: Placebo	Celon Pharma SA	National Center for Research and Development, Poland	Recruiting	18 Years	75 Years	All	100	Phase 2	Poland
39	NCT05380934 (ClinicalTrials.gov)	May 2022	16/5/2022	A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects	A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of TQH3821 in Adult Healthy Subjects	Rheumatoid Arthritis	Drug: TQH3821 tablets;Drug: TQH3821 tablets (Placebo);Drug: Methotrexate tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	NULL	Recruiting	18 Years	55 Years	All	62	Phase 1	China
40	NCT05246293 (ClinicalTrials.gov)	April 1, 2022	17/1/2022	Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.	Safety and Tolerability of Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease (RAILDTo Trial).	Rheumatoid Arthritis;Interstitial Lung Disease	Drug: Tofacitinib	National Institute of Respiratory Diseases, Mexico	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	Mexico
41	NCT05166304 (ClinicalTrials.gov)	April 2022	8/12/2021	Rebamipide in Patients With Active Rheumatoid Arthritis	Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rebamipide;Drug: Placebo	October 6 University	NULL	Not yet recruiting	18 Years	60 Years	All	100	Phase 1/Phase 2	NULL
42	NCT05424393 (ClinicalTrials.gov)	March 4, 2022	15/6/2022	Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients	Long-term Real-world Prospectiv Observational Study on Maintenance Treatment With YISAIPU, an Etanercept Biosimilar, for Patients Wih Rheumatoid Arthritis of Fujian Province of China	Rheumatoid Arthritis	Drug: YISAIPU ® ( An etanercept biosimilar);Drug: csDMARDs	The First Affiliated Hospital of Xiamen University	NULL	Recruiting	18 Years	75 Years	All	500		China
43	NCT05246280 (ClinicalTrials.gov)	March 2, 2022	16/12/2021	Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFa Therapy Response in Moderate to Severe Active RA	Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFa Therapy Response in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: TC99m-tilmanocept	Navidea Biopharmaceuticals	NULL	Recruiting	18 Years	N/A	All	523	Phase 3	United States
44	NCT05182203 (ClinicalTrials.gov)	March 1, 2022	18/12/2021	Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience	Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience	Rheumatoid Arthritis;Drug Use	Drug: biologic/targeted therapy	Tuen Mun Hospital	NULL	Completed	18 Years	N/A	All	1732		China
45	NCT05245448 (ClinicalTrials.gov)	February 22, 2022	22/1/2022	Tetrandrine in the Treatment of Rheumatoid Arthritis	Comparing the Efficacy of Tetrandrine Combined With Methotrexate and Methotrexate Alone in the Treatment of Rheumatoid arthritis---a Randomized, Double-blinded, Placebo-controlled, Multicenter Study	Rheumatoid Arthritis	Drug: Tetrandrine;Drug: Placebo	Peking University People's Hospital	NULL	Not yet recruiting	18 Years	65 Years	All	240	N/A	China
46	NCT05240859 (ClinicalTrials.gov)	February 22, 2022	6/2/2022	Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis	A Multicenter, Prospective, Observational Real World Study For the Efficacy and Safety of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Geleli	Peking University People's Hospital	NULL	Not yet recruiting	N/A	N/A	All	1600		China
47	NCT05133297 (ClinicalTrials.gov)	February 16, 2022	15/11/2021	The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis	A Phase 2A, Randomized, Double-blind, Double-dummy, Tofacitinib-parallel-group Study to Evaluate the Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Methotrexate.	Rheumatoid Arthritis	Drug: TLL-018;Drug: Tofacitinib	Hangzhou Highlightll Pharmaceutical Co., Ltd	NULL	Recruiting	18 Years	75 Years	All	100	Phase 2	China
48	NCT05671627 (ClinicalTrials.gov)	February 2, 2022	19/9/2022	Cortisol Circadian Rhythm in Patients With RA	An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?	Rheumatoid Arthritis	Drug: DMARDs	National and Kapodistrian University of Athens	NULL	Recruiting	20 Years	80 Years	All	50		Greece
49	NCT05279417 (ClinicalTrials.gov)	February 2, 2022	18/2/2022	ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA	ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA Who Have Had an Inadequate Response to MTX Alone	Rheumatoid Arthritis	Drug: ATI-450 50mg oral tablet BID;Drug: Placebo oral tablet;Drug: Methotrexate;Drug: ATI-450 20mg oral tablet BID	Aclaris Therapeutics, Inc.	NULL	Recruiting	18 Years	75 Years	All	240	Phase 2	United States;Czechia;Poland
50	NCT04876781 (ClinicalTrials.gov)	January 12, 2022	20/4/2021	Korean Post-marketing Surveillance for Xeljanz XR	Korean Post-marketing Surveillance for Xeljanz XR (Registered)	Active Moderate to Severe Rheumatoid Arthritis;Active Ankylosing Spondylitis	Drug: Tofacitinib XR	Pfizer	NULL	Recruiting	18 Years	N/A	All	200		Korea, Republic of
51	NCT05053165 (ClinicalTrials.gov)	January 4, 2022	16/9/2021	A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants	A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants	Rheumatoid Arthritis;Non-Alcoholic Steatohepatitis	Drug: LB-P6;Drug: LB-P8;Drug: Placebo	LISCure Biosciences	NULL	Completed	18 Years	65 Years	All	31	Phase 1	Australia
52	NCT05090124 (ClinicalTrials.gov)	January 1, 2022	20/7/2021	Experimental Medicine Studies of Brain and Peripheral Immune Mechanisms for Sickness Behaviours in Patients With Rheumatoid Arthritis	Experimental Medicine Studies of Brain and Peripheral Immune Mechanisms for Sickness Behaviours in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Placebo	NHS Greater Glasgow and Clyde	University of Glasgow	Not yet recruiting	18 Years	74 Years	All	50	N/A	NULL
53	NCT05153200 (ClinicalTrials.gov)	January 2022	29/11/2021	Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.	Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.	Rheumatoid Arthritis	Drug: Upadacitinib;Drug: Adalimumab	Ottawa Hospital Research Institute	The Ottawa Hospital;University of Ottawa	Not yet recruiting	18 Years	N/A	All	40	Phase 4	NULL
54	NCT05313061 (ClinicalTrials.gov)	December 29, 2021	28/12/2021	MTX Hold During Covid-19 Booster	Effect of One-week Discontinuation of Methotrexate on Immunogenicity of COVID-19 Booster Vaccination in Patients With Rheumatoid Arthritis: A Randomized Pilot Study	Rheumatoid Arthritis	Drug: MTX	Seoul National University Hospital	NULL	Recruiting	19 Years	N/A	All	40	Phase 3	Korea, Republic of
55	NCT05626348 (ClinicalTrials.gov)	December 22, 2021	15/11/2022	The Clinical Efficacy of Immunomodulators in RA Patients	The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Iguratimod;Drug: Methotrexate;Drug: Adalimumab Injection;Drug: Leflunomide;Drug: Hydroxychloroquine	Qilu Hospital of Shandong University	NULL	Recruiting	18 Years	80 Years	All	400	Phase 4	China
56	NCT05198310 (ClinicalTrials.gov)	December 14, 2021	3/1/2022	Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor	A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor	Arthritis, Rheumatoid	Drug: KPL-404;Drug: Placebo	Kiniksa Pharmaceuticals, Ltd.	NULL	Recruiting	18 Years	80 Years	All	91	Phase 2	United States;Czechia
57	NCT05080218 (ClinicalTrials.gov)	November 15, 2021	6/10/2021	COVID-19 VaccinE Response in Rheumatology Patients	The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy	Rheumatoid Arthritis;Psoriatic Arthritis;Spondylarthritis	Drug: Upadacitinib;Drug: Abatacept;Drug: Secukinumab;Drug: Tofacitinib;Drug: TNF Inhibitor;Drug: Canakinumab Injection;Drug: Baricitinib;Drug: Ixekizumab	Jeffrey Curtis	University of Alabama at Birmingham;University of Nebraska;University of Pennsylvania;AbbVie;Bristol-Myers Squibb;Novartis;Eli Lilly and Company;Pfizer	Recruiting	18 Years	85 Years	All	1000	Phase 4	United States
58	NCT04834557 (ClinicalTrials.gov)	November 1, 2021	2/4/2021	Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis	Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis in Egypt	Rheumatoid Arthritis	Drug: Placebo;Drug: Digoxin 0.25 mg;Drug: Ursodeoxycholic acid (UDCA) 500 mg	Tanta University	NULL	Recruiting	18 Years	80 Years	All	90	Phase 2	Egypt
59	NCT04985812 (ClinicalTrials.gov)	October 18, 2021	6/7/2021	A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis	A Multicenter, Double-blind, Placebo-controlled, Randomized, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-67484703 in Participants With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: JNJ-67484703;Drug: Placebo	Janssen Research & Development, LLC	NULL	Recruiting	18 Years	65 Years	All	47	Phase 1	United States;Georgia;Hungary;Moldova, Republic of;Spain;Ukraine
60	NCT04911127 (ClinicalTrials.gov)	October 5, 2021	14/5/2021	Therapeutic Response of Cannabidiol in Rheumatoid Arthritis	Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis;Cannabis	Drug: 200mg Cannabidiol by capsules twice daily;Drug: 400mg Cannabidiol by capsules twice daily;Drug: Placebo capsules	University of California, Los Angeles	NULL	Recruiting	18 Years	N/A	All	60	Phase 1/Phase 2	United States
61	NCT05069714 (ClinicalTrials.gov)	October 1, 2021	26/9/2021	One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.	Effect of One-week vs Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial	Rheumatoid Arthritis;Autoimmune Diseases;Influenza;Vaccine Reaction	Drug: MTX -hold	Seoul National University Hospital	NULL	Completed	19 Years	N/A	All	184	Phase 3	Korea, Republic of
62	NCT04692493 (ClinicalTrials.gov)	September 22, 2021	15/12/2020	RA-PRO PRAGMATIC TRIAL	A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR)	Rheumatoid Arthritis	Drug: targeted synthetic DMARD class;Drug: non-TNFi-biologic class	University of Alabama at Birmingham	Patient-Centered Outcomes Research Institute	Recruiting	18 Years	N/A	All	924	Phase 3	United States
63	NCT04909801 (ClinicalTrials.gov)	September 15, 2021	28/5/2021	A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment With Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive Rheumatoid Arthritis Who Have Shared Epitope HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Adalimumab;Drug: Methotrexate	Bristol-Myers Squibb	NULL	Active, not recruiting	18 Years	N/A	All	300	Phase 3	Taiwan;United Kingdom;United States;Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland
64	NCT04078191 (ClinicalTrials.gov)	September 14, 2021	21/8/2019	Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue of Subjects With Rheumatoid Arthritis (RA)	A Comparison of Tc 99m Tilmanocept Quantitative Imaging With Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue From Subjects Clinically Diagnosed With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tc 99m tilmanocept	Navidea Biopharmaceuticals	NULL	Recruiting	18 Years	N/A	All	24	Phase 2	United States;United Kingdom
65	NCT05251870 (ClinicalTrials.gov)	August 17, 2021	21/12/2021	Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis	Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis: the TOLERANT Trial	Rheumatoid Arthritis	Drug: autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70	UMC Utrecht	Radboud University Medical Center;Utrecht University;Trajectum Pharma B.V.;Dutch Arthritis Association;ZonMw: The Netherlands Organisation for Health Research and Development;Health Holland	Recruiting	18 Years	N/A	All	18	Phase 1/Phase 2	Netherlands
66	NCT05651373 (ClinicalTrials.gov)	July 30, 2021	15/11/2022	The Clinical Features and Pregnancy Outcomes of RA Patients	The Clinical Features and Pregnancy Outcomes of Patients With Rheumatoid Arthritis :a Prospective Cohort Study	Rheumatoid Arthritis;Pregnancy Related	Drug: Prednisone;Drug: Hydroxychloroquine;Drug: CertolizumabPegol injection	Qilu Hospital of Shandong University	NULL	Recruiting	20 Years	45 Years	Female	100		China
67	NCT04870203 (ClinicalTrials.gov)	July 15, 2021	26/4/2021	Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis	Combination of Baricitinib and Adalimumab vs. Baricitinib in Patients With Rheumatoid Arthritis: a Randomized Placebo-controlled Phase III Trial	Rheumatoid Arthritis	Drug: baricitinib treatment;Drug: adalimumab;Drug: Placebo	University Hospital, Bordeaux	Eli Lilly and Company;Biogen;Ministry for Health and Solidarity, France	Recruiting	18 Years	75 Years	All	178	Phase 3	France;Monaco
68	NCT05117593 (ClinicalTrials.gov)	June 28, 2021	23/9/2021	Investigate the Safety, Tolerability and Pharmacokinetics of FBL-MTX	Phase 1 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single-Ascending Doses of FBL-MTX in Healthy Subjects	Rheumatoid Arthritis	Drug: FBL-MTX;Drug: Placebo	SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd	NULL	Completed	18 Years	55 Years	All	32	Phase 1	Portugal
69	NCT04909931 (ClinicalTrials.gov)	June 15, 2021	11/5/2021	Vitamin D Supplementation on Outcome and Disease Activity.	Vitamin D Supplementation on Outcome and Disease Activity in Rheumatoid Arthritis Patients at Rajavithi Hospital : A Randomized Clinical Trial	Rheumatoid Arthritis, Vitamin D , Disease Activity, DAS28ESR	Drug: Vitamin D 2;Drug: Placebo	Rajavithi Hospital	NULL	Recruiting	18 Years	N/A	All	60	N/A	Thailand
70	NCT04888585 (ClinicalTrials.gov)	June 2, 2021	13/5/2021	Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs)	Rheumatoid Arthritis (RA)	Drug: ABBV-154;Drug: Placebo	AbbVie	NULL	Active, not recruiting	18 Years	75 Years	All	473	Phase 2	United States;Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;France;United Kingdom
71	NCT04885751 (ClinicalTrials.gov)	June 1, 2021	26/4/2021	Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy	Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy in Patients With NSAIDs and Low Dose Steroid: A Single-center, Randomized, Open Labeled, Pilot Study	Rheumatoid Arthritis;Osteoarthritis;Ankylosing Spondylitis;Other Musculoskeletal Disorder;Gastric Ulcer;Enteritis;NSAID-Associated Gastropathy;NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy	Drug: Eupatilin;Drug: Rebamipide	Seoul National University Boramae Hospital	Dong-A ST Co., Ltd.	Not yet recruiting	19 Years	70 Years	All	50	Phase 4	NULL
72	NCT04927000 (ClinicalTrials.gov)	May 31, 2021	31/5/2021	The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis	The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tofacitinib	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	30 Years	65 Years	Female	170	Phase 4	China
73	NCT04885829 (ClinicalTrials.gov)	May 31, 2021	3/5/2021	Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers	A Single Dose, Double-Blind, Two-Period, Crossover, Comparative Pharmacokinetic Study of Three Tocilizumab Products Administered by the Subcutaneous Route to Normal Healthy Volunteers	Rheumatoid Arthritis;Giant Cell Arteritis	Drug: Tocilizumab Prefilled Syringe	Syneos Health	Dr. Reddy's Laboratories Limited	Active, not recruiting	18 Years	50 Years	All	300	Phase 1	Australia;India;New Zealand
74	NCT04842981 (ClinicalTrials.gov)	May 25, 2021	23/3/2021	Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis	Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid;Interaction	Drug: Tocilizumab;Drug: Sarilumab	University of Southern Denmark	Odense University Hospital;Hospital of South West Jutland;King Christian X´Hospital for Rheumatic Diseases;Sygehus Lillebaelt;Odense Patient Data Explorative Network	Terminated	18 Years	75 Years	All	3	Phase 1/Phase 2	Denmark
75	NCT04884880 (ClinicalTrials.gov)	May 14, 2021	30/4/2021	Efficacy and Safety of Luo-Fu-Shan Plaster in Patients With Rheumatoid Arthritis	Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled Clinical Trial of Luo-Fu-Shan Plaster in the Treatment of Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Luo-Fu-Shan Plaster;Drug: The placebo 10g	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Not yet recruiting	18 Years	75 Years	All	180	N/A	China
76	NCT04985435 (ClinicalTrials.gov)	May 12, 2021	19/7/2021	Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)	Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in Patients With Active Rheumatoid Arthritis (BACH)	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Anti-Tumor Necrosis Factor Alpha Drug (Product);Behavioral: 50 patients will have a Free Choice between Filgotinib and anti TNF	R.Bos	Galapagos NV;Medical Centre Leeuwarden;Leiden University Medical Center	Recruiting	18 Years	101 Years	All	100	Phase 4	Netherlands
77	NCT04947137 (ClinicalTrials.gov)	May 12, 2021	10/5/2021	Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept	Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept	Rheumatoid Arthritis	Drug: Tc99m tilmanocept	Navidea Biopharmaceuticals	NULL	Active, not recruiting	18 Years	N/A	All	135	Phase 2	United States
78	NCT04871919 (ClinicalTrials.gov)	May 11, 2021	29/4/2021	Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis	A Prospective, Non-interventional Study of the Effectiveness, Safety, and Health Related Outcomes in Patients With Moderate to Severe Active Rheumatoid Arthritis Receiving Filgotinib	Rheumatoid Arthritis	Drug: Filgotinib	Galapagos NV	NULL	Recruiting	18 Years	N/A	All	1500		Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
79	NCT04246762 (ClinicalTrials.gov)	April 6, 2021	27/1/2020	Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4	A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4	Rheumatoid Arthritis	Drug: Olokizumab;Drug: Omeprazole;Drug: Caffeine;Drug: Warfarin + Vitamin K;Drug: Midazolam	R-Pharm International, LLC	IQVIA RDS Ireland Ltd;Thermo Fisher Scientific FS	Completed	18 Years	70 Years	All	16	Phase 1	Bulgaria;Moldova, Republic of
80	NCT04815148 (ClinicalTrials.gov)	April 1, 2021	19/3/2021	MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis	A Phase Ia/Ib Study to Evaluate the Safety, Tolerability and PK of MH004 Topical Cream in Healthy Adult Volunteers and to Investigate Its Efficacy and Safety Profile in Participants With Atopic Dermatitis or Rheumatoid Arthritis	Atopic Dermatitis;Rheumatoid Arthritis	Drug: MH004 Ia(0.1%);Drug: MH004 Ia(0.3%);Drug: MH004 Ia(1%);Drug: MH004 Ia(3%);Drug: MH004 Ib-1(0.1%);Drug: MH004 Ib-1(0.3%);Drug: MH004 Ib-1(1%);Drug: MH004 Ib-2(0.3%);Drug: MH004 Ib-2(1%);Drug: MH004 Ib-2(3%)	Minghui Pharmaceutical Pty Ltd	NULL	Not yet recruiting	18 Years	70 Years	All	72	Phase 1	NULL
81	NCT05247216 (ClinicalTrials.gov)	March 26, 2021	31/5/2021	A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Hemay007 in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Hemay007 800 mg QD group;Drug: Hemay007 1200 mg QD group;Drug: Hemay007 600 mg QD group;Drug: Hemay007 placebo group	Tianjin Hemay Pharmaceutical Co.,Ltd	NULL	Recruiting	18 Years	75 Years	All	140	Phase 2	China
82	NCT04286789 (ClinicalTrials.gov)	March 22, 2021	25/2/2020	Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs	A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs	Rheumatoid Arthritis	Drug: Low dose ORTD-1;Drug: Low dose vehicle control;Drug: High dose ORTD-1;Drug: High dose vehicle control	Oryn Therapeutics, LLC	NULL	Completed	18 Years	N/A	All	17	Phase 1	United States
83	NCT04798287 (ClinicalTrials.gov)	March 10, 2021	11/3/2021	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: TNF Inhibitor	Brigham and Women's Hospital	NULL	Completed	18 Years	N/A	All	105711		United States
84	NCT05090410 (ClinicalTrials.gov)	March 3, 2021	30/9/2021	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate: Comparative Study With Filgotinib and Tocilizumab Examined by Clinical Index as Well as Musculoskeletal Ultrasound Assessment	Rheumatoid Arthritis;JAK Inhibitor;IL-6 Inhibitor;Musculoskeletal Ultrasound;Biomarker	Drug: filgotinib 200mg/day;Drug: subcutaneous tocilizumab 162mg/biweekly	Atsushi Kawakami	Gilead Sciences	Recruiting	20 Years	N/A	All	400	Phase 3	Japan
85	NCT04772248 (ClinicalTrials.gov)	February 22, 2021	23/2/2021	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints	Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: TNF Inhibitor	Brigham and Women's Hospital	NULL	Completed	18 Years	N/A	All	105711		United States
86	NCT04757571 (ClinicalTrials.gov)	February 1, 2021	12/2/2021	The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients	The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients. A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.	Rheumatoid Arthritis	Drug: Paroxetine;Drug: Placebo	Sadat City University	NULL	Recruiting	18 Years	60 Years	All	120	Phase 1/Phase 2	Egypt
87	NCT04530305 (ClinicalTrials.gov)	January 7, 2021	24/8/2020	Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor	Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor	Rheumatoid Arthritis	Drug: Tofacitinib 5 MG [Xeljanz]	University Hospital, Montpellier	NULL	Recruiting	18 Years	N/A	All	60		France
88	NCT04535427 (ClinicalTrials.gov)	January 1, 2021	22/8/2020	Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis	Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: L-arginine;Drug: Placebo	RenJi Hospital	NULL	Not yet recruiting	18 Years	45 Years	All	144	Phase 2	China
89	NCT04691505 (ClinicalTrials.gov)	December 23, 2020	28/12/2020	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Methotrexate vs Hydroxychloroquine	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Hydroxychloroquine	Brigham and Women's Hospital	National Institute on Aging (NIA);Rutgers University;Johns Hopkins University	Completed	18 Years	N/A	All	133553		United States
90	NCT04196868 (ClinicalTrials.gov)	December 3, 2020	5/12/2019	Methotrexate and Metformin in Rheumatoid Arthritis Patients	Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients	Arthritis, Rheumatoid	Drug: Metformin treatment;Other: Placebo;Drug: Methotrexate treatment	University Hospital, Bordeaux	Ministry for Health and Solidarity, France	Recruiting	18 Years	N/A	All	128	Phase 2	France
91	NCT04649697 (ClinicalTrials.gov)	December 1, 2020	26/10/2020	Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients	Evaluation of Topical Rebamipide Versus Topical Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients: Randomized-Controlled Clinical Trial	Rheumatoid Arthritis	Drug: Rebamipide;Drug: Nanoparticulated Rebamipide;Drug: Clobetasol Propionate	Cairo University	NULL	Not yet recruiting	20 Years	70 Years	All	39	Phase 3	NULL
92	NCT04569890 (ClinicalTrials.gov)	December 1, 2020	20/9/2020	Treatment of Pregnancy RA	Study on the Treatment Strategy of Patients With Rheumatoid Arthritis During Pregnancy, a Randomized Control Trial in China	Rheumatoid Arthritis;Pregnancy Related	Drug: Certolizumab Pegol 200 MG/ML [Cimzia];Drug: Hydroxychloroquine;Drug: Prednisone	RenJi Hospital	NULL	Not yet recruiting	20 Years	40 Years	Female	100	N/A	China
93	NCT04311567 (ClinicalTrials.gov)	November 7, 2020	5/3/2020	Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease	Effects of Tofacitinib vs Methotrexate on Clinical and Molecular Disease Activity Markers in Joints and Lungs in Early Rheumatoid Arthritis (PULMORA) - A Randomized, Controlled, Open-label, Assessor-blinded, Phase IV Trial	Rheumatoid Arthritis;Interstitial Lung Disease Due to Systemic Disease (Disorder);RA;ILD	Drug: Tofacitinib;Drug: Methotrexate	Vastra Gotaland Region	Göteborg University	Recruiting	18 Years	80 Years	All	48	Phase 4	Sweden
94	NCT04608344 (ClinicalTrials.gov)	November 4, 2020	23/10/2020	Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	A Phase 1 Study to Evaluate OATP Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	Rheumatoid Arthritis	Drug: Atorvastatin;Drug: Pravastatin;Drug: Rosuvastatin;Drug: Filgotinib	Gilead Sciences	Galapagos NV	Completed	18 Years	55 Years	All	27	Phase 1	United States
95	NCT04577781 (ClinicalTrials.gov)	October 12, 2020	30/9/2020	A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: GLPG3970;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	64 Years	All	28	Phase 2	Bulgaria;Georgia;Poland;Ukraine
96	NCT04378621 (ClinicalTrials.gov)	October 1, 2020	8/4/2020	Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients	Treatment of Inflammation Versus Hand Training to Prevent and Revert Neuropsychiatric Comorbidity in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Pain;Fatigue;Cognitive Decline;Depression;Brain Diseases;Hand Rheumatism	Drug: TNF-a inhibitor OR JAK inhibitor;Other: Hand training	Vastra Gotaland Region	NULL	Active, not recruiting	45 Years	75 Years	All	212	N/A	Sweden
97	NCT04638426 (ClinicalTrials.gov)	September 10, 2020	13/11/2020	Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis	For 12 Weeks, the Multi Center, Randomized, Double Blinded, Placebo Controlled, Parallel, Dose-finding Clinical Study for the Therapeutic Exploration of Safety and Efficacy Assessment of HL237 Tablet in Patients With Rheumatoid Arthritis (Phase IIa)	Rheumatoid Arthritis	Drug: HL237 tablet;Drug: Placebo of HL237 tablet	Hanlim Pharm. Co., Ltd.	NULL	Enrolling by invitation	19 Years	N/A	All	196	Phase 2	Korea, Republic of
98	NCT04255134 (ClinicalTrials.gov)	September 7, 2020	14/11/2019	Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)	Comparison of Abatacept With Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis Pain: A Phase IV Trial	Rheumatoid Arthritis	Drug: Abatacept Injection;Drug: Adalimumab Injection	St George's, University of London	NULL	Recruiting	18 Years	75 Years	All	60	Phase 4	United Kingdom
99	NCT04421313 (ClinicalTrials.gov)	September 2, 2020	18/5/2020	Fibres Supplementation in Rheumatoid Arthritis	Supplementation of Rheumatoid Arthritis Patients With Dietary Fibre to Improve Their Gut Microbiota	Rheumatoid Arthritis	Drug: Dietary Fiber Supplementation	University Hospital, Montpellier	University of Sydney;Institut de Génétique Moléculaire de Montpellier	Recruiting	18 Years	85 Years	All	87	N/A	France
100	NCT04514614 (ClinicalTrials.gov)	September 1, 2020	7/8/2020	Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT	Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT	Arthritis	Drug: 68Ga-FAPI	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	90 Years	All	100	Early Phase 1	China
101	NCT04529876 (ClinicalTrials.gov)	August 17, 2020	25/8/2020	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - Tofacitinib vs Abatacept	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: Abatacept	Brigham and Women's Hospital	National Institute on Aging (NIA);Rutgers University;Johns Hopkins University	Completed	18 Years	N/A	All	29464		United States
102	NCT04529902 (ClinicalTrials.gov)	August 17, 2020	25/8/2020	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - Tumor Necrosis Factor Inhibitors vs Abatacept	Rheumatoid Arthritis	Drug: Tumor Necrosis Factor Inhibitors;Drug: Abatacept	Brigham and Women's Hospital	National Institute on Aging (NIA);Rutgers University;Johns Hopkins University	Completed	18 Years	N/A	All	63013		United States
103	NCT04529863 (ClinicalTrials.gov)	August 17, 2020	25/8/2020	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept	Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Tocilizumab vs Abatacept	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Abatacept	Brigham and Women's Hospital	National Institute on Aging (NIA);Rutgers University;Johns Hopkins University	Completed	18 Years	N/A	All	30432		United States
104	NCT05214677 (ClinicalTrials.gov)	August 15, 2020	12/12/2021	A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809	A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW1809 and DW1809-1 in Healthy Adult Volunteers	Osteoarthritis;Rheumatoid Arthritis;Back Pain;Acute Upper Respiratory Tract Infection	Drug: DW1809;Drug: DW1809 -1	Daewon Pharmaceutical Co., Ltd.	NULL	Completed	19 Years	N/A	All	38	Phase 1	Korea, Republic of
105	NCT05214690 (ClinicalTrials.gov)	August 13, 2020	12/12/2021	A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2	A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW1809-T2 and DW1809-1 in Healthy Adult Volunteers	Osteoarthritis;Rheumatoid Arthritis;Back Pain;Acute Upper Respiratory Tract Infection	Drug: DW1809-T2;Drug: DW1809-1	Daewon Pharmaceutical Co., Ltd.	NULL	Completed	19 Years	N/A	All	37	Phase 1	Korea, Republic of
106	NCT04512001 (ClinicalTrials.gov)	August 3, 2020	11/8/2020	MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis	A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union-approved RoActemra® in Patients With Moderately to Severely Active Rheumatoid Arthritis (APTURA I Study)	Rheumatoid Arthritis	Drug: MSB11456;Drug: EU-approved RoActemra	Fresenius Kabi SwissBioSim GmbH	NULL	Completed	18 Years	N/A	All	604	Phase 3	Bulgaria;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia
107	NCT04333771 (ClinicalTrials.gov)	July 31, 2020	2/4/2020	A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.	Rheumatoid Arthritis	Drug: SHR0302;Drug: Placebo	Jiangsu HengRui Medicine Co., Ltd.	NULL	Recruiting	18 Years	75 Years	All	600	Phase 3	China
108	NCT04413617 (ClinicalTrials.gov)	July 29, 2020	19/5/2020	TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE	A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600 (RITLECITINIB) AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH MODERATELY-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE	Rheumatoid Arthritis	Drug: PF-06650833;Drug: PF-06651600;Drug: Tofacitinib	Pfizer	NULL	Completed	18 Years	70 Years	All	460	Phase 2	Bulgaria;Canada;Chile;Czechia;Georgia;Hungary;Poland;Slovakia;Spain;Ukraine;Bosnia and Herzegovina;Colombia;Sweden
109	NCT05659407 (ClinicalTrials.gov)	July 24, 2020	13/12/2022	BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis	The BAFF-var Polymorphism as a Biomarker of Response to B-depletive Treatment in Patients Affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis: a Prospective Study	Systemic Lupus Erythematosus;Rheumatoid Arthritis;BLyS Polymorphism	Drug: Belimumab in SLE patients / Rituximab in RA patients	University of Cagliari	Azienda Ospedaliero Universitaria di Cagliari	Recruiting	18 Years	N/A	All	60		Italy
110	NCT04324892 (ClinicalTrials.gov)	July 12, 2020	25/3/2020	Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthritis: an HR-pQCT Study	Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthritis: an HR-pQCT Study	Rheumatoid Arthritis	Drug: Treat to target	Chinese University of Hong Kong	NULL	Not yet recruiting	18 Years	N/A	All	110		NULL
111	NCT04428424 (ClinicalTrials.gov)	July 5, 2020	10/6/2020	Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients	The Impact of RF, and Anti-CCP on RA Patients in Response to Etanercept	Arthritis, Rheumatoid	Drug: Enbrel	Pfizer	NULL	Completed	18 Years	N/A	All	1		Iraq
112	NCT04163016 (ClinicalTrials.gov)	June 19, 2020	24/10/2019	A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)	A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)	Rheumatoid Arthritis;Psoriatic Arthritis;Crohn's Disease;Axial Spondyloarthritis;Plaque Psoriasis	Drug: Pharmacokinetics of certolizumab pegol	UCB Biopharma S.P.R.L.	NULL	Active, not recruiting	18 Years	N/A	Female	22	Phase 1	United States;France;Germany;Spain;Switzerland;Canada;Netherlands
113	NCT05665985 (ClinicalTrials.gov)	May 1, 2020	26/11/2022	Effect Of Moringa Leaf Extract On Disease Activity In Rheumatoid Arthritis Patients	Effect Of Moringa Leaf Extract On Disease Activity In Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Moringa Oleifera	Universitas Sebelas Maret	NULL	Completed	18 Years	60 Years	Female	30	Phase 1/Phase 2	Indonesia
114	NCT04350216 (ClinicalTrials.gov)	April 30, 2020	8/4/2020	Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)	Effect of Sarilumab Therapy on Atherosclerotic Disease Assessed by Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Atherosclerosis	Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]	Instituto de Investigación Marqués de Valdecilla	NULL	Not yet recruiting	18 Years	100 Years	All	20	Phase 4	NULL
115	NCT04449224 (ClinicalTrials.gov)	April 27, 2020	7/6/2020	Comparative Effectiveness of Targeted Therapy in RA Patients	Comparative Effectiveness of Biologic Disease-modifying Antirheumatic Drugs and Small Molecular Inhibitors in Patients With Moderate to Severe RA: Prospective Observational Study	Rheumatoid Arthritis	Drug: Adalimuab, Etanercept, Tocilizumab, or Abatacept;Drug: Tofacitinib or Baricitinib	Hanyang University	Ministry of Health, Republic of Korea	Recruiting	19 Years	N/A	All	506		Korea, Republic of
116	NCT04361513 (ClinicalTrials.gov)	April 15, 2020	22/4/2020	Genicular Nerve Block in Rheuamtoid Arthritis	Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial	Pain;Joint Function Disorder;Inflammation	Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer);Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)	Sohag University	NULL	Completed	18 Years	N/A	All	64	Phase 4	Egypt
117	NCT04115423 (ClinicalTrials.gov)	April 1, 2020	2/10/2019	A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab	A Retrospective Cohort Study to Examine the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared With Tumor Necrosis Factor Inhibitors Using the National Health Insurance Database	Infection;Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)	Sungkyunkwan University	Ministry of Food and Drug Safety, Korea	Active, not recruiting	18 Years	N/A	All	9508		Korea, Republic of
118	NCT04434118 (ClinicalTrials.gov)	March 20, 2020	13/6/2020	Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients	Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study	Rheumatoid Arthritis;COVID	Drug: Traditional antirheumatic drugs	Sadat City University	NULL	Withdrawn	18 Years	60 Years	All	0		Egypt
119	NCT04247815 (ClinicalTrials.gov)	March 16, 2020	16/1/2020	Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA	A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ATI-450;Drug: Placebo oral tablet;Drug: Methotrexate	Aclaris Therapeutics, Inc.	NULL	Completed	18 Years	70 Years	All	19	Phase 2	United States
120	NCT04389320 (ClinicalTrials.gov)	March 15, 2020	11/5/2020	Antimalarial and Covid 19 in Rheumatoid Arthritis	Antimalarial and Covid 19 in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Hydroxychloroquine	Assiut University	NULL	Completed	20 Years	70 Years	All	60		Egypt
121	NCT03559686 (ClinicalTrials.gov)	March 2, 2020	5/6/2018	Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)	Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Arthritis (RA) Who Participated in Open Label Studies C87015, C87028 and C87051	Rheumatoid Arthritis	Drug: Certolizumab Pegol	UCB Biopharma S.P.R.L.	NULL	Available	18 Years	N/A	All			NULL
122	NCT03895879 (ClinicalTrials.gov)	March 1, 2020	26/3/2019	Use of Tocilizumab Drug Levels to Optimize Treatment in RA	Concentration-guided Dose Reduction Versus Standard Dosing in Tocilizumab-treated Rheumatoid Arthritis Patients: a Randomised, Multicenter, Non-inferiority Trial (TODORA)	Rheumatoid Arthritis	Drug: Tocilizumab	Reade Rheumatology Research Institute	ZonMw: The Netherlands Organisation for Health Research and Development	Recruiting	18 Years	N/A	All	98	Phase 4	Netherlands
123	NCT04928066 (ClinicalTrials.gov)	March 1, 2020	9/6/2021	The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA	Efficacy and Safety of Tofacitinib (TF) Combined With Iguratimod(IGU) in the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: Iguratimod;Drug: Tofacitinib;Drug: Pred	Qilu Hospital of Shandong University	NULL	Recruiting	18 Years	80 Years	All	100	Phase 4	China
124	NCT03976245 (ClinicalTrials.gov)	March 1, 2020	3/6/2019	Advanced Therapeutics in Rheumatoid Arthritis (RA)	Advanced Therapeutics in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept;Drug: tofacitinib	Lawson Health Research Institute	Academic Medical Organization of Southwestern Ontario	Recruiting	18 Years	N/A	All	144	Phase 4	Canada
125	NCT04175886 (ClinicalTrials.gov)	February 25, 2020	20/11/2019	Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project	Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project	Rheumatoid Arthritis	Drug: Tofacitinib	University Hospital, Lille	Pfizer	Recruiting	18 Years	N/A	All	72		France
126	NCT04086745 (ClinicalTrials.gov)	February 14, 2020	10/9/2019	A Study of Baricitinib in Participants With Rheumatoid Arthritis	A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Baricitinib;Drug: TNF Inhibitor	Eli Lilly and Company	Incyte Corporation	Recruiting	18 Years	N/A	All	1300	Phase 4	United States
127	NCT04779892 (ClinicalTrials.gov)	February 1, 2020	26/2/2021	The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety	The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety	Rheumatoid Arthritis	Drug: Infliximab	Taizhou Mabtech Pharmaceutical Co.,Ltd	NULL	Completed	18 Years	45 Years	Male	90	Phase 1	China
128	NCT04230213 (ClinicalTrials.gov)	January 13, 2020	14/1/2020	A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis	A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS	Rheumatoid Arthritis	Drug: PF-06410293;Drug: adalimumab	Pfizer	NULL	Completed	18 Years	70 Years	All	455	Phase 3	United States;Bosnia and Herzegovina;Bulgaria;Czechia;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine
129	NCT04186871 (ClinicalTrials.gov)	January 7, 2020	28/11/2019	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis	Autoimmune Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Primary Sjögren's Syndrome	Drug: branebrutinib;Drug: abatacept;Drug: branebrutinib placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	75 Years	All	112	Phase 2	United States;Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;Australia
130	NCT04115397 (ClinicalTrials.gov)	January 2020	2/10/2019	Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints	Towards Efficient Prediction and Prevention of Rheumatoid Arthritis	Seropositive Muskuloskeletal Complaints	Drug: Zoledronic Acid;Drug: Placebo	Karolinska Institutet	NULL	Not yet recruiting	18 Years	N/A	All	80	Phase 4	NULL
131	NCT04046146 (ClinicalTrials.gov)	December 15, 2019	23/7/2019	Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport	Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport	Rheumatoid Arthritis	Drug: Indocyanine Green;Device: MultiSpectral Imaging System	University of Rochester	NULL	Completed	18 Years	89 Years	All	2	Phase 1	United States
132	NCT04163991 (ClinicalTrials.gov)	December 9, 2019	12/11/2019	A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: VIB4920;Drug: Placebo	Viela Bio	NULL	Completed	18 Years	99 Years	All	78	Phase 2	United States;Poland
133	NCT04136262 (ClinicalTrials.gov)	November 25, 2019	21/10/2019	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis: a Randomized Controlled Trial	Rheumatoid Arthritis	Drug: Tripterygium wilfordii Hook F (TwHF);Drug: Methotrexate;Other: Dummy Tripterygium wilfordii Hook F (TwHF)	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Recruiting	N/A	N/A	Female	300	Phase 2/Phase 3	China
134	NCT04485325 (ClinicalTrials.gov)	November 4, 2019	30/4/2020	Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients	Capability of Tofacitinib or Etanercept to Accelerate Clinical Relevant Tapering of Non-steroidal Anti-inflammatory Drugs (NSAID) and Treat-to-target Guided De-escalation of Corticosteroids in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Previous csDMARD Therapy (AcceleRAte)	Rheumatic Arthritis	Drug: Tofacitinib;Biological: Etanercept	Dr. Frank Behrens	Pfizer	Recruiting	18 Years	65 Years	All	192	Phase 4	Germany
135	NCT04170504 (ClinicalTrials.gov)	November 2019	14/11/2019	Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis	Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis: A Randomized Controlled Trial	Rheumatoid Arthritis	Drug: Qing Re Huo Xue (QRHX);Drug: Methotrexate;Drug: dummy Qing Re Huo Xue (QRHX)	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Not yet recruiting	18 Years	N/A	All	204	Phase 2/Phase 3	NULL
136	NCT04049448 (ClinicalTrials.gov)	October 24, 2019	6/8/2019	Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis	A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ABX464	Abivax S.A.	NULL	Completed	18 Years	76 Years	All	40	Phase 2	Belgium;Czechia;France;Hungary;Poland
137	NCT04130178 (ClinicalTrials.gov)	October 15, 2019	11/10/2019	Nerve Block of the Proximal Interphalangeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study	Nerve Block of the Proximal Interphalyngeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study	Rheumatoid Arthritis	Drug: Nerve block	Sohag University	NULL	Completed	18 Years	N/A	All	48	N/A	Egypt
138	NCT04120831 (ClinicalTrials.gov)	October 7, 2019	4/10/2019	TOLERA: Tolerance Enhancement in RA	Sequential B Cell/T Cell Therapy to Re-induce Humoral Immune TOLErance in ACPA- Positive Rheumatoid Arthritis A Prospective, Randomized Controlled Open Label Single-centre Clinical Trial in Adult Subjects With Active ACPA-positive Rheumatoid Arthritis Failing Methotrexate	Rheumatoid Arthritis	Drug: Abatacept Injection	University of Erlangen-Nürnberg Medical School	NULL	Recruiting	18 Years	N/A	All	20	Phase 2	Germany
139	NCT04077567 (ClinicalTrials.gov)	October 1, 2019	29/8/2019	An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis	An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TS-152	Taisho Pharmaceutical Co., Ltd.	NULL	Active, not recruiting	20 Years	N/A	All	401	Phase 3	Japan
140	NCT04273334 (ClinicalTrials.gov)	October 1, 2019	15/2/2020	Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders	Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc.	Lymphatic Disorders	Drug: 68Ga-NEB	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	90	Phase 1	China
141	NCT03194204 (ClinicalTrials.gov)	October 1, 2019	10/6/2017	Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial	Efficacy of Doxycycline as a Combination Therapy in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Doxycycline Tablets	Assiut University	NULL	Completed	18 Years	60 Years	All	160	N/A	Egypt
142	NCT04472481 (ClinicalTrials.gov)	September 6, 2019	7/7/2020	Vitamin D Effect in Rheumatoid Arthritis.	Vitamin D: Does It Help Tregs in Active Rheumatoid Arthritis Patients.	Active Rheumatoid Arthritis	Drug: Ergocalciferol 1.25 mg tablet	Tanta University	NULL	Completed	33 Years	60 Years	All	20	Phase 4	Egypt
143	NCT03971253 (ClinicalTrials.gov)	September 2, 2019	30/5/2019	Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis	Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Drug: Peficitinib	Astellas Pharma Inc	NULL	Recruiting	N/A	N/A	All	3000		Japan
144	NCT04004429 (ClinicalTrials.gov)	August 26, 2019	26/6/2019	A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease	A Double-blind, Multicenter, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients With Active Joint Disease	Rheumatoid Arthritis	Drug: 50 mg AP1189;Drug: AP1189;Drug: Placebo	SynAct Pharma Aps	NULL	Completed	18 Years	85 Years	All	105	Phase 2	Denmark;Norway
145	NCT04068246 (ClinicalTrials.gov)	August 1, 2019	21/8/2019	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.	Rheumatoid Arthritis	Drug: Metformin;Drug: Placebo	Sadat City University	NULL	Completed	18 Years	N/A	All	120	Phase 1/Phase 2	Egypt
146	NCT02418273 (ClinicalTrials.gov)	August 1, 2019	6/4/2015	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders	Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study	Osteoporosis;Juvenile Rheumatoid Arthritis;Dermatomyositis;Polyarthritis;Systemic Lupus Erythematosis;Vasculitis;Glucocorticoid-induced Osteoporosis	Drug: denosumab	Indiana University	NULL	Withdrawn	4 Years	16 Years	All	0	Phase 1/Phase 2	United States
147	NCT04018599 (ClinicalTrials.gov)	July 15, 2019	11/7/2019	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects	Rheumatoid Arthritis;Polyarticular Juvenile Idiopathic Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis;Crohn Disease;Ulcerative Colitis;Plaque Psoriasis;Pediatric Plaque Psoriasis;Pediatric Crohns Disease;Hidradenitis Suppurativa;Non-infectious Uveitis	Drug: 40 mg MSB11022	Fresenius Kabi SwissBioSim GmbH	PRA Health Sciences	Completed	18 Years	55 Years	All	216	Phase 1	United States
148	NCT04464642 (ClinicalTrials.gov)	July 10, 2019	6/7/2020	Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis	Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Tofacitinib	Dr. Mohammad Mamun Khan	NULL	Active, not recruiting	18 Years	N/A	All	110	Phase 4	Bangladesh
149	NCT03619876 (ClinicalTrials.gov)	July 10, 2019	3/8/2018	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis	Rheumatoid Arthritis;Myocardial Inflammation	Drug: Abatacept;Drug: Adalimumab	Columbia University	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	20	Phase 4	United States
150	NCT03813199 (ClinicalTrials.gov)	July 4, 2019	15/1/2019	Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis	Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfa, or Intolerance to Anti-Tnfa	Rheumatoid Arthritis	Drug: ABX464 50mg;Drug: Matching Placebo;Drug: ABX464 100mg;Drug: Methotrexate	Abivax S.A.	NULL	Completed	18 Years	75 Years	All	60	Phase 2	Belgium;Czechia;France;Hungary;Poland
151	NCT04188249 (ClinicalTrials.gov)	July 1, 2019	27/6/2019	Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis	A Prospective Multicenter Registry of Golimumab in Chinese Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Golimumab	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	200		China
152	NCT03656627 (ClinicalTrials.gov)	June 27, 2019	31/8/2018	Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Autoimmune Diseases;Non-small Cell Lung Cancer;Rheumatoid Arthritis;Psoriasis;Giant Cell Arteritis;Polymyalgia Rheumatica;Systemic Lupus Erythematosus;Crohn Disease;Multiple Sclerosis;Ulcerative Colitis	Drug: Nivolumab	Alliance Foundation Trials, LLC.	Bristol-Myers Squibb	Terminated	18 Years	N/A	All	7	Phase 1	United States
153	NCT03912428 (ClinicalTrials.gov)	June 14, 2019	10/4/2019	Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis	Evaluation of Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis	Myositis;Inflammatory;Rheumatoid Arthritis;Healthy Volunteers	Drug: Celecoxib;Diagnostic Test: 11C-MC1;Diagnostic Test: 11C-ER176	National Institute of Mental Health (NIMH)	NULL	Recruiting	18 Years	99 Years	All	96	Phase 1	United States
154	NCT03652961 (ClinicalTrials.gov)	June 2, 2019	23/8/2018	Rheumatoid Arthritis Memory B Cells and Abatacept	Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA)	Rheumatoid Arthritis	Drug: Abatacept;Drug: DMARDs	NYU Langone Health	Dartmouth-Hitchcock Medical Center;Bristol-Myers Squibb	Active, not recruiting	18 Years	N/A	All	25	Phase 4	United States
155	NCT04344405 (ClinicalTrials.gov)	June 1, 2019	9/4/2020	Vitamin D as a Key Player in Rheumatoid Arthritis	Vitamin D as a Key Player in Rheumatoid Arthritis Immune Response	the Immunomodulatory Effect	Drug: Vitamin D;Drug: Steroid Drug	Assiut University	NULL	Completed	20 Years	70 Years	All	40	Phase 3	Egypt
156	NCT03882008 (ClinicalTrials.gov)	May 23, 2019	7/11/2018	A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis	Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept	University of Washington	Bristol-Myers Squibb	Enrolling by invitation	18 Years	N/A	All	25	Phase 4	United States
157	NCT03589833 (ClinicalTrials.gov)	May 14, 2019	5/7/2018	Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA	Effectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Tripterygium Wilfordii;Drug: Methotrexate;Drug: Yisaipu	Peking Union Medical College Hospital	NULL	Completed	18 Years	65 Years	All	504	Phase 4	China
158	NCT03823378 (ClinicalTrials.gov)	May 13, 2019	8/1/2019	A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.	A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial With ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599)	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: Upadacitinib placebo;Drug: ABBV-105 placebo;Drug: ABBV-105	AbbVie	NULL	Completed	18 Years	N/A	All	97	Phase 2	Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom
159	NCT03938636 (ClinicalTrials.gov)	April 8, 2019	24/4/2019	Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging	Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging	Rheumatoid Arthritis	Drug: TC99m-tilmanocept	Navidea Biopharmaceuticals	NULL	Completed	18 Years	N/A	All	95	Phase 2	United States
160	NCT03669367 (ClinicalTrials.gov)	April 1, 2019	26/7/2018	EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)	EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA)	Palindromic Rheumatism, Wrist	Drug: Abatacept Injection;Drug: hydroxycloroquina	Fundacion Clinic per a la Recerca Biomédica	NULL	Not yet recruiting	18 Years	N/A	All	98	Phase 4	NULL
161	NCT03700021 (ClinicalTrials.gov)	April 2019	2/10/2018	Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis	Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Abatacept + csDMARD	New York University School of Medicine	NULL	Not yet recruiting	18 Years	N/A	All	25	Phase 4	United States
162	NCT03823391 (ClinicalTrials.gov)	March 27, 2019	29/1/2019	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Drug: ABBV-3373;Drug: Placebo for ABBV-3373;Drug: Adalimumab;Drug: Placebo for adalimumab	AbbVie	NULL	Completed	18 Years	75 Years	All	48	Phase 2	United States;Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico
163	NCT04057118 (ClinicalTrials.gov)	March 20, 2019	13/8/2019	A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies	Rheumatoid Arthritis	Drug: SKI-O-703;Drug: Placebo	Oscotec Inc.	NULL	Active, not recruiting	18 Years	N/A	All	148	Phase 2	United States;Czechia;Poland;Russian Federation;Ukraine
164	NCT03885037 (ClinicalTrials.gov)	March 20, 2019	4/3/2019	Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Rheumatoid Arthritis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Recruiting	0 Years	N/A	All	300		Japan
165	NCT03890302 (ClinicalTrials.gov)	March 14, 2019	25/3/2019	Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A	A Phase 1, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Single and Multiple Ascending Doses of FB704A	Rheumatoid Arthritis	Drug: FB704A;Drug: Placebo	Fountain Biopharma Inc.	Oneness Biotech Co., Ltd.	Completed	18 Years	55 Years	All	31	Phase 1	United States
166	NCT03813771 (ClinicalTrials.gov)	March 2019	12/9/2018	Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification	Targeted Treatment Early With Etanercept Plus Methotrexate Versus T2T Care for DMARD-naïve Early RA Patients. A Prospective, Longitudinal Cohort Study With Embedded Pilot Randomised Controlled Trial to Assess Treatment Rationalisation Based on naïve T-cell Stratification.	Rheumatoid Arthritis	Drug: Benepali;Drug: Sulfasalazine;Drug: Methotrexate;Drug: Hydroxychloroquine	University of Leeds	Samsung Bioepis Co., Ltd.	Not yet recruiting	18 Years	N/A	All	106	Phase 4	United Kingdom
167	NCT03858725 (ClinicalTrials.gov)	February 26, 2019	27/2/2019	Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers	A Randomized, Open-label, Fasted, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteer	Rheumatoid Arthritis	Drug: D569 Tab.;Drug: CKD-374 5mg Tab.	Chong Kun Dang Pharmaceutical	NULL	Completed	19 Years	54 Years	All	36	Phase 1	Korea, Republic of
168	NCT03852355 (ClinicalTrials.gov)	February 25, 2019	22/2/2019	the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis	the Effectiveness of 3rd Occipital Radiofrequency Versus Systemic Steroid in Headache Management in Rheumatoid Arthritis; a Randomized Controlled Trial	Rheumatoid Arthritis;Headache	Drug: Radiofrequency;Drug: Steroids	Assiut University	NULL	Completed	18 Years	60 Years	All	60	N/A	Egypt
169	NCT03868072 (ClinicalTrials.gov)	February 22, 2019	6/3/2019	Study to Evaluate the Bioequivalence of Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical Chong Kun Dang Tofacitinib Tablet and Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	Rheumatoid Arthritis	Drug: XELJANZ 5Mg Tablet;Drug: Chong Kun Dang Tofacitinib Tablet	Chong Kun Dang Pharmaceutical	NULL	Completed	19 Years	N/A	All	40	Phase 1	Korea, Republic of
170	NCT03737708 (ClinicalTrials.gov)	February 13, 2019	8/11/2018	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)	Compare Efficacy and Safety Between Biologics + Methotrexate (MTX) vs Biologics + Tacrolimus (TAC) (Switched From Biologics + Methotrexate (MTX)) in the Patients With Rheumatoid Arthritis (RA): Randomized, Interventional, Open, Active Controlled, Parallel Group, Multicenter-designed, Phase 4 Clinical Trial	Rheumatoid Arthritis (RA)	Drug: tacrolimus;Drug: methotrexate;Biological: adalimumab;Biological: tocilizumab;Biological: abatacept	Astellas Pharma Korea, Inc.	NULL	Completed	19 Years	75 Years	All	21	Phase 4	Korea, Republic of
171	NCT03863405 (ClinicalTrials.gov)	January 9, 2019	4/3/2019	Metformin Use in Rheumatoid Arthritis	The Effect of Metformin on the Clinical Outcome of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Metformin;Drug: Conventional DMARDs;Drug: Placebo Oral Tablet	Ain Shams University	Future University in Egypt	Recruiting	18 Years	N/A	All	60	Phase 2	Egypt
172	NCT03981900 (ClinicalTrials.gov)	January 4, 2019	7/6/2019	IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis	IDentification of Predictive Factors of Continuation of Treatment With Tofacitinib in Patients With Rheumatoid Arthritis in Common Practice and the Impact of the Patient's Behavioural Strategies on Clinical Parameters: The DeFacTo Study.	Arthritis, Rheumatoid	Drug: Tofacitinib	Pfizer	NULL	Recruiting	18 Years	N/A	All	500		France
173	NCT03896594 (ClinicalTrials.gov)	December 24, 2018	28/3/2019	A Multiple Dose of HL237 in Healthy Male Subject	A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Oral Dose of HL237 in Healthy Male Subject	Rheumatoid Arthritis	Drug: HL237;Drug: Placebo Oral Tablet	Hanlim Pharm. Co., Ltd.	NULL	Recruiting	20 Years	45 Years	Male	36	Phase 1	Korea, Republic of
174	NCT03830203 (ClinicalTrials.gov)	December 19, 2018	22/1/2019	Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	A Randomized, Double-Blind, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: BAT1806;Drug: Actemra (EU-licensed)	Bio-Thera Solutions	NULL	Completed	18 Years	N/A	All	621	Phase 3	China
175	NCT03784261 (ClinicalTrials.gov)	December 17, 2018	17/12/2018	Usefulness of Non TNF Usage in RA Patients	Usefulness of Non TNF Usage in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Drug: Salirumab;Drug: Drug: Tocilizmab;Drug: Drug: Abatacept	Shinshu University	NULL	Recruiting	20 Years	100 Years	All	90	Phase 2	Japan
176	NCT03781310 (ClinicalTrials.gov)	December 2018	17/12/2018	Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis	Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis	Rheumatoid Arthritis;Tocilizumab	Drug: Tocilizumab	Tel-Aviv Sourasky Medical Center	Amsterdam Rheumatology and Immunology Center	Unknown status	18 Years	N/A	All	80	Phase 4	Israel
177	NCT04204603 (ClinicalTrials.gov)	November 30, 2018	17/12/2019	A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of CKD-506 Administered to Adult Subjects With Moderate-to- Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: CKD-506;Drug: Placebo	Chong Kun Dang Pharmaceutical	NULL	Completed	18 Years	65 Years	All	122	Phase 2	Czechia;Georgia;Poland;Russian Federation;Ukraine
178	NCT03729674 (ClinicalTrials.gov)	November 26, 2018	11/10/2018	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Rheumatoid Arthritis;Ankylosing Spondylitis;Ulcerative Colitis;Crohn's Disease	Drug: Biosimilar;Drug: Originator (legacy) drug	McGill University Health Centre/Research Institute of the McGill University Health Centre	Université de Sherbrooke;Institut de rhumatologie de Montréal;Hospital for Special Surgery, New York;University of Manitoba;University of Toronto;University of Alberta;University of British Columbia;Alberta Health Services;McMaster University;The Arthritis Program Research Group	Recruiting	18 Years	N/A	All	800		Canada
179	NCT03755466 (ClinicalTrials.gov)	November 21, 2018	21/11/2018	Examination of Efficacy and Safety of Baricitinib in RA Patients	Efficacy and Safety of Baricitinib in Rheumatoid Arthritis Patients Compared With Those Treated by Biologics or Tofacitinib	Rheumatoid Arthritis	Drug: Baricitinib , olumiant®;Drug: Biologics;Drug: Tofacitinib 5 MG [Xeljanz]	Shinshu University	NULL	Recruiting	20 Years	N/A	All	90	Phase 2	Japan
180	NCT03980639 (ClinicalTrials.gov)	November 20, 2018	18/1/2019	Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase	Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase	Rheumatoid Arthritis	Drug: patient treated with DMARD	University Hospital, Toulouse	NULL	Recruiting	18 Years	N/A	All	594226		France
181	NCT03714022 (ClinicalTrials.gov)	November 9, 2018	18/10/2018	A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes	A Randomized, Open-Label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of the Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process Relative to the Current Abatacept Drug Process in Healthy Participants	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	55 Years	All	140	Phase 1	United States
182	NCT04267614 (ClinicalTrials.gov)	November 1, 2018	11/2/2020	This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.	Clinical Outcomes of Early Versus Delayed Management of Iraqi Patients With Rheumatoid Arthritis With Etanercept	Arthritis Rheumatoid	Drug: Etanercept	Pfizer	NULL	Completed	N/A	N/A	All	1226		Iraq
183	NCT03718611 (ClinicalTrials.gov)	October 22, 2018	23/10/2018	To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects	A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects	Rheumatoid Arthritis	Drug: BR9001;Drug: BR900A	Boryung Pharmaceutical Co., Ltd	NULL	Completed	19 Years	50 Years	All	36	Phase 1	Korea, Republic of
184	NCT03682705 (ClinicalTrials.gov)	October 8, 2018	21/9/2018	A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.	A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: ABBV-105;Drug: Upadacitinib placebo;Drug: ABBV-105 placebo	AbbVie	NULL	Completed	18 Years	N/A	All	242	Phase 2	United States;Belgium;Canada;Czechia;Hungary;Poland;Puerto Rico;Spain;United Kingdom;Germany;Ireland
185	NCT03511625 (ClinicalTrials.gov)	October 2, 2018	10/4/2018	The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis	The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study	Rheumatoid Arthritis	Drug: Acthar Injectable Product;Drug: Depo medrol	Attune Health Research, Inc.	Mallinckrodt	Active, not recruiting	18 Years	N/A	All	6	Phase 3	United States
186	NCT03770702 (ClinicalTrials.gov)	October 1, 2018	7/12/2018	Statins and ARBs on Rheumatoid Activity	Investigational and Comparative Study Between the Anti-inflammatory Effectof Both Angiotensin Reeptor Blockers and Statins on Rheumatoid Arthritis Disease Activity on Egyptian Patients	Rheumatoid Arthritis	Drug: Angiotensin receptor blockers;Drug: Statins	Sherief Abd-Elsalam	NULL	Recruiting	18 Years	65 Years	All	45	Phase 3	Egypt
187	NCT03546335 (ClinicalTrials.gov)	October 1, 2018	30/4/2018	Zr-89 Cimzia PET Imaging Rheumatoid Arthritis	Zirconium-89 Certolizumab PET Imaging in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 89Zr-DFO-CZP	Robert Flavell, MD, PhD	NULL	Suspended	18 Years	N/A	All	10	Phase 1	United States
188	NCT03770923 (ClinicalTrials.gov)	October 1, 2018	7/12/2018	Effect of Some Drugs on Rheumatoid Arithritis Activity	Clinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid Arithritis	Rheumatoid Arthritis	Drug: Rupatadine;Drug: Montelukast	Sherief Abd-Elsalam	NULL	Recruiting	18 Years	N/A	All	75	Phase 3	Egypt
189	NCT03593837 (ClinicalTrials.gov)	October 1, 2018	10/7/2018	Efficacy and Safety of HQGZWWT Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Huang Qi GuiZhi Wu Wu Tang Granulesin Patients With Rheumatoid Arthritis	Huang Qi Gui Zhi Wu Wu Granule;Rheumatoid Arthritis	Drug: Huang qi gui zhi wu wu granule;Drug: Huang qi gui zhi wu wu granule placebo	Cui xuejun	NULL	Unknown status	18 Years	80 Years	All	100	Phase 2/Phase 3	NULL
190	NCT03660059 (ClinicalTrials.gov)	September 27, 2018	26/8/2018	A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)	A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX	Rheumatoid Arthritis (RA)	Drug: Peficitinib;Drug: Plaebo;Drug: Disease-modifying antirheumatic drugs (DMARDs)	Astellas Pharma China, Inc.	NULL	Completed	18 Years	N/A	All	385	Phase 3	China;Korea, Republic of;Taiwan
191	NCT03699293 (ClinicalTrials.gov)	September 22, 2018	21/9/2018	NSAIDs vs. Coxibs in the Presence of Aspirin	NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease	Rheumatoid Arthritis;Cardiovascular Diseases	Drug: celecoxib 200mg capsule;Drug: naproxen sodium 550mg tablet;Drug: Aspirin 81mg tablet	Inova Health Care Services	NULL	Unknown status	18 Years	75 Years	All	30	Phase 4	United States
192	NCT03701789 (ClinicalTrials.gov)	September 11, 2018	4/10/2018	Effect of Baricitinib Treatment on Peripheral Bone in RA	Evaluation of Bone Quality in Patients With Rheumatoid Arthritis Treated With Baricitinib: Single Centre, Mode of Action Study (BARE BONE)	Rheumatoid Arthritis;Bone Density;Finger Joints	Drug: Baricitinib	University of Erlangen-Nürnberg Medical School	NULL	Active, not recruiting	18 Years	74 Years	All	15	Phase 3	Germany
193	NCT04079374 (ClinicalTrials.gov)	September 3, 2018	3/9/2019	Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel	Open, Randomized, Comparative, Multicenter Study in Parallel Groups of the Efficacy, Safety, Immunogenicity of Etanercept and Enbrel, Lyophilisates for Solution for Subcutaneous Injection, in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Enbrel	Joint Stock Company Farmak	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Recruiting	18 Years	75 Years	All	160	Phase 3	Ukraine
194	NCT02927522 (ClinicalTrials.gov)	September 1, 2018	5/10/2016	Donepezil Attenuate Postoperative Cognitive Dysfunction	Donepezil Attenuate Postoperative Cognitive Dysfunction in Aged Patients- A Multi-center, Case Control, Randomized Clinical Trail	Osteoarthritis;Femoral Head Necrosis;Rheumatoid Arthritis	Drug: Donepezil;Drug: Placebo	RenJi Hospital	Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine	Recruiting	60 Years	N/A	All	550	Phase 3	China
195	NCT03605251 (ClinicalTrials.gov)	August 30, 2018	3/7/2018	Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.	An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: TAS5315 low dose;Drug: TAS5315 high dose;Drug: Placebos	Taiho Pharmaceutical Co., Ltd.	NULL	Completed	20 Years	64 Years	All	91	Phase 2	Japan
196	NCT03636984 (ClinicalTrials.gov)	August 24, 2018	13/8/2018	Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World	Efficacy and Safety Study of Anbainuo in Chinese Patients With Rheumatoid Arthritis/ Ankylosing Spondylitis in the Real World: a Prospective, Open-label, Multi-center Observational Study	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: recombinant TNF-a receptor: IgG Fc fusion protein	Zhejiang Hisun Pharmaceutical Co. Ltd.	NULL	Not yet recruiting	18 Years	N/A	All	1000		NULL
197	NCT04056039 (ClinicalTrials.gov)	August 14, 2018	21/6/2019	Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity in Patients With Rheumatoid Arthritis.	Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.	Cardiovascular Diseases;Arthritis, Rheumatoid	Drug: Atorvastatin;Drug: Colchicine	Hospital Central Dr. Ignacio Morones Prieto	NULL	Completed	18 Years	N/A	All	60	Phase 2	Mexico
198	NCT03535519 (ClinicalTrials.gov)	August 7, 2018	14/5/2018	Rheumatoid Arthritis Response to Methotrexate	Rheumatoid Arthritis Ultrasound Response to Methotrexate	Rheumatoid Arthritis	Drug: Methotrexate	Juan Carlos Nieto	Nordic Pharma SAS	Recruiting	18 Years	N/A	All	50		Spain
199	NCT04066803 (ClinicalTrials.gov)	August 1, 2018	11/12/2018	Optimal MTX Dose With Folic Acid Randomized Case-control Trial	Safety and Efficacy of Optimal Methotrexate With Folic Acid in Patients With Rheumatoid Arthritis in Meizhou, Guangdong: a Randomized Case-control Study	Rheumatoid Arthritis	Drug: MTX;Drug: Folic Acid;Drug: DMARDs	Sun Yat-sen University	Shanghai Pharmaceuticals Holding Co., Ltd	Recruiting	18 Years	70 Years	All	160	Phase 4	China
200	NCT03173040 (ClinicalTrials.gov)	July 2018	30/5/2017	The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis	The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis: a Study Protocol for a Multicenter, Randomized, Controlled Clinical Trial	Niu Bang Zi Pill;Rheumatoid Arthritis	Drug: NiuBangZi pill or NiuBangZi pill placebo	Cui xuejun	Shanghai Yueyang Integrated Medicine Hospital;Longhua Hospital;Shanghai Seventh People's Hospital	Unknown status	18 Years	80 Years	All	100	Phase 2/Phase 3	China
201	NCT02885597 (ClinicalTrials.gov)	July 2018	18/8/2016	Juanbi Pill for Rheumatoid Arthritis	Juanbi Pill Combined With Methotrexate for Rheumatoid Arthritis: Multi-center Random Controlled Clinical Trials	Juanbi Pill;Rheumatoid Arthritis	Drug: Juanbi pill;Drug: Juanbi pill placebo;Drug: Methotrexate	Cui xuejun	Shanghai Yueyang Integrated Medicine Hospital;Longhua Hospital;Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine	Unknown status	18 Years	80 Years	All	120	Phase 2/Phase 3	China
202	NCT03084419 (ClinicalTrials.gov)	June 26, 2018	7/3/2017	APRIL (AbatacePt in Rheumatoid Arthritis-ILD)	Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Feasibility Trial	Rheumatoid Arthritis;Interstitial Lung Disease	Drug: Abatacept	Cambridge University Hospitals NHS Foundation Trust	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	30	Phase 2	United Kingdom
203	NCT03606876 (ClinicalTrials.gov)	June 13, 2018	12/7/2018	Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects	A Randomized, Double-blinded, Single-dose, 3-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT1806 Injection vs Actemra® in Healthy Chinese Male Subjects	Rheumatoid Arthritis	Drug: BAT1806 injection	Bio-Thera Solutions	NULL	Completed	18 Years	55 Years	Male	138	Phase 1	China
204	NCT03535402 (ClinicalTrials.gov)	June 1, 2018	9/5/2018	Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics	Measurement of the Structural Efficacy in Active Rheumatoid Arthritis (RA) Patients Treated With Sarilumab in Combination With Methotrexate (MTX) and Naive to Biologics as Measured by Low-field MRI Using a Modified OMERACT-RAMRIS Score.	Rheumatoid Arthritis	Drug: Sarilumab	Gaylis, Norman B., M.D.	NULL	Active, not recruiting	18 Years	N/A	All	20	Phase 3	United States
205	NCT03522415 (ClinicalTrials.gov)	May 28, 2018	29/4/2018	Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HLX01 (Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection) Combined With MTX Therapy in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Moderately to Severely Active Rheumatoid Arthritis	Drug: HLX01;Drug: Methotrexate (MTX)	Shanghai Henlius Biotech	NULL	Completed	18 Years	75 Years	All	275	Phase 3	China
206	NCT03410056 (ClinicalTrials.gov)	May 22, 2018	3/1/2018	Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis	A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy	Rheumatoid Arthritis RA	Drug: AMG 592;Drug: Placebo	Amgen	NULL	Terminated	18 Years	70 Years	All	36	Phase 1/Phase 2	United States;Bulgaria;Germany;Poland;Spain
207	NCT03378219 (ClinicalTrials.gov)	May 18, 2018	15/12/2017	An Observational Study on Sarilumab-exposed Pregnancies	Kevzara® (Sarilumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study	Rheumatoid Arthritis -Exposure During Pregnancy	Drug: Sarilumab SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Active, not recruiting	N/A	N/A	Female	113		United States;Canada
208	NCT03508713 (ClinicalTrials.gov)	May 13, 2018	4/6/2017	Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)	Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND): a Multicenter Prospective Observational Study in Southern China	Rheumatoid Arthritis	Drug: disease modified antirheumatic drugs or biological agents	Nanfang Hospital of Southern Medical University	Southern Medical University, China	Not yet recruiting	18 Years	N/A	All	200		NULL
209	NCT03505008 (ClinicalTrials.gov)	April 18, 2018	16/4/2018	Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan	MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Adalimumab	Keio University	Eisai Co., Ltd.	Active, not recruiting	18 Years	N/A	All	300	Phase 4	Japan;Korea, Republic of;Taiwan
210	NCT03435601 (ClinicalTrials.gov)	April 18, 2018	31/1/2018	A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)	A Randomised, Double-blind, Placebo-controlled Phase II Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)	Rheumatoid Arthritis	Drug: Anifrolumab;Drug: Placebos	Josef Smolen, Univ. Prof. Dr.	NULL	Recruiting	18 Years	70 Years	All	24	Phase 2	Austria
211	NCT03417778 (ClinicalTrials.gov)	April 3, 2018	25/1/2018	Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function	A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of Filgotinib in Subjects With Impaired Hepatic Function	Rheumatoid Arthritis;Ulcerative Colitis;Crohn's Disease	Drug: Filgotinib	Gilead Sciences	Galapagos NV	Completed	18 Years	70 Years	All	20	Phase 1	United States;Germany;New Zealand
212	NCT03478111 (ClinicalTrials.gov)	March 30, 2018	16/3/2018	CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis	A Randomized, Double-blind, Methotrexate (MTX) Based, Parallel-group, Multicenter Phase III Study to Evaluate Efficacy and Safety of CMAB008 in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis, Compared to Remicade	Rheumatoid Arthritis	Drug: CMAB008;Drug: MTX;Drug: Remicade	Shanghai Biomabs Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	N/A	All	390	Phase 3	China
213	NCT03449758 (ClinicalTrials.gov)	March 5, 2018	8/2/2018	Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis	Effect of Sarilumab on Patient-reported Outcomes in Patients With Moderately to Severely Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors	Rheumatoid Arthritis	Drug: SARILUMAB;Drug: Azathioprine;Drug: Chloroquine;Drug: Hydroxychloroquine;Drug: Leflunomide;Drug: Methotrexate;Drug: Sulfasalazine	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	84	Phase 4	France
214	NCT03480529 (ClinicalTrials.gov)	March 1, 2018	21/3/2018	Monitoring the IMmUological TOXicity of Drugs	Monitoring the IMmUological TOXicity of Drugs	Arthritis;Systemic Lupus Erythematosus;Rheumatoid Arthritis;Capillary Leak Syndrome;Hepatitis	Drug: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom	Groupe Hospitalier Pitie-Salpetriere	Institut National de la Santé Et de la Recherche Médicale, France	Completed	18 Years	N/A	All	662		France
215	NCT03100253 (ClinicalTrials.gov)	March 1, 2018	17/3/2017	Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation	Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Etanercept;Drug: Infliximab;Drug: Adalimumab;Drug: Golimumab;Drug: Certolizumab Pegol	Mario Negri Institute for Pharmacological Research	NULL	Terminated	18 Years	N/A	All	208	Phase 4	Italy
216	NCT04022525 (ClinicalTrials.gov)	February 1, 2018	15/7/2019	Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches	Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches	Rheumatoid Arthritis	Drug: Leflunomide 20Mg Tab	Assiut University	NULL	Completed	18 Years	N/A	All	80		Egypt
217	NCT01694693 (ClinicalTrials.gov)	January 31, 2018	24/9/2012	Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study	Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study	Rheumatoid Arthritis	Drug: Orencia	Bristol-Myers Squibb	NULL	Withdrawn	18 Years	N/A	All	0	N/A	NULL
218	NCT03227419 (ClinicalTrials.gov)	January 22, 2018	19/7/2017	Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders	Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial	Arthritis, Rheumatoid	Drug: Tocilizumab Prefilled Syringe;Drug: Abatacept Prefilled Syringe	Lille Catholic University	NULL	Recruiting	18 Years	N/A	All	224	Phase 4	France
219	NCT03368235 (ClinicalTrials.gov)	January 18, 2018	3/11/2017	Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis	A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 Compared to Prednisolone 20 mg in Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: AZD9567;Drug: Prednisolone	AstraZeneca	NULL	Completed	18 Years	80 Years	All	21	Phase 2	Netherlands;Sweden;Denmark
220	NCT02955212 (ClinicalTrials.gov)	January 3, 2018	2/11/2016	A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	Rheumatoid Arthritis (RA)	Drug: Upadacitinib;Drug: Placebo	AbbVie	NULL	Completed	18 Years	N/A	All	338	Phase 3	Brazil;China;Korea, Republic of
221	NCT02795299 (ClinicalTrials.gov)	January 2018	2/5/2016	Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFa Antagonist Failed in Rheumatoid Arthritis	Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFa Antagonist	Rheumatoid Arthritis	Drug: Gerilimzumab;Drug: Methotrexate;Drug: Folic Acid;Drug: Placebo	Bird Rock Bio, Inc.	Techtrials Pesquisa e Tecnologia Ltda;Pharmagenix	Withdrawn	18 Years	80 Years	All	0	Phase 2	NULL
222	NCT04312815 (ClinicalTrials.gov)	December 28, 2017	16/3/2020	A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX	A Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severely Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis(RA)	Drug: SM03;Drug: Placebo;Drug: MTX	SinoMab Pty Ltd	NULL	Recruiting	18 Years	70 Years	All	510	Phase 3	China
223	NCT03254966 (ClinicalTrials.gov)	November 24, 2017	15/8/2017	Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SHR0302;Drug: Placebo	Jiangsu HengRui Medicine Co., Ltd.	NULL	Completed	18 Years	70 Years	All	194	Phase 2	China
224	NCT03334851 (ClinicalTrials.gov)	November 17, 2017	3/11/2017	Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis	A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: PF-06835375;Drug: Placebo	Pfizer	NULL	Completed	18 Years	70 Years	All	74	Phase 1	United States;Puerto Rico
225	NCT03357471 (ClinicalTrials.gov)	November 3, 2017	23/11/2017	Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondylitis;Moderately to Severely Active Crohn's Disease	Drug: e-Device	UCB Biopharma S.P.R.L.	NULL	Completed	18 Years	N/A	All	70	Phase 3	United States
226	NCT03329885 (ClinicalTrials.gov)	November 2, 2017	31/10/2017	A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis	A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis	Rheumatoid Arthritis;Psoriasis;Ankylosing Spondylitis;Inflammatory Bowel Diseases;Nonalcoholic Steatohepatitis	Drug: BMS-986251;Other: Placebo	Bristol-Myers Squibb	NULL	Terminated	18 Years	70 Years	All	38	Phase 1/Phase 2	Netherlands
227	NCT03387423 (ClinicalTrials.gov)	November 2, 2017	7/12/2017	Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis	ESCALATE-RA A NON-INTERVENTIONAL STUDY OF CRITICAL FACTORS FOR ESCALATING DRUG TREATMENT IN PATIENTS TREATED WITH TOFACITINIB FOR MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS	Arthritis, Rheumatoid	Drug: Tofacitinib	Pfizer	NULL	Recruiting	18 Years	N/A	All	1500		Germany
228	NCT03440892 (ClinicalTrials.gov)	November 1, 2017	14/2/2018	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin	Rheumatoid Arthritis	Drug: methotrexate;Drug: sulfasalazine;Drug: abatacept;Drug: tocilizumab;Drug: tofacitinib /baricitinib	Vastra Gotaland Region	NULL	Recruiting	20 Years	N/A	All	2500		Sweden
229	NCT02647762 (ClinicalTrials.gov)	October 30, 2017	16/12/2015	CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis	A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CF101 1 mg;Drug: CF101 2 mg;Drug: Placebo;Drug: MTX	Can-Fite BioPharma	NULL	Active, not recruiting	18 Years	75 Years	All	525	Phase 3	Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia
230	NCT03324412 (ClinicalTrials.gov)	October 28, 2017	25/10/2017	Efficacy and Safety of TwHF and MTX in Patients With Rheumatoid Arthritis	A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of TwHF and MTX Treating Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Treatment of MTX;Drug: Treatment of MTX and TwHF	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Not yet recruiting	45 Years	70 Years	All	216	Phase 2/Phase 3	NULL
231	NCT03337815 (ClinicalTrials.gov)	October 28, 2017	22/10/2017	A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid Arthritis	A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of Tripterygium Wilfordii Treating Rheumatoid Arthritis and Establish A Prediction Model	Rheumatoid Arthritis	Drug: Treatment of MTX and TwHF placebo;Drug: Treatment of TwHF and MTX placebo	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Recruiting	45 Years	70 Years	All	264	Phase 2/Phase 3	China
232	NCT03288584 (ClinicalTrials.gov)	October 27, 2017	16/9/2017	Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis	The Effect of Inhibition of Interleukin-6 Activity on Vascular, Endothelial and Left Ventricular Function in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Inflammation	Drug: Tocilizumab (Actemra®);Drug: Other biological agent;Drug: Corticosteroid and non-biological agents.	University of Athens	NULL	Recruiting	18 Years	80 Years	All	60		Greece
233	NCT03163966 (ClinicalTrials.gov)	October 5, 2017	8/5/2017	A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Oral CR6086 Administered at the Doses of 30, 90 or 180 mg Bid for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis, DMARD-naive and Early Disease Patients	Drug: CR6086;Drug: Methotrexate;Drug: Placebo	Rottapharm Biotech	NULL	Completed	18 Years	N/A	All	248	Phase 2	Czechia
234	NCT03257852 (ClinicalTrials.gov)	September 29, 2017	20/8/2017	A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis (RA)	Drug: ASP5094;Drug: Placebo;Other: Methotrexate therapy	Astellas Pharma Inc	NULL	Completed	20 Years	N/A	All	66	Phase 2	Japan
235	NCT03233230 (ClinicalTrials.gov)	September 18, 2017	25/7/2017	Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis	A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: M2591 25 mg QD;Drug: M2951 75 mg QD;Drug: M2951 50 mg BID;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Completed	18 Years	75 Years	All	390	Phase 2	United States;Argentina;Bulgaria;Chile;Colombia;Czechia;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;Brazil;Germany;Hungary;Romania;Slovakia;Spain
236	NCT03262740 (ClinicalTrials.gov)	September 11, 2017	24/8/2017	The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients	The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)	Bristol-Myers Squibb	NULL	Completed	18 Years	40 Years	Female	58	Phase 1	United States
237	NCT04177173 (ClinicalTrials.gov)	September 1, 2017	7/4/2019	Methotrexate and Statins With Methotrexate Alone in the Treatment of Rheumatoid Arthritis	Comparison of Combination of Methotrexate and Statins With Methotrexate Alone as an Anti-inflammatory Agent in the Treatment of Rheumatoid Arthritis.	Arthritis, Rheumatoid	Drug: Simvastatin 20 mg;Drug: Methotrexate 10 mg	King Edward Medical University	NULL	Completed	18 Years	N/A	All	100	Phase 4	Pakistan
238	NCT03241446 (ClinicalTrials.gov)	September 2017	25/7/2017	Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)	A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Tilmanocept	Navidea Biopharmaceuticals	NULL	Withdrawn	30 Years	65 Years	All	0	Phase 1	NULL
239	NCT03245515 (ClinicalTrials.gov)	August 15, 2017	8/8/2017	A Study of BMS-986195 in Healthy Male Subjects	Pharmacokinetics and Metabolism of [14C] BMS-986195 in Healthy Male Subjects	Rheumatoid Arthritis	Drug: BMS-986195	Bristol-Myers Squibb	NULL	Completed	18 Years	55 Years	Male	24	Phase 1	Netherlands
240	NCT03160001 (ClinicalTrials.gov)	August 15, 2017	11/5/2017	Niclosamide With Etanercept in Rheumatoid Arthritis	Adjuvant Use of Niclosamide With Etanercept in Rheumatoid Arthritis: Experimental and Clinical Study	Rheumatoid Arthritis (RA)	Drug: Placebo;Drug: Niclosamide;Drug: Etanercept	Faiq Gorial	NULL	Completed	18 Years	N/A	All	110	Phase 1/Phase 2	Iraq
241	NCT03156023 (ClinicalTrials.gov)	August 14, 2017	15/5/2017	Multiple Ascending Doses of AMG 570 in Subjects With Rheumatoid Arthritis	A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 570;Drug: Placebo	Amgen	NULL	Completed	18 Years	75 Years	All	34	Phase 1	United States;Germany
242	NCT03188081 (ClinicalTrials.gov)	August 4, 2017	12/6/2017	A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept	A Prospective, Multicentric, Observational Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life RA Patients Treated With Abatacept SC	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Recruiting	18 Years	N/A	All	300		Italy
243	NCT03155347 (ClinicalTrials.gov)	August 2, 2017	15/5/2017	An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy	A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: MTX;Drug: Placebo Matched to MTX;Drug: Placebo Matched to Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	70 Years	All	340	Phase 3	China
244	NCT03215407 (ClinicalTrials.gov)	August 1, 2017	22/6/2017	The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone	The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee	Rheumatoid Arthritis of Knee	Drug: Intra-articular Tocilizumab;Drug: Intra-articular Compound Betamethasone	Chinese PLA General Hospital	NULL	Not yet recruiting	18 Years	65 Years	All	60	Phase 4	NULL
245	NCT02541955 (ClinicalTrials.gov)	July 20, 2017	1/9/2015	Use of Acthar in Rheumatoid Arthritis (RA) Related Flares	Use of Acthar in Rheumatoid Arthritis Related Flares	Rheumatoid Arthritis (RA)	Drug: Acthar	Veena Ranganath, MD, MS	NULL	Recruiting	18 Years	N/A	All	40	Phase 4	United States
246	NCT03120949 (ClinicalTrials.gov)	July 4, 2017	7/2/2017	Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis	A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Olokizumab 64 mg SC q4w;Drug: Olokizumab 64 mg SC q2w	R-Pharm International, LLC	IQVIA Pvt. Ltd;OCT Clinical Trials	Completed	18 Years	N/A	All	2106	Phase 3	United States;Argentina;Belarus;Brazil;Bulgaria;Colombia;Czechia;Estonia;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;Korea, Republic of;Germany;Hungary
247	NCT03189017 (ClinicalTrials.gov)	July 3, 2017	12/6/2017	A Phase I Study of ICP-022 in Healthy Subjects	A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-022 Following Single and Multiple Escalating Dose	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: ICP-022;Drug: Placebos	Innocare Pharma Australia Pty Ltd	NULL	Completed	18 Years	55 Years	Male	64	Phase 1	Australia
248	NCT03394131 (ClinicalTrials.gov)	July 1, 2017	25/12/2017	?Efficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients	Treatment of Carpal Tunnel in Rheumatoid Arthritis	Treatment Resistant Carpal Tunnel in RA Patients	Drug: Hylase;Drug: Insulin;Other: saline	Assiut University	NULL	Unknown status	20 Years	80 Years	All	90	N/A	Egypt
249	NCT03278470 (ClinicalTrials.gov)	June 26, 2017	7/9/2017	A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject	A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximum Tolerable Dose After Single Oral Dose of HL237 in Healthy Male Subject	Rheumatoid Arthritis	Drug: HL237;Drug: Placebo Oral Tablet	Hanlim Pharm. Co., Ltd.	NULL	Completed	20 Years	45 Years	Male	57	Phase 1	Korea, Republic of
250	NCT03239080 (ClinicalTrials.gov)	June 19, 2017	1/8/2017	Effect of Denosumab in Erosion Healing in RA	Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT	Rheumatoid Arthritis	Drug: Denosumab;Other: Placebo	Chinese University of Hong Kong	NULL	Completed	18 Years	N/A	All	110	Phase 2	China
251	NCT03139136 (ClinicalTrials.gov)	May 30, 2017	26/4/2017	Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis	A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: MBS2320;Drug: Placebo	Modern Biosciences plc	NULL	Completed	18 Years	75 Years	All	121	Phase 2	Georgia;Moldova, Republic of;Romania
252	NCT03193957 (ClinicalTrials.gov)	May 15, 2017	19/6/2017	An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis	An Open-label, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Device: Autoinjector	Samsung Bioepis Co., Ltd.	NULL	Completed	18 Years	55 Years	All	50	Phase 2	Poland
253	NCT03131973 (ClinicalTrials.gov)	May 13, 2017	25/4/2017	Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin	Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: Pravastatin	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	All	26	Phase 1	United States
254	NCT03241108 (ClinicalTrials.gov)	May 10, 2017	26/6/2017	Study of an Anti-TLR4 mAb in Rheumatoid Arthritis	Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an Anti-Toll Like Receptor 4 Monoclonal Antibody in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: NI-0101;Other: Placebo	NovImmune SA	NULL	Completed	18 Years	N/A	All	90	Phase 2	Bosnia and Herzegovina;Bulgaria;Georgia;Hungary;Moldova, Republic of;Poland;Serbia
255	NCT02808871 (ClinicalTrials.gov)	April 7, 2017	20/3/2016	Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)	Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)	Rheumatoid Arthritis Interstitial Lung Disease	Drug: Pirfenidone;Drug: Placebo	Brigham and Women's Hospital	NULL	Completed	18 Years	85 Years	All	123	Phase 2	United States;Australia;Canada;United Kingdom
256	NCT02908490 (ClinicalTrials.gov)	April 1, 2017	8/7/2016	Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?	Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?	Arthritis, Rheumatoid;Atherosclerosis	Drug: Sildenafil;Other: Placebo	Kimberly Liang	NULL	Completed	18 Years	N/A	All	26	Phase 2	United States
257	NCT03275025 (ClinicalTrials.gov)	April 1, 2017	28/8/2017	A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of YRA-1909 in Patients With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Rheumatoid Arthritis	Drug: YRA-1909 low dose;Drug: YRA-1909 mid dose;Drug: YRA-1909 high dose;Drug: Placebo	Yungjin Pharm. Co., Ltd.	NULL	Completed	19 Years	80 Years	All	116	Phase 2	Korea, Republic of
258	NCT03291457 (ClinicalTrials.gov)	March 30, 2017	20/9/2017	A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice	A Prospective Non-Interventional Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Glucocorticoid Agent	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	101		Belgium
259	NCT03178955 (ClinicalTrials.gov)	March 27, 2017	2/6/2017	Circadian RA Study in Rheumatoid Arthritis Subjects	The Effects of Biologic Therapy With Disease Activity and Circadian Rhythm	Rheumatoid Arthritis	Drug: Etanercept	University of California, Davis	NULL	Withdrawn	18 Years	80 Years	All	0		United States
260	NCT03348046 (ClinicalTrials.gov)	March 23, 2017	16/11/2017	Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan	Post-Authorization Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan	Rheumatoid Arthritis	Drug: Biosimilar Infliximab	Hikma Pharmaceuticals LLC	Syneos Health	Completed	18 Years	N/A	All	22		Jordan
261	NCT03755258 (ClinicalTrials.gov)	March 16, 2017	21/11/2018	Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis	A Phase Ib Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GCK in Rheumatoid Arthritis Patients	Early Rheumatoid Arthritis	Drug: GCK 100 mg + Placebo 200 mg;Drug: GCK 200 mg + Placebo 100 mg;Drug: GCK 300 mg;Drug: Placebo 300mg	Zhejiang Hisun Pharmaceutical Co. Ltd.	NULL	Unknown status	18 Years	65 Years	All	128	Phase 1	China
262	NCT03082573 (ClinicalTrials.gov)	March 3, 2017	13/3/2017	Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs	Rheumatoid Arthritis	Drug: H.P. Acthar gel	Iraj Sabahi Research Inc.	Mallinckrodt	Recruiting	21 Years	N/A	All	30	Phase 4	United States
263	NCT03025308 (ClinicalTrials.gov)	February 28, 2017	17/1/2017	Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis	A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib	Galapagos NV	Gilead Sciences	Active, not recruiting	18 Years	N/A	All	2731	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Netherlands
264	NCT03667131 (ClinicalTrials.gov)	February 13, 2017	10/9/2018	Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.	Effect of Prophylactic Treatment With Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis Patients.	Rheumatoid Arthritis	Drug: Enalapril Maleate;Drug: Placebo	University of Guadalajara	NULL	Completed	18 Years	80 Years	Female	59	Phase 2	Mexico
265	NCT03052322 (ClinicalTrials.gov)	January 31, 2017	29/1/2017	MSB11022 in Moderate to Severe Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis	Moderate to Severe Rheumatoid Arthritis	Drug: MSB11022;Drug: EU-Humira	Fresenius Kabi SwissBioSim GmbH	NULL	Completed	18 Years	N/A	All	288	Phase 3	Bulgaria;Czechia;Germany;Hungary;Poland;United Kingdom;Czech Republic
266	NCT02997605 (ClinicalTrials.gov)	January 31, 2017	15/12/2016	Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients	Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients in Low Disease Activity or Remission.	RheumatoId Arthritis	Drug: GlucoCorticoid	University Hospital, Toulouse	NULL	Completed	18 Years	N/A	All	102	Phase 4	France
267	NCT03028467 (ClinicalTrials.gov)	January 24, 2017	10/1/2017	Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis	A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination With Methotrexate Therapy, in Japanese Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate	Arthritis, Rheumatoid	Drug: GSK3196165 Dose 1;Drug: GSK3196165 Dose 2;Drug: GSK3196165 Dose 3;Drug: Methotrexate;Drug: Placebo;Drug: Folic acid	GlaxoSmithKline	NULL	Completed	20 Years	N/A	All	15	Phase 1/Phase 2	Japan
268	NCT03085940 (ClinicalTrials.gov)	January 20, 2017	7/2/2017	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Hydroxychloroquine;Drug: Placebo	Indonesia University	NULL	Completed	18 Years	N/A	All	37	N/A	Indonesia
269	NCT02990806 (ClinicalTrials.gov)	January 19, 2017	21/11/2016	A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)	A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: NI-071;Drug: Remicade	Nichi-Iko Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	75 Years	All	683	Phase 3	United States;Czechia;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United Kingdom
270	NCT03112213 (ClinicalTrials.gov)	January 12, 2017	10/4/2017	Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment	CONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: NSAIDs	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	135		Germany
271	NCT02760433 (ClinicalTrials.gov)	January 9, 2017	29/4/2016	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease	A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy	Rheumatoid Arthritis	Drug: Olokizumab q4w;Drug: Olokizumab q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Active, not recruiting	18 Years	N/A	All	350	Phase 3	United States;Argentina;Brazil;Colombia;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Czech Republic;Turkey
272	NCT02865434 (ClinicalTrials.gov)	January 2017	5/8/2016	Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA	An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls	Arthritis, Rheumatoid	Drug: Tc99m-tilmanocept;Procedure: SPECT Imaging (60 Minutes post-injection);Procedure: SPECT Imaging (180 Minutes post-injection);Procedure: Whole body planar SPECT imaging (15 Minutes post-injection);Procedure: Whole body planar SPECT imaging (60 Minutes post-injection);Procedure: Whole body planar SPECT imaging (180 Minutes post-injection);Procedure: Whole body planar SPECT imaging (18-20 Hours post-injection);Procedure: Blood Collection for PK Testing (15 Mins Before Injection);Procedure: Blood Collection for PK Testing (after injection);Procedure: Blood Collection for PK Testing (15 minutes post injection);Procedure: Blood Collection for PK Testing (60 minutes post injection);Procedure: Blood Collection for PK Testing (180 minutes post injection);Procedure: Blood Collection for PK Testing (18-20 hours post injection);Procedure: Planar Image with both Hands in Field of View	Navidea Biopharmaceuticals	NULL	Completed	18 Years	N/A	All	39	Phase 1/Phase 2	United States
273	NCT02965599 (ClinicalTrials.gov)	December 27, 2016	14/11/2016	Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis	A Randomised, Multi-center, Double Blind (Sponsor Open), Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Severe, Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GSK3117391;Drug: Placebo	GlaxoSmithKline	NULL	Terminated	18 Years	N/A	All	3	Phase 2	Poland;Romania;Mexico
274	NCT03001219 (ClinicalTrials.gov)	December 22, 2016	20/12/2016	A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Study to Evaluate The Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-alpha Inhibitors	Rheumatoid Arthritis	Drug: Anti-TNF-alpha;Drug: Methotrexate;Drug: Placebo;Drug: RO7123520	Hoffmann-La Roche	NULL	Terminated	18 Years	N/A	All	109	Phase 2	United States;Argentina;Austria;Colombia;Germany;Guatemala;Italy;Mexico;Peru;Spain;United Kingdom;Czech Republic;Czechia;Poland
275	NCT02969044 (ClinicalTrials.gov)	December 20, 2016	17/11/2016	Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate	A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: PF-06651600	Pfizer	NULL	Completed	18 Years	75 Years	All	70	Phase 2	United States;Bulgaria;Czechia;Georgia;Germany;Hungary;Poland;Serbia;Slovakia
276	NCT02862574 (ClinicalTrials.gov)	December 15, 2016	8/8/2016	Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis	Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Andecaliximab;Drug: Placebo;Drug: Methotrexate;Drug: TNF Inhibitor	Gilead Sciences	NULL	Terminated	18 Years	80 Years	All	15	Phase 2	United States;Australia;Hungary;Taiwan
277	NCT02982083 (ClinicalTrials.gov)	December 2016	1/12/2016	Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis	Clinical Trial on the Efficacy of Raloxifene on Disease Activity and Glucocorticoid-induced Osteoporosis in Postmenopausal Women With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Raloxifene hydrochloride;Drug: Placebo Oral Tablet	Sara Saeidi Shahri	NULL	Not yet recruiting	50 Years	N/A	Female	40	N/A	NULL
278	NCT02983227 (ClinicalTrials.gov)	November 30, 2016	29/11/2016	A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350	A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: GDC-0853	Genentech, Inc.	NULL	Completed	18 Years	76 Years	All	496	Phase 2	United States;Argentina;Brazil;Bulgaria;Colombia;Mexico;Poland;Russian Federation;Serbia;Ukraine;Chile;Korea, Republic of
279	NCT02986139 (ClinicalTrials.gov)	November 29, 2016	2/11/2016	Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis	A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis	Arthritis, Rheumatoid; Arthritis, Psoriatic	Drug: Commercial Formulation Etanercept;Drug: New Formulation Etanercept	Amgen	NULL	Completed	18 Years	N/A	All	111	Phase 3	United States;Puerto Rico
280	NCT02960490 (ClinicalTrials.gov)	November 26, 2016	3/11/2016	A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics	A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics	Rheumatoid Arthritis	Drug: E6011;Drug: Placebo	Eisai Co., Ltd.	NULL	Completed	18 Years	75 Years	All	64	Phase 2	Japan
281	NCT02874092 (ClinicalTrials.gov)	November 15, 2016	17/8/2016	Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis	Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Ticagrelor;Drug: MTX therapy	NYU Langone Health	NULL	Completed	18 Years	N/A	All	9	Phase 4	United States
282	NCT02996500 (ClinicalTrials.gov)	November 10, 2016	13/10/2016	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE	Rheumatoid Arthritis	Drug: PF-06650833;Drug: Placebo;Drug: Tofacitinib	Pfizer	NULL	Completed	18 Years	75 Years	All	269	Phase 2	United States;Australia;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine
283	NCT02919761 (ClinicalTrials.gov)	November 7, 2016	26/9/2016	Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis	A Multicenter, 2 Part Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease Despite Dual-DMARD Treatment	Arthritis, Rheumatoid	Drug: Acthar Gel;Drug: Placebo	Mallinckrodt	NULL	Completed	18 Years	N/A	All	259	Phase 4	United States;Argentina;Mexico;Peru;Puerto Rico;Colombia
284	NCT02960438 (ClinicalTrials.gov)	November 2, 2016	3/11/2016	A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate	A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate	Rheumatoid Arthritis	Drug: E6011;Drug: Placebo	Eisai Co., Ltd.	NULL	Completed	18 Years	75 Years	All	190	Phase 2	Japan
285	NCT03061838 (ClinicalTrials.gov)	October 27, 2016	20/2/2017	Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®	Multicenter Double-blind Randomized Clinical Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Biosimilar Drug Ritumax® Compared to Original Drug MabThera® in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MabThera ®;Drug: Ritumax®	Biointegrator LLC	NULL	Terminated	18 Years	N/A	All	8	Phase 1	Russian Federation
286	NCT02858492 (ClinicalTrials.gov)	October 17, 2016	20/7/2016	Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	A Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GSK2982772 60 mg;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	All	52	Phase 2	Germany;Italy;Poland;Russian Federation;Spain;United Kingdom
287	NCT03403140 (ClinicalTrials.gov)	October 6, 2016	30/11/2017	Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )	Multicenter Extension Study To 104 Weeks To Asses The Efficacy, Safety And Immunogenicity Of Enerceptan® In Combination With Methotrexate For The Treatment Of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept	Gema Biotech S.A.	QUID Quality in Drugs and Devices Latin American Consulting SRL	Unknown status	19 Years	99 Years	All	141	Phase 3	Argentina
288	NCT02805010 (ClinicalTrials.gov)	October 2016	12/6/2016	Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously	A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects	Rheumatoid Arthritis (RA)	Drug: Abatacept;Other: Placebo	Jiangsu Simcere Pharmaceutical Co., Ltd.	Bristol-Myers Squibb	Active, not recruiting	18 Years	45 Years	Both	22	Phase 1	NULL
289	NCT02037737 (ClinicalTrials.gov)	September 30, 2016	21/11/2013	Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting	Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	153		NULL
290	NCT02885181 (ClinicalTrials.gov)	September 21, 2016	26/8/2016	Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate	Rheumatoid Arthritis	Drug: GS-9876;Drug: Filgotinib;Drug: GS-9876 placebo;Drug: Filgotinib placebo;Drug: Methotrexate	Gilead Sciences	NULL	Completed	18 Years	75 Years	All	83	Phase 2	United States;Bulgaria;Czechia;Georgia;Moldova, Republic of;Poland;Ukraine;Czech Republic;Hungary
291	NCT02884635 (ClinicalTrials.gov)	September 16, 2016	26/8/2016	A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate	Phase IIa Study of ASP1707 A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Phase 2a Study of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)	Rheumatoid Arthritis	Drug: ASP1707;Drug: Placebo;Drug: Methotrexate	Astellas Pharma Inc	NULL	Completed	N/A	N/A	Female	72	Phase 2	Japan
292	NCT02919475 (ClinicalTrials.gov)	September 14, 2016	27/9/2016	Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)	Rheumatoid Arthritis	Drug: JTE-051;Drug: Placebo	Akros Pharma Inc.	NULL	Completed	18 Years	75 Years	All	260	Phase 2	United States;Argentina;Bulgaria;Colombia;Mexico;Peru;Poland;Romania;Russian Federation;Ukraine
293	NCT02833350 (ClinicalTrials.gov)	September 9, 2016	12/7/2016	Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)	A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)	Rheumatoid Arthritis	Drug: GDC-0853;Drug: Adalimumab;Drug: Folic Acid;Drug: MTX;Drug: Placebo	Genentech, Inc.	NULL	Completed	18 Years	75 Years	All	578	Phase 2	United States;Argentina;Brazil;Bulgaria;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;Chile
294	NCT02831855 (ClinicalTrials.gov)	September 1, 2016	11/7/2016	Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis	A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION	Rheumatoid Arthritis	Drug: CP -690,550;Drug: Methotrexate;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	694	Phase 4	United States;Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom
295	NCT03011281 (ClinicalTrials.gov)	September 2016	30/12/2016	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tofacitinib	Hanyang University	NULL	Recruiting	19 Years	N/A	All	378		Korea, Republic of
296	NCT02666443 (ClinicalTrials.gov)	September 2016	24/1/2016	Low Dose Dexamethasone in Supraclavicular Blocks	Low Dose Dexamethasone as an Adjuvant to Supraclavicular Brachial Plexus Blocks: A Prospective Randomized, Double Blinded, Control Study	Rheumatoid Arthritis;Osteoarthritis;Nerve Entrapment;Ligament Injury	Drug: Control intervention (no dexamethasone);Drug: Peri-neural Dexamethasone 1 mg;Drug: Intravenous Dexamethasone 1 mg	University of Calgary	NULL	Recruiting	18 Years	80 Years	Both	306	N/A	Canada
297	NCT02930343 (ClinicalTrials.gov)	September 2016	13/9/2016	Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy	Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid;Drug: Sulfasalazine	Jawaharlal Institute of Postgraduate Medical Education & Research	NULL	Terminated	18 Years	65 Years	All	136	Phase 3	India
298	NCT02897011 (ClinicalTrials.gov)	September 2016	7/9/2016	2-week dc of MTX and Influenza Vaccination in RA	Effect of Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial	Rheumatoid Arthritis;Influenza;Methotrexate	Drug: Methotrexate	Seoul National University Hospital	NULL	Recruiting	18 Years	65 Years	Both	318	N/A	Korea, Republic of
299	NCT02889796 (ClinicalTrials.gov)	August 30, 2016	31/8/2016	Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: Adalimumab;Drug: Placebo to match adalimumab;Drug: MTX	Gilead Sciences	Galapagos NV	Completed	18 Years	N/A	All	1759	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic;France
300	NCT02628028 (ClinicalTrials.gov)	August 22, 2016	9/12/2015	A Study of LY3337641 in Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study	Rheumatoid Arthritis	Drug: LY3337641;Drug: Placebo	Eli Lilly and Company	NULL	Terminated	18 Years	65 Years	All	286	Phase 2	United States;Argentina;Australia;Austria;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Slovakia;South Africa;Spain;Germany
301	NCT02705989 (ClinicalTrials.gov)	August 18, 2016	7/3/2016	Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects	A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects	Rheumatoid Arthritis	Drug: BMS-986195;Other: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	55 Years	All	439	Phase 1	Australia
302	NCT02886728 (ClinicalTrials.gov)	August 8, 2016	29/8/2016	Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy	A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: MTX;Drug: Placebo to match MTX	Gilead Sciences	Galapagos NV	Completed	18 Years	N/A	All	1252	Phase 3	United States;Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic
303	NCT03775824 (ClinicalTrials.gov)	August 1, 2016	11/12/2018	Faecal Analyses in Rheumatoid Arthritis Therapy	Faecal Analyses in Rheumatoid Arthritis Therapy: An Prospective Observational Study of the Intestinal Microbiome in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy	Rheumatoid Arthritis	Drug: MTX start;Drug: TNF start	Region Skane	NULL	Completed	18 Years	N/A	All	50		NULL
304	NCT02722694 (ClinicalTrials.gov)	August 2016	10/3/2016	A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept 125mg Administered Subcutaneously in Chinese Subjects With Active Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis (RA)	Drug: Subcutaneous(SC) Abatacept;Other: Placebo;Drug: Methotrexate	Jiangsu Simcere Pharmaceutical Co., Ltd.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	Both	360	Phase 3	China
305	NCT02892370 (ClinicalTrials.gov)	August 2016	2/9/2016	Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects	An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on SHR0302 and Mass Balance in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302	Jiangsu HengRui Medicine Co., Ltd.	NULL	Recruiting	18 Years	45 Years	Male	14	Phase 1	China
306	NCT02940561 (ClinicalTrials.gov)	August 2016	15/9/2016	BE Study in Patients - Methotrexate Tablets	A Multicenter, Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single-dose, Two-way, Crossover, Bioequivalence Study of Methotrexate Tablets USP, 2.5 mg Manufactured by Amneal Pharmaceuticals, With Methotrexate Tablets USP 2.5 mg Manufactured for DAVA Pharmaceuticals, Inc., Fort Lee, NJ 07024 USA in Patients With Mild to Severe Psoriasis or Rheumatoid Arthritis, Who Are Already on Established Regimens of 2.5 mg Every 12 Hours Under Fasting Condition.	Psoriasis;Rheumatoid Arthritis	Drug: Methotrexate - Amneal;Drug: Methotrexate - DAVA	Amneal Pharmaceuticals, LLC	Accutest Research Laboratories (I) Pvt. Ltd.	Recruiting	18 Years	65 Years	Both	48	Phase 1	India
307	NCT02784106 (ClinicalTrials.gov)	July 31, 2016	24/5/2016	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects With Rheumatoid Arthritis on Stable Methotrexate Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: M2951	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Completed	18 Years	75 Years	All	65	Phase 2	United States;Germany
308	NCT02873936 (ClinicalTrials.gov)	July 27, 2016	17/8/2016	Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment	Rheumatoid Arthritis	Drug: Filgotinib;Drug: Placebo to match filgotinib;Drug: csDMARDs	Gilead Sciences	Galapagos NV	Completed	18 Years	N/A	All	449	Phase 3	United States;Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Japan;Korea, Republic of;Mexico;Poland;Spain;Switzerland;United Kingdom;Italy;Netherlands
309	NCT02867306 (ClinicalTrials.gov)	July 25, 2016	11/8/2016	A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis	A Phase 1 Open-label, Single-sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ASP1707;Drug: methotrexate (MTX)	Astellas Pharma Global Development, Inc.	NULL	Completed	18 Years	65 Years	All	10	Phase 1	Moldova, Republic of
310	NCT02683421 (ClinicalTrials.gov)	July 2016	22/1/2016	Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging	Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging	Rheumatoid Arthritis	Drug: Tilmanocept	Navidea Biopharmaceuticals	NULL	Completed	21 Years	N/A	All	18	Phase 1	United States
311	NCT02585258 (ClinicalTrials.gov)	June 30, 2016	20/10/2015	The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study	The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis	RheumatoId Arthritis	Drug: Prednisolone;Other: Placebo	VU University Medical Center	European Commission	Completed	65 Years	N/A	All	451	Phase 4	Germany;Hungary;Italy;Netherlands;Portugal;Romania;Slovakia;Finland
312	NCT02765074 (ClinicalTrials.gov)	June 30, 2016	19/4/2016	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis	Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizumab in Rheumatoid Arthritis Phase IV Prospective Multicentrique Study	Rheumatoid Arthritis	Drug: subcutaneous tocilizumab	Centre Hospitalier Régional d'Orléans	Rennes University Hospital	Recruiting	18 Years	85 Years	All	60	Phase 4	France
313	NCT03106259 (ClinicalTrials.gov)	June 29, 2016	3/4/2017	Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj	Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj	Rheumatoid Arthritis	Drug: FURESTEM-RA Inj.	Kang Stem Biotech Co., Ltd.	NULL	Active, not recruiting	19 Years	80 Years	All	9	Phase 1	Korea, Republic of
314	NCT02799472 (ClinicalTrials.gov)	June 15, 2016	26/5/2016	Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis	A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs	Arthritis, Rheumatoid	Drug: GSK3196165;Drug: Placebo;Drug: MTX;Drug: Folic (or folinic) acid	GlaxoSmithKline	Parexel	Completed	18 Years	N/A	All	39	Phase 2	United States;Germany;Poland
315	NCT02797769 (ClinicalTrials.gov)	June 2, 2016	8/6/2016	A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)	Risk of Cardiovascular Events in Patients Using Tocilizumab as Compared With Other Biologics in Multiple Large Healthcare Databases	Rheumatoid Arthritis	Drug: Other Biologics;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	48950		NULL
316	NCT02804204 (ClinicalTrials.gov)	June 2016	8/6/2016	Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF	Analysis of Circulant Rheumatoid Factor, Cyclic Citrullinated Anti-peptide Anti-bodies and Albumin as a Potential Predictor in the Response to the Treatment With Anti-TNF in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Anti-TNF	Hospital Universitari Vall d'Hebron Research Institute	UCB Pharma	Unknown status	18 Years	N/A	All	200		Spain
317	NCT02760407 (ClinicalTrials.gov)	May 24, 2016	29/4/2016	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease	A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	Rheumatoid Arthritis	Drug: Olokizumab 64mg q4w;Drug: Olokizumab 64mg q2w;Drug: Adalimumab 40mg q2w;Drug: Placebo q2w	R-Pharm	Quintiles, Inc.;OCT Clinical Trials	Active, not recruiting	18 Years	N/A	All	1575	Phase 3	United States;Argentina;Brazil;Bulgaria;Colombia;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;China;Czech Republic
318	NCT02659150 (ClinicalTrials.gov)	May 18, 2016	21/12/2015	Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis	A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab	Massachusetts General Hospital	Brigham and Women's Hospital	Unknown status	50 Years	75 Years	Female	21	Phase 4	NULL
319	NCT02792699 (ClinicalTrials.gov)	May 17, 2016	25/4/2016	Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab	A Randomized, Double-blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: ABP 798;Drug: Rituximab (US);Drug: Rituximab (EU)	Amgen	NULL	Completed	18 Years	80 Years	All	311	Phase 3	United States;Bulgaria;Estonia;Germany;Hungary;Poland;Canada
320	NCT02780388 (ClinicalTrials.gov)	May 12, 2016	3/5/2016	A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis	A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis	Adult Onset Rheumatoid Arthritis	Drug: VIB4920;Other: Placebo	Viela Bio	NULL	Completed	18 Years	70 Years	All	57	Phase 1	United States;Poland
321	NCT02760316 (ClinicalTrials.gov)	May 2, 2016	25/4/2016	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.	A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control	Rheumatoid Arthritis	Drug: AZD9567 10 mg;Drug: AZD9567 20 mg;Drug: AZD9567 40 mg;Drug: AZD9567 80 mg;Drug: Prednisolone 20 mg;Drug: AZD9567 125 mg;Drug: AZD9567 155 mg;Drug: Prednisolone 5 mg;Drug: Prednisolone 40 mg	AstraZeneca	NULL	Completed	18 Years	55 Years	All	64	Phase 1	Germany;United Kingdom
322	NCT02762123 (ClinicalTrials.gov)	May 2016	3/5/2016	A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates	Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy Subjects	Rheumatoid Arthritis	Drug: BMS-986142 200mg;Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin);Drug: BMS-986142 350mg	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	Both	28	Phase 1	United States
323	NCT02665910 (ClinicalTrials.gov)	May 2016	24/1/2016	Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients	A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.	NULL	Not yet recruiting	18 Years	70 Years	Both	48	Phase 1	China
324	NCT02760368 (ClinicalTrials.gov)	May 2016	29/4/2016	Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy	Rheumatoid Arthritis	Drug: Olokizumab;Drug: Placebo	R-Pharm International, LLC	Quintiles, Inc.;OCT Clinical Trials;Mene Research	Completed	18 Years	N/A	All	428	Phase 3	Belarus;Bulgaria;Russian Federation;Turkey
325	NCT02603146 (ClinicalTrials.gov)	April 27, 2016	10/11/2015	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis	Healthy Participants;Rheumatoid Arthritis (RA) Prevention	Drug: Hydroxychloroquine;Drug: HCQ Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Completed	18 Years	N/A	All	144	Phase 2	United States
326	NCT02746380 (ClinicalTrials.gov)	April 13, 2016	5/4/2016	A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate the Similarity of Efficacy and Safety of LBAL 40mg Subcutaneous Biweekly Injection to Humira® 40mg Subcutaneous Biweekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Arthritis, Rheumatoid	Drug: LBAL;Drug: Humira®	LG Life Sciences	Mochida Pharmaceutical Company, Ltd.	Completed	20 Years	75 Years	All	383	Phase 3	Japan;Korea, Republic of
327	NCT02770794 (ClinicalTrials.gov)	April 1, 2016	11/5/2016	Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis	Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity	Arthritis, Rheumatoid	Drug: Infliximab	Chiba University	NULL	Completed	18 Years	N/A	All	211	Phase 4	Japan
328	NCT02715908 (ClinicalTrials.gov)	April 2016	17/3/2016	A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)	A Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With RA Who Have Completed the Treatment Period of LG-ECCL002	Rheumatoid Arthritis	Drug: LBEC0101	LG Life Sciences	NULL	Completed	20 Years	75 Years	All	148	Phase 3	Korea, Republic of
329	NCT02573012 (ClinicalTrials.gov)	March 29, 2016	1/10/2015	Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants	Prospective, Multicentre, Placebo-controlled, Double-blind Interventional Study to Compare the Efficacy of Maintenance Treatment With Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Placebo matched to prednisone;Drug: Prednisone;Biological: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	314	Phase 4	France;Germany;Italy;Russian Federation;Serbia;Tunisia;Egypt;Switzerland;Turkey
330	NCT02679001 (ClinicalTrials.gov)	March 24, 2016	8/2/2016	A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.	A COMPARATIVE OBSERVATIONAL STUDY FOLLOWING THE USE OF CONCOMITANT CORTICOSTEROID TREATMENT IN RA PATIENTS WHO ARE TREATED WITH A TNF INHIBITOR OR TOCILIZUMAB AS THEIR SECOND BIOLOGICAL TREATMENT	Rheumatoid Arthritis	Drug: TNF inhibitor/TCZ	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	200		Sweden
331	NCT02720523 (ClinicalTrials.gov)	March 22, 2016	22/3/2016	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Rheumatoid Arthritis	Drug: Placebo;Drug: Upadacitinib	AbbVie	NULL	Active, not recruiting	18 Years	N/A	All	197	Phase 2/Phase 3	Japan
332	NCT02706847 (ClinicalTrials.gov)	March 15, 2016	18/2/2016	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)	Rheumatoid Arthritis	Drug: Upadacitinib;Drug: Placebo	AbbVie	NULL	Completed	18 Years	99 Years	All	499	Phase 3	United States;Australia;Austria;Belgium;Canada;Czechia;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Hong Kong;Italy;Mexico;Norway;Slovenia
333	NCT02706873 (ClinicalTrials.gov)	February 23, 2016	18/2/2016	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo to Upadacitinib;Drug: Methotrexate;Drug: Placebo to Methotrexate;Drug: Upadacitinib	AbbVie	NULL	Completed	18 Years	N/A	All	1002	Phase 3	United States;Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Latvia;Lithuania;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;Czech Republic;Finland;Malaysia;Netherlands
334	NCT02698657 (ClinicalTrials.gov)	February 23, 2016	10/2/2016	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate	A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis (RA)	Drug: ASP5094;Drug: Placebo	Astellas Pharma Global Development, Inc.	NULL	Completed	18 Years	65 Years	All	30	Phase 1	United States;Poland
335	NCT02638948 (ClinicalTrials.gov)	February 16, 2016	21/12/2015	Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis	Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors	Rheumatoid Arthritis	Drug: BMS-986142;Drug: Placebo;Drug: Methotrexate	Bristol-Myers Squibb	NULL	Completed	18 Years	120 Years	All	508	Phase 2	United States;Argentina;Austria;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;Belgium
336	NCT02321930 (ClinicalTrials.gov)	February 16, 2016	23/9/2014	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: tofacitinib 5mg po bid	University of California, Los Angeles	NULL	Completed	18 Years	N/A	All	37	Phase 4	United States
337	NCT02683564 (ClinicalTrials.gov)	February 2016	9/2/2016	BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study	A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study	Rheumatoid Arthritis	Drug: BOW015;Drug: Remicade	Epirus Biopharmaceuticals (Switzerland) GmbH	NULL	Not yet recruiting	18 Years	80 Years	Both	548	Phase 3	NULL
338	NCT03355872 (ClinicalTrials.gov)	February 2016	22/11/2017	A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs	A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs	Rheumatoid Arthritis	Drug: HLX01	Shanghai Henlius Biotech	NULL	Completed	18 Years	65 Years	All	194	Phase 1/Phase 2	NULL
339	NCT02626026 (ClinicalTrials.gov)	January 26, 2016	3/12/2015	Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)	A Phase 1, Placebo-Controlled, Randomized Study Evaluating the Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tirabrutinib;Drug: Placebo	Gilead Sciences	Ono Pharmaceutical Co. Ltd	Completed	18 Years	65 Years	All	42	Phase 1	United States
340	NCT02640612 (ClinicalTrials.gov)	January 22, 2016	18/12/2015	Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis	Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab	Arthritis, Rheumatoid	Drug: BI 695501	Boehringer Ingelheim	NULL	Completed	18 Years	80 Years	All	430	Phase 3	United States;Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine
341	NCT02636907 (ClinicalTrials.gov)	January 6, 2016	18/12/2015	Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe	Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe	Arthritis, Rheumatoid	Drug: BI 695501 Autoinjector;Drug: BI 695501 Prefilled syringe	Boehringer Ingelheim	NULL	Completed	18 Years	80 Years	All	77	Phase 2	United States;Poland;Ukraine
342	NCT03855007 (ClinicalTrials.gov)	January 1, 2016	15/2/2019	The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment	Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Iguratimod;Drug: MTX;Drug: HCQ;Drug: Pred	Qilu Hospital of Shandong University	NULL	Active, not recruiting	16 Years	90 Years	All	200	Phase 4	China
343	NCT02652273 (ClinicalTrials.gov)	January 2016	8/1/2016	Inhibition of Co-Stimulation in Rheumatoid Arthritis	Inhibition of Co-Stimulation in Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Abatacept	NHS Greater Glasgow and Clyde	University of Glasgow	Not yet recruiting	18 Years	N/A	Both	25	Phase 4	United Kingdom
344	NCT02878161 (ClinicalTrials.gov)	January 2016	12/7/2016	Predictability Studies on the Efficacy of TNF-a Inhibitors in Chinese RA From Real World	Screening Protein Predictive of Response to Tumor Necrosis Factor-a Inhibitors Treatment in Chinese Rheumatoid Arthritis From Real World and Investigating Its Mechanism Through Signal Pathway	Rheumatoid Arthritis	Drug: methotrexate (necessary);Biological: infliximab;Biological: etanercept;Biological: adalimumab;Drug: leflunomide (permitted, not necessary);Drug: NSAIDs (permitted,not necessary);Drug: Glucocorticoids (permitted,not necessary)	Fen Li	NULL	Enrolling by invitation	18 Years	75 Years	Both	240	Phase 4	NULL
345	NCT02608112 (ClinicalTrials.gov)	December 31, 2015	16/11/2015	Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year	Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	291		France
346	NCT02644499 (ClinicalTrials.gov)	December 31, 2015	30/12/2015	Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis	Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Leflunomide;Drug: Hydroxychloroquine;Drug: Prednisolone;Drug: Folic Acid	Jawaharlal Institute of Postgraduate Medical Education & Research	NULL	Completed	18 Years	N/A	All	186	Phase 4	India
347	NCT02675426 (ClinicalTrials.gov)	December 17, 2015	11/12/2015	A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	Rheumatoid Arthritis	Drug: Placebo;Drug: Upadacitinib	AbbVie	NULL	Active, not recruiting	18 Years	99 Years	All	661	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;Belarus;Brazil;Colombia;Czech Republic;Denmark;Israel;Netherlands;Norway;Serbia;Singapore
348	NCT02680067 (ClinicalTrials.gov)	December 8, 2015	7/12/2015	NIR Fluorescence Imaging of Lymphatic Transport Using ICG	Near InfraRed Fluorescence Imaging of Lymphatic Transport Using Indocyanine Green	Rheumatoid Arthritis	Drug: Indocyanine Green;Device: MultiSpectral Imaging System	University of Rochester	National Institutes of Health (NIH);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	89 Years	All	23	Phase 1	United States
349	NCT02629159 (ClinicalTrials.gov)	December 1, 2015	10/12/2015	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate	A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)	Rheumatoid Arthritis	Drug: Placebo for Adalimumab;Drug: Adalimumab;Drug: Placebo for Upadacitinib;Drug: Upadacitinib	AbbVie	NULL	Active, not recruiting	18 Years	N/A	All	1629	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;Czech Republic;Finland;Netherlands
350	NCT02944799 (ClinicalTrials.gov)	December 2015	27/6/2016	Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis	Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass	Rheumatoid Arthritis;Osteoporosis	Drug: Placebo;Drug: Alendronate;Drug: Calcium;Drug: Vitamin D	University of Aarhus	NULL	Active, not recruiting	18 Years	N/A	All	69	Phase 2	Denmark
351	NCT02557100 (ClinicalTrials.gov)	November 19, 2015	4/9/2015	Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis	A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Abatacept;Drug: Adalimumab;Drug: Methotrexate	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	80	Phase 4	United States;Canada;Mexico;Algeria
352	NCT02512575 (ClinicalTrials.gov)	November 18, 2015	6/7/2015	A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.	A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.	Safety;Tolerability;Pharmacokinetics;Pharmacodynamics;Healthy Subjects;Rheumatoid Arthritis	Drug: AZD9567 Monohydrat;Drug: Placebo oral suspension/ Placebo capsule;Drug: Prednisolone	AstraZeneca	NULL	Completed	18 Years	55 Years	Male	72	Phase 1	Germany
353	NCT03172325 (ClinicalTrials.gov)	November 18, 2015	24/5/2017	Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA	A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active Controlled Clinical Trial to Determine the Non-inferior Efficacy and Safety of CinnoRA® (Adalimumab, CinnaGen Co.) Versus Humira® for Treatment of Active RA	Active Rheumatoid Arthritis	Drug: Adalimumab;Drug: Methotrexate;Drug: Folic Acid;Drug: Prednisolone	Cinnagen	NULL	Completed	18 Years	75 Years	All	136	Phase 3	Iran, Islamic Republic of
354	NCT02780323 (ClinicalTrials.gov)	November 2, 2015	19/5/2016	Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis	A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CELBESTA®;Drug: CELEBREX®;Drug: CELEBREX® placebo;Drug: CELBESTA® placebo	Dong-A ST Co., Ltd.	NULL	Completed	19 Years	N/A	All	119	Phase 4	Korea, Republic of
355	NCT02723760 (ClinicalTrials.gov)	November 2015	10/3/2016	99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	Clinical Study of 99mTc-3PRGD2 SPECT/CT in Diagnosis and Efficacy Evaluation of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 99mTc-3PRGD2	First Affiliated Hospital of Fujian Medical University	NULL	Recruiting	20 Years	70 Years	Both	40	Phase 0	China
356	NCT02534896 (ClinicalTrials.gov)	November 2015	25/8/2015	To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis	To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis	Active Rheumatoid Arthritis	Drug: Treatment I;Drug: Treatment II;Drug: Treatment III	Sun Pharmaceutical Industries Limited	NULL	Terminated	18 Years	90 Years	All	150	Phase 3	Belgium;Netherlands
357	NCT02543931 (ClinicalTrials.gov)	November 2015	6/8/2015	Curcuma Longa L in Rheumatoid Arthritis	Phase Ib Randomized, Double-Blind, Placebo-Controlled Study of Meriva in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Meriva;Drug: placebo	University of Arizona	Vanderbilt University;National Center for Complementary and Integrative Health (NCCIH);National Institutes of Health (NIH)	Terminated	18 Years	N/A	Both	3	Phase 1	United States
358	NCT02552940 (ClinicalTrials.gov)	October 31, 2015	16/9/2015	An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice	A PROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE CLINICAL EFFECTIVENESS, THE CONSISTENCY OF EVALUATION SCORES, QUALITY OF LIFE, SAFETY AND TOLERABILITY OF TOCILIZUMAB SUBCUTANEOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	nv Roche sa	Completed	18 Years	N/A	All	140		Belgium;Luxembourg
359	NCT02534311 (ClinicalTrials.gov)	October 13, 2015	25/8/2015	A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)	Prospective Evaluation of Rheumatoid Arthritis Activity Using DAS28 in Patients Treated With Subcutaneously Administered Tocilizumab on Local Level	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	60	Phase 4	Slovakia
360	NCT02882087 (ClinicalTrials.gov)	October 2015	24/8/2016	A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-a Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis	A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Inadequate Response of TNF-a Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis	Moderate and Severe Rheumatoid Arthritis	Drug: Placebo plus MTX;Drug: RC18 160 mg plus MTX	RemeGen	NULL	Terminated	18 Years	65 Years	All	60	Phase 2	China
361	NCT02320630 (ClinicalTrials.gov)	October 2015	16/12/2014	Combination Therapy Prevents the Relapse of RA	The Efficacy, Safety and Cost-effectiveness of Hydroxychloroquine, Sulfasalazine, Methotrexate Triple Therapy in Preventing Relapse Among Patients With Rheumatoid Arthritis Achieving Clinical Remission or Low Disease Activity	Recurrence (Disease Attribute)	Drug: Entanercept;Drug: HCQ;Drug: MTX	Peking University First Hospital	Peking University People's Hospital;Peking University Third Hospital;Beijing Hospital;Beijing Jishuitan Hospital;Peking University Shougang Hospital;Beijing Shijitan Hospital	Recruiting	18 Years	70 Years	All	240	N/A	China
362	NCT02778789 (ClinicalTrials.gov)	October 2015	16/5/2016	Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers	Non Randomized Parallel-group Clinical Study to Compare the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers.	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: TNF-alpha Inhibitor	University of Erlangen-Nürnberg Medical School	NULL	Completed	18 Years	N/A	All	66		Germany
363	NCT02605642 (ClinicalTrials.gov)	September 10, 2015	2/9/2015	Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade	PERSIST: PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS PERSISTENCE OF CT-P13 (INFLIXIMAB) IN PATIENTS WITH RHEUMATOID DISEASES WHO ARE EITHER NAIVE TO BIOLOGICS OR SWITCHED FROM STABLE REMICADE(R) (INFLIXIMAB)	Rheumatoid Diseases;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: CT-P13	Pfizer	Hospira, now a wholly owned subsidiary of Pfizer	Completed	18 Years	N/A	All	351		Bulgaria;Canada;Czechia;Germany;Greece;Spain;United Kingdom;Czech Republic;France;Italy
364	NCT02504268 (ClinicalTrials.gov)	September 3, 2015	20/7/2015	Effects of Abatacept in Patients With Early Rheumatoid Arthritis	A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Other: Abatacept Placebo;Other: Methotrexate Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	994	Phase 3	United States;Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Singapore;South Africa;Spain;Sweden;Taiwan;United Kingdom;Czech Republic;Puerto Rico;Saudi Arabia;United Arab Emirates
365	NCT05116228 (ClinicalTrials.gov)	September 1, 2015	21/3/2018	Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission	Randomized, Prospective, Active-comparator Controlled, Patient-blinded Study to Demonstrate Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis Patients in Low Disease Activity and Remission - the REDOREM Study	Rheumatoid Arthritis;Remission	Drug: 500mg RTX Group;Drug: 1000mg RTX Group	Medical University of Vienna	NULL	Terminated	18 Years	N/A	All	21	Phase 4	Austria
366	NCT02717988 (ClinicalTrials.gov)	September 2015	4/3/2016	Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers	A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SKI-O-703 capsule;Drug: Placebo capsule	Oscotec Inc.	PPD	Completed	18 Years	55 Years	All	48	Phase 1	United States
367	NCT02535832 (ClinicalTrials.gov)	September 2015	24/8/2015	Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)	Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis;Insulin Resistance	Drug: Pioglitazone;Drug: Placebo	Ohio State University	NULL	Recruiting	35 Years	65 Years	All	36	Phase 1	United States
368	NCT02748785 (ClinicalTrials.gov)	September 2015	8/9/2015	MTX Discontinuation and Vaccine Response	Effect of Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial	Arthritis, Rheumatoid	Drug: Methotrexate;Biological: Seasonal Influenza vaccine	Seoul National University Hospital	NULL	Completed	18 Years	N/A	Both	277	Phase 4	Korea, Republic of
369	NCT02764515 (ClinicalTrials.gov)	September 2015	26/3/2016	Kunxian for the Treatment of Rheumatoid Arthritis	Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Kunxian Capsule;Drug: Methotrexate	Chinese SLE Treatment And Research Group	CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group;CHINESE RHEUMATISM DATA CENTER	Recruiting	40 Years	70 Years	All	428	Phase 4	China
370	NCT02565810 (ClinicalTrials.gov)	September 2015	23/9/2015	An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis	An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab PFS and Pen	Samsung Bioepis Co., Ltd.	NULL	Completed	18 Years	55 Years	All	49	Phase 2	Poland
371	NCT02553018 (ClinicalTrials.gov)	September 2015	16/9/2015	Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe	A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.	Arthritis, Rheumatoid	Drug: Methotrexate	Nordic Pharma SAS	NULL	Completed	18 Years	N/A	All	278	Phase 3	France
372	NCT02481180 (ClinicalTrials.gov)	July 31, 2015	18/6/2015	Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)	An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance?Pharmacokinetics?Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: T0001;Drug: Enbrel	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	NULL	Terminated	18 Years	65 Years	All	36	Phase 1	China
373	NCT02504671 (ClinicalTrials.gov)	July 23, 2015	20/7/2015	Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis	A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate	Arthritis, Rheumatoid	Drug: GSK3196165;Drug: MTX;Drug: Folic acid;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	N/A	All	222	Phase 2	Bulgaria;Canada;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic
374	NCT02467504 (ClinicalTrials.gov)	July 1, 2015	4/6/2015	Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Methotrexate (MTX)-Naive Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: hrIL-2 active;Drug: hrIL-2 placebo;Drug: MTX;Drug: Folic Acid;Drug: Loxoprofen	Peking University People's Hospital	Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd.	Completed	18 Years	70 Years	All	47	Phase 2	China
375	NCT02598466 (ClinicalTrials.gov)	July 2015	4/11/2015	Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa	Patient-Reported Efficacy of Subcutaneous Abatacept in Rheumatoid Arthritis: An Evaluation Of Patients In a Compassionate Use Programme in South Africa	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	Hexor, South Africa	Completed	18 Years	N/A	Both	69	N/A	NULL
376	NCT02242474 (ClinicalTrials.gov)	July 2015	15/9/2014	Anti-TNFa Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis	Prospective Randomized Multicentric Trial on Anti-TNFa Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Anti-TNF suspended perioperatively;Drug: Anti-TNFa continued perioperatively	CHU de Quebec-Universite Laval	NULL	Unknown status	18 Years	N/A	All	660	Phase 4	Canada
377	NCT02480946 (ClinicalTrials.gov)	July 2015	16/6/2015	Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis	A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate	Arthritis, Rheumatoid	Drug: MBS2320;Drug: Placebo;Drug: Methotrexate	Modern Biosciences plc	Covance	Completed	18 Years	70 Years	All	105	Phase 1	United Kingdom
378	NCT02486939 (ClinicalTrials.gov)	July 2015	26/6/2015	A Long Term Safety Extension Study (CHS-0214-05)	An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)	Rheumatoid Arthritis;Plaque Psoriasis	Drug: CHS-0214	Coherus Biosciences, Inc.	Daiichi Sankyo Co., Ltd.;Shire	Completed	18 Years	N/A	All	359	Phase 3	Japan
379	NCT02405780 (ClinicalTrials.gov)	June 10, 2015	17/3/2015	A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients	An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate	Arthritis, Rheumatoid	Drug: FKB327;Drug: Humira®	Fujifilm Kyowa Kirin Biologics Co., Ltd.	NULL	Completed	18 Years	N/A	All	645	Phase 3	United States;Canada;Chile;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;Bulgaria;Czech Republic
380	NCT02402686 (ClinicalTrials.gov)	May 20, 2015	25/3/2015	Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)	Open-Label, Multi-Center, Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab SC Monotherapy in Daily Clinical Practice (SIMPACT)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	353		Hungary
381	NCT02456844 (ClinicalTrials.gov)	May 2015	27/5/2015	Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients	Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects	Rheumatoid Arthritis	Drug: Montelukast , Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate , Leucovorin and BMS-986142	Bristol-Myers Squibb	NULL	Completed	18 Years	50 Years	Both	24	Phase 1	NULL
382	NCT02404558 (ClinicalTrials.gov)	May 2015	26/3/2015	Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis	An Open-label, Randomized, Parallel Group, Single-dose Study to Describe the Safety of IL-6 Receptor Blockade With Sarilumab or Tocilizumab Monotherapy in Japanese Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: tocilizumab	Sanofi	Regeneron Pharmaceuticals	Completed	20 Years	N/A	Both	30	Phase 1	Japan
383	NCT02566967 (ClinicalTrials.gov)	May 2015	1/10/2015	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target	Rheumatoid Arthritis	Drug: tofacitinib	Norman B. Gaylis, MD	NULL	Completed	18 Years	N/A	All	20	Phase 3	United States
384	NCT02460393 (ClinicalTrials.gov)	May 2015	18/1/2015	A Trial With Humanized TNFa Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects	A Randomized, Double Blind, Placebo Controlled Trial With Humanized TNFa Monoclonal Antibody Injection by Single Dose and Dose Escalation to Explore the Tolerance, Safety and Pharmacokinetic Characteristics in Healthy Subjects	Rheumatoid Arthritis	Drug: Humanized TNFa monoclonal antibody;Other: placebo	Shenyang Sunshine Pharmaceutical Co., LTD.	NULL	Completed	18 Years	45 Years	All	72	Phase 1	China
385	NCT02393378 (ClinicalTrials.gov)	April 8, 2015	15/3/2015	Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate	A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate	Rheumatoid Arthritis	Drug: Namilumab;Drug: Adalimumab;Drug: Methotrexate;Drug: Folic Acid	Takeda	NULL	Terminated	18 Years	N/A	All	7	Phase 2	Czechia;Estonia;Russian Federation;Spain;United Kingdom;Czech Republic
386	NCT02423538 (ClinicalTrials.gov)	April 2015	7/4/2015	First-in-Human Single Ascending Dose of SHR0302	A Phase I, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.	NULL	Active, not recruiting	18 Years	45 Years	Both	64	Phase 1	China
387	NCT02800811 (ClinicalTrials.gov)	April 2015	20/5/2016	Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104	Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Intravenous Doses of FR104 in Healthy Subjects	Rheumatoid Arthritis;Complication of Transplant	Drug: FR104;Drug: Placebo	OSE Immunotherapeutics	NULL	Completed	18 Years	60 Years	Both	64	Phase 1	Belgium
388	NCT02387762 (ClinicalTrials.gov)	April 2015	1/3/2015	ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate	A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate	Rheumatoid Arthritis	Drug: acalabrutinib;Drug: Placebo	Acerta Pharma BV	NULL	Completed	18 Years	75 Years	All	31	Phase 2	United States
389	NCT02499315 (ClinicalTrials.gov)	April 2015	10/4/2015	Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 357;Drug: Placebo	Amgen	NULL	Terminated	25 Years	70 Years	Female	32	Phase 1	United States
390	NCT02433340 (ClinicalTrials.gov)	April 2015	2/4/2015	Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study	Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)	Rheumatoid Arthritis	Drug: ABT-122	AbbVie	NULL	Completed	18 Years	99 Years	All	158	Phase 2	Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey
391	NCT02486302 (ClinicalTrials.gov)	March 24, 2015	28/6/2015	A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.	A PROSPECTIVE, MULTICENTER NON-INTERVENTIONAL STUDY TO EVALUATE THE EFFICACY OF ENBREL (REGISTERED) (ETANERCEPT) OVER A PERIOD OF 12 MONTHS IN THE ROUTINE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, OR PLAQUE PSORIASIS WITH PARTICULAR FOCUS ON THE CLINICAL STATUS IMPROVEMENTS STILL OBSERVABLE AFTER 12 WEEKS OF TREATMENT	Rheumatoid Arthritis;Psoriatic Arthritis;Axial Spondyloarthritis;Plaque Psoriasis	Drug: Etanercept	Pfizer	NULL	Completed	18 Years	N/A	All	1534		Germany
392	NCT02304354 (ClinicalTrials.gov)	March 9, 2015	4/11/2014	Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)	Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)	Rheumatoid Arthritis	Drug: Rituximab	University Hospital, Tours	NULL	Completed	18 Years	N/A	All	70	Phase 3	France
393	NCT02620189 (ClinicalTrials.gov)	March 2015	12/10/2015	Th17 Responses Evaluated in RA Patients on Inhibitors of TNFa	A Study to Investigate the Role of IL-17 and Th17 Pathway Activation in RA Patients With Inadequate Response to Anti-TNFa Therapies	Rheumatoid Arthritis	Drug: Anti-TNF Biologics Therapy	Queen Mary University of London	NULL	Completed	18 Years	N/A	All	60		United Kingdom
394	NCT02353780 (ClinicalTrials.gov)	March 2015	30/6/2013	Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept	Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept	Rheumatoid Arthritis (RA)	Drug: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi);Drug: Abatacept;Drug: Tocilizumab	Dr. Larry W. Moreland	Genentech, Inc.;Bristol-Myers Squibb	Terminated	18 Years	64 Years	All	10	Phase 4	United States
395	NCT02638259 (ClinicalTrials.gov)	February 21, 2015	16/12/2015	Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: GP2015	Sandoz	NULL	Completed	18 Years	N/A	All	376	Phase 3	United States;Bulgaria;Czechia;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;Czech Republic
396	NCT02373813 (ClinicalTrials.gov)	February 20, 2015	12/1/2015	Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission	A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: etanercept pre-filled syringe subcutaneous injection;Drug: Oral methotrexate;Drug: Placebo for etanercept subcutaneous injection;Drug: Placebo for methotrexate;Dietary Supplement: Folic acid (non-investigational product)	Amgen	NULL	Completed	18 Years	N/A	All	371	Phase 3	United States;Argentina;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;Czech Republic
397	NCT02357069 (ClinicalTrials.gov)	February 2015	29/1/2015	A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate Similarity of Efficacy and Safety of LBEC0101 50mg Subcutaneous Weekly Injection to Enbrel® 50mg Subcutaneous Weekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Arthritis, Rheumatoid	Drug: Enbrel;Drug: LBEC0101	LG Life Sciences	Mochida Pharmaceutical Company, Ltd.	Active, not recruiting	20 Years	75 Years	Both	372	Phase 3	Japan;Korea, Republic of
398	NCT02373202 (ClinicalTrials.gov)	February 2015	12/2/2015	A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)	A Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Bucillamine;Drug: Tacrolimus;Drug: Mizoribine	Sanofi	Regeneron Pharmaceuticals	Completed	20 Years	N/A	All	91	Phase 3	Japan
399	NCT02633332 (ClinicalTrials.gov)	February 2015	30/11/2015	Use of Well Known Drugs for New Destination - RA Improvement (RANT)	Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used Treatments	Rheumatoid Arthritis;Autoimmune Diseases;Disorder of Synovium;Sjogren's Syndrome;Acute and Chronic Inflammation;Disorder of Pleura and Pleural Cavity;Felty's Syndrome;Rheumatoid Nodules	Drug: Vitamin D3;Drug: Lipitor®;Drug: Acycloguanosine;Drug: Tetracycline;Drug: methotrexate;Drug: etanercept	Università Popolare Homo & Natura	NULL	Completed	18 Years	75 Years	Both	15	Phase 1	Italy
400	NCT02330445 (ClinicalTrials.gov)	February 2015	18/12/2014	6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection	Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers	Arthritis, Rheumatoid	Drug: PRTX-100	Protalex, Inc.	NULL	Completed	18 Years	N/A	All	13	Phase 1/Phase 2	United States
401	NCT02332590 (ClinicalTrials.gov)	January 28, 2015	5/1/2015	Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)	A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Adalimumab;Drug: Placebo (for sarilumab);Drug: Placebo (for adalimumab)	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	369	Phase 3	United States;Chile;Czechia;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic;France
402	NCT02137226 (ClinicalTrials.gov)	January 26, 2015	12/5/2014	BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis	Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial	Arthritis, Rheumatoid	Drug: BI 695501;Drug: US-licensed Humira®	Boehringer Ingelheim	NULL	Completed	18 Years	80 Years	All	645	Phase 3	United States;Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;Argentina;Colombia;Mexico;Philippines;South Africa
403	NCT02927535 (ClinicalTrials.gov)	January 2015	16/9/2016	Evaluation of TNFa Blockers Monotherapy in Early Rheumatoid Arthritis in France		Rheumatoid Arthritis	Drug: TNF blockers monotherapy	Centre Hospitalier Universitaire de Nimes	Pfizer;Pfizer	Completed	18 Years	70 Years	Both	813	N/A	NULL
404	NCT02837978 (ClinicalTrials.gov)	January 2015	13/7/2016	The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment	Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China	Arthritis, Rheumatoid	Drug: Tacrolimus;Drug: MTX	Qiang Shu	NULL	Recruiting	18 Years	80 Years	All	150	Phase 4	China
405	NCT02371096 (ClinicalTrials.gov)	January 2015	5/2/2015	Comparative Pharmacokinetic Trial of RGB-03 and MabThera		Rheumatoid Arthritis	Drug: MabThera (rituximab);Drug: RGB-03	Gedeon Richter Plc.	NULL	Not yet recruiting	18 Years	75 Years	Both		Phase 1	NULL
406	NCT04192617 (ClinicalTrials.gov)	December 31, 2014	5/12/2019	A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate	A Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase II Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severe Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: SM03;Drug: Placebo;Drug: Methotrexate	SinoMab Pty Ltd	NULL	Completed	18 Years	75 Years	All	156	Phase 2	China
407	NCT02379091 (ClinicalTrials.gov)	December 17, 2014	28/11/2014	Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)	A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Namilumab;Drug: Placebo;Drug: Methotrexate;Drug: Folic/folinic acid	Takeda	NULL	Completed	18 Years	N/A	All	108	Phase 2	Bulgaria;Czechia;Japan;Korea, Republic of;Poland;Russian Federation;Spain;United Kingdom;Argentina;Brazil;Colombia;Czech Republic;Germany;Mexico
408	NCT02328027 (ClinicalTrials.gov)	December 11, 2014	18/12/2014	99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)	A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: 99mTc-rhAnnexin V-128	Advanced Accelerator Applications	NULL	Terminated	18 Years	N/A	All	16	Phase 1/Phase 2	Switzerland
409	NCT02260791 (ClinicalTrials.gov)	December 2014	29/7/2014	A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients	A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate	Arthritis, Rheumatoid	Drug: FKB327;Drug: Humira®	Fujifilm Kyowa Kirin Biologics Co., Ltd.	NULL	Completed	18 Years	N/A	All	728	Phase 3	United States;Bulgaria;Canada;Chile;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;Czech Republic;Serbia
410	NCT02876874 (ClinicalTrials.gov)	December 2014	3/2/2015	Relationship Between the Activity of Rheumatoid Arthritis and Lymph Node Morphology and Lymphatics Drainage	the Relationship Between the Activity of Rheumatoid Arthritis(RA) and Popliteal/Epitrochlear Lymph Node Morphology and the Drainage of Hand/Foot Superficial Lymphatic Vessels	Rheumatoid Arthritis;Lymph Node Mass;Lymphatic Vessel; Dilatation	Drug: indocyanine green (ICG)	Shanghai University of Traditional Chinese Medicine	NULL	Recruiting	18 Years	65 Years	Both	21	N/A	China
411	NCT02281552 (ClinicalTrials.gov)	November 18, 2014	30/10/2014	A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate	Rheumatoid Arthritis	Drug: Tofacitinib	Pfizer	NULL	Completed	20 Years	N/A	All	209	Phase 3	Japan
412	NCT02319642 (ClinicalTrials.gov)	November 2014	15/12/2014	An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044	A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.	Rheumatoid Arthritis	Drug: Certolizumab Pegol	UCB Pharma SA	Parexel	Completed	18 Years	N/A	All	347	Phase 3	China
413	NCT02293902 (ClinicalTrials.gov)	November 2014	13/11/2014	A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)	A Randomized, Double-blind, Multicenter Study With a Placebo-controlled Period Assessing the Efficacy and Safety of Sarilumab Added to Methotrexate (MTX) in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy	Rheumatoid Arthritis	Drug: Sarilumab SAR153191 (REGN88);Other: Placebo (for sarilumab);Drug: Methotrexate;Drug: Folic acid	Sanofi	Regeneron Pharmaceuticals	Completed	20 Years	75 Years	All	243	Phase 3	Japan
414	NCT02551575 (ClinicalTrials.gov)	November 2014	26/8/2015	Efficacy and Safety of Traditional Chinese Medicine (TCM) Comprehensive Therapy in Patients With Rheumatoid Arthritis	Efficacy and Safety of Qingre Huoxue Comprehensive Therapy in the Treatment of Rheumatoid Arthritis (RA): A Randomized, Double-blind, Double-dummy, Multi-center Trial	Rheumatoid Arthritis	Drug: Treatment of MTX and HCQ;Drug: Treatment of TCM;Drug: Integrative Medicine	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Active, not recruiting	18 Years	65 Years	Both	468	Phase 2/Phase 3	China
415	NCT02287610 (ClinicalTrials.gov)	November 2014	6/11/2014	A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis	A Non-Interventional Study to Evaluate the Effectiveness of Delayed-Release Prednisone (RAYOS) on Clinical Assessments and Serologic Disease Activity in Patients With Active Rheumatoid Arthritis in the Clinical Practice Setting	Rheumatoid Arthritis	Drug: RAYOS (delayed-release prednisone)	Horizon Pharma Ireland, Ltd., Dublin Ireland	NULL	Completed	18 Years	N/A	All	75	N/A	NULL
416	NCT02342977 (ClinicalTrials.gov)	November 2014	18/12/2014	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.	Osteoarthritis;Rheumatoid Arthritis;Avascular Necrosis	Drug: Placebo;Drug: Lacosamide	Indiana University School of Medicine	VA Office of Research and Development	Withdrawn	18 Years	70 Years	Both	0	Phase 2	United States
417	NCT02030028 (ClinicalTrials.gov)	November 2014	6/1/2014	ACTH Gel Therapy in Rheumatoid Arthritis	Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ACTHAR gel	Dana Ascherman	Mallinckrodt	Completed	18 Years	100 Years	All	20	N/A	United States
418	NCT02270632 (ClinicalTrials.gov)	October 1, 2014	16/10/2014	A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.	Rheumatoid Arthritis	Drug: F8IL10;Drug: MTX;Drug: Placebo	Philogen S.p.A.	NULL	Active, not recruiting	18 Years	74 Years	All	27	Phase 2	Germany;Italy;Switzerland
419	NCT02265705 (ClinicalTrials.gov)	October 2014	13/10/2014	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Baricitinib;Drug: Placebo	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	290	Phase 3	Argentina;Brazil;China
420	NCT02500498 (ClinicalTrials.gov)	October 2014	15/7/2015	Safety Profile of Nulojix in Home Infusion Settings	Safety Profile of Nulojix in Home Infusion Settings	Rheumatoid Arthritis	Drug: Nulojix	Bristol-Myers Squibb	BiologicTx, LLC	Completed	18 Years	N/A	Both	37	N/A	NULL
421	NCT02148640 (ClinicalTrials.gov)	October 2014	23/5/2014	The NOR-SWITCH Study	A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY	Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis;Ulcerative Colitis;Crohn's Disease;Psoriasis Chronic	Drug: Innovator infliximab;Drug: Biosimilar infliximab	Diakonhjemmet Hospital	South-Eastern Norway Regional Health Authority	Completed	18 Years	N/A	All	482	Phase 4	Norway
422	NCT02150473 (ClinicalTrials.gov)	October 2014	27/2/2014	The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients	Delayed Gadolinium-enhanced Magnetic Resonance (MR) Imaging of Cartilage - A Pilot Study to Measure the Effect of Adalimumab Plus MTX Versus Placebo Plus MTX on Cartilage in Early RA Patients	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Placebo	Heinrich-Heine University, Duesseldorf	Abbott	Terminated	18 Years	80 Years	All	21	Phase 3	Germany
423	NCT02102594 (ClinicalTrials.gov)	October 2014	25/3/2014	Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)	Myasthenia Gravis;Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: Bortezomib	Charite University, Berlin, Germany	Prof. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology);NeuroCure Clinical Research Center, Charite, Berlin	Terminated	18 Years	75 Years	All	11	Phase 2	Germany
424	NCT02097264 (ClinicalTrials.gov)	September 2014	24/3/2014	A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Randomised, Active Comparator, Double-blind, Multi Centre, Parallel, Phase 2a Trial, Investigating the Mechanism of Action, of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Inflammation;Rheumatoid Arthritis	Drug: NNC0109-0012;Drug: Adalimumab;Drug: placebo	Novo Nordisk A/S	NULL	Withdrawn	18 Years	75 Years	Both	0	Phase 2	Ireland;Portugal;Spain;United Kingdom
425	NCT01717859 (ClinicalTrials.gov)	September 2014	19/10/2012	Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab	Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab	Rheumatoid Arthritis	Drug: Tocilizumab	University of California, Los Angeles	Genentech, Inc.	Completed	18 Years	N/A	All	74	Phase 4	United States
426	NCT02202837 (ClinicalTrials.gov)	August 12, 2014	15/7/2014	Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice	Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Rheumatoid Arthritis Patients Treated With Etanercept (Enbrel (Registered))	Rheumatoid Arthritis	Drug: etanercept	Pfizer	NULL	Completed	18 Years	N/A	All	157		Belgium
427	NCT02308163 (ClinicalTrials.gov)	August 8, 2014	2/12/2014	A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs	Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs	Rheumatoid Arthritis	Drug: Peficitinib;Drug: Placebo;Biological: Etanercept	Astellas Pharma Inc	NULL	Completed	20 Years	N/A	All	509	Phase 3	Japan;Korea, Republic of;Taiwan
428	NCT02219191 (ClinicalTrials.gov)	August 2014	16/7/2014	Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases	The Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases	Rheumatoid Arthritis	Drug: puerarin tablet 50 mg;Drug: Atorvastatin tablet 20 mg	Chengdu PLA General Hospital	NULL	Active, not recruiting	18 Years	75 Years	All	150	N/A	China
429	NCT02187055 (ClinicalTrials.gov)	August 2014	8/7/2014	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis	Rhematoid Arthritis	Drug: Tofacitinib with methotrexate;Drug: Tofacitinib without methotrexate;Biological: Adalimumab with methotrexate	Pfizer	NULL	Completed	18 Years	N/A	All	1152	Phase 4	United States;Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Czechia;Estonia;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;Croatia;Czech Republic;France
430	NCT02264301 (ClinicalTrials.gov)	August 2014	3/10/2014	Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis	The Effect of Qingkailing Injection on Corticosteroids Withdrawal Rate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Puerarin injection 400 mg;Drug: Qingkailing injection 40 ml	Chengdu PLA General Hospital	NULL	Enrolling by invitation	18 Years	75 Years	All	150	N/A	China
431	NCT04752748 (ClinicalTrials.gov)	August 2014	10/2/2021	Power Doppler in Hand Joints of Early RA Patients	Power Doppler in Hand Joints is a Predictor of Therapeutic Failure in Women With Early Rheumatoid Arthritis Naive for Treatment	Early Rheumatoid Arthritis	Drug: Drug protocol	Federal University of São Paulo	NULL	Completed	18 Years	65 Years	Female	48		NULL
432	NCT02176876 (ClinicalTrials.gov)	August 2014	25/6/2014	Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis	A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: GS-5745;Drug: Placebo to match GS-5745	Gilead Sciences	NULL	Completed	18 Years	70 Years	Both	18	Phase 1	Czech Republic;Hungary
433	NCT02234960 (ClinicalTrials.gov)	August 2014	5/9/2014	Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)	TOCILIZUMAB IN FIRST LINE BIOLOGIC TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE IN POLAND - MULTICENTER, NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY (ACT-POL)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	102	N/A	Poland
434	NCT02219347 (ClinicalTrials.gov)	August 2014	15/8/2014	Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)	Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)	Rheumatoid Arthritis	Drug: DMARD cessation	Newcastle-upon-Tyne Hospitals NHS Trust	Newcastle University;Wellcome Trust	Completed	18 Years	N/A	All	74	N/A	United Kingdom
435	NCT02211469 (ClinicalTrials.gov)	August 2014	6/8/2014	A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects	A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects	Rheumatoid Arthritis	Drug: BMS-986104;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	49 Years	Male	41	Phase 1	United States
436	NCT02305849 (ClinicalTrials.gov)	July 25, 2014	1/12/2014	A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment	Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX	Rheumatoid Arthritis	Drug: Peficitinib;Drug: Placebo;Drug: Methotrexate	Astellas Pharma Inc	NULL	Completed	20 Years	N/A	All	519	Phase 3	Japan
437	NCT02053727 (ClinicalTrials.gov)	July 2014	6/11/2013	Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background	Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.	Rheumatoid Arthritis;Chronic Hepatitis B	Drug: Abatacept;Drug: Placebo	University of California, Los Angeles	NULL	Withdrawn	18 Years	N/A	All	0	N/A	United States
438	NCT02011334 (ClinicalTrials.gov)	July 2014	4/12/2013	A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.	A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	285	Phase 3	Argentina;Brazil;Colombia;Dominican Republic;Mexico;Venezuela;Ecuador;Uruguay
439	NCT01984268 (ClinicalTrials.gov)	June 2014	8/11/2013	ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Adenocorticotrophic Hormone for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: ACTHAR	Dartmouth-Hitchcock Medical Center	Mallinckrodt	Recruiting	18 Years	70 Years	Both	60	Phase 2	United States
440	NCT02147587 (ClinicalTrials.gov)	June 2014	22/5/2014	A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate	A Randomized, Double-blind, Placebo-controlled, Phase 2 Study To Assess The Immune Response Following Administration Of Zoster Vaccine To Subjects With Rheumatoid Arthritis Receiving Tofacitinib (Cp-690,550) Or Placebo With Background Methotrexate Treatment	Rheumatoid Arthritis	Drug: Tofacitinib;Drug: Placebo	Pfizer	NULL	Completed	50 Years	N/A	All	112	Phase 2	United States;United Kingdom
441	NCT02121210 (ClinicalTrials.gov)	June 2014	21/4/2014	To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)	An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	132	Phase 3	United States;Chile;Czechia;Estonia;Hungary;Poland;Russian Federation;Czech Republic
442	NCT02202395 (ClinicalTrials.gov)	June 2014	23/7/2014	Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: LTS 0.25mg;Drug: LTS 0.5mg;Drug: LTS 1.0mg;Drug: Placebo	Shanghai Pharmaceuticals Holding Co., Ltd	NULL	Completed	35 Years	65 Years	Female	120	Phase 1/Phase 2	China
443	NCT02046616 (ClinicalTrials.gov)	May 28, 2014	24/1/2014	A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)	Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-Arm, Open-Label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will Be Measured by Ultrasound.	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Methotrexate;Drug: Non-Biologic DMARDs	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	133	Phase 3	Denmark;Finland;Norway;Sweden
444	NCT02196558 (ClinicalTrials.gov)	May 26, 2014	16/7/2014	A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis	A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: E6011	Eisai Co., Ltd.	NULL	Completed	20 Years	64 Years	All	53	Phase 1/Phase 2	Japan
445	NCT02115750 (ClinicalTrials.gov)	May 2014	14/4/2014	Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate	Rheumatoid Arthritis	Drug: Etanercept;Drug: CHS-0214	Coherus Biosciences, Inc.	Daiichi Sankyo Co., Ltd.	Completed	18 Years	N/A	All	647	Phase 3	United States;Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom
446	NCT02927509 (ClinicalTrials.gov)	May 2014	15/9/2016	Evaluation of Tumour Necrosis Factor Alpha (TNFa) Blockers in Early Rheumatoid Arthritis in France		Rheumatoid Arthritis	Drug: TNF alpha blockers	Centre Hospitalier Universitaire de Nimes	Pfizer;Pfizer	Completed	18 Years	70 Years	Both	813	N/A	NULL
447	NCT02157012 (ClinicalTrials.gov)	May 2014	1/6/2014	Evaluation of the Condition of Rheumatoid Arthritis After Treatment	Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: The effectiveness of Xeljanz in rheumatoid arthritis patients	Shinshu University	Showa Inan General Hospital	Recruiting	20 Years	90 Years	All	100	Phase 4	Japan
448	NCT02087696 (ClinicalTrials.gov)	May 2014	6/3/2014	Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis	Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy	Arthritis, Rheumatoid	Drug: Tocilizumab	Spanish Foundation of Rheumatology	Roche Farma, S.A	Recruiting	18 Years	N/A	Both	122	Phase 4	Spain
449	NCT02151474 (ClinicalTrials.gov)	May 2014	28/5/2014	INCB047986 in Rheumatoid Arthritis	A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: INCB047986;Drug: Placebo	Incyte Corporation	NULL	Recruiting	18 Years	N/A	Both	60	Phase 2	United States
450	NCT02105129 (ClinicalTrials.gov)	May 2014	19/3/2014	A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523	Rheumatoid Arthritis (RA)	Drug: HMPL-523;Drug: Placebo	Hutchison Medipharma Limited	NULL	Completed	18 Years	45 Years	Male	118	Phase 1	Australia
451	NCT02123264 (ClinicalTrials.gov)	May 2014	23/4/2014	Zoledronic Acid in Rheumatoid Arthritis	Randomized Clinical Trial on the Prevention of Radiographic Progression With Zoledronic Acid in Patients With Early Rheumatoid Arthritis and Low Disease Activity	Arthritis, Rheumatoid	Drug: Zoledronic acid	Carmen Gómez-Vaquero	NULL	Terminated	18 Years	N/A	All	28	Phase 3	Spain
452	NCT02167139 (ClinicalTrials.gov)	May 2014	16/6/2014	A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Humira (adalimumab);Drug: SB5 (proposed biosimilar to adalimumab)	Samsung Bioepis Co., Ltd.	NULL	Completed	18 Years	75 Years	All	544	Phase 3	Lithuania;Poland
453	NCT04582084 (ClinicalTrials.gov)	April 4, 2014	3/10/2020	Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis	Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): a Multicenter Post-marketing Surveillance Study	Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: Etanercept	AryoGen Pharmed Co.	NULL	Completed	18 Years	N/A	All	583		Iran, Islamic Republic of
454	NCT02109289 (ClinicalTrials.gov)	April 2014	3/4/2014	Etanercept in Rheumatoid Arthritis and Vascular Inflammation	Pilot Open-label Study of the Effect of Etanercept on Vascular Inflammation in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis;Vascular Inflammation	Drug: etanercept	Innovaderm Research Inc.	NULL	Terminated	18 Years	80 Years	All	5	Phase 4	Canada
455	NCT02066389 (ClinicalTrials.gov)	March 26, 2014	17/2/2014	A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone	Rheumatoid Arthritis	Drug: Placebo;Drug: Upadacitinib	AbbVie	NULL	Completed	18 Years	100 Years	All	300	Phase 2	United States;Bulgaria;Chile;Czechia;Hungary;Israel;Latvia;Mexico;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;Czech Republic;Romania;Serbia
456	NCT02092467 (ClinicalTrials.gov)	March 14, 2014	3/3/2014	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS	Arthritis, Rheumatoid	Drug: tofacitinib;Biological: adalimumab;Biological: etanercept	Pfizer	NULL	Completed	50 Years	N/A	All	4372	Phase 4	United States;Argentina;Australia;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;Austria;Czech Republic;Sweden
457	NCT02046603 (ClinicalTrials.gov)	March 4, 2014	24/1/2014	A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent	Open-Label, Phase IIIb Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab Monotherapy or Combination Therapy With Methotrexate (MTX) or Other Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Patients With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-Tumour Necrosis Factor (Anti-TNF) Biologic Agent	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: DMARDs;Drug: Oral Corticosteroids;Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	162	Phase 3	United Kingdom
458	NCT02057250 (ClinicalTrials.gov)	March 2014	31/1/2014	To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy	RA	Drug: Sarilumab;Device: Auto-Injector Device (AID);Device: Pre-filled Syringe (PFS);Drug: Methotrexate;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Hydroxychloroquine	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	217	Phase 3	United States;Chile;Mexico;Poland;Russian Federation;South Africa;France
459	NCT02097524 (ClinicalTrials.gov)	March 2014	3/3/2014	Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)		Rheumatoid Arthritis	Drug: Sarilumab;Drug: Tocilizumab	Regeneron Pharmaceuticals	Sanofi	Completed	18 Years	N/A	Both	105	Phase 1	United States
460	NCT02029599 (ClinicalTrials.gov)	March 2014	26/12/2013	The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis	A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Fang yi qing feng shi granule;Drug: placebo;Drug: Methotrexate;Drug: Acetaminophen tablets	Maoxiang Group Jilin Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	65 Years	Both	240	Phase 2	China
461	NCT02065700 (ClinicalTrials.gov)	February 25, 2014	14/2/2014	Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients	A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Filgotinib	Galapagos NV	Gilead Sciences	Completed	18 Years	N/A	All	739	Phase 2	United States;Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;Czech Republic
462	NCT02434757 (ClinicalTrials.gov)	February 2014	30/4/2015	Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis	Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: H.P. Acthar Gel	Ronald J. Rapoport, MD	Questcor Pharmaceuticals, Inc.	Recruiting	18 Years	N/A	Both	10	N/A	United States
463	NCT02169544 (ClinicalTrials.gov)	January 31, 2014	14/5/2014	Post-marketing Study Assessing the Long-Term Safety of Abatacept	Post-marketing Study Assessing the Long-Term Safety of Abatacept	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	100000	N/A	NULL
464	NCT01987479 (ClinicalTrials.gov)	January 30, 2014	8/11/2013	A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis	Multi-Center, Open Label, Single Arm Phase IIIB Study on Safety and Efficacy of Subcutaneous Tocilizumab in Monotherapy or in Combination With Methotrexate or Other Non-Biologic Disease Modifying Antirheumatic Drugs in Rheumatoid Arthritis Patients With an Inadequate Response to Non-Biologic DMARDs - OSCAR	Rheumatoid Arthritis	Drug: Non-Biologic DMARDs;Drug: Tocilizumab;Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	150	Phase 3	Netherlands
465	NCT02049138 (ClinicalTrials.gov)	January 24, 2014	28/1/2014	An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects	A Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)	Rheumatoid Arthritis	Drug: ABT-494	AbbVie	NULL	Completed	18 Years	100 Years	All	494	Phase 2	New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;Belgium;Bulgaria;Chile;Czechia;Hungary;Israel;Latvia;Mexico;United States;Australia;Czech Republic
466	NCT01988506 (ClinicalTrials.gov)	January 6, 2014	7/11/2013	Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases	Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach	Rheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic Sclerosis	Drug: Interleukin 2	Assistance Publique - Hôpitaux de Paris	Iltoo Pharma	Completed	18 Years	N/A	All	81	Phase 2	France
467	NCT02000336 (ClinicalTrials.gov)	January 2014	19/11/2013	Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis	Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial	Progression of Rheumatoid Arthritis	Drug: Prednisolone;Drug: Placebo	Prof. Dr. rer. nat. H.J. Trampisch	Ruhr University of Bochum	Completed	18 Years	N/A	All	395	Phase 3	Germany
468	NCT02017639 (ClinicalTrials.gov)	January 2014	2/12/2013	Sarilumab Effect on the Pharmacokinetics of Simvastatin	A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: simvastatin	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	75 Years	Both	19	Phase 1	United States;Korea, Republic of;Moldova, Republic of
469	NCT02031471 (ClinicalTrials.gov)	January 2014	16/12/2013	TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment	TOSCARA: An Open-label, Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Tocilizumab (TCZ) Subcutaneous in TCZ-naïve Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	57	Phase 3	Belgium;Luxembourg
470	NCT02001987 (ClinicalTrials.gov)	January 2014	29/11/2013	A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy	A Multi-Center Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Tocilizumab in Tocilizumab-Naive Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARD and/or Biologic Therapy	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Methotrexate;Drug: csDMARDs	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	139	Phase 3	France
471	NCT01668966 (ClinicalTrials.gov)	December 9, 2013	16/8/2012	A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)	A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Months	N/A	All	23	Phase 3	Brazil
472	NCT02056184 (ClinicalTrials.gov)	December 2013	30/1/2014	Targeted Ultrasound in Rheumatoid Arthritis	Targeted Ultrasound in Rheumatoid Arthritis	Rheumatoid Arthritis;Targeted Ultrasound	Drug: Adalimumab	University of Leeds	AbbVie;Theorem	Completed	18 Years	N/A	All	183	Phase 4	United Kingdom
473	NCT02047604 (ClinicalTrials.gov)	December 2013	22/1/2014	(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).	Rheumatoid Arthritis	Drug: SAN-300 0.5 mg/kg QW;Drug: SAN-300 1.0 mg/kg QW;Drug: SAN-300 2.0 mg/kg QOW;Drug: SAN-300 4.0 mg/kg QOW;Drug: SAN-300 4.0 mg/kg QW;Drug: Placebo	Bausch Health Americas, Inc.	NULL	Completed	18 Years	75 Years	All	41	Phase 2	United States
474	NCT03736044 (ClinicalTrials.gov)	November 25, 2013	11/10/2018	Reconstitution of CD4+CD25highCD127low/-Tcell	Analysis of T Cell Population to Obtain a Free-drug Remission in Patients Affected by Rheumatoid Athritis in Remission Phase Induced by TNF-blocker Therapy	Rheumatoid Arthritis	Drug: TNF-blockers suspension in patients with rheumatoid arthritis	University Hospital of Ferrara	NULL	Completed	18 Years	N/A	All	48	Phase 1	NULL
475	NCT01941095 (ClinicalTrials.gov)	November 20, 2013	30/8/2013	A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis	Multicenter, Open Label, Phase IIIb Study to Evaluate the Safety and Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Azathioprine;Drug: Chloroquine;Drug: Hydroxychloroquine;Drug: Leflunomide;Drug: Methotrexate;Drug: Sulfasalazine;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	100	Phase 3	Greece
476	NCT01855789 (ClinicalTrials.gov)	November 2013	14/5/2013	A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: Placebo;Drug: Tocilizumab;Drug: methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	718	Phase 3	United States
477	NCT02254655 (ClinicalTrials.gov)	November 2013	18/11/2013	The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis	The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis, a Controlled and Randomized Trial	Rheumatoid Arthritis	Drug: Puerarin injection 400 mg;Drug: Control	Chengdu PLA General Hospital	NULL	Completed	18 Years	75 Years	All	119	Phase 2	China
478	NCT02293590 (ClinicalTrials.gov)	November 2013	30/10/2014	RICE: Remission by Intra-articular Injection Plus CErtolizumab	An Open Label, Randomised Study to Compare the Efficacy of Certolizumab Pegol (CZP) Plus a Dynamic or Fixed Dose Treatment Strategy in Patients With Rheumatoid Arthritis, a Phase II Study	Rheumatoid Arthritis	Drug: Certolizumab Pegol	Rüdiger B. Müller	UCB Pharma	Completed	18 Years	N/A	All	43	Phase 2	Switzerland
479	NCT01990157 (ClinicalTrials.gov)	November 2013	5/11/2013	Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis	Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis in Which Methotrexate (MTX) Treatment is Not Effective	Rheumatoid Arthritis	Drug: TAB08	Theramab LLC	NULL	Completed	18 Years	65 Years	All	18	Phase 1/Phase 2	Russian Federation
480	NCT02027298 (ClinicalTrials.gov)	November 2013	18/11/2013	Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study	Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study	Primary Sjogren's Syndrome;Secondary Sjogren's Syndrome;Inflammatory Arthritis;Rheumatoid Arthritis	Drug: Abatacept	The Cleveland Clinic	Bristol-Myers Squibb	Withdrawn	18 Years	N/A	All	0	Phase 2	United States
481	NCT02005757 (ClinicalTrials.gov)	November 2013	4/12/2013	Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)	Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug	Rheumatoid Arthritis	Drug: Bredinin tablet 150mg;Drug: Bredinin tablet 50mg	Chong Kun Dang Pharmaceutical	NULL	Recruiting	20 Years	80 Years	Both	60	Phase 2	Korea, Republic of
482	NCT01951170 (ClinicalTrials.gov)	November 2013	23/9/2013	An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis	An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	52	Phase 3	Australia
483	NCT01894516 (ClinicalTrials.gov)	October 8, 2013	4/7/2013	Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone	Rheumatoid Arthritis	Drug: GLPG0634;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	N/A	All	287	Phase 2	United States;Argentina;Australia;Austria;Bulgaria;Chile;Colombia;Germany;Guatemala;Hungary;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine
484	NCT01962337 (ClinicalTrials.gov)	October 2013	10/10/2013	A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis	A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis	Healthy;Rheumatoid Arthritis	Drug: FPA008;Drug: Placebo	Five Prime Therapeutics, Inc.	NULL	Terminated	21 Years	70 Years	All	66	Phase 1	Hungary;Netherlands;Poland
485	NCT01973569 (ClinicalTrials.gov)	October 2013	25/10/2013	AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment	A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)	Rheumatoid Arthritis	Drug: denosumab;Drug: placebo	Daiichi Sankyo, Inc.	NULL	Completed	20 Years	N/A	All	679	Phase 3	Japan
486	NCT01999192 (ClinicalTrials.gov)	October 2013	17/11/2013	Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis	A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)	Rheumatoid Arthritis	Drug: Tregalizumab;Drug: Placebo	Biotest	AbbVie	Terminated	18 Years	75 Years	All	321	Phase 2	United States;Bulgaria;Canada;Czechia;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Ukraine;Czech Republic;Sweden
487	NCT01960855 (ClinicalTrials.gov)	October 2013	9/10/2013	A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy	Rheumatoid Arthritis	Drug: ABT-494;Drug: Placebo	AbbVie	NULL	Completed	18 Years	N/A	All	276	Phase 2	Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;New Zealand;Poland;Puerto Rico;Spain;United Kingdom;United States
488	NCT01966718 (ClinicalTrials.gov)	October 2013	14/10/2013	Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.	Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action	Rheumatoid Arthritis	Drug: Repository corticotropin injection	Arthritis Treatment Center, Maryland	NULL	Completed	18 Years	80 Years	All	8	Phase 4	United States
489	NCT01773681 (ClinicalTrials.gov)	October 2013	16/1/2013	Novel Imaging Markers for Rheumatoid Arthritis	Novel Imaging Markers for Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Cimzia;Device: Magnetic Resonance Imaging (MRI);Device: High-resolution peripheral quantitative computed tomography (HR-pQCT)	University of California, San Francisco	NULL	Completed	18 Years	N/A	All	30		United States
490	NCT01975610 (ClinicalTrials.gov)	October 2013	29/10/2013	Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis	A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CC -292;Drug: Placebo	Celgene	NULL	Completed	18 Years	80 Years	Female	47	Phase 2	United States
491	NCT01907230 (ClinicalTrials.gov)	September 10, 2013	14/7/2013	Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients	Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial	Rheumatoid Arthritis;Hepatitis B Reactivation;Exposure to Hepatitis B Virus	Drug: Entecavir	Taipei Veterans General Hospital, Taiwan	NULL	Active, not recruiting	20 Years	90 Years	All	115	Phase 4	Taiwan
492	NCT01941940 (ClinicalTrials.gov)	September 5, 2013	2/9/2013	A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants	A National, Open-Label, Single-Arm, Phase IIIb Study to Evaluate the Efficacy of Weekly Tocilizumab Subcutaneous, Administered as Monotherapy or in Combination With Methotrexate and/or Other DMARDs in Rheumatoid Arthritis (RA) Patients	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: DMARDs	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	227	Phase 3	Italy
493	NCT02072200 (ClinicalTrials.gov)	September 2013	14/2/2014	Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)	A New Modified-Release Tablet Formulation of Prednisone in Patients With Rheumatoid Arthritis- Multicenter, Phase IV, Interventional Study to Assess Reduction of Morning Stiffness	Rheumatoid Arthritis	Drug: Lodotra®	Mundipharma Korea Ltd	NULL	Completed	20 Years	80 Years	All	147	Phase 4	Korea, Republic of
494	NCT02600468 (ClinicalTrials.gov)	September 2013	6/11/2015	Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg	Outline of Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg	Rheumatoid Arthritis	Drug: Orencia	Bristol-Myers Squibb	Ono Pharmaceutical Co. Ltd	Completed	18 Years	N/A	All	671	N/A	NULL
495	NCT01955603 (ClinicalTrials.gov)	September 2013	24/9/2013	A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis	A Randomised, Placebo-controlled, Double-blind Within Cohort, Dose Escalation, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered Subcutaneously to Subjects With Moderate to Severe Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0215-0384;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	Both	24	Phase 1	Germany;Hungary;Poland;Russian Federation
496	NCT01787149 (ClinicalTrials.gov)	September 2013	6/2/2013	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis	Combination With DMARDs	Drug: DMARDs	Mycenax Biotech Inc.	NULL	Unknown status	20 Years	N/A	All	98	Phase 3	Taiwan
497	NCT02275299 (ClinicalTrials.gov)	September 2013	23/10/2014	Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Iguratimod;Drug: Leflunomide;Drug: Methotrexate	Jiangsu Simcere Pharmaceutical Co., Ltd.	NULL	Recruiting	18 Years	70 Years	Both	240	Phase 4	China
498	NCT01948388 (ClinicalTrials.gov)	September 2013	9/9/2013	The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients	Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging	Rheumatoid Arthritis	Drug: corticotrophin 80 units	Gaylis, Norman B., M.D.	NULL	Completed	18 Years	N/A	All	20	Phase 4	United States
499	NCT01995201 (ClinicalTrials.gov)	September 2013	1/11/2013	A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis	A Phase IIIb Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous (SC) Tocilizumab (TCZ) Given as Monotherapy or in Combination With Methotrexate (MTX) or Other Non Biologics DMARDs in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: DMARD;Drug: methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	N/A	Both	401	Phase 3	Ireland;Portugal;Spain
500	NCT02600455 (ClinicalTrials.gov)	September 2013	6/11/2015	Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL	Outline of Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL	Rheumatoid Arthritis	Drug: Orencia	Bristol-Myers Squibb	Ono Pharmaceutical Co. Ltd	Completed	18 Years	N/A	All	505	N/A	Japan
501	NCT01783015 (ClinicalTrials.gov)	September 2013	31/1/2013	Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate	A Randomized, Double-blind, Placebo-controlled Study Of The Safety And Efficacy Of Etanercept In Subjects With Rheumatoid Arthritis Who Have Had An Inadequate Response To Adalimumab Or Infliximab Plus Methotrexate	Rheumatoid Arthritis	Drug: Etanercept;Drug: Placebo	Pfizer	NULL	Terminated	18 Years	79 Years	All	16	Phase 4	Australia;Belgium;France;Hong Kong;Israel;Russian Federation;Spain;Netherlands
502	NCT01856309 (ClinicalTrials.gov)	August 7, 2013	15/5/2013	Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003	A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)	Arthritis, Rheumatoid	Drug: Sirukumab 100 mg;Drug: Sirukumab 50 mg;Drug: Placebo	Janssen Research & Development, LLC	GlaxoSmithKline	Completed	18 Years	N/A	All	1820	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;France;Germany;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom
503	NCT01905735 (ClinicalTrials.gov)	August 2013	19/7/2013	A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis	A Multicentric,Double-blind,Placebo Controlled,Phase-2 Study to Assess the Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis .	Rheumatoid Arthritis.	Drug: Rhustoxicodendron 30;Drug: placebo	Healthcare Homoeo Charitable Society	NULL	Recruiting	25 Years	60 Years	Both	60	Phase 2	India
504	NCT01394913 (ClinicalTrials.gov)	August 2013	12/7/2011	Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis	A Prospective, Double-blind, Randomized Study to Compare Efficacy of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Reumatocept (etanercept);Drug: Enbrel (etanercept)	EMS	NULL	Withdrawn	18 Years	70 Years	All	0	Phase 3	Brazil
505	NCT01936181 (ClinicalTrials.gov)	August 2013	2/9/2013	A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Remicade (infliximab);Drug: SB2 (proposed biosimilar to infliximab)	Samsung Bioepis Co., Ltd.	NULL	Completed	18 Years	75 Years	All	584	Phase 3	Bulgaria;Lithuania
506	NCT01915537 (ClinicalTrials.gov)	August 2013	30/7/2013	Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients	A Prospective Cohort Study to Observe the Difference of Efficacy Between Infliximab With Methotrexate and Classic DMARDs in the Severe Rheumatoid Arthritis Patients With Poor Prognosis	Rheumatoid Arthritis(RA)	Drug: Infliximab group;Drug: Classic DMARDs treatment group	Zhang, Xiao, M.D.	Central South University;Tianjin Medical University General Hospital;Xijing Hospital	Not yet recruiting	18 Years	70 Years	Both	170	N/A	China
507	NCT01932372 (ClinicalTrials.gov)	July 26, 2013	30/7/2013	Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis	XELJANZ (REGISTERED) TABLETS 5MG SPECIAL INVESTIGATION (ALL-CASES SURVEILLANCE)	Rheumatoid Arthritis	Drug: Tofacitinib (Xeljanz);Drug: Etanercept , other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc	Pfizer	NULL	Completed	N/A	N/A	All	9968		Japan
508	NCT01888874 (ClinicalTrials.gov)	July 17, 2013	26/6/2013	Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone	Rheumatoid Arthritis	Drug: GLPG0634;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	N/A	All	599	Phase 2	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Russian Federation;Spain;Ukraine;Czech Republic;Peru;Puerto Rico
509	NCT01774877 (ClinicalTrials.gov)	July 2013	22/1/2013	A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome	Efficacy and Safety of Xinfeng Capsule in the Treatment of Rheumatoid Arthritis (RA):A Randomized, Double-blind, Double-dummy, Multi-center Trial	Rheumatoid Arthritis	Drug: Xinfeng capsule;Drug: leflunomide	The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine	Ministry of Science and Technology of the People´s Republic of China	Completed	18 Years	65 Years	Both	304	N/A	China
510	NCT01893996 (ClinicalTrials.gov)	July 2013	2/7/2013	Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease	Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease	Rheumatoid Arthritis;Cardiovascular Disease	Drug: Adalimumab;Drug: Placebo	Jonathan Graf	American College of Rheumatology Research and Education Foundation;AbbVie	Completed	18 Years	N/A	All	63	Phase 4	United States
511	NCT01864265 (ClinicalTrials.gov)	July 2013	21/5/2013	Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain	Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)	Rheumatoid Arthritis	Drug: Certolizumab Pegol;Drug: Placebo	University of Erlangen-Nürnberg Medical School	NULL	Completed	18 Years	N/A	All	156	Phase 3	Germany;Portugal;Serbia;Belgium;United Kingdom;United States
512	NCT01890473 (ClinicalTrials.gov)	July 2013	27/6/2013	Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe	Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	356	Phase 1	United States;Argentina;Mexico;Peru;South Africa
513	NCT01851070 (ClinicalTrials.gov)	July 2013	19/4/2013	A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFa Inhibitor	A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFa Inhibitor	Rheumatoid Arthritis	Drug: Allogeneic Mesenchymal Precursor Cells;Drug: Normal Saline	Mesoblast, Ltd.	PPD	Completed	18 Years	80 Years	All	48	Phase 2	United States;Australia
514	NCT02519387 (ClinicalTrials.gov)	July 2013	15/7/2015	Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity	Multicentre Study for Evaluation of the Efficacy and Safety of Buprenorphine Transdermal Patch (SOVENOR®) 5mg and 10mg in Patients With Non-malignant Pain of Moderate Intensity Due to Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain and Joint/Muscle Pain, When an Opioid is Necessary for Obtaining Adequate Analgesia	Osteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle Pain	Drug: Buprenorphine Transdermal Patch	Mundipharma Pharmaceuticals Sdn. Bhd.	NULL	Completed	40 Years	N/A	All	78	Phase 4	Malaysia
515	NCT01862224 (ClinicalTrials.gov)	July 2013	2/5/2013	A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: JNJ-38518168;Drug: Placebo;Drug: Placebo / JNJ-38518168	Janssen Research & Development, LLC	NULL	Terminated	18 Years	65 Years	Both	21	Phase 2	United States;Moldova, Republic of
516	NCT02236481 (ClinicalTrials.gov)	July 2013	8/9/2014	Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes	No-profit Study to Ensure Normal Clinical Practice, to Evaluate the Efficacy of Anakinra in Reducing the Glycated Haemoglobin in Patients Affected by Rheumatoid Arthritis and Diabetes; Randomized, Open Label, Parallel Group,Controlled Clinical Study	Diabetes Mellitus, Type 2;Arthritis, Rheumatoid	Drug: Anakinra;Drug: TNF alpha inhibitors	Prof. Roberto Giacomelli	NULL	Terminated	18 Years	N/A	All	41	Phase 4	Italy
517	NCT01885078 (ClinicalTrials.gov)	June 27, 2013	19/6/2013	An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis	A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Baricitinib;Drug: Placebo	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	2877	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;Czech Republic
518	NCT01881308 (ClinicalTrials.gov)	June 17, 2013	17/6/2013	Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis	REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design	Rheumatoid Arthritis	Drug: TNF inhibitors;Drug: Synthetic DMARD(s);Drug: Co-medication: Synthetic DMARDs	Diakonhjemmet Hospital	The Research Council of Norway;South-Eastern Norway Regional Health Authority	Completed	18 Years	80 Years	All	320	Phase 4	Norway
519	NCT01901185 (ClinicalTrials.gov)	June 11, 2013	17/5/2013	Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept	A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept	Rheumatoid Arthritis;Psoriatic Arthritis	Drug: Etanercept / Autoinjector A	Amgen	NULL	Completed	18 Years	N/A	All	77	Phase 3	United States
520	NCT01875991 (ClinicalTrials.gov)	June 5, 2013	10/6/2013	Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept	An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept	Rheumatoid Arthritis;Plaque Psoriasis	Drug: Etanercept via Autoinjector A;Drug: Etanercept via Autoinjector B	Amgen	NULL	Completed	18 Years	N/A	All	217	Phase 4	United States;Canada
521	NCT02132234 (ClinicalTrials.gov)	June 2013	28/4/2014	Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis	Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis	Rheumatoid Arthritis;Psoriatic Arthritis;Ankylosing Spondylitis;Hypertension	Drug: Etanercept;Drug: Adalimumab;Drug: Certolizumab;Drug: Infliximab	Jagiellonian University	Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland	Recruiting	18 Years	N/A	Both	100	Phase 4	Poland
522	NCT01878318 (ClinicalTrials.gov)	June 2013	6/6/2013	A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs	Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs	Rheumatoid Arthritis	Drug: methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 4	Venezuela
523	NCT01895309 (ClinicalTrials.gov)	June 2013	3/7/2013	A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Enbrel (etanercept);Drug: SB4 (proposed biosimilar to etanercept)	Samsung Bioepis Co., Ltd.	NULL	Completed	18 Years	75 Years	All	596	Phase 3	Poland;United Kingdom
524	NCT01909427 (ClinicalTrials.gov)	June 2013	10/7/2013	An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO 6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: CNTO 6785 200 mg;Drug: CNTO 6785 100 mg;Drug: CNTO 6785 50 mg;Drug: CNTO 6785 15 mg	Janssen Research & Development, LLC	NULL	Completed	18 Years	80 Years	Both	257	Phase 2	Argentina;Colombia;Czech Republic;Philippines;Poland;Russian Federation;Thailand
525	NCT01961271 (ClinicalTrials.gov)	June 2013	7/10/2013	Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain	Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia	Osteoarthritis;Rheumatoid Arthritis;Lower Back Pain;Joint Pain;Muscle Pain	Drug: Buprenorphine transdermal patch	Mundipharma Pte Ltd.	Mundipharma Korea Ltd;Mundipharma (Hong Kong) Ltd;Mundipharma Distribution GmBH (Philippine Branch)	Completed	18 Years	80 Years	All	114	Phase 4	Hong Kong;Korea, Republic of;Philippines
526	NCT01955733 (ClinicalTrials.gov)	May 31, 2013	30/9/2013	Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis	Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial	Arthritis, Rheumatoid	Drug: BI 695500	Boehringer Ingelheim	NULL	Terminated	18 Years	82 Years	All	91	Phase 3	United States;Belgium;Bulgaria;Germany;Greece;Netherlands;Poland;Portugal;Spain;Argentina;Brazil;Canada;Chile;Hungary;Ireland;Mexico;United Kingdom
527	NCT01873443 (ClinicalTrials.gov)	May 2013	22/5/2013	Long-Term Efficacy and Safety of CT-P10 in Patients With RA	An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1	Rheumatoid Arthritis	Drug: Rituximab , MTX, folic acid	Celltrion	NULL	Completed	18 Years	75 Years	Both	87	Phase 1	Korea, Republic of
528	NCT04157010 (ClinicalTrials.gov)	May 2013	15/4/2014	Tocilizumab REMission in Early RA	Prospective, Single-centre, Open-Label, Randomised, Pilot Study Assessing the Changes in Expression of Janus Kinase/Signal Transducers and Activators of Transcription (JAK-STAT) and Speed & Depth of Remission Induced by Tocilizumab & Methotrexate Combination and Tocilizumab Monotherapy in Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Methotrexate	University of Leeds	Hoffmann-La Roche	Completed	18 Years	N/A	All	20	Phase 4	United Kingdom
529	NCT01846975 (ClinicalTrials.gov)	May 2013	19/4/2013	Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday	A Phase IV, Open Label Study Introducing a Single IV Treatment With Abatacept in Patients With Rheumatoid Arthritis Currently Receiving Weekly Injections of SC Abatacept to Simulate a Holiday or Patient Vacation	Rheumatoid Arthritis	Drug: IV Abatacept	Rüdiger B. Müller	Bristol-Myers Squibb	Completed	18 Years	N/A	Both	49	Phase 4	Switzerland
530	NCT02468791 (ClinicalTrials.gov)	May 2013	9/6/2015	MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab	Mabion SA	NULL	Completed	18 Years	80 Years	All	709	Phase 3	Bosnia and Herzegovina;Georgia;Poland;Serbia;Ukraine
531	NCT02035800 (ClinicalTrials.gov)	May 2013	10/12/2013	Bone Resorption, Osteoclastogenesis and Adalimumab	Bone Resorption, Osteoclastogenesis and Adalimumab	RheumatoId Arthritis	Drug: Adalimumab	Université de Sherbrooke	AbbVie	Unknown status	18 Years	N/A	All	120	Phase 4	Canada
532	NCT01357759 (ClinicalTrials.gov)	May 2013	18/5/2011	Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects	A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MORAb-022	Morphotek	NULL	Completed	18 Years	75 Years	Both	20	Phase 1	United States;Netherlands
533	NCT01764997 (ClinicalTrials.gov)	April 2013	8/1/2013	An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate	A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Etanercept;Drug: Methotrexate;Drug: Placebo (for sarilumab);Drug: Placebo (for etanercept);Drug: Adalimumab	Sanofi	Regeneron Pharmaceuticals	Terminated	18 Years	N/A	All	776	Phase 3	United States;Argentina;Australia;Brazil;Chile;Colombia;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Czech Republic
534	NCT01830985 (ClinicalTrials.gov)	April 2013	10/4/2013	A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis	A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: VX-509	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	65 Years	Both	39	Phase 2/Phase 3	United States;Estonia;Lithuania;South Africa
535	NCT01851707 (ClinicalTrials.gov)	April 2013	8/5/2013	A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone	A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of Duvelisib With Background Methotrexate in Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone	Rheumatoid Arthritis	Drug: IPI-145;Drug: Placebo	SecuraBio	NULL	Completed	18 Years	70 Years	All	322	Phase 2	Bulgaria;Colombia;Germany;Hungary;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Ukraine
536	NCT01844895 (ClinicalTrials.gov)	April 2013	5/4/2013	Methotrexate-Inadequate Response Autoinjector Device Sub Study	Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	120	Phase 3	NULL
537	NCT01851278 (ClinicalTrials.gov)	April 2013	12/4/2013	Effectiveness Intraarticular Corticosteroid	Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose	Rheumatoid Arthritis	Drug: Triamcinolone hexacetonide	Federal University of São Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Recruiting	18 Years	65 Years	Both	60	N/A	Brazil
538	NCT01850680 (ClinicalTrials.gov)	April 2013	1/5/2013	Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered Sarilumab in Japanese Patients With Rheumatoid Arthritis Receiving Concomitant Methotrexate	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: placebo;Drug: methotrexate;Drug: folic acid	Sanofi	Regeneron Pharmaceuticals	Completed	20 Years	65 Years	Both	61	Phase 1	Japan
539	NCT02843789 (ClinicalTrials.gov)	March 2013	19/7/2016	Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy	Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy	Arthritis, Rheumatoid	Drug: Tocilizumab	Centre Hospitalier Universitaire de Besancon	NULL	Completed	18 Years	80 Years	All	109	Phase 4	France
540	NCT01768572 (ClinicalTrials.gov)	March 2013	11/1/2013	To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)	A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists	Rheumatoid Arthritis	Drug: sarilumab SAR153191 (REGN88);Drug: tocilizumab;Drug: hydroxychloroquine;Drug: methotrexate;Drug: sulfasalazine;Drug: leflunomide;Drug: subcutaneous placebo;Drug: intravenous placebo	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	202	Phase 3	United States;Argentina;Belgium;Brazil;Czechia;Estonia;Finland;Hungary;Israel;Italy;Mexico;Netherlands;Norway;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;Czech Republic
541	NCT01558089 (ClinicalTrials.gov)	March 2013	15/2/2012	Good EULAR Response In Patients With Early Rheumatoid Arthritis	Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece	Rheumatoid Arthritis	Drug: etanercept;Drug: methotrexate	Pfizer	NULL	Completed	18 Years	N/A	All	76	N/A	Greece
542	NCT01768858 (ClinicalTrials.gov)	February 5, 2013	14/1/2013	Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice	Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice	Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Crohn´s Disease;Ulcerative Colitis;Plaque Psoriasis	Drug: Adalimumab	AbbVie	Raffeiner GmbH	Completed	18 Years	99 Years	All	96		Austria
543	NCT01724931 (ClinicalTrials.gov)	February 2013	7/11/2012	Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis	A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: LD-aminopterin;Drug: placebo	Syntrix Biosystems, Inc.	NULL	Completed	18 Years	N/A	Both	175	Phase 2	Ukraine
544	NCT01715831 (ClinicalTrials.gov)	January 15, 2013	25/10/2012	A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488	A Multicenter, Open-Label, Single-Arm Extension Study to Describe the Safety of Tocilizumab Treatment In Brazilian Patients With DMARDs Refractory Rheumatoid Arthritis Which Completed Studies ML21530 and MA21488 and Presenting an Indication of Maintaining the Tocilizumab Treatment	Arthritis, Rheumatoid	Drug: DMARDs;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	26	Phase 4	Brazil
545	NCT01965132 (ClinicalTrials.gov)	January 1, 2013	11/10/2013	Korean College of Rheumatology Biologics Registry	Korean College of Rheumatology Biologics Registry	Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: Biologic DMARD	Seoul National University Hospital	NULL	Recruiting	18 Years	N/A	All	7000		Korea, Republic of
546	NCT01754935 (ClinicalTrials.gov)	January 2013	18/12/2012	A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX-509 Using Magnetic Resonance Imaging and Arthroscopic Biopsies in Subjects With Active Rheumatoid Arthritis on Stable Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: VX-509;Drug: VX-509 matching placebo	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	65 Years	Both	43	Phase 2	United States;Denmark;Estonia;Lithuania;Netherlands;South Africa
547	NCT01793519 (ClinicalTrials.gov)	January 2013	14/2/2013	Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis	Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical Trial	Rheumatoid Arthritis	Drug: Etanercept;Drug: Infliximab;Drug: Adalimumab;Drug: Placebo	Georgetown University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);University of Maryland, College Park;Washington D.C. Veterans Affairs Medical Center;Medstar Health Research Institute;Patient-Centered Outcomes Research Institute;Arthritis and Pain Associates of PG County;Arthritis & Rheumatism Associates, P.C.;Rheumatology Associates of Baltimore, L.L.C.;The Arthritis Clinic of Northern Virginia, P.C.;Arthritis and Rheumatic Disease Associates, P.C.	Recruiting	18 Years	N/A	All	290	Phase 4	United States
548	NCT01721044 (ClinicalTrials.gov)	January 2013	1/11/2012	A Moderate to Severe Rheumatoid Arthritis Study	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors	Rheumatoid Arthritis	Drug: Placebo;Drug: Baricitinib;Drug: cDMARD	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	527	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;Croatia;India
549	NCT01765478 (ClinicalTrials.gov)	January 2013	7/1/2013	Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers	A Phase1 Study, to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered HM71224 in Healthy, Adult Male Volunteers	Rheumatoid Arthritis	Drug: HM71224 single ascending dose;Drug: HM71224 food effect;Drug: HM71224 Multiple ascending dose	Hanmi Pharmaceutical Company Limited	NULL	Completed	18 Years	65 Years	Male	62	Phase 1	Netherlands
550	NCT01389388 (ClinicalTrials.gov)	January 2013	16/4/2010	Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease	Cholesterol Plaques in Carotid and Coronary Arteries and the Effect of Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases	Carotid Artery Plaque;Ankylosing Spondylitis;Rheumatoid Arthritis	Drug: Rosuvastatin	Diakonhjemmet Hospital	NULL	Completed	35 Years	80 Years	Both	114	N/A	Norway
551	NCT01751776 (ClinicalTrials.gov)	December 2012	14/12/2012	Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy	A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy	Arthritis, Rheumatoid;Healthy	Drug: BI 655064 medium dose;Drug: BI 655064 high dose;Drug: Placebo;Drug: BI 655064 low dose	Boehringer Ingelheim	NULL	Completed	18 Years	70 Years	Both	107	Phase 1	Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;Romania
552	NCT01717846 (ClinicalTrials.gov)	December 2012	24/10/2012	Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis	In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis	Apoptotic DNA Damage;Rheumatoid Arthritis;T-cell Lymphocytosis	Drug: Group 1 or Orencia treated group;Other: Group 2 (DMARDS treated group)	University of California, Los Angeles	Bristol-Myers Squibb	Withdrawn	18 Years	85 Years	Both	0	Phase 4	United States
553	NCT01721057 (ClinicalTrials.gov)	December 2012	1/11/2012	A Study in Moderate to Severe Rheumatoid Arthritis Participants	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo;Drug: Baricitinib;Drug: cDMARD	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	684	Phase 3	United States;Argentina;Australia;Belgium;Canada;Croatia;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;Czech Republic
554	NCT01772316 (ClinicalTrials.gov)	December 2012	17/1/2013	A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-label, Long-term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	47	Phase 3	Spain
555	NCT01759030 (ClinicalTrials.gov)	December 2012	20/12/2012	Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis	Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies	Rheumatoid Arthritis	Drug: Rituximab	Biocad	NULL	Completed	18 Years	80 Years	All	181	Phase 3	Belarus;India;Russian Federation;Ukraine;Colombia
556	NCT01770106 (ClinicalTrials.gov)	December 2012	3/1/2013	RA Denosumab on Bone Microstructure Study	Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture in Rheumatoid Arthritis Females With Low Bone Mass: A Randomized Controlled Trial	Rheumatoid Arthritis	Drug: Denosumab;Drug: Alendronate	Chinese University of Hong Kong	NULL	Completed	18 Years	80 Years	Female	40	Phase 4	Hong Kong
557	NCT01741493 (ClinicalTrials.gov)	November 2012	3/12/2012	A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494	A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494	Rheumatoid Arthritis	Drug: ABT-494;Drug: Placebo;Drug: Tofacitinib	AbbVie (prior sponsor, Abbott)	NULL	Completed	18 Years	75 Years	All	67	Phase 1	United States
558	NCT01709760 (ClinicalTrials.gov)	November 2012	16/10/2012	A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA	A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: ENIA11;Drug: Placebo	Mycenax Biotech Inc.	NULL	Unknown status	20 Years	N/A	All	91	Phase 3	Taiwan
559	NCT01749787 (ClinicalTrials.gov)	November 2012	6/12/2012	Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis	A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: PRTX-100 at 1.5 mcg/kg;Drug: PRTX-100 at 3.0 mcg/kg;Drug: PRTX-100 at 6.0 mcg/kg;Drug: PRTX-100 at 12.0 mcg/kg;Drug: PRTX-100 at 240 mcg;Drug: Placebo;Drug: PRTX-100 at 420 mcg	Protalex, Inc.	NULL	Completed	18 Years	N/A	Both	61	Phase 1	United States
560	NCT01725230 (ClinicalTrials.gov)	November 2012	7/11/2012	Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib	An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily	Rheumatoid Arthritis	Drug: Fostamatinib;Drug: Rosuvastatin;Drug: Simvastatin	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	42	Phase 1	United States
561	NCT01711359 (ClinicalTrials.gov)	November 2012	18/10/2012	A Study in Participants With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: Baricitinib;Drug: Methotrexate;Drug: Baricitinib Placebo;Drug: MTX Placebo;Drug: Folic Acid	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	588	Phase 3	United States;Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Puerto Rico;Russian Federation;South Africa;Sweden;United Kingdom
562	NCT01689532 (ClinicalTrials.gov)	November 2012	18/9/2012	A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine	A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously as Monotherapy, in Japanese Subjects With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine	Arthritis, Rheumatoid	Drug: Sirukumab 100 mg;Drug: Sirukumab 50 mg;Drug: Placebo	Janssen Pharmaceutical K.K.	GlaxoSmithKline	Completed	20 Years	N/A	All	122	Phase 3	Japan
563	NCT01679951 (ClinicalTrials.gov)	October 31, 2012	3/9/2012	A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate	A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Dose Range Finding Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: JNJ-38518168 (3 mg);Drug: JNJ-38518168 (10 mg);Drug: JNJ-38518168 (30 mg);Drug: Methotrexate	Janssen Research & Development, LLC	NULL	Terminated	18 Years	80 Years	All	272	Phase 2	United States;Argentina;Chile;Colombia;Czechia;Hungary;Japan;Korea, Republic of;Latvia;Mexico;Poland;Romania;Russian Federation;Taiwan;Thailand;Ukraine;Czech Republic
564	NCT01636843 (ClinicalTrials.gov)	October 30, 2012	6/7/2012	A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate	A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate	Inflammation;Rheumatoid Arthritis	Drug: NNC0109-0012;Drug: placebo	Novo Nordisk A/S	NULL	Terminated	18 Years	75 Years	All	298	Phase 2	United States;Argentina;Belgium;Brazil;Czechia;France;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Spain;Ukraine;Czech Republic
565	NCT01590966 (ClinicalTrials.gov)	October 18, 2012	30/4/2012	Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFa in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis	Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFa in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis	Axial and Peripheral Spondyloarthritis;Rheumatoid Arthritis	Drug: administration of Cimzia®;Drug: Immunoscintigraphy with radiolabeled Cimzia®.	University Hospital, Ghent	UCB Pharma SA	Completed	18 Years	70 Years	All	41	Phase 3	Belgium
566	NCT01636557 (ClinicalTrials.gov)	October 11, 2012	6/7/2012	A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis	A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Sirukumab;Drug: Midazolam;Drug: Warfarin;Drug: Vitamin K;Drug: Omeprazole;Drug: Caffeine	Janssen Research & Development, LLC	NULL	Completed	18 Years	65 Years	All	12	Phase 1	Germany;Korea, Republic of;Moldova, Republic of;South Africa
567	NCT01736189 (ClinicalTrials.gov)	October 11, 2012	27/11/2012	Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice	Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice (Combo Study; Adalimumab With High Dose MTX)	Rheumatoid Arthritis	Drug: Adalimumab	AbbVie (prior sponsor, Abbott)	NULL	Completed	16 Years	99 Years	All	346		Japan
568	NCT01619176 (ClinicalTrials.gov)	October 2012	5/6/2012	Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood	Non Inferiority Trial for the Study of Acupuncture on Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: methotrexate;Drug: non-steroidal anti-inflammatory drug (NSAID);Drug: leflunomide;Procedure: Acupuncture	Chinese Academy of Sciences	Shanghai GuangHua Hospital of integrated traditional and western medicine	Completed	18 Years	65 Years	Female	15	N/A	China
569	NCT01709578 (ClinicalTrials.gov)	October 2012	15/10/2012	To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)	A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-a Antagonists	Rheumatoid Arthritis	Drug: Sarilumab;Drug: placebo;Drug: hydroxychloroquine;Drug: methotrexate;Drug: sulfasalazine;Drug: leflunomide	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	546	Phase 3	United States;Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czechia;Ecuador;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;Czech Republic;Hong Kong
570	NCT01734993 (ClinicalTrials.gov)	October 2012	19/11/2012	A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).	A Multicenter, Open-Label Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	11	Phase 3	France
571	NCT01871961 (ClinicalTrials.gov)	October 2012	14/5/2013	Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient	Evaluation of Rheumatoid Arthritis Patient Performance Using the Metoject® Prefilled Pen (Methotrexate 50 mg/mL, Prefilled Pen) for Subcutaneous Injection and Subsequent Pharmacokinetic Assessment of Drug Delivery	Rheumatoid Arthritis (RA)	Drug: Methotrexate (Metoject® prefilled pen)	medac GmbH	PPD (CRO)	Completed	16 Years	N/A	Both	105	Phase 1	United States
572	NCT01730456 (ClinicalTrials.gov)	October 2012	15/11/2012	A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926	A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	13	Phase 3	Macedonia, The Former Yugoslav Republic of
573	NCT02915094 (ClinicalTrials.gov)	October 2012	23/9/2016	Kineret in the Treatment of Rheumatoid Arthritis	Kineret in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Anakinra	Swedish Orphan Biovitrum	NULL	Completed	18 Years	N/A	All	30	N/A	Germany
574	NCT01710358 (ClinicalTrials.gov)	October 2012	17/10/2012	A Study in Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Baricitinib;Drug: Methotrexate;Drug: Adalimumab Placebo;Drug: Baricitinib Placebo	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	1307	Phase 3	United States;Argentina;Belgium;Canada;China;Croatia;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;Czech Republic;Netherlands
575	NCT01711814 (ClinicalTrials.gov)	September 26, 2012	19/10/2012	A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	A Phase 2 Open-Label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	Arthritis, Rheumatoid	Drug: peficitinib	Astellas Pharma Global Development, Inc.	Janssen Biotech, Inc.	Completed	18 Years	N/A	All	611	Phase 2	United States;Belgium;Bulgaria;Colombia;Czechia;Hungary;Mexico;Poland;Czech Republic
576	NCT01850966 (ClinicalTrials.gov)	September 12, 2012	8/5/2013	Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis	Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Iguratimod	Eisai Co., Ltd.	NULL	Completed	N/A	N/A	All	2747		Japan
577	NCT01682512 (ClinicalTrials.gov)	September 5, 2012	10/8/2012	Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis	Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.	Arthritis, Rheumatoid	Drug: BI 695500;Drug: Rituxan®;Drug: MabThera ®	Boehringer Ingelheim	NULL	Terminated	18 Years	80 Years	All	294	Phase 3	United States;Argentina;Belgium;Bulgaria;Canada;Chile;Germany;Greece;Hungary;Ireland;Mexico;Netherlands;Poland;Portugal;Spain;Ukraine;United Kingdom;Brazil;Estonia;France;Guatemala;Italy;New Zealand;Norway;Peru;Russian Federation;Serbia;South Africa;Sweden
578	NCT01694264 (ClinicalTrials.gov)	September 1, 2012	24/9/2012	Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFa	A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFa Treatment	Chronic Hepatitis B;Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Juvenile Idiopathic Arthritis	Drug: Entecavir;Drug: Placebo	Seoul National University Hospital	Konkuk University Medical Center;Kyungpook National University;Kyunghee University Medical Center;Kyung Hee University Hospital at Gangdong;Gachon University Gil Medical Center;Daegu Catholic University Medical Center;Eulji University Hospital;SMG-SNU Boramae Medical Center;The Catholic University of Korea;Severance Hospital;Ajou University School of Medicine;Ewha Womans University Mokdong Hospital;Inha University Hospital;Chonnam National University Hospital;Chonbuk National University Hospital;Chungnam National University Hospital;Hallym University Medical Center;Hanyang University;Dong-A University;Korea University Guro Hospital	Terminated	16 Years	85 Years	All	43	Phase 3	Korea, Republic of
579	NCT01647451 (ClinicalTrials.gov)	September 2012	19/7/2012	A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0114-0006;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	62	Phase 2	Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain
580	NCT01676701 (ClinicalTrials.gov)	September 2012	29/8/2012	Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)	Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Tabalumab Auto-Injector;Drug: Tabalumab Prefilled Syringe	Eli Lilly and Company	NULL	Terminated	18 Years	N/A	All	8	Phase 3	United States;Argentina;Czechia;Poland;Puerto Rico;Russian Federation;Czech Republic
581	NCT01661140 (ClinicalTrials.gov)	September 2012	7/8/2012	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage	Randomized, Phase IV, Placebo-controlled, Comparative Study to Evaluate the Efficacy and Safety of Tapering Methotrexate (MTX) Dosage Versus Maintaining the Dosage in Patients With Severe Active Rheumatoid Arthritis (RA) Who Have Demonstrated an Inadequate Response (IR) to Prior Disease-modifying Anti-rheumatic Drugs (DMARDs) Treatment and Have Initiated RoActemra (RoActemra, TCZ) in Combination With MTX	Rheumatoid Arthritis	Drug: Methotrexate (stable dose);Drug: Tocilizumab;Drug: Methotrexate (tapering dose)	Hoffmann-La Roche	NULL	Terminated	18 Years	N/A	All	427	Phase 4	United Kingdom
582	NCT01635686 (ClinicalTrials.gov)	September 2012	4/7/2012	Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers	A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers	Rheumatoid Arthritis	Drug: DWP422 25mg;Drug: ENBREL 25MG PFS INJ.	Daewoong Pharmaceutical Co. LTD.	NULL	Not yet recruiting	20 Years	45 Years	Male	38	Phase 1	Korea, Republic of
583	NCT04704492 (ClinicalTrials.gov)	August 14, 2012	6/1/2021	A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis	An Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Preliminary Clinical Activity and Safety of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Biological: SM03	SinoMab Pty Ltd	NULL	Completed	18 Years	65 Years	All	8	Phase 1	China
584	NCT01606761 (ClinicalTrials.gov)	August 6, 2012	24/5/2012	A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy	Arthritis, Rheumatoid	Drug: Placebo;Drug: Sirukumab	Janssen Research & Development, LLC	GlaxoSmithKline	Completed	18 Years	N/A	All	878	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Taiwan;United Kingdom;Brazil;China
585	NCT01651936 (ClinicalTrials.gov)	August 2012	25/7/2012	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)	A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Subjects With Active Rheumatoid Arthritis and an Inadequate Response or Intolerance to Anti-TNF-a Therapy	Rheumatoid Arthritis	Drug: MK-8457 100 mg;Drug: Methotrexate;Drug: Dose-match placebo	Merck Sharp & Dohme Corp.	NULL	Terminated	18 Years	N/A	All	56	Phase 2	Australia;Colombia;Denmark;France;Greece;Hungary;Italy;Korea, Republic of;New Zealand;Poland;South Africa;Spain;United Kingdom;United States
586	NCT01652937 (ClinicalTrials.gov)	August 2012	19/7/2012	BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs	A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BIIB057 in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs	Rheumatoid Arthritis	Drug: BIIB057;Drug: Placebo	Biogen Idec	NULL	Withdrawn	18 Years	N/A	Female	0	Phase 2	Canada
587	NCT01645280 (ClinicalTrials.gov)	August 2012	6/6/2012	A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy	Arthritis, Rheumatoid	Drug: Placebo + methotrexate (MTX) (Group 1);Drug: Ustekinumab + MTX (Group 2);Drug: Ustekinumab + MTX (Group 3);Drug: CNTO 1959 + MTX (Group 4);Drug: CNTO 1959 + MTX (Group 5)	Janssen Research & Development, LLC	NULL	Completed	18 Years	80 Years	All	274	Phase 2	United States;Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Poland;Russian Federation;Singapore;Ukraine;Korea, Republic of;Mexico;Peru;Turkey
588	NCT01870908 (ClinicalTrials.gov)	August 2012	4/6/2013	Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients	Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biological Agents in Daily Clinical Settings	Rheumatoid Arthritis	Drug: tacrolimus;Drug: biological agents	Astellas Pharma Inc	NULL	Completed	N/A	N/A	Both	664	N/A	Japan
589	NCT01662063 (ClinicalTrials.gov)	August 2012	30/7/2012	A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)	A Multicenter Open-Label, Long-Term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Genentech, Inc.	NULL	Completed	18 Years	N/A	All	218	Phase 3	United States;Puerto Rico
590	NCT01604343 (ClinicalTrials.gov)	August 2012	21/5/2012	A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy	Arthritis, Rheumatoid	Drug: Placebo;Drug: Sirukumab	Janssen Research & Development, LLC	GlaxoSmithKline	Completed	18 Years	N/A	Both	1670	Phase 3	United States;Bulgaria;Canada;Chile;Colombia;Croatia;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;Argentina;Brazil;India;Peru
591	NCT01746680 (ClinicalTrials.gov)	August 2012	4/12/2012	Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis	Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tacrolimus with Methotrexate	Chong Kun Dang Pharmaceutical	NULL	Completed	20 Years	N/A	Both	111	Phase 4	Korea, Republic of
592	NCT01636817 (ClinicalTrials.gov)	August 2012	6/7/2012	A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics	A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics	Inflammation;Rheumatoid Arthritis	Drug: NNC0109-0012;Drug: placebo	Novo Nordisk A/S	NULL	Terminated	18 Years	75 Years	All	239	Phase 2	United States;Argentina;Belgium;Brazil;Czechia;France;Germany;Hungary;Italy;Mexico;Poland;Spain;United Kingdom;Czech Republic
593	NCT01705730 (ClinicalTrials.gov)	July 31, 2012	10/10/2012	A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy	Mon-ACT: A Multi-center, Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab in Monotherapy	Rheumatoid Arthritis	Drug: tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	71		Belgium
594	NCT01554696 (ClinicalTrials.gov)	July 6, 2012	13/3/2012	A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate	A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo Controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients Who Have Had an Inadequate Response to Methotrexate	Arthritis, Rheumatoid	Drug: peficitinib;Drug: Placebo;Drug: methotrexate	Astellas Pharma Inc	NULL	Completed	18 Years	N/A	All	379	Phase 2	United States;Belgium;Bulgaria;Colombia;Czechia;Hungary;Mexico;Poland;Czech Republic
595	NCT01665430 (ClinicalTrials.gov)	July 2012	13/8/2012	A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-Label, Single Arm, Long-Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Terminated	18 Years	N/A	All	38	Phase 3	Poland
596	NCT01640054 (ClinicalTrials.gov)	July 2012	2/7/2012	A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis	(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia	Rheumatoid Arthritis	Drug: Fostamatinib	AstraZeneca	NULL	Terminated	18 Years	N/A	All	115	Phase 2	Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam
597	NCT01578850 (ClinicalTrials.gov)	July 2012	12/4/2012	Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening	A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s)	Rheumatoid Arthritis	Drug: Etanercept;Drug: placebo	Pfizer	NULL	Completed	18 Years	70 Years	All	491	Phase 4	Brazil;China;Colombia;Czech Republic;Egypt;Hungary;Jordan;Lebanon;Malaysia;Mexico;Philippines;Qatar;Romania;Russian Federation;South Africa;Taiwan;Thailand;Ukraine;United Arab Emirates;Saudi Arabia
598	NCT01597739 (ClinicalTrials.gov)	July 2012	10/5/2012	A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy	A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy	Arthritis, Rheumatoid	Drug: JNJ-40346527;Drug: Placebo	Janssen Research & Development, LLC	NULL	Completed	18 Years	80 Years	Both	96	Phase 2	Argentina;Bulgaria;Chile;Czech Republic;Hungary;Korea, Republic of;Poland;Russian Federation;Singapore;Ukraine
599	NCT01659242 (ClinicalTrials.gov)	July 2012	3/8/2012	Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study	Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis Patients With Active Disease Despite Methotrexate: an Ultrasound and Magnetic Resonance Imaging Study	Rheumatoid Arthritis	Drug: Methotrexate plus sulfasalazine;Drug: Leflunomide	Singapore General Hospital	NULL	Terminated	21 Years	65 Years	Both	1	Phase 4	Singapore
600	NCT01649804 (ClinicalTrials.gov)	July 2012	23/7/2012	A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis	A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG-TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	12	Phase 3	Hungary
601	NCT01793259 (ClinicalTrials.gov)	July 2012	14/2/2013	Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)	An Open-label, Randomized, Two-period Cross-over Study of Repeated Subcutaneous Injections of Methotrexate 50mg/ml Solution Either by a Pre-filled Syringe (Reference) or by a Disposable Pre-filled Pen (Test) to Assess Patient's Preference and Self-injection Experience and to Compare the Local Tolerability in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: methotrexate prefilled pen;Drug: methotrexate prefilled syringe	medac GmbH	NULL	Completed	18 Years	75 Years	Both	120	Phase 3	Germany
602	NCT01893151 (ClinicalTrials.gov)	July 2012	2/7/2013	Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI	A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI)	Rheumatoid Arthritis	Drug: Iguratimod;Drug: Iguratimod placebo	Jiangsu Simcere Pharmaceutical Co., Ltd.	NULL	Recruiting	18 Years	65 Years	Both	200	Phase 4	China
603	NCT01565655 (ClinicalTrials.gov)	June 19, 2012	27/3/2012	A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis	A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients	Arthritis, Rheumatoid	Drug: peficitinib;Drug: Placebo	Astellas Pharma Global Development, Inc.	NULL	Completed	18 Years	N/A	All	289	Phase 2	United States;Bulgaria;Czechia;Hungary;Mexico;Poland;Czech Republic
604	NCT01638013 (ClinicalTrials.gov)	June 13, 2012	9/7/2012	A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K	Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K	Arthritis, Rheumatoid	Drug: Peficitinib	Astellas Pharma Inc	NULL	Completed	20 Years	N/A	All	843	Phase 3	Japan;Korea, Republic of;Taiwan
605	NCT01611688 (ClinicalTrials.gov)	June 4, 2012	1/6/2012	First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis	First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0215-0384;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	36	Phase 1	Germany
606	NCT01602302 (ClinicalTrials.gov)	June 2012	16/5/2012	Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis	Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)	Medical University of Graz	NULL	Terminated	18 Years	90 Years	All	40	Phase 4	Austria
607	NCT02015520 (ClinicalTrials.gov)	June 2012	6/12/2013	Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis	A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors	Rheumatoid Arthritis	Drug: Clazakizumab;Drug: Placebo (Matching with Clazakizumab)	CSL Behring	NULL	Completed	18 Years	N/A	All	143	Phase 2	United States;Argentina;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;Australia
608	NCT02052375 (ClinicalTrials.gov)	June 2012	30/1/2014	A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis;Pharmacokinetics of ASP2408	Drug: ASP2408;Drug: Placebo	Astellas Pharma Global Development, Inc.	NULL	Completed	18 Years	75 Years	Both	24	Phase 1	United States
609	NCT01664104 (ClinicalTrials.gov)	June 2012	7/8/2012	A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting	CRP and BMI Study: Evaluation in Real Life of Clinical Remission Rate and Correlation Between CRP and BMI in Patients Treated With Tocilizumab	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	151	N/A	Italy
610	NCT01569152 (ClinicalTrials.gov)	May 22, 2012	30/3/2012	Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial With a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis (RA)	Drug: MK-8457 100 mg;Drug: Dose-Matched Placebo;Drug: Methotrexate	Merck Sharp & Dohme Corp.	NULL	Terminated	18 Years	N/A	All	82	Phase 2	Canada;Chile;Denmark;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Moldova, Republic of;Peru;Poland;South Africa;Taiwan;United Kingdom;United States
611	NCT01548001 (ClinicalTrials.gov)	May 2012	5/3/2012	Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Iguratimod;Drug: Methotrexate	Jiangsu Simcere Pharmaceutical Co., Ltd.	NULL	Active, not recruiting	18 Years	65 Years	Both	910	Phase 4	China
612	NCT01638715 (ClinicalTrials.gov)	May 2012	3/7/2012	A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action	A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action	Rheumatoid Arthritis	Drug: Remicade;Drug: Orencia;Drug: Ro-Actemra;Drug: Mabthera	Medical University of Vienna	NULL	Completed	18 Years	75 Years	All	115	Phase 4	Austria;Czechia;Russian Federation;Switzerland;Czech Republic;Saudi Arabia
613	NCT01618968 (ClinicalTrials.gov)	May 2012	4/6/2012	Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device	Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis (RA)	Drug: MTX	Antares Pharma Inc.	NULL	Completed	18 Years	N/A	All	49	Phase 2	United States
614	NCT01579006 (ClinicalTrials.gov)	May 2012	16/4/2012	Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis	A Multi National, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (Actemra)	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	Clalit Health Services	Completed	18 Years	N/A	All	184	N/A	Israel
615	NCT01664598 (ClinicalTrials.gov)	May 2012	10/8/2012	An Extension Study of WA19926 of the Long-Term Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	49	Phase 3	Russian Federation
616	NCT01617590 (ClinicalTrials.gov)	May 2012	28/5/2012	Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research	A 48-week, Multi-center, Randomized, Open-lable, Controlled Study to Assess the Response (ACR20) Using Different Disease-Modifying Antirheumatic Drugs Cycle Combination Regimen in Adult Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: leflunomide;Drug: methotrexate	Shanxi Medical University	NULL	Recruiting	18 Years	75 Years	Both	500	N/A	China
617	NCT01668641 (ClinicalTrials.gov)	May 2012	14/8/2012	Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone	Rheumatoid Arthritis	Drug: GLPG0634;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	70 Years	Both	91	Phase 2	Hungary;Moldova, Republic of;Russian Federation;Ukraine
618	NCT01617005 (ClinicalTrials.gov)	May 2012	8/6/2012	A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)	Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	50	N/A	Montenegro
619	NCT01576549 (ClinicalTrials.gov)	May 2012	10/4/2012	A Study of LY2127399 in Rheumatoid Arthritis	An Exploratory Open-Label Biomarker Study of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Synovial Biopsies	Rheumatoid Arthritis	Drug: LY2127399	Eli Lilly and Company	NULL	Terminated	18 Years	N/A	All	2	Phase 2	United States
620	NCT01724268 (ClinicalTrials.gov)	May 2012	7/11/2012	Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient	Randomized Controlled Clinical Trial of Low Dose Corticosteroids vs Anti TNF Treatment in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient- a Pilot Study	RHEUMATOID ARTHRITIS	Drug: Pred + Meth;Drug: Anti TNF + Meth	Hamad Medical Corporation	NULL	Recruiting	18 Years	N/A	Both	80	Phase 3	Qatar
621	NCT01613079 (ClinicalTrials.gov)	May 2012	4/6/2012	Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis	Evaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.	Arthritis, Rheumatoid	Drug: Tripterygium wilfordii Hook F;Drug: Methotrexate	Peking Union Medical College Hospital	NULL	Completed	18 Years	65 Years	Both	201	Phase 2/Phase 3	China
622	NCT01554917 (ClinicalTrials.gov)	May 2012	12/3/2012	A Study of Iguratimod in Patients With Active Rheumatoid Arthritis	A Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Iguratimod	Jiangsu Simcere Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	N/A	All	1759	Phase 4	China
623	NCT01655381 (ClinicalTrials.gov)	April 2012	30/7/2012	A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis	A Multicenter, Open-label, Single Arm, Long-term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	15	Phase 3	France
624	NCT01583959 (ClinicalTrials.gov)	April 2012	15/3/2012	Study of Different Doses of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis	Randomized Trial of 10 mg Versus 30 mg Per Week of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Folic Acid;Drug: Placebo	Postgraduate Institute of Medical Education and Research	NULL	Completed	18 Years	75 Years	Both	100	Phase 4	India
625	NCT01557374 (ClinicalTrials.gov)	April 2012	16/3/2012	TOward the Lowest Effective DOse of Abatacept or Tocilizumab	Tapering Abatacept or Tocilizumab in Rheumatoid Arthritis in Remission. An Evaluation of Disease Activity, Relapse Risk, Structural Progression and the Economic Impact of a Tapering Strategy	Rheumatoid Arthritis	Drug: Tocilizumab , Abatacept;Drug: Decrease Tocilizumab, Abatacept	Assistance Publique - Hôpitaux de Paris	Ministry of Health, France	Completed	18 Years	N/A	All	232	Phase 4	France
626	NCT01569074 (ClinicalTrials.gov)	April 2012	30/3/2012	Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis	(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Fostamatinib;Drug: Placebo	AstraZeneca	NULL	Terminated	18 Years	N/A	All	163	Phase 2	Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam
627	NCT02171143 (ClinicalTrials.gov)	April 2012	18/6/2014	A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis;Pharmacokinetics of ASP2409	Drug: ASP2409;Drug: Placebo	Astellas Pharma Global Development, Inc.	NULL	Completed	18 Years	75 Years	Both	58	Phase 1	United States
628	NCT01579890 (ClinicalTrials.gov)	April 2012	16/4/2012	Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis	A Non-blinded, Non-placebo Controlled, Compassionate Use, Open Treatment, Open-ended Program of the Safety of Pennsaid Topical Lotion (Diclofenac) in the Treatment of Osteo or Rheumatoid Arthritis	Osteoarthritis of the Hand	Drug: Diclofenac	Mallinckrodt	Nuvo Research Inc.	Approved for marketing	N/A	N/A	Both		N/A	NULL
629	NCT01484561 (ClinicalTrials.gov)	April 2012	30/11/2011	A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis	A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP -690,550 or Placebo;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	148	Phase 1	United States;Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain
630	NCT02818361 (ClinicalTrials.gov)	April 2012	15/6/2016	Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis	Topical Tripterygium Wilfordii Gel for Treatment in Patients With Moderate Activity Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Topical tripterygium gel;Drug: Placebo gel	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Completed	18 Years	65 Years	All	70	N/A	China
631	NCT01563978 (ClinicalTrials.gov)	April 2012	23/3/2012	Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis	OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: fostamatinib;Drug: placebo	AstraZeneca	NULL	Completed	18 Years	N/A	All	266	Phase 2	United States;Bulgaria;Czech Republic;Germany;Poland;South Africa;Ukraine;Argentina;Mexico;Peru
632	NCT01590459 (ClinicalTrials.gov)	April 2012	27/4/2012	24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate	A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension	Rheumatoid Arthritis	Drug: VX-509;Drug: VX-509 matching placebo	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	80 Years	Both	359	Phase 2	United States;Argentina;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine
633	NCT01649999 (ClinicalTrials.gov)	March 1, 2012	23/7/2012	A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects	Phase 2b Study of ASP015K - A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients	Arthritis, Rheumatoid	Drug: peficitinib;Drug: Placebo	Astellas Pharma Inc	NULL	Completed	20 Years	75 Years	All	281	Phase 2	Japan
634	NCT01582880 (ClinicalTrials.gov)	March 2012	10/4/2012	Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis	The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis	Chemical Injuries;Unspecified Complication of Corneal Transplant;Autoimmune Diseases;Ocular Cicatricial Pemphigoid;Stevens Johnson Syndrome;Lupus Erythematosus, Systemic;Rheumatoid Arthritis;Other Autoimmune Diseases	Drug: Riboflavin	Joseph B. Ciolino, MD	NULL	Completed	18 Years	N/A	All	1	Phase 1/Phase 2	United States
635	NCT01565408 (ClinicalTrials.gov)	March 2012	21/3/2012	Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis	Safety and Tolerability of NNC0114-0006 Following Multiple s.c. Dosing at Escalating Dose Levels in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0114-0006;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	32	Phase 1	Germany;Russian Federation
636	NCT01670045 (ClinicalTrials.gov)	March 2012	17/8/2012	A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	43	N/A	Indonesia;Greece
637	NCT01626573 (ClinicalTrials.gov)	March 2012	3/5/2012	A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis	A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Itacitinib;Drug: Itacitinib Placebo	Incyte Corporation	NULL	Completed	18 Years	75 Years	All	106	Phase 2	United States;Puerto Rico
638	NCT01612377 (ClinicalTrials.gov)	March 2012	22/2/2012	Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis	A Phase II, Double-blind, Controlled, Multi-center, Randomized, Long Term Safety Trial of z102 and Prednisone (5 mg or 7.5 mg) in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisolone -Dipyridamole;Drug: Prednisone;Drug: prednisone	Zalicus	NULL	Terminated	18 Years	N/A	Both	18	Phase 2	Serbia
639	NCT01587989 (ClinicalTrials.gov)	February 2012	12/3/2012	A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate	A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) Versus Tocilizumab Monotherapy in Patients With Mild to Moderate Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 < 4,5 and >2,6)	Rheumatoid Arthritis	Drug: methotrexate;Drug: placebo;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	77	Phase 3	Austria
640	NCT01395251 (ClinicalTrials.gov)	February 2012	12/7/2011	Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis	Phase II/III Study of Oral Prednisolone Test in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisolone	Rheumazentrum Ruhrgebiet	NULL	Completed	18 Years	N/A	Both	130	Phase 2/Phase 3	Germany
641	NCT01352858 (ClinicalTrials.gov)	February 2012	11/5/2011	Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA)	Phase 1 Study of Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TolDC;Drug: Arthroscopy & saline irrigation alone	Newcastle University	Arthritis Research UK;Newcastle-upon-Tyne Hospitals NHS Trust	Unknown status	18 Years	N/A	All	15	Phase 1	United Kingdom
642	NCT01623752 (ClinicalTrials.gov)	February 2012	18/6/2012	Prospective Evaluation of the Radiographic Efficacy of Enbrel	A PROSPECTIVE EVALUATION OF THE RADIOGRAPHIC EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIATIC ARTHRITIS.	Rheumatoid Arthritis;Psoriasis Arthritis	Drug: Etanercept	Pfizer	NULL	Completed	18 Years	N/A	All	1821		NULL
643	NCT01940926 (ClinicalTrials.gov)	February 2012	9/9/2013	68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	Diagnostic Performance and Evaluation Efficacy of 68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: 68Ga-BNOTA-PRGD2	Peking Union Medical College Hospital	NULL	Unknown status	18 Years	N/A	All	50	Early Phase 1	China
644	NCT01562327 (ClinicalTrials.gov)	February 2012	21/3/2012	A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis	A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab Actemra	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	50	N/A	Argentina
645	NCT01438892 (ClinicalTrials.gov)	February 2012	20/9/2011	Impact Of RA Therapy Compliance On Patient-Reported Outcomes	Impact Of RA Therapy Compliance On Patient-Reported Outcomes	Rheumatoid Arthritis	Drug: tDMARDs;Drug: biodmards	Pfizer	NULL	Completed	18 Years	N/A	Both	396	N/A	United States
646	NCT01646385 (ClinicalTrials.gov)	February 2012	12/4/2012	Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry	Long-term Safety and Efficacy of Etanercept in a UK Observational Cohort Study - a Retrospective Database Analysis of British Society of Rheumatology Biologics Registry (BSRBR) Data	Rheumatoid Arthritis	Drug: etanercept;Drug: non-biologic anti-rheumatic drugs	Pfizer	NULL	Completed	18 Years	N/A	All	6393	N/A	NULL
647	NCT02090556 (ClinicalTrials.gov)	January 31, 2012	19/2/2014	Long-term Experience With Abatacept SC in Routine Clinical Practice	Long-term Experience With Abatacept SC in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	inVentiv Health Clinical;PharmaNet	Unknown status	18 Years	N/A	All	2896		Australia;Austria;France;Germany;Greece;Italy;Monaco;Netherlands;Spain;Switzerland;United Kingdom
648	NCT02922192 (ClinicalTrials.gov)	January 1, 2012	28/9/2016	Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis	Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis	Rheumatoid Arthritis;Inflammatory Bowel Disease;Psoriasis;Psoriatic Arthritis;Ankylosing Spondylitis	Drug: TNF-a antagonists, non-TNFs, DMARD non-biologics	Biologics & Biosimilars Collective Intelligence Consortium	HealthCore, Inc.;Aetna, Inc.;University of Alabama; Rheumatologist and Healthcare Research;AbbVie;Amgen;Boehringer Ingelheim;Kaiser Permanente;Harvard Pilgrim Health Care;Merck Sharp & Dohme Corp.;Momenta Pharmaceuticals, Inc.;Pfizer;University of Pittsburgh	Completed	18 Years	N/A	All	90360		NULL
649	NCT01506661 (ClinicalTrials.gov)	January 2012	5/1/2012	Safety of Zostavax Vaccination in Rheumatoid Arthritis	Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis;Varicella Zoster	Drug: Zostavax (varicella zoster virus) vaccine	Oklahoma Medical Research Foundation	NULL	Completed	50 Years	80 Years	All	20	Phase 1	United States
650	NCT01511003 (ClinicalTrials.gov)	December 5, 2011	4/1/2012	A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)	An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs	Rheumatoid Arthritis	Drug: Tacrolimus	Astellas Pharma Inc	Astellas Pharma Korea, Inc.	Completed	20 Years	75 Years	All	128	Phase 4	Korea, Republic of
651	NCT01480388 (ClinicalTrials.gov)	December 2011	23/11/2011	A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate	A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy	Active Rheumatoid Arthritis; Rheumatoid Arthritis	Drug: Placebo/JNJ-39758979 (300 mg/d);Drug: JNJ-39758979 (10 mg);Drug: JNJ-39758979 (30 mg);Drug: JNJ-39758979 (100 mg);Drug: JNJ-39758979 (300 mg)	Janssen Research & Development, LLC	NULL	Withdrawn	18 Years	80 Years	Both	0	Phase 2	United States
652	NCT01326962 (ClinicalTrials.gov)	November 30, 2011	7/3/2011	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF	Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	28	Phase 3	Saudi Arabia
653	NCT01251120 (ClinicalTrials.gov)	November 2011	30/11/2010	A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis	A Pragmatic, Randomized, Parallel Group Study of the Effect on Disease Remission, Work Productivity and Tolerability of Tocilizumab in Combination With DMARDs and Individually Designed Best Practice DMARD Therapy in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: DMARD	Hoffmann-La Roche	NULL	Terminated	18 Years	N/A	All	2	Phase 4	Finland
654	NCT01469013 (ClinicalTrials.gov)	November 2011	8/11/2011	Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of Baricitinib (LY3009104) in Japanese Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy	Arthritis, Rheumatoid	Drug: Placebo;Drug: Baricitinib;Drug: Methotrexate	Eli Lilly and Company	NULL	Completed	20 Years	75 Years	All	145	Phase 2	Japan
655	NCT01592292 (ClinicalTrials.gov)	November 2011	11/4/2012	An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy	A Non-interventional Study for Relative Efficacy Outcome of Rituximab Treatment in RA Patients Who Have Inadequate Response or Have Been Intolerant to a First Anti-TNF Agent	Rheumatoid Arthritis	Drug: Rituximab;Drug: Adalimumab;Drug: Etanercept;Drug: Infliximab	Hoffmann-La Roche	NULL	Completed	20 Years	N/A	All	90	N/A	Korea, Republic of
656	NCT01468077 (ClinicalTrials.gov)	November 2011	7/11/2011	A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment	Multicenter, Randomized, Parallel Group Study to Compare the Incidence of Tocilizumab Related Infusion Reactions in Patients With Moderate to Severe Active RA, When Infusion is Given Over 31 Minutes Compared to 1 Hour	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	47	Phase 2	Denmark;Iceland
657	NCT01408602 (ClinicalTrials.gov)	November 2011	2/8/2011	A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients	A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MRC375;Drug: Matching Placebo;Drug: MRC375 150mg	Molecular Research Center, Inc.	Camargo Pharmaceutical Services;Clin Data Services;Harrison Clinical Research;BARC Global Central Laboratory;Bilcare Global Clinical Supplies	Active, not recruiting	18 Years	N/A	Both	300	Phase 2	United States
658	NCT01451203 (ClinicalTrials.gov)	October 11, 2011	25/9/2011	Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors	Rheumatoid Arthritis	Drug: Placebo;Drug: CZP;Drug: methotrexate (MTX)	Astellas Pharma Inc	UCB Japan Co. Ltd.	Completed	20 Years	64 Years	All	319	Phase 3	Japan
659	NCT01548768 (ClinicalTrials.gov)	October 10, 2011	6/3/2012	RHYTHM (Formerly Escape II Myocardium)	RHYTHM (RHeumatoid Arthritis studY of THe Myocardium): How Rheumatoid Arthritis (RA) and Tumor Necrosis Factor (TNF) Inhibitors Affect the Myocardial Structure and Function.	Rheumatoid Arthritis	Drug: TNF inhibitors;Drug: DMARDs	Columbia University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	N/A	All	149	Phase 4	United States
660	NCT01961505 (ClinicalTrials.gov)	October 2011	23/9/2013	Topical Compound Tripterygium Wilfordii Hook F for Patients With Active Rheumatoid Arthritis	A Randomized Controlled Study to Determine the Effects and Safety of Topical Compound Tripterygium Wilfordii Hook F in Patients With Active Rheumatoid Arthritis.	Active Rheumatoid Arthritis	Drug: Topical compound tripterygium;Drug: Placebo	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Completed	18 Years	65 Years	All	70	N/A	NULL
661	NCT01292616 (ClinicalTrials.gov)	October 2011	8/2/2011	Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement		Rheumatoid Arthritis	Drug: therapy with disease-modifying anti rheumatic drugs (DMARD)	University of Zurich	NULL	Recruiting	18 Years	N/A	Both	15	N/A	Switzerland
662	NCT01641952 (ClinicalTrials.gov)	October 2011	13/7/2012	An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent	Non-interventional, Prospective, Multicenter Study to Assess Efficacy and Safety of MabtheRA (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One Anti-TNF Agent - FAST 2 SWITCH Program	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	505	N/A	Romania
663	NCT04169100 (ClinicalTrials.gov)	September 28, 2011	14/11/2019	Novel Form of Acquired Long QT Syndrome	Novel Form of Acquired Long QT Syndrome	Long QT Syndrome;Connective Tissue Diseases;Rheumatoid Arthritis	Drug: Prednisone	Narrows Institute for Biomedical Research	VA New York Harbor Healthcare System	Recruiting	18 Years	89 Years	All	25	Phase 4	United States
664	NCT01417052 (ClinicalTrials.gov)	September 2011	12/8/2011	A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis	A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: 50 mg LX3305 QD;Drug: 100 mg LX3305 QD;Drug: 150 mg LX3305 QD;Drug: 200 mg LX3305 QD;Drug: 250 mg LX3305 QD;Drug: 300 mg LX3305 QD;Drug: 400 mg LX3305 QD;Drug: 250 mg LX3305 BID;Drug: 500 mg LX3305 QD;Drug: Placebo	Lexicon Pharmaceuticals	NULL	Completed	18 Years	75 Years	Both	10	Phase 1	United States
665	NCT02164214 (ClinicalTrials.gov)	September 2011	4/7/2013	Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?	DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)?	Inflammatory Rheumatism;Psoriatic Arthritis;Rheumatoid Arthritis	Drug: etanercept Treatment	Assistance Publique Hopitaux De Marseille	NULL	Completed	18 Years	N/A	Both	60	Phase 3	France
666	NCT01245439 (ClinicalTrials.gov)	September 2011	17/11/2010	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis	Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	65	Phase 3	Turkey
667	NCT01399697 (ClinicalTrials.gov)	September 2011	20/7/2011	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With MTX Versus Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 > 3,2)	Rheumatoid Arthritis	Drug: methotrexate;Drug: placebo;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	261	Phase 4	Spain
668	NCT01404585 (ClinicalTrials.gov)	September 2011	27/7/2011	Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: BMS-817399	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	Both	123	Phase 2	United States;Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain
669	NCT01374971 (ClinicalTrials.gov)	September 2011	14/6/2011	Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)	Open-Label Pre and Post Treatment Arthroscopic Synovial Biopsy Study for the Assessment of Certolizumab Pegol Immunomodulatory Synovial Effects on Select Biomarkers and Gene Expression	Rheumatoid Arthritis	Drug: Certolizumab Pegol (CZP);Procedure: Arthroscopic synovial tissue biopsy	Nathan Wei, MD, FACP, FACR:	University of California, San Diego	Completed	18 Years	N/A	All	12	Phase 3	United States
670	NCT02076659 (ClinicalTrials.gov)	September 2011	24/2/2014	Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients	A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: F8IL10;Drug: Methotrexate	Philogen S.p.A.	NULL	Completed	18 Years	75 Years	All	36	Phase 1	Italy
671	NCT01430507 (ClinicalTrials.gov)	September 2011	7/9/2011	A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis	A Phase IIb, 12 Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Revamilast in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Revamilast;Drug: Placebo Comparator	Glenmark Pharmaceuticals Ltd. India	Glenmark Pharmaceuticals S.A.	Completed	18 Years	65 Years	Both	406	Phase 2	India;Philippines;Poland;Sri Lanka;United Kingdom
672	NCT01359150 (ClinicalTrials.gov)	September 2011	11/5/2011	A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo	A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Background Methotrexate	Rheumatoid Arthritis	Drug: CP -690,550;Drug: placebo	Pfizer	NULL	Completed	18 Years	N/A	All	223	Phase 2	United States;Poland
673	NCT01462162 (ClinicalTrials.gov)	September 2011	27/10/2011	A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis	A Prospective Observational Study to Evaluate and Correlate the Impact of Treatment With Tocilizumab (RoActemra®) on Fatigue and Different Factors Influencing Fatigue in Participants With Rheumatoid Arthritis in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	122	N/A	Spain
674	NCT01393639 (ClinicalTrials.gov)	September 2011	13/6/2011	Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis	A Phase 2, Randomized, Double Blind Assessment Of Efficacy And Safety Of Pf 04171327(1, 5, 10, 15 Mg Dose, Daily) Compared To 5 Mg And 10 Mg Prednisone Daily And Placebo Daily In Subjects With Rheumatoid Arthritis Over An 8 Week Period Followed By A 4 Week Period Of Tapering Of Study Drug.	Rheumatoid Arthritis	Drug: PF-04171327;Drug: prednisone;Other: prednisone;Other: placebo	Pfizer	NULL	Completed	18 Years	N/A	All	323	Phase 2	United States;Bulgaria;Colombia;Czechia;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;Canada;Czech Republic
675	NCT01331837 (ClinicalTrials.gov)	August 2, 2011	7/4/2011	A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors	A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	50 Years	N/A	All	3080	Phase 4	United States;Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czechia;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;Brazil;China;Czech Republic
676	NCT01400516 (ClinicalTrials.gov)	August 2011	21/7/2011	Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial	Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial	Rheumatoid Arthritis	Drug: Teriparatide;Drug: calcium citrate;Drug: Vitamin D;Drug: TNF antagonist	Brigham and Women's Hospital	Eli Lilly and Company	Completed	45 Years	N/A	All	26	Phase 4	United States
677	NCT01390545 (ClinicalTrials.gov)	August 2011	5/7/2011	VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis	VELVET (Veltuzumab Various Doses Exploratory Trial), a Randomized, Double Blind, Placebo Controlled, Multicentre, Multinational Phase II Dose Range Finding Trial in Subjects With Moderate to Severe Rheumatoid Arthritis Insufficiently Controlled With Either Methotrexate Alone or Methotrexate Plus Anti-tumour Necrosis Factor Biological Treatment, Comparing 3 Different Subcutaneous Dosages of Anti-CD20 Monoclonal Antibody Veltuzumab to Placebo as an add-on Therapy to Methotrexate.	Rheumatoid Arthritis	Drug: Veltuzumab	Takeda	NULL	Terminated	18 Years	N/A	Both	300	Phase 2	United States;Argentina;Canada;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Spain;United Kingdom
678	NCT01442545 (ClinicalTrials.gov)	August 2011	23/8/2011	A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants	A Study to Investigate the Effect of Multiple Doses of JNJ 39758979 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients on a Stable Methotrexate Dose	Rheumatoid Arthritis	Drug: JNJ-39758979 / MTX	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	NULL	Completed	18 Years	75 Years	Both	21	Phase 1	United States;Germany
679	NCT01295151 (ClinicalTrials.gov)	August 2011	11/2/2011	SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.	Randomised-controlled Trial of Switching to Alternative Tumour-necrosis Factor (TNF)-Blocking Drugs or Abatacept or Rituximab in Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug	Rheumatoid Arthritis	Drug: Etanercept;Drug: Abatacept;Biological: Rituximab;Drug: Adalimumab;Drug: Certolizumab Pegol;Drug: Infliximab;Drug: Golimumab	Julia Brown	NULL	Completed	18 Years	N/A	Both	122	Phase 4	United Kingdom
680	NCT01414101 (ClinicalTrials.gov)	August 2011	21/7/2011	Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ISIS CRP Rx or Placebo	Isis Pharmaceuticals	NULL	Completed	18 Years	75 Years	Both	51	Phase 2	Canada;Russian Federation
681	NCT01426789 (ClinicalTrials.gov)	August 2011	12/8/2011	A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients	A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension	Rheumatoid Arthritis	Drug: Placebo;Drug: Secukinumab	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	100	Phase 2	United States;Belgium;Germany;Russian Federation;United Kingdom
682	NCT01382940 (ClinicalTrials.gov)	July 26, 2011	24/6/2011	A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis	A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: rituximab;Drug: methotrexate;Drug: methylprednisolone;Drug: acetaminophen;Drug: antihistamine	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	351	Phase 4	United States
683	NCT02433184 (ClinicalTrials.gov)	July 2011	23/4/2015	Very Early Versus Delayed Etanercept in Patients With RA	A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine	University of Leeds	NULL	Completed	18 Years	80 Years	All	120	Phase 4	United Kingdom
684	NCT01410695 (ClinicalTrials.gov)	July 2011	4/8/2011	Masitinib in Refractory Active Rheumatoid Arthritis	A 24-week With Possible Extension, Prospective, Multicenter, Randomised, Double-blind, Controlled, 3-parallel Groups, Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib at 3 and 6 mg/kg/Day to Methotrexate, With a Randomisation 1:1:1, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including at Least One Biologic Drug if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Biologic Drugs	Rheumatoid Arthritis (RA)	Drug: masitinib 3 mg;Drug: masitinib 6.0 mg;Drug: methotrexate;Drug: Placebo (methotrexate);Drug: Placebo (masitinib)	AB Science	NULL	Terminated	18 Years	N/A	All	324	Phase 2/Phase 3	Czechia;Czech Republic;France;United States
685	NCT01215942 (ClinicalTrials.gov)	June 2011	5/10/2010	An Open Label Study for Participants With Rheumatoid Arthritis	A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: LY2127399	Eli Lilly and Company	NULL	Terminated	18 Years	N/A	All	1086	Phase 3	United States;Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;France;Germany;Greece;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sri Lanka;Taiwan;Ukraine;Italy;Peru
686	NCT01373151 (ClinicalTrials.gov)	June 2011	13/6/2011	Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate	A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.	Rheumatoid Arthritis	Drug: BMS-945429 Placebo;Biological: BMS-945429;Drug: Methotrexate;Drug: Methotrexate Placebo;Drug: Adalimumab Placebo;Drug: Adalimumab	CSL Behring	NULL	Completed	18 Years	N/A	All	418	Phase 2	United States;Argentina;Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;Czech Republic;Peru
687	NCT01355354 (ClinicalTrials.gov)	June 2011	17/5/2011	Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects	An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily	Healthy Volunteers;Rheumatoid Arthritis	Drug: Digoxin;Drug: Fostamatinib	AstraZeneca	NULL	Completed	18 Years	45 Years	Both	21	Phase 1	United Kingdom
688	NCT01450982 (ClinicalTrials.gov)	June 2011	13/6/2011	A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants	A Study to Investigate the Effects of JNJ-38518168 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Participants on a Stable Methotrexate Dose	Rheumatoid Arthritis	Drug: JNJ-38518168 / MTX	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	NULL	Completed	18 Years	75 Years	Both	20	Phase 1	United States
689	NCT01384422 (ClinicalTrials.gov)	June 2011	27/6/2011	Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients		Rheumatoid Arthritis	Drug: GLPG0634	Galapagos NV	NULL	Completed	18 Years	70 Years	Both	36	Phase 2	Moldova, Republic of
690	NCT01405118 (ClinicalTrials.gov)	June 2011	7/7/2011	Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers	A Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers	Rheumatoid Arthritis	Drug: Metformin /CP-690,550	Pfizer	NULL	Completed	18 Years	55 Years	Both	24	Phase 1	Belgium
691	NCT01369745 (ClinicalTrials.gov)	June 2011	7/6/2011	A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis	A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisolone;Drug: dipyridamole;Drug: Prednisone;Drug: Z102;Other: placebo	Zalicus	NULL	Completed	18 Years	N/A	All	294	Phase 2	United States
692	NCT01404429 (ClinicalTrials.gov)	May 2011	26/7/2011	Study of Two Different Starting Doses of Methotrexate When Starting Treatment in Rheumatoid Arthritis	Randomized Controlled Trial of Two Different Starting Doses of Methotrexate in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate	Postgraduate Institute of Medical Education and Research	NULL	Completed	18 Years	65 Years	All	100	Phase 4	India
693	NCT01328522 (ClinicalTrials.gov)	May 2011	31/3/2011	Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients		Rheumatoid Arthritis	Drug: SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	75 Years	Both	32	Phase 1	United States
694	NCT01347983 (ClinicalTrials.gov)	May 2011	3/5/2011	Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Tocilizumab +Methotrexate(MTX)	Chugai Pharma Taiwan	NULL	Completed	20 Years	75 Years	Both	72	Phase 3	Taiwan
695	NCT01370902 (ClinicalTrials.gov)	May 2011	31/5/2011	Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Single-dose and Multiple-dose, Dose-escalation Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC 0141-0000-0100;Drug: placebo	Innate Pharma	NULL	Completed	18 Years	75 Years	Both	92	Phase 1	Germany
696	NCT01262118 (ClinicalTrials.gov)	May 2011	15/11/2010	Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis	An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP -690,550 (tasocitinib)	Pfizer	NULL	Completed	18 Years	N/A	All	69	Phase 1	United States;Hungary
697	NCT01283971 (ClinicalTrials.gov)	May 2011	25/1/2011	A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor	A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: adalimumab;Drug: placebo to tocilizumab;Drug: placebo to adalimumab;Drug: methotrexate;Drug: folate	Hoffmann-La Roche	NULL	Terminated	18 Years	N/A	All	96	Phase 4	United States;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom
698	NCT01329991 (ClinicalTrials.gov)	May 2011	4/4/2011	Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate	A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interaction of PLX5622 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate	Rheumatoid Arthritis	Drug: PLX5622;Drug: Placebo	Plexxikon	NULL	Completed	18 Years	N/A	Both	26	Phase 1	United States
699	NCT01416493 (ClinicalTrials.gov)	May 2011	11/8/2011	Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis	An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase (bIAP), an Inflammation Modulating Moiety, in RA Patients	Acute Rheumatoid Arthritis	Drug: s.c. injections of bovine intestinal Alkaline Phosphatase	Alloksys Life Sciences B.V.	Aix Scientifics	Completed	18 Years	N/A	Both	6	Phase 1/Phase 2	United Kingdom
700	NCT01336218 (ClinicalTrials.gov)	April 2011	14/4/2011	Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.	An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin	Rheumatoid Arthritis;Healthy Volunteers	Drug: fostamatinib;Drug: rifampicin	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	15	Phase 1	United States
701	NCT01313520 (ClinicalTrials.gov)	March 1, 2011	25/2/2011	A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)	A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)	Arthritis, Rheumatoid	Drug: Infliximab;Drug: Placebo	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	N/A	All	61	Phase 2	Moldova, Republic of;Romania
702	NCT01332994 (ClinicalTrials.gov)	March 2011	18/3/2011	A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis	Efficacy and Safety Study of a Sequential Therapy of Tocilizumab (TCZ) and, if Initially Inadequately Responded to Tocilizumab (TCZ), Followed by Rituximab (RTX) in DMARD-IR Patients With Rheumatoid Arthritis (MIRAI)	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	519	Phase 3	Germany
703	NCT01309854 (ClinicalTrials.gov)	March 2011	21/2/2011	Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects	An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily	Rheumatoid Arthritis;Healthy Volunteers;Pharmacokinetics;Pioglitazone;Drug-drug Interaction;Amount of Pioglitazone in Blood	Drug: fostamatinib;Drug: pioglitazone	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	15	Phase 1	United States
704	NCT01232569 (ClinicalTrials.gov)	March 2011	1/11/2010	A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab 162 mg;Drug: Placebo	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	656	Phase 3	United States;Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Greece;Guatemala;Hungary;Israel;Malaysia;Mexico;New Zealand;Panama;Philippines;Poland;Russian Federation;South Africa;Spain;Switzerland;Thailand;Peru
705	NCT01299961 (ClinicalTrials.gov)	March 2011	18/2/2011	Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis	Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: abatacept	University of California, Los Angeles	NULL	Completed	18 Years	N/A	All	25	Phase 3	United States
706	NCT01276262 (ClinicalTrials.gov)	March 2011	12/1/2011	Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects	A Single-blind, Placebo-controlled, 2-period, Fixed Sequence Study to Determine the Effects of Coadministration of Fostamatinib 100 mg Twice Daily on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects	Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction;Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction	Drug: fostamatinib;Drug: Microgynon® 30 (Oral contraceptive);Drug: Placebo	AstraZeneca	NULL	Completed	18 Years	45 Years	Female	22	Phase 1	United Kingdom
707	NCT01311622 (ClinicalTrials.gov)	March 2011	21/2/2011	Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects	An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Co-Administered With Fostamatinib in Healthy Subjects	Rheumatoid Arthritis;Healthy Subjects	Drug: warfarin;Drug: fostamatinib	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	15	Phase 1	United Kingdom
708	NCT01313208 (ClinicalTrials.gov)	March 2011	10/3/2011	Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy	Rheumatoid Arthritis	Drug: etanercept;Drug: Placebo;Drug: DMARD Therapy	Amgen	NULL	Completed	18 Years	80 Years	All	210	Phase 4	United States;Canada
709	NCT01353859 (ClinicalTrials.gov)	March 2011	13/5/2011	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs	An Open Label, Local, Multicenter , Phase IIIb Interventional Study to Assess the Efficacy of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) in Indonesian Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	39	Phase 3	Indonesia;Greece
710	NCT01566201 (ClinicalTrials.gov)	March 2011	27/3/2012	Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease	The Effect of Inhibition of Interleukin-1 Activity on Vascular and Left Ventricular Function in Patients With Coronary Artery Disease and Coexistent Rheumatoid Arthritis	Rheumatoid Arthritis;Coronary Artery Disease;Inflammation	Drug: anakinra;Drug: placebo	University of Athens	NULL	Completed	18 Years	N/A	Both	80	N/A	Greece
711	NCT01317797 (ClinicalTrials.gov)	March 2011	18/2/2011	A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis	A Phase Ib Double-blind, Placebo-controlled, Randomized, Dose-escalating Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Subcutaneous Injections of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis on Treatment With Methotrexate	Rheumatoid Arthritis	Drug: namilumab (MT203);Drug: Placebo	Takeda	NULL	Completed	18 Years	N/A	All	24	Phase 1	Bulgaria;Netherlands
712	NCT01294397 (ClinicalTrials.gov)	March 2011	13/1/2011	Effects of Denosumab on the Pharmacokinetics of Etanercept	The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis	Postmenopausal;Osteopenia;Rheumatoid Arthritis;Osteoporosis	Drug: Etanercept;Drug: Denosumab	Amgen	NULL	Terminated	45 Years	80 Years	Female	19	Phase 1	United States
713	NCT01339481 (ClinicalTrials.gov)	February 2011	13/4/2011	A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept	A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept	Rheumatoid Arthritis	Drug: abatacept	Astellas Pharma Inc	Perseid Therapeutics LLC	Completed	18 Years	N/A	Both	26	N/A	United States
714	NCT01235507 (ClinicalTrials.gov)	February 2011	15/10/2010	A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)	Actemra - Local Bosnian Open, Multicentric, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis After Inadequate Response to DMARDs	Rheumatoid Arthritis	Drug: methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	71	Phase 3	Bosnia and Herzegovina
715	NCT02092961 (ClinicalTrials.gov)	February 2011	19/3/2014	Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study	A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Placebo or Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study	Rheumatoid Arthritis	Drug: Fostamatinib;Drug: Adalimumab;Drug: Placebo of Fostamatinib;Drug: Placebo of Adalimumab	AstraZeneca	NULL	Terminated	18 Years	N/A	All	198	Phase 2	United States;Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom
716	NCT01285752 (ClinicalTrials.gov)	February 2011	27/1/2011	A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)		Rheumatoid Arthritis	Drug: AK106-001616;Drug: Active comparator	Asahi Kasei Pharma Corporation	NULL	Completed	18 Years	65 Years	Both	240	Phase 2	Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom
717	NCT01282255 (ClinicalTrials.gov)	February 2011	21/1/2011	Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis	A Randomised, Double Blind, Placebo-controlled, Multiple Dose Trial of Anti-IL-20 (109-0012) in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC109-0012;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	67	Phase 2	Czech Republic;Germany;Italy;Poland;Portugal;Romania;Spain;United Kingdom
718	NCT01254331 (ClinicalTrials.gov)	February 2011	3/12/2010	An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment	Open Label, Multicenter, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	51	Phase 3	Tunisia
719	NCT01242514 (ClinicalTrials.gov)	January 2011	10/11/2010	Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)	(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Fostamatinib	AstraZeneca	NULL	Terminated	18 Years	N/A	All	1917	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;Netherlands;Turkey
720	NCT01270035 (ClinicalTrials.gov)	January 2011	4/1/2011	Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate		Rheumatoid Arthritis	Drug: Adalimumab	Keio University	Saitama Medical University	Recruiting	N/A	N/A	Both	40	Phase 4	Japan
721	NCT01207453 (ClinicalTrials.gov)	January 2011	21/9/2010	Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis	Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Milnacipran;Drug: Placebo	Brigham and Women's Hospital	Forest Laboratories;National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	24 Years	N/A	All	49	Phase 4	United States
722	NCT02586246 (ClinicalTrials.gov)	January 2011	23/10/2015	Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870	Long-term Treatment Study of CDP870 Self-injection. A Multicenter, Open-label, Long-term Safety Study to Evaluate the Safety and Efficacy of CDP870 Self-injection Administered at a Dose of 200 mg Biweekly for 24 Weeks or Longer in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 Administered Concomitantly With or Without Methotrexate (MTX)	Active Rheumatoid Arthritis	Drug: CDP870	Astellas Pharma Inc	UCB Japan Co. Ltd.	Completed	N/A	N/A	Both	86	Phase 3	Japan
723	NCT01264770 (ClinicalTrials.gov)	January 2011	17/12/2010	Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)	(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Fostamatinib and placebo injections;Drug: Adalimumab and placebo of fostamatinib;Drug: Placebo of fostamatinib, fostamatinib, and placebo injections	AstraZeneca	NULL	Terminated	18 Years	N/A	All	644	Phase 2	United States;Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom
724	NCT01737944 (ClinicalTrials.gov)	January 2011	27/11/2012	Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration	Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate (MTX)	Antares Pharma Inc.	NULL	Completed	18 Years	N/A	All	38	Phase 1/Phase 2	United States
725	NCT01351805 (ClinicalTrials.gov)	January 2011	4/5/2011	Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain	Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain	Autoimmune Diseases;Systemic Inflammatory Process;Knee Pain Chronic;Osteoarthritis;Rheumatoid Arthritis	Drug: Fish Oil;Dietary Supplement: Vitamin D;Other: placebo pill	Brigham and Women's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Active, not recruiting	50 Years	N/A	All	25876	N/A	United States
726	NCT01202760 (ClinicalTrials.gov)	January 2011	14/9/2010	A Rheumatoid Arthritis Study in Participants	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)	Rheumatoid Arthritis	Drug: LY2127399;Drug: Placebo	Eli Lilly and Company	NULL	Completed	18 Years	N/A	All	1004	Phase 3	United States;Argentina;Australia;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;Peru
727	NCT01411215 (ClinicalTrials.gov)	January 2011	13/5/2011	A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department	A Non-Interventional Study of the Treatment With Etanercept in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) Subjects in Rheumatology Department	Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: Enbrel	Pfizer	NULL	Terminated	18 Years	N/A	All	160	N/A	China
728	NCT01202773 (ClinicalTrials.gov)	January 2011	14/9/2010	A Study in Participants With Rheumatoid Arthritis	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to One or More TNF-a Inhibitors (FLEX V)	Rheumatoid Arthritis	Drug: LY2127399;Drug: Placebo Q4W;Drug: Placebo Q2W	Eli Lilly and Company	NULL	Terminated	18 Years	N/A	All	456	Phase 3	United States;Argentina;Australia;Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Russian Federation;South Africa;Spain;Taiwan
729	NCT01219933 (ClinicalTrials.gov)	January 2011	11/10/2010	A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)	An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE)	Rheumatoid Arthritis	Drug: methylprednisolone;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	68	Phase 4	Belgium
730	NCT01223911 (ClinicalTrials.gov)	January 2011	14/10/2010	A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC 0151-0000-0000;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	34	Phase 2	Czech Republic;Denmark;Hungary;Poland;Romania;United Kingdom
731	NCT01285310 (ClinicalTrials.gov)	December 9, 2010	19/11/2010	Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Apremilast 30 mg;Drug: Apremilast 20 mg;Drug: Placebo	Amgen	NULL	Terminated	18 Years	N/A	All	237	Phase 2	United States;Czechia;Poland;Spain;Czech Republic
732	NCT01142726 (ClinicalTrials.gov)	December 2010	3/6/2010	Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis	A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Drug: Abatacept placebo;Drug: Methotrexate placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	511	Phase 3	United States;Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;Norway
733	NCT01198002 (ClinicalTrials.gov)	December 2010	8/9/2010	A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate Therapy (FLEX M)	Rheumatoid Arthritis	Drug: LY2127399;Drug: Placebo Q2W;Drug: Placebo Q4W;Drug: Methotrexate	Eli Lilly and Company	NULL	Terminated	18 Years	N/A	All	1041	Phase 3	United States;Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;Peru
734	NCT01258712 (ClinicalTrials.gov)	December 2010	8/12/2010	Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Randomized, Placebo-controlled Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients	Rheumatoid Arthritis (RA)	Drug: Tocilizumab + methotrexate(MTX);Drug: Tocilizumab placebo + methotrexate(MTX)	Chugai Pharma Taiwan	NULL	Completed	20 Years	75 Years	Both	86	Phase 3	Taiwan
735	NCT01236118 (ClinicalTrials.gov)	December 2010	4/11/2010	A Study of LY2439821 in Rheumatoid Arthritis	An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate	Rheumatoid Arthritis	Drug: LY2439821	Eli Lilly and Company	NULL	Completed	20 Years	N/A	All	28	Phase 1	Japan
736	NCT01287858 (ClinicalTrials.gov)	November 2010	12/1/2011	Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects	A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects	Rheumatoid Arthritis	Drug: AC430	Daiichi Sankyo Inc.	NULL	Completed	18 Years	45 Years	Both	88	Phase 1	United States
737	NCT01225393 (ClinicalTrials.gov)	November 2010	18/10/2010	A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis	A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patient With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MLTA3698A;Drug: adalimumab;Drug: leflunomide;Drug: methotrexate;Drug: placebo	Genentech, Inc.	NULL	Completed	18 Years	75 Years	Both	211	Phase 2	Romania;Spain;Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;United States
738	NCT01225991 (ClinicalTrials.gov)	November 2010	20/10/2010	Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis	An Open-label Trial of Milnacipran for the Treatment of Pain in Rheumatoid Arthritis (RA) in Older Adults	Rheumatoid Arthritis	Drug: Milnacipran	University of California, Los Angeles	Forest Laboratories	Completed	50 Years	N/A	All	18	Phase 4	United States
739	NCT01217814 (ClinicalTrials.gov)	November 2010	7/10/2010	Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-a Blockers	A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of MTX in Patients With Active RA Who Have Failed Previous TNF-a Antagonists	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Placebo;Drug: Golimumab;Drug: methotrexate (MTX);Drug: Folic/folinic acid	Sanofi	Regeneron Pharmaceuticals	Terminated	18 Years	75 Years	All	16	Phase 2	United States;Colombia;Czechia;Italy;Mexico;Spain;Brazil;Canada;Czech Republic;Germany;Hungary;Norway
740	NCT01245790 (ClinicalTrials.gov)	November 2010	19/11/2010	A Study of Fostamatinib in Subjects With Impaired Kidney Function	An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg	Rheumatoid Arthritis;Renal Impairment	Drug: fostamatinib	AstraZeneca	NULL	Completed	18 Years	N/A	Both	24	Phase 1	United States
741	NCT01362062 (ClinicalTrials.gov)	October 26, 2010	26/5/2011	Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy	A Study to Observe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti TNF Therapy.	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	110	N/A	India
742	NCT01197144 (ClinicalTrials.gov)	October 2010	3/9/2010	Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab	Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)	Arthritis, Rheumatoid;Pain;Fatigue	Drug: adalimumab;Drug: Placebo	Karolinska Institutet	Abbott;Swedish Foundation for Strategic Research;The Swedish Research Council	Completed	18 Years	N/A	All	70	N/A	Sweden
743	NCT01185353 (ClinicalTrials.gov)	October 2010	18/8/2010	A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy	Arthritis, Rheumatoid	Drug: LY3009104;Drug: Placebo;Drug: Methotrexate	Eli Lilly and Company	Incyte Corporation	Completed	18 Years	75 Years	All	301	Phase 2	United States;Croatia;Czechia;Hungary;India;Mexico;Poland;Romania;Ukraine;Argentina;Czech Republic;Peru;United Kingdom
744	NCT01221636 (ClinicalTrials.gov)	October 2010	13/10/2010	Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept	A Study to Compare the Pharmacokinetics of Abatacept (BMS-188667) Drug Product Using Active Pharmaceutical Ingredient Manufactured With a High Concentration of Metals Relative to the Active Pharmaceutical Ingredient Manufactured With a Low Concentration of Metals	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Withdrawn	18 Years	55 Years	Both	0	Phase 1	United States
745	NCT01098201 (ClinicalTrials.gov)	October 2010	30/3/2010	Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)	The Effect of Certolizumab on Lower Extremity Lymph Flow in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Certolizumab	University of Rochester	NULL	Completed	18 Years	N/A	Both	5		United States
746	NCT01214733 (ClinicalTrials.gov)	October 2010	4/10/2010	A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis	An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	30	Phase 3	South Africa
747	NCT01149057 (ClinicalTrials.gov)	October 2010	22/6/2010	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS	An Open-Label Study to Evaluate the Efficacy and Safety Of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARDs and/or Biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	Clalit Health Services	Completed	18 Years	N/A	All	145	Phase 4	Israel
748	NCT01211249 (ClinicalTrials.gov)	October 2010	28/9/2010	GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis	Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: GLPG0259 oral capsule;Drug: Placebo;Drug: GLPG0259 (Part B);Drug: Placebo (Part B)	Galapagos NV	NULL	Completed	18 Years	70 Years	Both	30	Phase 2	Belgium;Netherlands;Poland;Russian Federation;Ukraine
749	NCT01164579 (ClinicalTrials.gov)	October 2010	15/7/2010	Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)	An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tasocitinib plus Methotrexate;Drug: Tofacitinib plus placebo methotrexate;Drug: Placebo tofacitinib plus Methotrexate	Pfizer	NULL	Completed	18 Years	N/A	All	109	Phase 2	United States;Argentina;Chile;Croatia;Czech Republic;Hungary;Mexico;Poland;Puerto Rico
750	NCT01264211 (ClinicalTrials.gov)	October 2010	28/6/2010	Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)	A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study	Rheumatoid Arthritis	Drug: Diacerein;Drug: Placebo	TRB Chemedica	NULL	Completed	18 Years	65 Years	Both	40	Phase 2	Thailand
751	NCT01781702 (ClinicalTrials.gov)	October 2010	30/1/2013	Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients	A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients	Pelubiprofen;Celebrex;Rheumatoid Arthritis	Drug: Pelubiprofen 30 mg;Drug: Celebrex 200 mg	Daewon Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	80 Years	Both	120	Phase 3	NULL
752	NCT01034306 (ClinicalTrials.gov)	October 2010	16/12/2009	Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis	A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors	Rheumatoid Arthritis	Drug: CF101;Drug: Placebo control	Can-Fite BioPharma	NULL	Completed	18 Years	75 Years	All	79	Phase 2	Bulgaria;Israel
753	NCT01217086 (ClinicalTrials.gov)	October 2010	4/10/2010	Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)	Randomized, Double-blind, Parallel-group, Phase 3 Study	Rheumatoid Arthritis	Drug: Infliximab	Celltrion	NULL	Completed	18 Years	75 Years	Both	617	Phase 3	Korea, Republic of
754	NCT01208181 (ClinicalTrials.gov)	September 27, 2010	22/9/2010	A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)	A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Etoricoxib 60 mg;Drug: Etoricoxib 90 mg;Drug: Placebo to Etoricoxib 60 mg;Drug: Placebo to Etoricoxib 90 mg	Organon and Co	NULL	Completed	18 Years	N/A	All	1404	Phase 3	Argentina;Austria;Canada;Colombia;Czech Republic;Finland;Germany;Guatemala;India;Lithuania;Mexico;Panama;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
755	NCT01184001 (ClinicalTrials.gov)	September 2010	17/8/2010	A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects	A Phase 1, Randomized, 2-Period, 2-Sequence, Open Label, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On Pharmacokinetics Of Tasocitinib (CP-690,550) Tablets In Healthy Subjects	Rheumatoid Arthritis	Drug: Treatment A;Drug: Treatment B	Pfizer	NULL	Completed	21 Years	55 Years	Both	16	Phase 1	Singapore
756	NCT01154647 (ClinicalTrials.gov)	September 2010	28/6/2010	Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes	Unraveling Impaired Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes: a Series of Experiments Targeting Brain Neurotransmission	Fatigue Syndrome, Chronic;Fibromyalgia;Arthritis, Rheumatoid	Drug: citalopram;Drug: 1 ml 0.9 % NaCl	Vrije Universiteit Brussel	Research Foundation Flanders;Universiteit Antwerpen;University Hospital, Antwerp;Artesis University College, Antwerp	Not yet recruiting	18 Years	65 Years	Female	70	N/A	Belgium
757	NCT01197534 (ClinicalTrials.gov)	September 2010	8/9/2010	Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.	(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs	Rheumatoid Arthritis	Drug: fostamatinib;Drug: placebo, fostamatinib	AstraZeneca	NULL	Completed	18 Years	N/A	All	913	Phase 3	United States;Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom
758	NCT01116141 (ClinicalTrials.gov)	September 2010	3/5/2010	A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)	A Phase II, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy	Rheumatoid Arthritis	Drug: CH-4051;Drug: Methotrexate (MTX);Drug: Folic Acid	Chelsea Therapeutics	NULL	Completed	18 Years	80 Years	Both	250	Phase 2	NULL
759	NCT01242917 (ClinicalTrials.gov)	September 2010	15/11/2010	A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy	Rheumatoid Arthritis	Drug: CCX-354 -C;Drug: Placebo;Drug: CCX354 -C	ChemoCentryx	NULL	Completed	18 Years	75 Years	Both	159	Phase 2	Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine
760	NCT01248780 (ClinicalTrials.gov)	September 2010	24/11/2010	Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Golimumab;Drug: Placebo;Drug: Methotrexate (MTX)	Centocor, Inc.	Schering-Plough	Completed	18 Years	N/A	All	264	Phase 3	China
761	NCT01208506 (ClinicalTrials.gov)	September 2010	23/9/2010	First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis	First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis;Healthy	Drug: NNC0114-0000-0005;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	64	Phase 1	Germany
762	NCT01213017 (ClinicalTrials.gov)	September 2010	29/9/2010	The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients	The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: certolizumab pegol	Oklahoma Medical Research Foundation	UCB Pharma	Completed	18 Years	N/A	All	20	Phase 3	United States
763	NCT01197755 (ClinicalTrials.gov)	September 2010	8/9/2010	Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist	(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist	Rheumatoid Arthritis	Drug: fostamatinib;Drug: placebo	AstraZeneca	NULL	Completed	18 Years	N/A	All	323	Phase 3	United States;Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;Australia
764	NCT01194414 (ClinicalTrials.gov)	September 2010	1/9/2010	A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab SC;Drug: tocilizumab IV;Drug: placebo to tocilizumab SC;Drug: placebo to tocilizumab IV;Drug: Disease-modifying antirheumatic drugs (DMARDs)	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	1262	Phase 3	United States;Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom
765	NCT01197521 (ClinicalTrials.gov)	September 2010	8/9/2010	Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.	(OSKIRA-1): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: fostamatinib;Drug: placebo, fostamatinib	AstraZeneca	NULL	Completed	18 Years	N/A	All	923	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Hungary;India;Mexico;Peru;Poland;Slovakia;Ukraine;United Kingdom;Germany;Russian Federation
766	NCT01181050 (ClinicalTrials.gov)	August 2010	12/8/2010	Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)	A Randomised, Single-dose, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0142-0002 in Subjects With Active Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0142-0002;Drug: placebo	Janssen Research & Development, LLC	NULL	Completed	18 Years	75 Years	All	63	Phase 2	Germany;Russian Federation;Ukraine
767	NCT01184092 (ClinicalTrials.gov)	August 2010	16/8/2010	A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)	Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, Cross-Over, Bioequivalence Study Comparing Phase 2b, Phase 3 And Commercial Image Tablet Formulations Of Tasocitinib (CP-690,550) Under Fasted Conditions	Rheumatoid Arthritis	Drug: Treatment A;Drug: Treatment B;Drug: Treatment C	Pfizer	NULL	Completed	21 Years	55 Years	Both	24	Phase 1	Singapore
768	NCT01195272 (ClinicalTrials.gov)	August 2010	2/9/2010	A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.	A 52 Week, Single Center, Open-label Study to Evaluate Neutrophil Function and Survival Effects of Tocilizumab (TCZ) in Patients With Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	21	Phase 4	United Kingdom
769	NCT01593332 (ClinicalTrials.gov)	July 2010	7/1/2012	Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis		DMARD Resistant Rheumatoid Arthritis	Drug: Rituximab	Mashhad University of Medical Sciences	Roche Pharma AG	Completed	19 Years	75 Years	Both	44	Phase 4	Iran, Islamic Republic of
770	NCT01147341 (ClinicalTrials.gov)	July 2010	17/6/2010	Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia	Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase	Rheumatoid Arthritis	Drug: Cimzia;Drug: Placebo	Michael Schiff, MD	UCB Pharma	Completed	18 Years	75 Years	All	37	Phase 4	United States
771	NCT01146652 (ClinicalTrials.gov)	June 21, 2010	15/6/2010	Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)	A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: SAR153191 (REGN88)	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	N/A	All	2023	Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czechia;Ecuador;Estonia;Finland;Germany;Greece;Guatemala;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;Czech Republic
772	NCT01132118 (ClinicalTrials.gov)	June 2010	25/5/2010	Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis	Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis	Rheumatoid Arthritis;Insulin Resistance	Drug: Hydroxychloroquine	Brigham and Women's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	N/A	All	30	Phase 3	United States
773	NCT01143337 (ClinicalTrials.gov)	June 2010	9/6/2010	Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis	A Multicenter Randomized, Double-blind, Placebo-controlled Study of MP-435 in Combination With MTX in Patients With Rheumatoid Arthritis - Exploratory Study	Rheumatoid Arthritis	Drug: MP-435(dose1) + Methotrexate;Drug: Placebo + Methotrexate	Mitsubishi Tanabe Pharma Corporation	NULL	Completed	20 Years	75 Years	All	112	Phase 2	Japan
774	NCT01101555 (ClinicalTrials.gov)	May 12, 2010	8/4/2010	Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study	A Randomised, Single-blind, Placebo-controlled, Study Toevaluate the Safety, Tolerability, Pharmacodynamics Andpharmacokinetics of Repeat Subcutaneous Administration Ofotelixizumab in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: subcutanious administration;Other: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	All	28	Phase 1	Russian Federation
775	NCT01253265 (ClinicalTrials.gov)	May 2010	1/12/2010	A Study in Rheumatoid Arthritis	Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate Treatment	Rheumatoid Arthritis	Drug: LY2439821;Drug: Placebo	Eli Lilly and Company	NULL	Completed	20 Years	75 Years	All	32	Phase 1	Japan
776	NCT01245452 (ClinicalTrials.gov)	May 2010	19/11/2010	Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate	Comparative Study of the Clinical Response and Cardiorespiratory Endurance in Early Rheumatoid Arthritis Patients Treated With Tocilizumab or Methotrexate Addendum Protocol : Global Gene Expression Profiles in Synovial Biopsies	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Methotrexate	Patrick Durez	NULL	Completed	18 Years	70 Years	Both	30	N/A	Belgium
777	NCT01253291 (ClinicalTrials.gov)	May 2010	1/12/2010	A Study of Japanese Rheumatoid Arthritis Participants	An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate	Rheumatoid Arthritis	Drug: LY2127399	Eli Lilly and Company	NULL	Completed	20 Years	75 Years	All	26	Phase 1	Japan
778	NCT01119859 (ClinicalTrials.gov)	May 2010	1/4/2010	A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis	A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Adalimumab;Drug: Placebo to tocilizumab;Drug: Placebo to adalimumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	326	Phase 4	United States;Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;Norway
779	NCT01090570 (ClinicalTrials.gov)	May 2010	15/3/2010	Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate		Rheumatoid Arthritis	Drug: PLX3397	Plexxikon	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 1	United States
780	NCT01059448 (ClinicalTrials.gov)	May 2010	28/1/2010	Safety and Efficacy of AMG 827 in Subjects With RA	A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 827	Amgen	NULL	Terminated	N/A	N/A	Both	211	Phase 2	United States;Bulgaria;Canada;Czech Republic;Latvia;Mexico;Poland;United Kingdom
781	NCT01077531 (ClinicalTrials.gov)	April 28, 2010	25/2/2010	Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis	A Randomized, Placebo-controlled, Single-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Otelixizumab in Rheumatoid Arthritis Subjects	Arthritis, Rheumatoid	Drug: Otelixizumab;Drug: Matching placebo	GlaxoSmithKline	NULL	Terminated	18 Years	75 Years	All	12	Phase 1	Russian Federation;Spain;United Kingdom
782	NCT01067430 (ClinicalTrials.gov)	April 2010	10/2/2010	Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)	Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Etoricoxib;Drug: Diclofenac	Northumbria Healthcare NHS Foundation Trust	NULL	Withdrawn	18 Years	N/A	All	0	Phase 4	United Kingdom
783	NCT01021735 (ClinicalTrials.gov)	April 2010	27/11/2009	Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy	Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy	Rheumatoid Arthritis	Drug: etanercept or adalimumab;Drug: Rituximab	University of Glasgow	Arthritis Research Campaign;NHS Lothian;NHS Grampian;NHS Tayside;NHS Borders;NHS Fife	Completed	18 Years	N/A	Both	302	Phase 4	United Kingdom
784	NCT01313858 (ClinicalTrials.gov)	April 2010	10/3/2011	A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)	Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis	Arthritis, Rheumatoid;Arthritis, Psoriatic;Spondylitis, Ankylosing	Drug: Simponi ®;Drug: Methotrexate	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	N/A	All	1613	N/A	Germany
785	NCT01287533 (ClinicalTrials.gov)	April 2010	30/1/2011	Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids	Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids	Rheumatoid Arthritis;Osteoporosis;Osteopenia	Drug: Ibandronate;Drug: Placebo	Yeong-Wook Song	NULL	Completed	18 Years	75 Years	Female	167	Phase 4	Korea, Republic of
786	NCT01117129 (ClinicalTrials.gov)	April 2010	4/5/2010	A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)	Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study)	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: placebo;Drug: methotrexate;Drug: rituximab [Mabthera/Rituxan]	Hoffmann-La Roche	NULL	Terminated	18 Years	75 Years	Both	2	Phase 4	Spain
787	NCT01060098 (ClinicalTrials.gov)	April 2010	29/1/2010	T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade	T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents	Rheumatoid Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis	Drug: anti-TNF therapy (etanercept or adalimumab)	Imperial College London	NULL	Completed	18 Years	80 Years	All	48		United Kingdom
788	NCT01034397 (ClinicalTrials.gov)	March 2010	16/12/2009	A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs	A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: placebo;Drug: non-biological DMARDs	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	54	Phase 4	Portugal
789	NCT01197066 (ClinicalTrials.gov)	March 2010	17/3/2010	Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis	A Phase ? Multicenter, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate, in Patients With Active Rheumatoid Arthritis Who Participated in Study 101-KOA-0801i	Rheumatoid Arthritis	Drug: Certolizumab Pegol	Korea Otsuka Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	N/A	All	110	Phase 3	Korea, Republic of
790	NCT01256736 (ClinicalTrials.gov)	March 2010	28/10/2010	To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: DMARDs	JW Pharmaceutical	NULL	Completed	18 Years	N/A	Both	89	Phase 3	Korea, Republic of
791	NCT01061736 (ClinicalTrials.gov)	March 2010	2/2/2010	Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients	A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy	Rheumatoid Arthritis	Drug: Sarilumab;Drug: Placebo (for sarilumab);Drug: Methotrexate;Drug: Folic Acid	Sanofi	Regeneron Pharmaceuticals	Completed	18 Years	75 Years	All	1675	Phase 2/Phase 3	United States;Argentina;Australia;Austria;Belarus;Belgium;Brazil;Canada;Chile;Colombia;Czechia;Egypt;Estonia;Finland;Germany;Greece;Hungary;India;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Philippines;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;Czech Republic
792	NCT02010216 (ClinicalTrials.gov)	March 2010	4/12/2013	A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)	Non-Randomized Phase IV Trial on Efficacy and Safety of Actemra in the Treatment of Adult Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	23	Phase 4	Kazakhstan
793	NCT01610791 (ClinicalTrials.gov)	March 2010	31/5/2012	A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)	A Single Arm, Open Label Study to Assess the Safety, Tolerability and Efficacy of Tocilizumab in Active Rheumatoid Arthritis Patients With Inadequate Response to the DMARDs (REMISSION Study)	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	121	Phase 3	Morocco
794	NCT01063062 (ClinicalTrials.gov)	February 28, 2010	3/2/2010	A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)	A Single-arm, Open-label, Multicenter Study of Tocilizumab Monotherapy or in Combination With Methotrexate to Assess Safety and the Efficacy in Reducing Disease Activity in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs (PICTURE)	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	107	Phase 3	Egypt
795	NCT00979771 (ClinicalTrials.gov)	February 2010	17/9/2009	A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GSK706769;Drug: Placebo	GlaxoSmithKline	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2	Netherlands
796	NCT01063803 (ClinicalTrials.gov)	February 2010	2/2/2010	Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis	An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ATN-103	Ablynx	NULL	Completed	18 Years	80 Years	Both	266	Phase 2	United States;Canada;Hungary;Japan;Russian Federation;Serbia;South Africa;Switzerland
797	NCT01038674 (ClinicalTrials.gov)	February 2010	22/12/2009	Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis	A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Dose-escalation, Phase 1 Trial of Anti-IL-20 in Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: anti-IL-20;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	16	Phase 1	Belgium;Poland
798	NCT01052194 (ClinicalTrials.gov)	February 2010	18/1/2010	A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis	A 12-week, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo;Drug: VX-509	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	75 Years	Both	206	Phase 2	United States;Belgium;Croatia;Germany;Hungary;Poland;Puerto Rico;Romania;Russian Federation;Serbia
799	NCT01059864 (ClinicalTrials.gov)	February 2010	28/1/2010	Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550	Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP -690,550;Drug: Atorvastatin;Drug: Atorvastatin Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	111	Phase 2	United States;Korea, Republic of
800	NCT00941707 (ClinicalTrials.gov)	February 2010	16/7/2009	An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis	A Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy With Synovial Biopsy Substudy	Rheumatoid Arthritis	Drug: JNJ 38518168;Drug: Placebo	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	NULL	Terminated	18 Years	75 Years	Both	86	Phase 2	Belgium;Czech Republic;Ireland;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United Kingdom;Ukraine
801	NCT01754805 (ClinicalTrials.gov)	January 22, 2010	19/12/2012	A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis	A Phase 1b, Open-Label, Single Sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: peficitinib;Drug: methotrexate	Astellas Pharma Inc	NULL	Completed	18 Years	65 Years	All	15	Phase 1	United States
802	NCT00752154 (ClinicalTrials.gov)	January 2010	11/9/2008	Curcumin in Rheumatoid Arthritis	Curcumin in Rheumatoid Arthritis - ACross-Over Pilot Study	Rheumatoid Arthritis	Drug: Curcumin (Longvida™)	University of California, Los Angeles	NULL	Recruiting	18 Years	N/A	Both	40	Phase 0	United States
803	NCT01034137 (ClinicalTrials.gov)	January 2010	16/12/2009	A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis	U-ACT-EARLY: A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Evaluate Remission in DMARD and Biological naïve Early Rheumatoid Arthritis (RA) Subjects Treated With Tocilizumab (TCZ) Plus Tight Control Methotrexate (MTX) , TCZ Monotherapy or Tight Control MTX Monotherapy	Rheumatoid Arthritis	Drug: methotrexate;Drug: placebo MTX;Drug: placebo TCZ;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	317	Phase 3	Netherlands
804	NCT01089023 (ClinicalTrials.gov)	January 2010	8/3/2010	A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and the Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti- TNF Therapy.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	95	Phase 4	Bahrain;Iran, Islamic Republic of;Kuwait;Qatar;United Arab Emirates
805	NCT01071798 (ClinicalTrials.gov)	January 2010	18/2/2010	An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis	A Prospective, Multi-center, Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months (in Case of Re-therapy the First 12 Months) of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	1653	N/A	Germany;United States
806	NCT01198509 (ClinicalTrials.gov)	January 2010	8/9/2010	Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)	Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis;Psoriatic Arthritis;Periodontal Disease	Drug: doxycycline;Drug: vancomycin	New York University School of Medicine	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Memorial Sloan Kettering Cancer Center	Completed	18 Years	70 Years	All	178	N/A	United States
807	NCT01039688 (ClinicalTrials.gov)	January 2010	23/12/2009	Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX	Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP -690,550;Drug: Disease-modifying antirheumatic drug	Pfizer	NULL	Completed	18 Years	99 Years	All	956	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;Czech Republic
808	NCT02368093 (ClinicalTrials.gov)	January 2010	4/2/2015	Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis	A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Dextromethorphan hydrobromide	Taichung Veterans General Hospital	TSH Biopharm Corporation Limited	Completed	18 Years	N/A	All	48	N/A	NULL
809	NCT02731560 (ClinicalTrials.gov)	January 2010	6/3/2016	Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)	Efficacy and Safety of Rituximab in Pakistani Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Rituximab	Prof. Abid Z. Farooqi	Aga Khan University;Fatima Memorial Hospital;Fauji Foundation Hospital, Rawalpindi	Completed	18 Years	80 Years	Both	74	Phase 4	NULL
810	NCT01000441 (ClinicalTrials.gov)	December 23, 2009	22/10/2009	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: infliximab , etanercept, adalimumab;Drug: abatacept , rituximab or tocilizumab	University Hospital, Strasbourg, France	NULL	Completed	18 Years	N/A	All	300	Phase 4	France;Monaco
811	NCT01001832 (ClinicalTrials.gov)	December 2009	26/10/2009	Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients	A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Intravenous (IV) abatacept;Drug: Subcutaneous (SC) abatacept	Bristol-Myers Squibb	NULL	Completed	20 Years	N/A	All	118	Phase 2/Phase 3	Japan
812	NCT01029613 (ClinicalTrials.gov)	December 2009	9/12/2009	Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers	Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers	Rheumatoid Arthritis	Drug: Adalimumab	Glostrup University Hospital, Copenhagen	NULL	Completed	18 Years	85 Years	Both	40	N/A	Denmark
813	NCT01008852 (ClinicalTrials.gov)	December 2009	5/11/2009	Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis	Randomized, Parallel, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate	Active Rheumatoid Arthritis	Drug: SBI-087;Drug: Placebo	Pfizer	Emergent Product Development Seattle LLC	Completed	18 Years	N/A	Both	210	Phase 2	United States;Argentina;Canada;Chile;Hungary;Japan;Mexico;Poland;Serbia;Spain;Greece;Turkey
814	NCT01044498 (ClinicalTrials.gov)	December 2009	7/1/2010	A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis	An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Ortho-Novum ® 1/35	Hoffmann-La Roche	NULL	Completed	18 Years	44 Years	Female	46	Phase 3	United States
815	NCT00950989 (ClinicalTrials.gov)	December 2009	30/7/2009	AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate	A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: AMG 827 70 mg;Drug: AMG 827 140 mg;Drug: AMG 827 210 mg;Drug: Placebo;Drug: Stable weekly dose of methotrexate	Amgen	NULL	Completed	18 Years	70 Years	Both	240	Phase 2	Bulgaria;Canada;Czech Republic;Hungary;Latvia;Mexico;Poland;United Kingdom;United States
816	NCT01004432 (ClinicalTrials.gov)	December 2009	29/10/2009	Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)	A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)	Arthritis;Arthritis, Rheumatoid;Autoimmune Diseases	Drug: Golimumab 50 mg SC;Drug: Golimumab 2 mg/kg IV;Drug: Methotrexate (MTX);Drug: Placebo SC;Drug: Placebo IV	Janssen Biotech, Inc.	Merck Sharp & Dohme Corp.	Completed	18 Years	N/A	All	433	Phase 3	United States;Austria;Belgium;Canada;Germany;Greece;Sweden;United Kingdom;France;Spain
817	NCT01027728 (ClinicalTrials.gov)	December 2009	7/12/2009	Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CCX 354 -C	ChemoCentryx	NULL	Completed	18 Years	75 Years	Both	24	Phase 1/Phase 2	Belgium;Romania
818	NCT01023256 (ClinicalTrials.gov)	December 2009	19/11/2009	Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MOR103	MorphoSys AG	NULL	Completed	18 Years	N/A	All	96	Phase 1/Phase 2	Bulgaria;Germany;Netherlands;Poland;Ukraine
819	NCT00844714 (ClinicalTrials.gov)	November 2009	12/2/2009	Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy	Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy	Endothelial Function;Rheumatoid Arthritis;Inflammation	Drug: Rituxan	University of California, San Francisco	Genentech, Inc.	Completed	18 Years	N/A	All	20	N/A	United States
820	NCT00976599 (ClinicalTrials.gov)	November 2009	11/9/2009	A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis	An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP -690,550 + methotrexate;Drug: Placebo + Methotrexate	Pfizer	NULL	Completed	18 Years	N/A	All	29	Phase 2	United States
821	NCT01009879 (ClinicalTrials.gov)	November 2009	5/11/2009	Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants	Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants	Rheumatoid Arthritis	Drug: Etanercept	University of Pittsburgh	Amgen	Withdrawn	18 Years	N/A	Both	0	Phase 4	United States
822	NCT01010581 (ClinicalTrials.gov)	November 2009	9/11/2009	SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SC12267 (4SC-101);Drug: Placebo;Drug: Methotrexate;Drug: Folic Acid	4SC AG	NULL	Completed	18 Years	N/A	Both	266	Phase 2	Bulgaria;Czech Republic;Poland;Romania
823	NCT00996203 (ClinicalTrials.gov)	October 31, 2009	15/10/2009	A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.	Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ)	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: DMARDs (disease-modifying antirheumatic drugs)	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	201	Phase 4	Russian Federation
824	NCT00951275 (ClinicalTrials.gov)	October 31, 2009	30/7/2009	A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Single Arm, Open-label Study of Early Improvement of Anemia and Fatigue During Treatment With Tocilizumab (TCZ) in Combination With DMARDs, in Adult Patients With Moderate to Severe Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	105	Phase 3	Italy
825	NCT01007435 (ClinicalTrials.gov)	October 31, 2009	3/11/2009	A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Placebo to tocilizumab;Drug: Methotrexate;Drug: Placebo to methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	1162	Phase 3	United States;Argentina;Australia;Austria;Brazil;Canada;China;Colombia;Denmark;Finland;France;Germany;Greece;Guatemala;Hong Kong;Hungary;Ireland;Israel;Italy;Macedonia, The Former Yugoslav Republic of;Mexico;New Zealand;Panama;Peru;Philippines;Poland;Portugal;Puerto Rico;Russian Federation;Singapore;South Africa;Spain;Sweden;Thailand;Turkey;United Kingdom;Czech Republic
826	NCT00929864 (ClinicalTrials.gov)	October 2009	29/6/2009	Abatacept Versus Adalimumab Head-to-Head	A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept;Drug: Adalimumab	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	869	Phase 3	United States;Argentina;Canada;Chile;Peru
827	NCT00960440 (ClinicalTrials.gov)	October 2009	14/8/2009	Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors	Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors	Arthritis, Rheumatoid	Drug: CP -690,550;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	399	Phase 3	United States;Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Puerto Rico;Spain;Taiwan;United Kingdom
828	NCT00938587 (ClinicalTrials.gov)	October 2009	13/7/2009	A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis	A Phase 2a, Randomized, Double-Blind, Active And Placebo-Controlled Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: PF-04171327 10 mg;Other: Prednisone Placebo;Drug: PF-04171327 25 mg;Drug: Prednisone 5 mg;Other: Placebo for PF-04171327;Other: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	86	Phase 2	United States;Czechia;Hong Kong;Hungary;Korea, Republic of;Russian Federation;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;Czech Republic
829	NCT01120366 (ClinicalTrials.gov)	October 2009	6/5/2010	Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation	Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation	Rheumatoid Arthritis	Drug: Tocilizumab plus methotrexate;Drug: Tocilizumab	SURPRISE Study Group	NULL	Completed	20 Years	75 Years	Both	233	Phase 4	Japan
830	NCT00996606 (ClinicalTrials.gov)	October 2009	15/10/2009	A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs	Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: DMARDs;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	58	Phase 3	Italy
831	NCT00993317 (ClinicalTrials.gov)	October 2009	9/10/2009	A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis	A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate	Rheumatoid Arthritis	Drug: Placebo of CDP870;Drug: CDP870 200mg;Drug: Methotrexate	Korea Otsuka Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	75 Years	All	127	Phase 3	Korea, Republic of
832	NCT01123655 (ClinicalTrials.gov)	October 2009	12/5/2010	Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients	Phase 1 Trial of CII APL A12 in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: APLA12;Drug: Placebo	VA Office of Research and Development	NULL	Completed	18 Years	85 Years	All	22	Phase 1	United States
833	NCT01211834 (ClinicalTrials.gov)	October 2009	29/9/2010	Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and the Safety During Treatment With Tocilizumab vs Placebo in Combination With Traditional DMARD Therapy in Patients With Moderate to Severe Active RA and an Inadequate Response to Current DMARD Therapy	Rheumatoid Arthritis	Drug: tocilizumab;Drug: DMARDs;Drug: Placebo	JW Pharmaceutical	NULL	Completed	18 Years	N/A	Both	90	Phase 3	Korea, Republic of
834	NCT01075477 (ClinicalTrials.gov)	September 2009	24/2/2010	An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)	Naturalistic Prospective Non-interventional Study on Rheumatoid Arthritis (RA) Patients Treated With Rituximab According to Local Treatment Guidelines	Rheumatoid Arthritis	Drug: rituximab [Mabthera/Rituxan]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	151	N/A	Finland;United States
835	NCT00959036 (ClinicalTrials.gov)	September 2009	13/8/2009	Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis	A Seamless, Phase 1/2, Multiple Ascending Dose, Proof Of Concept Study Of ATN-103 Administered To Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate	Active Rheumatoid Arthritis	Drug: ATN-103;Drug: Placebo;Drug: Methotrexate	Ablynx	NULL	Completed	18 Years	80 Years	Both	252	Phase 1/Phase 2	United States;Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland
836	NCT00984815 (ClinicalTrials.gov)	September 2009	23/9/2009	Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment	Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment	Osteoarthritis;Rheumatoid Arthritis;Chronic Low Back Pain;Chronic Regional Pain Syndrome;Chronic Soft Tissue Pain	Drug: HZT-501	Horizon Pharma Ireland, Ltd., Dublin Ireland	NULL	Completed	40 Years	80 Years	All	86	Phase 3	United States
837	NCT00973479 (ClinicalTrials.gov)	September 2009	4/9/2009	An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Arthritis, Rheumatoid	Drug: Golimumab;Other: Placebo;Drug: methotrexate (MTX)	Centocor, Inc.	Schering-Plough	Completed	18 Years	N/A	All	592	Phase 3	United States;Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine
838	NCT01253226 (ClinicalTrials.gov)	September 2009	1/12/2010	A Study for Japanese Participants With Rheumatoid Arthritis (RA)	Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate	Rheumatoid Arthritis	Drug: LY2127399 (Tabalumab);Drug: Placebo	Eli Lilly and Company	NULL	Completed	20 Years	75 Years	All	32	Phase 1	Japan
839	NCT00913458 (ClinicalTrials.gov)	September 2009	26/5/2009	Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis	A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate	Active Rheumatoid Arthritis;Arthritis, Rheumatoid;Rheumatoid Arthritis	Drug: etanercept	Pfizer	NULL	Completed	18 Years	N/A	All	306	Phase 4	France;Germany;Ireland;Italy;Monaco;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Switzerland;United Kingdom
840	NCT00965653 (ClinicalTrials.gov)	August 2009	18/8/2009	A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis	Open-label, Multicenter, Randomized, Parallel Study to Investigate pk, pd, Efficacy and Safety of Tocilizumab (TCZ, RO4877533) Following Subcutaneous Administration of TCZ 162 mg Weekly or Every Other Week in Combination With Methotrexate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: folic acid;Drug: methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	75 Years	Both	29	Phase 1	Canada;New Zealand;Spain;United Kingdom
841	NCT01224041 (ClinicalTrials.gov)	August 2009	18/10/2010	Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate	Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study	Rheumatoid Arthritis	Drug: Tacrolimus	Astellas Pharma Inc	Astellas Pharma Korea, Inc.	Completed	18 Years	75 Years	Both	78	Phase 4	Korea, Republic of
842	NCT00929357 (ClinicalTrials.gov)	August 2009	25/6/2009	Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment	A Retrospective Evaluation of the Radiographic Efficacy of Different Conventional Systemic Therapies and Biologics in Patients With Rheumatoid Arthritis in Routine Practice.	Rheumatoid Arthritis	Drug: DMARDs or Biologics	Pfizer	NULL	Completed	18 Years	N/A	All	156	N/A	Denmark
843	NCT01870128 (ClinicalTrials.gov)	August 2009	30/5/2013	Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial	Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial	Rheumatoid Arthritis	Drug: Combination Steroid;Drug: Methotrexate;Drug: Combination	All India Institute of Medical Sciences, New Delhi	NULL	Completed	18 Years	60 Years	Both	60	Phase 3	India
844	NCT00965757 (ClinicalTrials.gov)	July 31, 2009	25/8/2009	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: T-614;Drug: Placebo	Eisai Co., Ltd.	FUJIFILM Toyama Chemical Co., Ltd.	Completed	20 Years	69 Years	All	253	Phase 3	Japan
845	NCT00903383 (ClinicalTrials.gov)	July 2009	14/5/2009	Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate	A Phase 2, Multi-center, Randomized, Double Blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy	Rheumatoid Arthritis	Drug: LX3305 low dose;Drug: LX3305 mid dose;Drug: LX3305 high dose;Drug: Placebo	Lexicon Pharmaceuticals	NULL	Completed	18 Years	75 Years	All	208	Phase 2	United States;Bulgaria;Czech Republic;Hungary;Poland;Serbia
846	NCT00928512 (ClinicalTrials.gov)	July 2009	25/6/2009	Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)	A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate	Rheumatoid Arthritis	Drug: Secukinmab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	237	Phase 2	United States;Belgium;Czech Republic;Germany;Hungary;Japan;Korea, Republic of;Poland;Russian Federation;Slovakia;Taiwan;Puerto Rico
847	NCT00977106 (ClinicalTrials.gov)	June 2009	18/8/2009	TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF	Comparative Double Blind Placebo Controlled Clinical Study on Tocilizumab Rapid Efficacy on Patients Relief in rheumatoïd Arthritis With an Inadequate Response to DMARDs or Anti TNF :TORPEDO	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: placebo	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	103	Phase 3	France
848	NCT00927927 (ClinicalTrials.gov)	June 2009	24/6/2009	First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Dose-escalation, Single and Multiple Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0142-0002 Administered Subcutaneously to Subjects With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis	Drug: NNC0142-0002;Drug: placebo	Janssen Research & Development, LLC	NULL	Completed	18 Years	75 Years	All	65	Phase 1	Germany
849	NCT01010503 (ClinicalTrials.gov)	June 2009	9/11/2009	A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.	Evaluation of Adherence and Persistence to Tocilizumab in Combination With Methotrexate or Tocilizumab Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis in Local Environment.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	32	Phase 4	Slovakia
850	NCT00838565 (ClinicalTrials.gov)	May 20, 2009	4/2/2009	Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis	Phase 1, Randomized, Patient And Investigator-blind, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of Pf-04236921 In Patients With Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: dose level 1;Drug: dose level 2;Drug: dose level 3;Drug: dose level 4	Pfizer	NULL	Completed	18 Years	70 Years	All	41	Phase 1	United States;Korea, Republic of;Spain
851	NCT00891020 (ClinicalTrials.gov)	May 2009	29/4/2009	A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)	Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Nonbiologic DMARDs of investigator's choice	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	886	Phase 3	United States;Puerto Rico;United Kingdom
852	NCT00887341 (ClinicalTrials.gov)	May 2009	22/4/2009	A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis	Phase II Multi-centre, Randomized, Parallel Group, Pilot Trial to Compare the Incidence of Tocilizumab Related Infusion Reactions in Moderate to Severe RA Patients When Infusion is Made Over 1 Hour Against 31 Minutes	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	76	Phase 2	Spain
853	NCT00853385 (ClinicalTrials.gov)	May 2009	27/2/2009	A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis	Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate	Rheumatoid Arthritis	Drug: CP 690,550;Drug: CP -690,550;Other: Placebo;Biological: Biologic TNFi	Pfizer	NULL	Completed	18 Years	N/A	All	717	Phase 3	United States;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom
854	NCT00279461 (ClinicalTrials.gov)	May 2009	17/1/2006	Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis	Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells	Arthritis, Rheumatoid;Vitamin D Deficiency	Drug: Placebo in arm A and Vitamin D in arm B;Drug: vitamin D 3 for arm A ,and matching placebo for arm B	Indiana University	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 2	United States
855	NCT00920608 (ClinicalTrials.gov)	May 2009	12/6/2009	A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients	A Phase I, Multi-centre, Open-label, Fixed-sequence Study to Assess the Pharmacokinetics of Methotrexate Alone and When Co-administered With AZD9056 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AZD9056;Drug: Methotrexate	AstraZeneca	NULL	Withdrawn	18 Years	70 Years	Both	12	Phase 1	NULL
856	NCT00902486 (ClinicalTrials.gov)	May 2009	13/5/2009	INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs	A Randomized, Double-blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients With Active RA With Inadequate Response to Any Disease Modifying Anti-Rheumatic Drugs (DMARD) Therapy Including Biologics	Rheumatoid Arthritis	Drug: INCB028050;Drug: Placebo	Incyte Corporation	NULL	Completed	18 Years	N/A	All	127	Phase 2	United States;Czechia;Czech Republic
857	NCT00902369 (ClinicalTrials.gov)	May 2009	14/5/2009	A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)		Rheumatoid Arthritis	Drug: AK106-001616;Drug: Placebo;Drug: Active comparator	Asahi Kasei Pharma Corporation	NULL	Completed	18 Years	65 Years	Both	130	Phase 2	Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom
858	NCT00856544 (ClinicalTrials.gov)	May 2009	3/3/2009	A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications	Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS	Arthritis, Rheumatoid	Drug: CP -690,550;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	795	Phase 3	United States;Australia;Chile;China;Colombia;Croatia;Denmark;Finland;Germany;Greece;Malaysia;Mexico;Poland;Russian Federation;Slovakia;Spain;Sweden;Thailand;United Kingdom;Venezuela
859	NCT00888745 (ClinicalTrials.gov)	May 2009	27/4/2009	A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: placebo;Drug: PRO283698	Genentech, Inc.	NULL	Completed	18 Years	75 Years	Both	65	Phase 1	United States;Hungary;United Kingdom
860	NCT01081717 (ClinicalTrials.gov)	April 14, 2009	4/3/2010	Golimumab Safety and Surveillance Program Using the Ingenix NHI Database	A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments	Rheumatoid Arthritis;Arthritis, Psoriatic;Ankylosing Spondylitis	Drug: systemic non-biological treatments;Biological: anti-TNF biologics;Biological: golimumab;Biological: non-anti-TNF biologics;Other: general population	Janssen Biotech, Inc.	NULL	Completed	N/A	99 Years	All	1064		United States
861	NCT00887770 (ClinicalTrials.gov)	April 2009	23/4/2009	A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart	A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers	Rheumatoid Arthritis	Drug: AZD5672;Drug: Moxifloxacin;Drug: placebo	AstraZeneca	Quintiles Limited	Completed	18 Years	45 Years	Male	64	Phase 1	United Kingdom
862	NCT00763139 (ClinicalTrials.gov)	April 2009	26/9/2008	Inflammation and Insulin Resistance in Rheumatoid Arthritis	Inflammation and Insulin Resistance in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Pioglitazone;Drug: Placebo	Vanderbilt University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	N/A	All	34	N/A	United States
863	NCT01075711 (ClinicalTrials.gov)	April 2009	24/2/2010	Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)	Non-interventional Study for Determining the Improvement in the Activity Status / Life Quality of Patients With Rheumatoid Arthritis Being Treated With the Tempus Tablet	Arthritis, Rheumatoid	Drug: Prednisone	Merck KGaA	Merck Serono GmbH, Germany	Completed	18 Years	N/A	Both	2728	N/A	Germany
864	NCT00928317 (ClinicalTrials.gov)	April 2009	24/6/2009	Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate	Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate	Rheumatoid Arthritis	Drug: ART621;Drug: Placebo	Arana Therapeutics Ltd	NULL	Terminated	18 Years	80 Years	Both	13	Phase 2	United States;Argentina;Australia;Czech Republic;India;Malaysia;New Zealand;Poland
865	NCT00931086 (ClinicalTrials.gov)	April 2009	30/6/2009	Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99	An Expanded Access Trial of Belimumab Antibody (Monoclonal Anti-BLyS Antibody) in Patients With Rheumatoid Arthritis (RA) Who Were Previously Treated Under HGS Protocol LBRA99	Rheumatoid Arthritis	Drug: belimumab	Human Genome Sciences Inc., a GSK Company	GlaxoSmithKline	No longer available	18 Years	N/A	Both		Phase 4	United States
866	NCT00808210 (ClinicalTrials.gov)	March 5, 2009	11/12/2008	A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab	A PHASE II RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE, COMPARED TO INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB	Rheumatoid Arthritis	Drug: Infliximab;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Ocrelizumab;Drug: Placebo	Genentech, Inc.	NULL	Terminated	18 Years	N/A	All	28	Phase 2	United States
867	NCT00882024 (ClinicalTrials.gov)	March 2009	14/4/2009	Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)	A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast With Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients With Active Rheumatoid Arthritis (RA)	Active Rheumatoid Arthritis	Drug: Tranilast;Drug: Placebo	Nuon Therapeutics, Inc.	NULL	Completed	18 Years	75 Years	Both	250	Phase 2	United States;Argentina;Bulgaria;Czech Republic;Germany;Mexico;Serbia;United Kingdom
868	NCT00837434 (ClinicalTrials.gov)	March 2009	3/2/2009	Anti-TNF Agents for the Treatment of Rheumatoid Arthritis	A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Adalimumab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Completed	18 Years	75 Years	All	63	Phase 4	United States
869	NCT00847613 (ClinicalTrials.gov)	March 2009	17/2/2009	A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate	Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate	Arthritis, Rheumatoid	Drug: CP -690,550;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	800	Phase 3	United States;Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Greece;India;Japan;Korea, Republic of;Mexico;Poland;Taiwan;Ukraine;Venezuela
870	NCT00871767 (ClinicalTrials.gov)	March 2009	26/3/2009	AZD5672 Bioavailability Study in Healthy Male and Female Subjects	An Open-Label, Randomized, 4 Period Crossover, Replicate Study to Assess the Relative Bioavailability of the Phase III and Phase IIb Formulations of AZD5672 in Healthy Male and Female Subjects	Rheumatoid Arthritis	Drug: AZD5672	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	24	Phase 1	United Kingdom
871	NCT00687193 (ClinicalTrials.gov)	March 2009	22/5/2008	Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD	Arthritis, Rheumatoid	Drug: Placebo;Drug: CP -690,550	Pfizer	NULL	Completed	20 Years	70 Years	All	318	Phase 2	Japan
872	NCT00845832 (ClinicalTrials.gov)	March 2009	17/2/2009	A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate	A Randomized, Active Controlled, Double-blind, Study to Compare the Safety and Reduction in Disease Activity With the Combination of Rituximab (MabThera®)and Tocilizumab (RoActemra®) Versus Tocilizumab in Patients With Active Rheumatoid Arthritis With an Incomplete Response to Methotrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: rituximab [MabThera/Rituxan];Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Terminated	18 Years	65 Years	All	24	Phase 2	France;Germany;Greece;Netherlands;Poland;Spain;Switzerland;United Kingdom;Belgium;Sweden
873	NCT00850343 (ClinicalTrials.gov)	March 2009	23/2/2009	Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients	A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered Without Coadministration of Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-003)	Rheumatoid Arthritis	Drug: Certolizumab pegol	Astellas Pharma Inc	UCB Japan Co. Ltd.	Completed	20 Years	74 Years	All	208	Phase 3	Japan
874	NCT00810199 (ClinicalTrials.gov)	March 2009	16/12/2008	A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment	Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients...	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: methotrexate;Drug: placebo	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	556	Phase 3	United States;Brazil;Croatia;Denmark;Estonia;France;Germany;Greece;Israel;Italy;Latvia;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Sweden;Thailand;United Kingdom;Monaco
875	NCT00883753 (ClinicalTrials.gov)	March 2009	17/4/2009	An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy	An Extension Phase of the Multi-National Open-Label Study (MA21573) to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	934	Phase 3	Australia;Canada;Czech Republic;France;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Saudi Arabia;Spain;United Kingdom;Austria;Turkey
876	NCT02721004 (ClinicalTrials.gov)	March 2009	2/3/2016	Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis	Documentation of the Efficacy and Safety of RoActemra in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	N/A	N/A	Both	592	N/A	Austria
877	NCT00851318 (ClinicalTrials.gov)	March 2009	23/2/2009	Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients	A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered in Combination With Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-001)	Rheumatoid Arthritis	Drug: Certolizumab pegol;Drug: Methotrexate	Astellas Pharma Inc	UCB Japan Co. Ltd.	Completed	20 Years	74 Years	All	285	Phase 3	Japan
878	NCT00814307 (ClinicalTrials.gov)	February 2009	22/12/2008	A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis	Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP -690,550;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	611	Phase 3	United States;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Dominican Republic;Germany;India;Malaysia;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;Ukraine
879	NCT00847886 (ClinicalTrials.gov)	February 2009	17/2/2009	Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: LX3305;Drug: LX3305 Placebo;Drug: Methotrexate	Lexicon Pharmaceuticals	NULL	Completed	18 Years	N/A	All	15	Phase 1	United States
880	NCT00854685 (ClinicalTrials.gov)	February 2009	1/3/2009	Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate	A Factorial-design, Randomised, Double-blind, Placebo-controlled, Dose Optimisation Study to Investigate the Safety, Efficacy, Immunogenicity and Pharmacokinetics of ART621 Following Multiple Dose Administration in Subjects Diagnosed With Rheumatoid Arthritis Concomitantly Taking Methotrexate	Rheumatoid Arthritis	Drug: ART621;Drug: Placebo	Arana Therapeutics Ltd	Trident Clinical Research Pty Ltd	Completed	18 Years	80 Years	Both	27	Phase 2	Sri Lanka
881	NCT00754572 (ClinicalTrials.gov)	February 2009	17/9/2008	A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	418	Phase 3	Argentina;Brazil;Chile;Colombia;Costa Rica;Ecuador;Mexico;Peru;Uruguay;Venezuela
882	NCT01172639 (ClinicalTrials.gov)	February 2009	28/7/2010	Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.	A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Prednisone	P. Verschueren	Agentschap voor Innovatie door Wetenschap en Technologie	Completed	18 Years	N/A	All	400	Phase 4	Belgium
883	NCT00851240 (ClinicalTrials.gov)	February 2009	2/2/2009	BTT-1023 in Rheumatoid Arthritis	A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Rheumatoid Arthritis - a Double-blind Randomized Placebo-controlled Sequential Group Trial	Rheumatoid Arthritis	Drug: BTT-1023;Drug: Placebo	Biotie Therapies Corp.	NULL	Completed	18 Years	75 Years	Both	24	Phase 1	Bulgaria
884	NCT00777816 (ClinicalTrials.gov)	February 2009	17/10/2008	Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis	A Blinded, Placebo-controlled, Study of the Safety and Pharmacokinetics of XOMA 052 Administered to Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: XOMA 052;Drug: Placebo	XOMA (US) LLC	NULL	Suspended	18 Years	75 Years	Both	18	Phase 2	United States
885	NCT01426347 (ClinicalTrials.gov)	January 2009	29/8/2011	Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis	Vitamin Therapy in Rheumatoid Arthritis	Rheumatoid Arthritis;Vitamin D Deficiency	Drug: Placebo sugar pill;Drug: Ergocalciferol	Johns Hopkins University	NULL	Completed	18 Years	75 Years	All	139	N/A	United States
886	NCT02809833 (ClinicalTrials.gov)	January 2009	20/6/2016	Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine	Tocilizumab for the Treatment of Rheumatoid Arthritis: Findings on The Use of Tocilizumab in Daily Clinical Routine	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	850	N/A	Germany
887	NCT02779114 (ClinicalTrials.gov)	January 2009	16/5/2016	RETRO (REduction of Therapy in RA Patients in Ongoing Remission)	A Phase 3, Multicenter, Randomized, Open, Prospective, Controlled, Parallel Group Study of Reduction of Therapy in Patients With Rheumatoid Arthritis in Ongoing Remission.	Rheumatoid Arthritis	Drug: Control group;Other: Reduction group 1;Other: Reduction group 2	University of Erlangen-Nürnberg Medical School	NULL	Recruiting	18 Years	N/A	Both	318	Phase 3	Germany
888	NCT00838058 (ClinicalTrials.gov)	January 2009	2/2/2009	A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.	An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Controlled And Immediate Release Formulations In Healthy Volunteers	Rheumatoid Arthritis;Healthy Volunteers	Drug: CE-224,535;Drug: CE 224,535	Pfizer	NULL	Completed	18 Years	55 Years	Both	11	Phase 1	United States
889	NCT00858780 (ClinicalTrials.gov)	January 2009	6/3/2009	Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA	Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA)	Rheumatoid Arthritis	Drug: Etanercept;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	91	Phase 4	Denmark;Finland;Hungary;Iceland;Norway;Sweden
890	NCT00848120 (ClinicalTrials.gov)	December 31, 2008	19/2/2009	A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis	An Open Label Study to Evaluate the Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	29	Phase 3	Philippines
891	NCT00815906 (ClinicalTrials.gov)	December 2008	18/12/2008	Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis	An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Japanese Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: SBI-087	Pfizer	Emergent Product Development Seattle LLC	Completed	20 Years	70 Years	Both	20	Phase 1	Japan
892	NCT00767325 (ClinicalTrials.gov)	December 2008	6/10/2008	A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography	Multi-Center, Open Label Study to Assess Early Response to Abatacept With Background Methotrexate Using Power Doppler Ultrasonography in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	104	Phase 3	Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom
893	NCT00818064 (ClinicalTrials.gov)	December 2008	30/12/2008	Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Single- Dose, Dose-escalation Trial of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis	Inflammation;Rheumatoid Arthritis;Healthy	Drug: anti-IL-20;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	75 Years	All	32	Phase 1	Netherlands
894	NCT00810836 (ClinicalTrials.gov)	December 2008	17/12/2008	Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis	A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of BG00012 When Given With Methotrexate to Subjects With Active RA Who Have Had an Inadequate Response to Conventional Disease-Modifying Anti-rheumatic Drug Therapy	Rheumatoid Arthritis	Drug: BG00012;Drug: placebo	Biogen Idec	NULL	Completed	18 Years	75 Years	Both	153	Phase 2	Australia;Canada;Czech Republic;India;Poland;Slovakia
895	NCT00810277 (ClinicalTrials.gov)	November 30, 2008	16/12/2008	A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs	An Open Label Study to Evaluate the Safety and Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARDs.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	14	Phase 3	Finland
896	NCT00791921 (ClinicalTrials.gov)	November 2008	14/11/2008	Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated.	Rheumatoid Arthritis	Drug: CDP870;Drug: Placebo of CDP870	Otsuka Pharmaceutical Co., Ltd.	UCB Japan Co. Ltd.	Completed	20 Years	74 Years	All	230	Phase 3	Japan
897	NCT00796705 (ClinicalTrials.gov)	November 2008	20/11/2008	Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)	Switching Anti-TNF-alpha Agents in Patients With RA With An Inadequate Response to TNF-alpha Inhibition	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Adalimumab placebo;Drug: Etanercept	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Terminated	18 Years	N/A	All	13	Phase 4	United States
898	NCT00948610 (ClinicalTrials.gov)	November 2008	28/7/2009	Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy	Sleep & Immune Mechanisms in Rheumatoid Arthritis: Remicade Substudy	Rheumatoid Arthritis	Drug: Remicade	University of California, Los Angeles	National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	85 Years	All	20	N/A	United States
899	NCT00771030 (ClinicalTrials.gov)	November 2008	9/10/2008	Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 827;Other: Placebo	Amgen	NULL	Completed	18 Years	70 Years	Both	40	Phase 1/Phase 2	Canada;Mexico;United States
900	NCT00791999 (ClinicalTrials.gov)	November 2008	14/11/2008	Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)	A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX.	Rheumatoid Arthritis	Drug: CDP870 400mg;Drug: CDP870 200mg;Drug: CDP870 100mg;Drug: Placebo of CDP870	Otsuka Pharmaceutical Co., Ltd.	UCB Japan Co. Ltd.	Completed	20 Years	74 Years	All	316	Phase 2/Phase 3	Japan
901	NCT00901550 (ClinicalTrials.gov)	November 2008	13/5/2009	The Chinese University of Hong Kong Early Arthritis Study	The Chinese University of Hong Kong Early Arthritis Study	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Infliximab	Chinese University of Hong Kong	NULL	Completed	18 Years	80 Years	Both	40	N/A	China
902	NCT00783536 (ClinicalTrials.gov)	November 2008	29/10/2008	A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis	An Randomized, Open Label, Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate With DMARD Therapy in Subjects With Active Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept + Methotrexate;Drug: DMARDS	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Withdrawn	18 Years	80 Years	All	0	Phase 4	NULL
903	NCT00773461 (ClinicalTrials.gov)	October 31, 2008	15/10/2008	A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.	A Randomized, Double Blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With DMARD Therapy, in Patients With Active Rheumatoid Arthritis and Inadequate Response to Current DMARD Therapy	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Placebo	Hoffmann-La Roche	NULL	Completed	18 Years	70 Years	All	209	Phase 3	China
904	NCT00771329 (ClinicalTrials.gov)	October 2008	10/10/2008	BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: BIIB023;Other: Placebo (sterile normal saline)	Biogen Idec	NULL	Completed	18 Years	65 Years	Both	53	Phase 1	United States;Russian Federation;Ukraine
905	NCT00771420 (ClinicalTrials.gov)	October 2008	10/10/2008	A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis	A Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: CAM-3001;Other: Placebo	MedImmune Ltd	NULL	Completed	18 Years	70 Years	Both	38	Phase 1	Germany
906	NCT00768053 (ClinicalTrials.gov)	October 2008	3/10/2008	Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients	Open-Label Study To Evaluate The EULAR-RAID Score, Rheumatoid Arthritis Impact Of Disease Score, In Rheumatoid Arthritis Patients Eligible To Etanercept And Who Will Receive Etanercept	Rheumatoid Arthritis	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	Lincoln Medical and Mental Health Center;Umanis;SODIA;depolabo	Completed	18 Years	N/A	All	108	Phase 4	France;Monaco
907	NCT00779220 (ClinicalTrials.gov)	October 2008	23/10/2008	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: placebo;Drug: methotrexate;Drug: ocrelizumabu 50mg;Drug: ocrelizumabu 200mg;Drug: ocrelizumab 500mg	Chugai Pharmaceutical	NULL	Terminated	20 Years	N/A	Both	152	Phase 2	Japan
908	NCT01026519 (ClinicalTrials.gov)	September 2008	2/12/2009	A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis	A Single-dose, Double-Blind, Placebo-Controlled, Parallel Group Safety, Tolerability and Pharmacodynamic Study of Subcutaneous REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate	Rheumatoid Arthritis	Drug: REGN88;Other: Placebo	Regeneron Pharmaceuticals	Sanofi	Completed	18 Years	N/A	Both	32	Phase 1	Russian Federation
909	NCT00753454 (ClinicalTrials.gov)	September 2008	5/6/2008	Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)	A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.	Rheumatoid Arthritis	Drug: Certolizumab pegol	UCB Pharma	NULL	Completed	18 Years	N/A	All	168	Phase 3	United States;Canada
910	NCT00746512 (ClinicalTrials.gov)	September 2008	3/9/2008	A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)	A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Access the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler Ultrasound Signal of Synovium in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Prednisone 15 mg;Drug: Placebo Tablets;Drug: Prednisone 7.5 mg;Drug: Placebo Over-Encapsulated Tablets	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	N/A	All	45	Phase 1	United Kingdom
911	NCT00750880 (ClinicalTrials.gov)	September 2008	10/9/2008	An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.	International Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	1681	Phase 3	Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Luxembourg;Netherlands;Poland;Portugal;Romania;Saudi Arabia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
912	NCT00724672 (ClinicalTrials.gov)	September 2008	25/7/2008	A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)	Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.	Rheumatoid Arthritis	Drug: etanercept;Drug: infliximab;Drug: adalimumab	Merck Sharp & Dohme Corp.	NULL	Withdrawn	18 Years	N/A	Both	0	N/A	NULL
913	NCT00717808 (ClinicalTrials.gov)	September 2008	14/7/2008	Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)	A Phase 1, Blinded, Randomised, Crossover Pilot Study to Investigate the Safety, Tolerability and Pharmacokinetics of Tranilast in Patients With Rheumatoid Arthritis on Methotrexate	Rheumatoid Arthritis	Drug: Tranilast;Drug: Placebo comparator	Imperial College London	Nuon Therapeutics, Inc.	Withdrawn	18 Years	75 Years	Both	0	Phase 1	United Kingdom
914	NCT00814866 (ClinicalTrials.gov)	September 2008	23/12/2008	Bone Resorption, Osteoclastogenesis and Adalimumab	Bone Resorption, Osteoclastogenesis and Adalimumab	Rheumatoid Arthritis	Drug: Adalimumab	Université de Sherbrooke	Abbott	Completed	18 Years	N/A	Both	28	N/A	Canada
915	NCT00706797 (ClinicalTrials.gov)	September 2008	25/6/2008	Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects	An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) Added to Methotrexate in Comparison With Usual Treatment in Subjects With Moderate Rheumatoid Arthritis Disease Activity	Rheumatoid Arthritis	Drug: etanercept (EnbrelTM);Drug: methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Terminated	18 Years	N/A	All	141	Phase 4	Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;Austria;Croatia;United States
916	NCT00780793 (ClinicalTrials.gov)	September 2008	27/10/2008	Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study	Effect of TNF-blocker Injections Spacing on Rheumatoid Arthritis Inflammatory Activity in Patients in Clinical Remission or Low Disease Activity	Rheumatoid Arthritis	Drug: progressive spacing of TNF-blocker injections;Drug: DMARD maintenance	Assistance Publique - Hôpitaux de Paris	French Society of Rheumatology	Completed	18 Years	N/A	Both	250	Phase 4	France
917	NCT00718718 (ClinicalTrials.gov)	August 11, 2008	17/7/2008	A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Arthritis, Rheumatoid	Drug: CNTO 136 100 mg;Drug: CNTO 136 50 mg;Drug: CNTO 136 25 mg;Drug: Placebo;Drug: Methotrexate	Centocor, Inc.	NULL	Completed	18 Years	N/A	All	187	Phase 2	United States;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Argentina;Taiwan;Ukraine
918	NCT00754559 (ClinicalTrials.gov)	August 2008	17/9/2008	A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.	Effectiveness After Four and Twentyfour Weeks and Safety of Tocilizumab in Patients With Active RA	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	286	Phase 3	Germany
919	NCT00805467 (ClinicalTrials.gov)	August 2008	5/12/2008	Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies	An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study	Rheumatoid Arthritis	Drug: Fostamatinib Disodium (R935788)	AstraZeneca	NULL	Terminated	18 Years	N/A	All	624	Phase 2	United States;Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania
920	NCT00713544 (ClinicalTrials.gov)	July 2008	9/7/2008	A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis	A Randomised, Double Blind, Placebo Controlled, Phase IIb Dose Ranging Study (With Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate.	Rheumatoid Arthritis	Drug: AZD5672;Drug: Etanercept;Drug: Placebo	AstraZeneca	NULL	Completed	18 Years	N/A	All	373	Phase 2	Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;Argentina;Netherlands;Peru
921	NCT00712114 (ClinicalTrials.gov)	July 2008	6/7/2008	Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis	A Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate	Rheumatoid Arthritis	Drug: HE3286	Harbor Therapeutics	NULL	Completed	18 Years	75 Years	Both	14	Phase 1/Phase 2	United States
922	NCT00782600 (ClinicalTrials.gov)	July 2008	27/10/2008	Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers	A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers	Rheumatoid Arthritis	Drug: suspension IR;Drug: CR 1;Drug: CR 2;Drug: CR 3	Pfizer	NULL	Completed	18 Years	55 Years	Both	16	Phase 1	United States
923	NCT00718588 (ClinicalTrials.gov)	July 2008	16/7/2008	A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MTRX1011A	Genentech, Inc.	NULL	Terminated	18 Years	80 Years	Both	66	Phase 1	United States
924	NCT00717236 (ClinicalTrials.gov)	July 2008	15/7/2008	Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis	A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Certolizumab pegol (CZP);Other: Placebo	UCB Pharma	NULL	Completed	18 Years	N/A	All	1648	Phase 3	United States;Canada;France;Germany;Italy;Netherlands;Spain
925	NCT00729209 (ClinicalTrials.gov)	July 2008	4/8/2008	A Study of ARRY-371797 in Patients With Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: ARRY-371797, p38 inhibitor; oral;Drug: Placebo	Array Biopharma, now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	All	28	Phase 1	United States
926	NCT00700986 (ClinicalTrials.gov)	June 2008	18/6/2008	Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056	A Randomised, Double-Blind, Placebo-Controlled, 2-Period Cross-Over Study in Healthy Male Volunteers, to Investigate Retinal Function Following a Single 800mg Oral Dose of AZD9056	Rheumatoid Arthritis	Drug: AZD9056;Drug: Placebo	AstraZeneca	NULL	Completed	18 Years	65 Years	Male	12	Phase 1	United Kingdom
927	NCT02151409 (ClinicalTrials.gov)	June 2008	28/5/2014	Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects	A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.	Inflammation;Systemic Lupus Erythematosus;Rheumatoid Arthritis;Healthy	Drug: NNC 0151-0000-0000;Drug: placebo	Novo Nordisk A/S	NULL	Completed	18 Years	55 Years	Male	60	Phase 1	Netherlands
928	NCT00711074 (ClinicalTrials.gov)	June 2008	3/7/2008	Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers	An Open-Label, Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of [14C]AZD5672 in Healthy Male Volunteers	Rheumatoid Arthritis	Drug: AZD5672	AstraZeneca	NULL	Completed	50 Years	N/A	Male	4	Phase 1	United Kingdom
929	NCT00147966 (ClinicalTrials.gov)	June 2008	2/9/2005	Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)	Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies	Rheumatoid Arthritis	Drug: rituximab	University of California, San Diego	Genentech, Inc.	Completed	18 Years	75 Years	All	24	Phase 2	United States
930	NCT00665925 (ClinicalTrials.gov)	May 2008	22/4/2008	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate	Rheumatoid Arthritis	Drug: Fostamatinib disodium (R935788);Drug: Placebo	Rigel Pharmaceuticals	NULL	Completed	18 Years	N/A	All	457	Phase 2	United States;Bulgaria;Colombia;Mexico;Poland;Romania;Israel
931	NCT00727987 (ClinicalTrials.gov)	May 2008	31/7/2008	A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Study of Golimumab (CNTO 148) Administered in Combination With Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CNTO 148;Drug: Placebo;Drug: Methotrexate (MTX)	Janssen Pharmaceutical K.K.	Mitsubishi Tanabe Pharma Corporation	Completed	20 Years	74 Years	Both	269	Phase 3	Japan
932	NCT00667758 (ClinicalTrials.gov)	May 2008	24/4/2008	Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis	Antagonist to Gonadotropin-Releasing Hormone in Rheumatoid Arthritis (AGRA): A Double-blind, Randomized, Placebo Controlled Trial	Rheumatoid Arthritis	Drug: Cetrorelix;Drug: Placebo	Betanien Hospital	Norwegian Foundation for Health and Rehabilitation;University of Oslo	Completed	18 Years	N/A	Both	104	Phase 2	Norway
933	NCT00665626 (ClinicalTrials.gov)	May 2008	22/4/2008	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic	Rheumatoid Arthritis	Drug: Fostamatinib disodium (R935788);Drug: Placebo	Rigel Pharmaceuticals	NULL	Completed	18 Years	N/A	All	219	Phase 2	United States;Belgium;Colombia;France;Germany;Italy;Peru;Brazil
934	NCT01224418 (ClinicalTrials.gov)	May 2008	14/10/2010	A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate	Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study	Rheumatoid Arthritis	Drug: Tacrolimus	Astellas Pharma Inc	Astellas Pharma Korea, Inc.	Completed	18 Years	75 Years	Both	50	Phase 4	Korea, Republic of
935	NCT00771251 (ClinicalTrials.gov)	May 2008	10/10/2008	A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)	A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CNTO 148;Drug: Placebo	Janssen Pharmaceutical K.K.	Mitsubishi Tanabe Pharma Corporation;Mitsubishi Tanabe Pharma Corporation	Completed	20 Years	74 Years	Both	311	Phase 3	Japan
936	NCT00695188 (ClinicalTrials.gov)	May 2008	9/6/2008	Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis	Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis A Multicenter, Randomized, Double-blind, Controlled Phase IV Trial	Rheumatoid Arthritis	Drug: methotrexate	Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation	NULL	Completed	18 Years	N/A	All	19	Phase 4	Austria
937	NCT00673920 (ClinicalTrials.gov)	April 24, 2008	5/5/2008	A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy	A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Ocrelizumab;Drug: Placebo	Genentech, Inc.	Roche Pharma AG	Terminated	18 Years	N/A	All	314	Phase 3	United States
938	NCT02622503 (ClinicalTrials.gov)	April 2008	2/12/2015	A Study on Rheumatoid Arthritis Patients Treated With Rituximab	Retrospective Data Collection on Rheumatoid Arthritis (RA) Patients Treated With Rituximab in Finland.	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche	NULL	Completed	N/A	N/A	Both	81	N/A	Finland
939	NCT00658047 (ClinicalTrials.gov)	April 2008	8/4/2008	A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis	A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CH-1504;Drug: Methotrexate (MTX)	Chelsea Therapeutics	NULL	Completed	18 Years	80 Years	Both	201	Phase 2	Canada
940	NCT00661661 (ClinicalTrials.gov)	April 2008	7/2/2008	Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan	A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP -690,550	Pfizer	NULL	Completed	20 Years	N/A	All	487	Phase 3	Japan
941	NCT00674635 (ClinicalTrials.gov)	April 2008	22/4/2008	Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Bayesian Adaptive Dose Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Intravenous Infusions GSK315234A in Patients With Active Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: GSK3152314A;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	Both	135	Phase 2	Australia;New Zealand;Russian Federation;Serbia;Ukraine;Former Serbia and Montenegro;United Kingdom
942	NCT01000610 (ClinicalTrials.gov)	March 17, 2008	21/10/2009	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate;Drug: methylprednisolone	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	18	Phase 4	Tunisia
943	NCT00641225 (ClinicalTrials.gov)	March 2008	18/3/2008	Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis	An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SBI-087	Pfizer	Emergent Product Development Seattle LLC	Completed	18 Years	70 Years	Both	62	Phase 1	United States;Canada
944	NCT00620685 (ClinicalTrials.gov)	March 2008	10/1/2008	A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate	A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate	Arthritis, Rheumatoid	Drug: Placebo;Drug: PH-797804	Pfizer	NULL	Completed	18 Years	N/A	All	27	Phase 2	United States
945	NCT00605735 (ClinicalTrials.gov)	March 2008	18/1/2008	PoC in Rheumatoid Arthritis With Methotrexate	A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate	Rheumatoid Arthritis, NOS	Drug: BMS-582949;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	Both	121	Phase 2	United States;Argentina;Czech Republic;France;Korea, Republic of;Mexico;Spain;Taiwan;Brazil
946	NCT00628095 (ClinicalTrials.gov)	March 2008	25/2/2008	Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CE-224,535, An Antagonist Of The P2x7 Receptor, In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate	Arthritis, Rheumatoid	Drug: CE-224,535;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	Both	100	Phase 2/Phase 3	United States;Chile;Czech Republic;Korea, Republic of;Mexico;Poland;Spain
947	NCT00565409 (ClinicalTrials.gov)	March 2008	28/11/2007	Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Etanercept;Drug: Methotrexate;Drug: Placebo	Pfizer	NULL	Completed	18 Years	70 Years	All	834	Phase 4	Australia;Austria;Belgium;Chile;Colombia;Czech Republic;Former Serbia and Montenegro;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;Brazil;Korea, Democratic People's Republic of;Serbia
948	NCT00634933 (ClinicalTrials.gov)	March 2008	5/3/2008	Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate	Arthritis, Rheumatoid	Drug: TRU-015;Drug: Methylprednisolone;Drug: Prednisone	Pfizer	Trubion Pharmaceuticals/Emergent BioSolutions Inc.	Terminated	18 Years	N/A	All	222	Phase 2	United States;Belgium;Canada;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;Austria
949	NCT02109666 (ClinicalTrials.gov)	March 2008	8/4/2014	Long Term Experience With Abatacept in Routine Clinical Practice	Long Term Experience With Abatacept in Routine Clinical Practice	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	2364	N/A	Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Spain;Switzerland
950	NCT00650767 (ClinicalTrials.gov)	March 2008	31/3/2008	A Study of ARRY-438162 in Patients With Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: ARRY-438162, MEK inhibitor; oral;Drug: Placebo	Array Biopharma, now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	All	201	Phase 2	United States;Argentina;Brazil;Hungary;Peru;Poland;Romania
951	NCT00650078 (ClinicalTrials.gov)	March 2008	28/3/2008	Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis	A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MR prednisone;Drug: Placebo	Horizon Pharma Ireland, Ltd., Dublin Ireland	NULL	Completed	18 Years	80 Years	All	350	Phase 3	United States;Canada;Germany;Hungary;Poland;United Kingdom
952	NCT00556894 (ClinicalTrials.gov)	February 2008	8/11/2007	Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CF101;Drug: Placebo	Can-Fite BioPharma	NULL	Completed	18 Years	75 Years	All	253	Phase 2	Bulgaria;Czechia;Israel;Poland;Serbia;Ukraine;Czech Republic;Former Serbia and Montenegro
953	NCT01072058 (ClinicalTrials.gov)	February 2008	18/2/2010	Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker	Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker	Arthritis, Rheumatoid;Spondylitis, Ankylosing	Drug: TNF blockers (infliximab, adalimumab, etanercept)	University of Sao Paulo	NULL	Active, not recruiting	18 Years	70 Years	Both	100	Phase 4	Brazil
954	NCT01017367 (ClinicalTrials.gov)	February 2008	16/11/2009	Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)	Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: MDX-1100;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	Both	70	Phase 2	Romania;Ukraine
955	NCT00655824 (ClinicalTrials.gov)	January 1, 2008	4/4/2008	Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403	An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo	Arthritis, Rheumatoid	Drug: ofatumumab	GlaxoSmithKline	NULL	Terminated	18 Years	N/A	All	124	Phase 2	United States;Denmark;Hungary;Poland;United Kingdom
956	NCT00611455 (ClinicalTrials.gov)	January 1, 2008	16/1/2008	Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy	A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy	Arthritis, Rheumatoid	Drug: ofatumumab;Drug: Placebo	GlaxoSmithKline	NULL	Terminated	18 Years	N/A	All	265	Phase 3	Argentina;Australia;Belgium;Chile;Czechia;Hungary;Peru;Poland;Romania;Russian Federation;South Africa;Spain;United Kingdom;Czech Republic
957	NCT00603525 (ClinicalTrials.gov)	January 2008	16/1/2008	Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-a Antagonist Therapy	A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Patients With Active Rheumatoid Arthritis Who Have Previously Had an Inadequate Response to One or More TNF Antagonist Therapies	Arthritis, Rheumatoid	Drug: Ofatumumab;Drug: Placebo	GlaxoSmithKline	NULL	Terminated	18 Years	N/A	All	169	Phase 3	Argentina;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;Norway;Peru;Spain;Sweden;United Kingdom
958	NCT00741104 (ClinicalTrials.gov)	January 2008	30/7/2008	A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)	A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients	Rheumatoid Arthritis	Drug: Infliximab	Merck Sharp & Dohme Corp.	NULL	Completed	N/A	N/A	All	363		NULL
959	NCT00603512 (ClinicalTrials.gov)	January 2008	17/1/2008	Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan	A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone	Arthritis, Rheumatoid	Drug: Placebo;Drug: CP -690,550	Pfizer	NULL	Completed	20 Years	70 Years	All	140	Phase 2	Japan
960	NCT00559585 (ClinicalTrials.gov)	January 2008	15/11/2007	Methotrexate-Inadequate Response Study	A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate	Rheumatoid Arthritis (RA)	Drug: Subcutaneous (SC) Abatacept;Drug: Intravenous (IV) Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	2492	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;Austria;Spain
961	NCT01362153 (ClinicalTrials.gov)	December 26, 2007	10/3/2011	A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)	An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Golimumab	Centocor, Inc.	NULL	Completed	18 Years	99 Years	All	49	Phase 1	United States
962	NCT01231321 (ClinicalTrials.gov)	December 2007	28/10/2010	A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis	An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira®) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: adalimumab	Abbott	NULL	Completed	18 Years	N/A	All	100	Phase 3	Russian Federation
963	NCT00576433 (ClinicalTrials.gov)	December 2007	18/12/2007	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.	An Open Label Study to Evaluate the Safety and Effect on Treatment Response of MabThera in Patients With Rheumatoid Arthritis Following Inadequate Response to One Prior Anti-TNF Inhibitor	Rheumatoid Arthritis	Drug: Methotrexate;Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche	NULL	Completed	18 Years	80 Years	Both	60	Phase 4	Russian Federation
964	NCT00647270 (ClinicalTrials.gov)	December 2007	27/3/2008	Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing	A Multi-center, Randomized, Double-blind,Placebo-controlled Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing	Rheumatoid Arthritis	Drug: adalimumab;Drug: Placebo	Abbott	NULL	Completed	18 Years	N/A	All	420	Phase 3	United States;Australia;Canada;Germany;Puerto Rico;United Kingdom
965	NCT00580229 (ClinicalTrials.gov)	December 2007	18/12/2007	A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.	A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: prednisone	University of South Florida	NULL	Completed	18 Years	80 Years	All	50	Phase 2/Phase 3	United States
966	NCT00596206 (ClinicalTrials.gov)	December 2007	4/1/2008	Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis	Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients	Arthritis, Rheumatoid	Drug: leflunomide	Sanofi	NULL	Completed	18 Years	N/A	Both	124	Phase 3	Czech Republic;Italy;Korea, Republic of;Portugal;Romania
967	NCT00963703 (ClinicalTrials.gov)	December 2007	20/8/2009	Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis	Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis Using Rituximab: A Pilot Study Evaluating Synovial Outcomes	Rheumatoid Arthritis	Drug: Rituximab	University of Manitoba	Hoffmann-La Roche	Completed	18 Years	N/A	Both	15	N/A	Canada
968	NCT00547521 (ClinicalTrials.gov)	December 2007	19/10/2007	Phase IIIB Subcutaneous Abatacept Monotherapy Study	A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate	Rheumatoid Arthritis (RA)	Drug: abatacept;Drug: Methotrexate (MTX)	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	119	Phase 3	United States;Australia;Mexico;South Africa;Brazil;Canada;Peru
969	NCT00576706 (ClinicalTrials.gov)	December 2007	17/12/2007	PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity	A Phase III, Randomized, Double-dummy, Double Blind, Misoprostol-comparative Clinical Trial to Evaluate the Efficacy and Safety of Mucosta® Tablet in the Prevention of NSAID-induced Gastrointestinal Complications	Rheumatoid Arthritis;Osteoarthritis;Ankylosing Spondylitis	Drug: Rebamipide;Drug: Misoprostol	Korea Otsuka Pharmaceutical Co.,Ltd.	NULL	Completed	19 Years	N/A	Both	396	Phase 3	Korea, Republic of
970	NCT00580840 (ClinicalTrials.gov)	December 2007	21/12/2007	Dosing Flexibility Study in Patients With Rheumatoid Arthritis	A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Certolizumab pegol;Other: Placebo	UCB Pharma	NULL	Completed	18 Years	N/A	All	333	Phase 4	United States;Canada;France;Austria
971	NCT00302952 (ClinicalTrials.gov)	November 6, 2007	13/3/2006	Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis	A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Lovastatin;Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Terminated	18 Years	70 Years	All	64	Phase 2	United States
972	NCT00533897 (ClinicalTrials.gov)	November 2007	20/9/2007	Phase IIIB Subcutaneous Missed Dose Study	A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	270	Phase 3	United States;Argentina;Canada;Mexico;South Africa;Brazil
973	NCT00554853 (ClinicalTrials.gov)	November 2007	6/11/2007	PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease	Peroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease	Rheumatoid Arthritis	Drug: pioglitazone;Drug: Sublingual nitroglycerine	University of Michigan	National Heart, Lung, and Blood Institute (NHLBI)	Completed	21 Years	100 Years	All	143	Phase 3	United States
974	NCT01245361 (ClinicalTrials.gov)	November 2007	19/11/2010	A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit	A Comparative Study Of A 6-Month Infliximab (Remicade®) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis (RA) : Clinical, Radiological (MRI) And Synovial Benefit P1200/001.	Undifferentiated Arthritis	Drug: Infliximab;Drug: sodium chloride	Patrick Durez	NULL	Completed	N/A	N/A	Both	30	N/A	Belgium
975	NCT00535782 (ClinicalTrials.gov)	October 31, 2007	24/9/2007	A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis	A Mechanism of Action Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) on Lipids, Arterial Stiffness, and Markers of Atherogenic Risk in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA).	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Placebo;Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	75 Years	All	132	Phase 3	United States;Canada;Puerto Rico;United Kingdom
976	NCT00502853 (ClinicalTrials.gov)	October 25, 2007	17/7/2007	A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.	Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	75 Years	All	10	Phase 4	Italy
977	NCT00595517 (ClinicalTrials.gov)	October 2007	7/1/2008	Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Gastric Ulcer;Duodenal Ulcer;Rheumatoid Arthritis;Osteoarthritis;Lumbago	Drug: Esomeprazole 20 mg	AstraZeneca	NULL	Completed	20 Years	N/A	All	395	Phase 3	Japan
978	NCT02699892 (ClinicalTrials.gov)	October 2007	25/2/2016	Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis	Post Marketing Non Interventional Clinical Research of Administration of Rituximab in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab	Hoffmann-La Roche	NULL	Completed	18 Years	80 Years	All	130	N/A	Serbia
979	NCT00550043 (ClinicalTrials.gov)	October 2007	24/10/2007	A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis	A Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: INCB018424;Drug: Placebo	Incyte Corporation	NULL	Completed	18 Years	70 Years	All	50	Phase 2	United States;Poland
980	NCT00531817 (ClinicalTrials.gov)	October 2007	18/9/2007	A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis	A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Placebo;Drug: Permitted DMARDs	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	619	Phase 3	United States;Puerto Rico
981	NCT00545454 (ClinicalTrials.gov)	October 2007	16/10/2007	Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis	Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis (RA): A 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of 90 µg Administered Once Daily and 90 µg Once Every Other Day	Rheumatoid Arthritis	Drug: SSR150106;Drug: Placebos	Sanofi	NULL	Completed	18 Years	75 Years	All	79	Phase 2	Bulgaria;Croatia;Czechia;Romania;Russian Federation;Slovakia;Ukraine;Czech Republic;Former Serbia and Montenegro
982	NCT00626275 (ClinicalTrials.gov)	October 2007	22/2/2008	Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis	A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ADL5859;Drug: Naproxen;Drug: Placebo	Cubist Pharmaceuticals LLC	NULL	Completed	18 Years	75 Years	All	46	Phase 2	United States
983	NCT00934648 (ClinicalTrials.gov)	October 2007	6/7/2009	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate	An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	15	Phase 4	Morocco
984	NCT00551707 (ClinicalTrials.gov)	October 2007	29/10/2007	Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: CRx-102 (2.7/180);Drug: prednisolone;Drug: dipyridamole;Drug: placebo;Drug: CRx-102 (2.7/360)	Zalicus	NULL	Completed	18 Years	N/A	All	51	Phase 2	United States;Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa
985	NCT00554606 (ClinicalTrials.gov)	October 2007	5/11/2007	Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis	A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ACZ885	Novartis	NULL	Completed	18 Years	75 Years	All	115	Phase 2	United States;Belgium;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;Turkey
986	NCT00525213 (ClinicalTrials.gov)	October 2007	4/9/2007	Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate	A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Stable Methotrexate	Rheumatoid Arthritis	Drug: Rob 803;Drug: Placebo	OxyPharma	NULL	Completed	18 Years	N/A	Both	224	Phase 2	Belgium;Bulgaria;Georgia;Latvia;Lithuania;Poland;Romania;Serbia;Sweden;United Kingdom;Former Serbia and Montenegro
987	NCT00539760 (ClinicalTrials.gov)	September 5, 2007	4/10/2007	A Phase I Rheumatoid Arthritis Study in Healthy Volunteers	A Phase I, Randomized, Observer- and Subject-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1827771 in Healthy Volunteers	Arthritis, Rheumatoid	Drug: GSK1827771;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	55 Years	All	45	Phase 1	United States
988	NCT00523692 (ClinicalTrials.gov)	September 2007	30/8/2007	Remission Induction in Very Early Rheumatoid Arthritis	Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy	Rheumatoid Arthritis	Drug: Etanercept , methotrexate and depomedrone;Drug: depemedrone	University Hospital Birmingham	Wyeth is now a wholly owned subsidiary of Pfizer	Not yet recruiting	18 Years	N/A	Both	20	Phase 4	United Kingdom
989	NCT00660647 (ClinicalTrials.gov)	September 2007	10/4/2008	Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)	Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Adalimumab;Drug: Placebo	University of Aarhus	Abbott;Meda Pharmaceuticals;Aarhus University Hospital	Completed	18 Years	N/A	Both	180	Phase 3	Denmark
990	NCT00595413 (ClinicalTrials.gov)	September 2007	7/1/2008	Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)	A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFa-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Placebo matched to atacicept;Drug: Atacicept : with loading dose;Drug: Atacicept;Biological: Adalimumab	EMD Serono	Merck KGaA	Completed	18 Years	N/A	All	311	Phase 2	United States;Germany
991	NCT00613106 (ClinicalTrials.gov)	September 2007	28/1/2008	Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)	Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)	Osteoarthritis;Rheumatoid Arthritis;Chronic Low Back Pain;Chronic Regional Pain Syndrome;Chronic Soft Tissue Pain	Drug: HZT-501;Drug: Ibuprofen	Horizon Pharma Ireland, Ltd., Dublin Ireland	NULL	Completed	40 Years	81 Years	All	179	Phase 3	United States
992	NCT00550446 (ClinicalTrials.gov)	September 2007	25/10/2007	A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis	A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Adalimumab;Drug: CP -690-550;Drug: CP -690,550;Drug: Placebo	Pfizer	NULL	Completed	18 Years	N/A	All	386	Phase 2	United States;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine
993	NCT00411424 (ClinicalTrials.gov)	September 2007	12/12/2006	Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis	Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Initial Efficacy of ASK8007 in Comparison With Placebo in Patients With Active Rheumatoid Arthritis - a Randomized, Double Blind, Placebo-controlled, Combined Single Dose Escalation and Multiple Dose Study	Rheumatoid Arthritis	Drug: ASK8007;Drug: Placebo	Astellas Pharma Inc	NULL	Completed	18 Years	N/A	Both	54	Phase 1/Phase 2	Belgium;Hungary;Ireland;Netherlands;Spain;United Kingdom;France
994	NCT00520572 (ClinicalTrials.gov)	August 2007	22/8/2007	A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)	A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine	Rheumatoid Arthritis	Drug: AZD9056;Drug: Etanercept;Drug: Placebo	AstraZeneca	NULL	Completed	18 Years	N/A	All	385	Phase 2	United States;Argentina;Australia;Belgium;Canada;Czech Republic;France;Mexico;Poland;Romania;Russian Federation;Slovakia;Hungary;Sweden
995	NCT00511329 (ClinicalTrials.gov)	August 2007	2/8/2007	Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease	Growth and the Effect of Genotropin in Chronically Ill Children With Juvenile Rheumatoid Arthritis and With Crohn's Disease	Arthritis, Juvenile Rheumatoid;Crohn Disease	Drug: somatropin [rDNA origin] for injection	Nationwide Children's Hospital	Pfizer	Terminated	5 Years	17 Years	All	10	Phase 2/Phase 3	United States
996	NCT00517543 (ClinicalTrials.gov)	August 2007	16/8/2007	A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability	A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553	Chronic Obstructive Pulmonary Disease (COPD);Rheumatoid Arthritis;Atherosclerosis	Drug: GW856553	GlaxoSmithKline	NULL	Completed	18 Years	60 Years	Both	36	Phase 1	United States
997	NCT00505089 (ClinicalTrials.gov)	August 2007	19/7/2007	Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis	An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: ACZ885	Novartis	NULL	Terminated	18 Years	75 Years	Both	11	Phase 1/Phase 2	Belgium;Germany;Netherlands;Poland
998	NCT00542789 (ClinicalTrials.gov)	August 2007	11/10/2007	Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID	A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Gastric Ulcer;Duodenal Ulcer;Rheumatoid Arthritis;Osteoarthritis;Lumbago	Drug: Esomeprazole;Drug: Placebo	AstraZeneca	NULL	Completed	20 Years	N/A	All	343	Phase 3	Japan
999	NCT00760968 (ClinicalTrials.gov)	August 2007	24/9/2008	Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: TAK-783 and methotrexate;Drug: Methotrexate	Takeda	NULL	Completed	18 Years	N/A	Both	224	Phase 2	Czech Republic;Latvia;Romania;Russian Federation;Slovakia;Ukraine
1000	NCT03414502 (ClinicalTrials.gov)	August 2007	2/1/2014	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Abatacept;Drug: Adalimumab;Drug: Azathioprine;Drug: Baricitinib;Drug: Certolizumab;Drug: Etanercept;Drug: Golimumab;Drug: Hydroxychloroquine;Drug: Infliximab;Drug: Leflunomide;Drug: Minocycline;Drug: Rituximab;Drug: Sarilumab;Drug: Sulfasalazine;Drug: Tofacitinib	University of Nebraska	NULL	Recruiting	19 Years	N/A	All	400	Phase 3	United States
1001	NCT00523328 (ClinicalTrials.gov)	August 2007	17/8/2007	BG9924 in Combination With Methotrexate Extension of Study 104RA203	An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects With Rheumatoid Arthritis Who Previously Participated in Study 104RA203	Rheumatoid Arthritis	Drug: BG9924	Biogen Idec	NULL	Terminated	18 Years	75 Years	Both	72	Phase 2	United States;Belgium;Canada;United Kingdom
1002	NCT00550355 (ClinicalTrials.gov)	August 2007	25/10/2007	Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis	A Randomized, Subject and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PD-0360324 in Patients With Rheumatoid Arthritis Receiving Methotrexate	Arthritis, Rheumatoid	Drug: PD 0360324;Drug: Placebo	Pfizer	NULL	Completed	21 Years	70 Years	Both	78	Phase 1	United States;Argentina;Bulgaria;Czech Republic;Mexico;Poland;Slovakia;Spain
1003	NCT00597818 (ClinicalTrials.gov)	August 2007	10/1/2008	Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury	A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients	NSAID-induced Gastroduodenal Injury;Ulcers;Rheumatoid Arthritis;Osteoarthritis	Drug: Cobiprostone;Drug: Placebo;Drug: Non-steroidal anti-inflammatory drug	Sucampo Pharma Americas, LLC	NULL	Completed	40 Years	70 Years	All	121	Phase 2	United States
1004	NCT00502840 (ClinicalTrials.gov)	July 23, 2007	17/7/2007	A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.	An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070).	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche	NULL	Completed	18 Years	75 Years	All	193	Phase 3	Germany
1005	NCT00555230 (ClinicalTrials.gov)	July 2007	7/11/2007	Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis	Effects of HMG-coA Reductase Inhibitor on Progression of Carotid Intima-Media Thickness and Arterial Stiffness in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rosuvastatin;Drug: Placebo	Chinese University of Hong Kong	NULL	Completed	18 Years	75 Years	Both	150	Phase 2	China
1006	NCT00405275 (ClinicalTrials.gov)	July 2007	29/11/2006	Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy	CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Etanercept;Drug: methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine;Drug: Placebo, triple;Drug: Placebo, etanercept	VA Office of Research and Development	Canadian Institutes of Health Research (CIHR);Rheumatoid Arthritis Investigational Network (RAIN);National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	N/A	All	353	N/A	United States;Canada
1007	NCT00504777 (ClinicalTrials.gov)	July 2007	19/7/2007	A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.	An Open Label Study to Evaluate the Safety, and Effect on Treatment Response, of MabThera in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One or More Anti-TNF Agents.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	36	Phase 4	Taiwan
1008	NCT00503139 (ClinicalTrials.gov)	July 2007	16/7/2007	Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan	Enbrel Special Use Result Surveillance	Rheumatoid Arthritis	Drug: Enbrel (etanercept)	Pfizer	NULL	Completed	10 Years	N/A	All	684		Japan
1009	NCT00485589 (ClinicalTrials.gov)	June 11, 2007	11/6/2007	A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)	A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Ocrelizumab;Drug: Placebo	Genentech, Inc.	Roche Pharma AG	Terminated	18 Years	N/A	All	613	Phase 3	United States
1010	NCT00896168 (ClinicalTrials.gov)	June 2007	7/5/2009	An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis	A Multi-Center, Pre-Marketing Clinical Trial to Evaluate the Efficacy and Safety of Infliximab Treatment on Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Infliximab;Drug: Methotrexate	Xian-Janssen Pharmaceutical Ltd.	NULL	Completed	18 Years	65 Years	All	234	Phase 4	NULL
1011	NCT00462345 (ClinicalTrials.gov)	June 2007	18/4/2007	A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.	An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Treatment Response in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies	Rheumatoid Arthritis	Drug: rituximab;Drug: Methotrexate;Drug: Corticosteroid or NSAID;Dietary Supplement: Folate	Hoffmann-La Roche	NULL	Completed	18 Years	80 Years	All	40	Phase 4	Korea, Republic of
1012	NCT00422227 (ClinicalTrials.gov)	June 2007	11/1/2007	Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region	A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept , Methotrexate;Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	70 Years	All	300	Phase 4	Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand
1013	NCT00447759 (ClinicalTrials.gov)	June 2007	14/3/2007	The Standard Care Versus Celecoxib Outcome Trial	Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's	Osteoarthritis;Rheumatoid Arthritis	Drug: Celecoxib;Drug: Diclofenac	University of Dundee	University of Glasgow;University of Nottingham	Completed	60 Years	N/A	All	7297	Phase 4	Denmark;Netherlands;United Kingdom
1014	NCT00476996 (ClinicalTrials.gov)	May 15, 2007	18/5/2007	A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-a Therapy (SCRIPT)	A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-a Therapy	Rheumatoid Arthritis	Drug: Leflunomide;Drug: Methotrexate;Drug: Ocrelizumab;Drug: Placebo	Genentech, Inc.	Roche Pharma AG	Terminated	18 Years	N/A	All	836	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;New Zealand;Panama;Peru;Poland;Slovakia;Slovenia;Spain;Sweden;Switzerland;Taiwan
1015	NCT00455208 (ClinicalTrials.gov)	May 2007	30/3/2007	A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis	Study Evaluating Cura-100 in Rheumatoid Arthritis and Osteoarthritis	Rheumatoid Arthritis;Osteoarthritis	Drug: Cura-100	Cura Biotech LLC	NULL	Not yet recruiting	20 Years	50 Years	Both	20	Phase 1/Phase 2	United States
1016	NCT00578565 (ClinicalTrials.gov)	May 2007	19/12/2007	Rituximab in Rheumatoid Arthritis Lung Disease	Rituximab for the Treatment of Rheumatoid Arthritis-Associated Interstitial Pneumonia: A Pilot Study	Rheumatoid Arthritis;Interstitial Pneumonia	Drug: Rituximab	Eric Matteson	Genentech, Inc.;National Center for Research Resources (NCRR)	Completed	18 Years	80 Years	All	10	Phase 3	United States
1017	NCT00420199 (ClinicalTrials.gov)	May 2007	8/1/2007	A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate	Active Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	50	Phase 3	Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;Austria
1018	NCT00480272 (ClinicalTrials.gov)	May 2007	29/5/2007	Prospective Study on Intensive Early Rheumatoid Arthritis Treatment	A Phase IV Multicenter, Randomized, Double-blind Study. prospeCtive Study on Intensive Early Rheumatoid Arthritis Treatment With adalimUmab: Induction of REmission and Maintenance	Rheumatoid Arthritis	Drug: adalimumab , plus prednisone;Drug: adalimumab plus placebo	IRCCS Policlinico S. Matteo	NULL	Completed	18 Years	70 Years	All	251	Phase 4	Italy
1019	NCT00443430 (ClinicalTrials.gov)	May 2007	2/3/2007	Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis	Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA)	Juvenile Chronic Polyarthritis;Juvenile Idiopathic Arthritis;Juvenile Rheumatoid Arthritis	Drug: methotrexate;Drug: methotrexate - etanercept - prednisolone arm	Seattle Children's Hospital	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Amgen	Completed	2 Years	17 Years	All	85	Phase 4	United States
1020	NCT00760669 (ClinicalTrials.gov)	May 2007	24/9/2008	An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants	Post Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Patients	Spondylitis, Ankylosing;Arthritis, Rheumatoid;Psoriasis;Arthritis, Psoriatic	Drug: Infliximab; observational study;Drug: Methotrexate	Janssen Korea, Ltd., Korea	NULL	Completed	N/A	N/A	All	1061		Korea, Republic of
1021	NCT00504595 (ClinicalTrials.gov)	May 2007	19/7/2007	Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis	A 12-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR20) and to Determine a Biomarker Profile in Adult Patients With Established Rheumatoid Arthritis Responding to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) as Compared to Healthy Subjects Exposed to ACZ885	Rheumatoid Arthritis	Drug: ACZ885 (investigational);Drug: Placebo	Novartis	NULL	Completed	18 Years	75 Years	All	80	Phase 2	Russian Federation;Spain;Switzerland;Turkey
1022	NCT00989235 (ClinicalTrials.gov)	April 2007	2/10/2009	Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis	A Phase 3B, Multi-Center, Randomized, Double-blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate-naïve Early Erosive Rheumatoid Arthritis Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate - Low Dose Sub-Study	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	108	Phase 3	NULL
1023	NCT00484237 (ClinicalTrials.gov)	April 2007	7/6/2007	A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis	A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Safety and Efficacy of Etanercept 10 mg Twice Weekly and 25 mg Once Weekly in Japanese Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	20 Years	75 Years	Both	80	Phase 3	Japan
1024	NCT00409838 (ClinicalTrials.gov)	April 2007	8/12/2006	A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept Administered Intravenously in Korean Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	113	Phase 3	Korea, Republic of
1025	NCT00446784 (ClinicalTrials.gov)	April 2007	9/3/2007	Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis	A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate	Arthritis, Rheumatoid	Drug: CE-224,535;Drug: Methotrexate	Pfizer	NULL	Completed	18 Years	N/A	Both	20	Phase 1	United States
1026	NCT00414661 (ClinicalTrials.gov)	April 2007	19/12/2006	Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550	A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550	Arthritis, Rheumatoid	Drug: CP -690,550	Pfizer	NULL	Completed	18 Years	N/A	All	162	N/A	United States;Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Dominican Republic;Finland;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Slovakia;Spain;Ukraine;Australia;Austria;Belgium;Costa Rica;Romania;Sweden
1027	NCT04144101 (ClinicalTrials.gov)	March 1, 2007	28/10/2019	Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis	Comparison of Lower Dosage of Etoricoxib Versus Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis: A Single-center, Parallel-group, Randomized Controlled Pilot Study	Rheumatoid Arthritis	Drug: Etoricoxib;Drug: Aceclofenac	Chung Shan Medical University	NULL	Completed	20 Years	80 Years	All	40	Phase 4	NULL
1028	NCT00487825 (ClinicalTrials.gov)	March 2007	18/6/2007	Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis	A 26-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR50) and to Determine a Biomarker Profile in Responders to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) Plus MTX as Compared to MTX Alone in Early Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Canakinumab (investigational);Drug: Placebo;Drug: Methotrexate (MTX)	Novartis	NULL	Completed	18 Years	75 Years	All	78	Phase 2	United States;Belgium;Germany;Italy;Netherlands;Spain
1029	NCT00458861 (ClinicalTrials.gov)	March 2007	22/3/2007	BG9924 in Combination With Methotrexate for Subjects With Active Rheumatoid Arthritis	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF	Rheumatoid Arthritis	Drug: BG9924;Other: Placebo Comparator	Biogen Idec	NULL	Terminated	18 Years	75 Years	Both	115	Phase 2	United States
1030	NCT00462072 (ClinicalTrials.gov)	March 2007	17/4/2007	Centocor Microarray Study of Patients	Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases	Rheumatoid Arthritis;Psoriatic Arthritis;Psoriasis;Crohn's Disease	Drug: Infliximab	University of Rochester	Centocor, Inc.	Completed	12 Years	N/A	All	31	Phase 4	United States
1031	NCT00913432 (ClinicalTrials.gov)	March 2007	3/6/2009	Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis	A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open Label, Uncontrolled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of AB1010 at 3 and 6 mg/kg/Day in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including Anti TNF Alpha if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Anti TNF Alpha	Rheumatoid Arthritis	Drug: masitinib	AB Science	NULL	Completed	18 Years	N/A	All	20	Phase 2	NULL
1032	NCT00413699 (ClinicalTrials.gov)	February 5, 2007	18/12/2006	Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis	A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: CP -690,550	Pfizer	NULL	Completed	18 Years	N/A	All	4488	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czechia;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;Czech Republic;United States Minor Outlying Islands
1033	NCT00458146 (ClinicalTrials.gov)	February 2007	5/4/2007	A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis	A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: MM-093	Merrimack Pharmaceuticals	NULL	Completed	18 Years	80 Years	Both	100	Phase 2	United States
1034	NCT00418717 (ClinicalTrials.gov)	February 2007	2/1/2007	Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA	An Open-label, Multicenter, Dose-regimen Study Evaluating the Efficacy and Safety of Etanercept 50 mg Once-weekly Dose in Japanese Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	20 Years	75 Years	All	42	Phase 3	Japan
1035	NCT00427934 (ClinicalTrials.gov)	February 2007	25/1/2007	Maraviroc in Rheumatoid Arthritis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate	Arthritis, Rheumatoid	Drug: Maraviroc;Drug: Maraviroc Placebo	Pfizer	NULL	Terminated	18 Years	N/A	All	128	Phase 2	United States;Australia;Germany;India;Italy;Mexico;Portugal;Spain;Ukraine
1036	NCT00716248 (ClinicalTrials.gov)	January 2007	8/7/2008	Bucillamine Study of Holding Remission After Infliximab Dose-off	The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: bucillamine;Drug: methotrexate	Saitama Medical University	Keio University	Active, not recruiting	20 Years	N/A	Both	40	Phase 4	Japan
1037	NCT00443651 (ClinicalTrials.gov)	January 2007	2/3/2007	A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis	An Open-Label, Prospective Study of the Safety of Rituximab in Combination With Other Disease-Modifying Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab;Drug: Anti-inflammatory drugs	Genentech, Inc.	Biogen	Completed	18 Years	80 Years	All	578	Phase 3	United States
1038	NCT00413660 (ClinicalTrials.gov)	January 2007	18/12/2006	Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis	A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone	Arthritis, Rheumatoid	Drug: CP -690,550;Other: placebo	Pfizer	NULL	Completed	18 Years	N/A	All	509	Phase 2	United States;Argentina;Brazil;Bulgaria;Chile;Czech Republic;Hungary;Mexico;Poland;Slovakia;Spain;Sweden;Turkey
1039	NCT00424502 (ClinicalTrials.gov)	January 2007	18/1/2007	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.	An Open-label Study to Evaluate the Effect of MabThera on Treatment Response in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Previous TNF Inhibition.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	20	Phase 4	Hungary
1040	NCT00427804 (ClinicalTrials.gov)	January 2007	25/1/2007	Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption	Tumor Necrosis Factor-a Induces Vitamin D Resistance in Small Intestinal Calcium Absorption	Rheumatoid Arthritis;Crohn's Disease	Drug: calcitriol	Atlanta VA Medical Center	Emory University	Completed	18 Years	50 Years	Male	9	N/A	United States
1041	NCT02886689 (ClinicalTrials.gov)	January 2007	29/8/2016	C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France	C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France	Arthritis, Rheumatoid;Spondylitis, Ankylosing;Arthritis, Psoriatic;Arthitis, Juvenile Idiopathic	Drug: TNF-alpha antagonist and other biotherapy	Central Hospital, Nancy, France	NULL	Completed	3 Years	75 Years	Both	5400	N/A	France
1042	NCT00406419 (ClinicalTrials.gov)	December 27, 2006	30/11/2006	A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)	A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment	Rheumatoid Arthritis	Drug: Methotrexate;Drug: ocrelizumab;Drug: Placebo	Genentech, Inc.	Roche Pharma AG	Terminated	18 Years	N/A	All	1015	Phase 3	United States
1043	NCT00430495 (ClinicalTrials.gov)	December 2006	30/1/2007	A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)	A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy	Rheumatoid Arthritis	Drug: Atacicept;Drug: Placebo matched to atacicept	EMD Serono	Merck KGaA	Completed	18 Years	N/A	All	256	Phase 2	United States;Canada
1044	NCT00484289 (ClinicalTrials.gov)	December 2006	7/6/2007	A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis	A Phase III, Multi-center, Open-label, Uncontrolled, Long-term Study to Evaluate the Safety of Abatacept (BMS-188667) in Japanese Subjects With Rheumatoid Arthritis Having Completed Clinical Studies IM101-071, IM101-034, and Also Special DMARD Failures	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	20 Years	N/A	All	217	Phase 3	Japan
1045	NCT00392951 (ClinicalTrials.gov)	December 2006	24/10/2006	Sirolimus for Autoimmune Disease of Blood Cells	Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series	Autoimmune Pancytopenia;Autoimmune Lymphoproliferative Syndrome (ALPS);Evans Syndrome;Idiopathic Thrombocytopenic Purpura;Anemia, Hemolytic, Autoimmune;Autoimmune Neutropenia;Lupus Erythematosus, Systemic;Inflammatory Bowel Disease;Rheumatoid Arthritis	Drug: sirolimus	Children's Hospital of Philadelphia	NULL	Completed	1 Year	30 Years	All	30	Phase 1/Phase 2	United States
1046	NCT00420927 (ClinicalTrials.gov)	December 2006	9/1/2007	Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis	A Multicenter, Randomized, Double-Period, Double - Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)	Rheumatoid Arthritis	Drug: methotrexate;Biological: placebo;Biological: adalimumab	Abbott	NULL	Completed	18 Years	N/A	All	1032	Phase 4	United States;Argentina;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Slovakia;South Africa;Spain;Sweden;United Kingdom;Greece
1047	NCT00425321 (ClinicalTrials.gov)	December 2006	19/1/2007	Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: RWJ-445380 100 mg;Drug: RWJ-445380 200 mg;Drug: RWJ-445380 300 mg;Drug: Placebo	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	NULL	Completed	18 Years	N/A	Both	259	Phase 2	United States;Argentina;Brazil;Czech Republic;Germany;Mexico;Poland
1048	NCT00440492 (ClinicalTrials.gov)	December 2006	23/2/2007	Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis	An Open-Label Study To Evaluate The Potential Pharmacokinetic Interaction Between PLA-695 And Methotrexate When Coadministered Orally To Adult Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: PLA-695	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	75 Years	Both		Phase 1	United States;Canada
1049	NCT00383188 (ClinicalTrials.gov)	December 2006	28/9/2006	An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis	A 12-Week, Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Safety, Pharmacokinetics, And Efficacy Of PH-797804, Administered Orally Once Daily In Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: placebo;Drug: PH-797804	Pfizer	NULL	Completed	18 Years	N/A	Both	305	Phase 2	Australia;Brazil;Chile;Czech Republic;Estonia;India;Korea, Republic of;Peru;Poland;Russian Federation;South Africa;Spain
1050	NCT00413452 (ClinicalTrials.gov)	December 2006	15/12/2006	Etanercept SFP in RA Patients	Open-Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Etanercept	Amgen	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	18 Years	N/A	Both	224	Phase 3	United States;Canada
1051	NCT02079532 (ClinicalTrials.gov)	November 2006	4/3/2014	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor	An Open-label Study to Evaluate the Safety of MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent	Rheumatoid Arthritis	Drug: rituximab [MabThera]	Hoffmann-La Roche	NULL	Completed	18 Years	75 Years	All	302	Phase 3	Germany
1052	NCT00761514 (ClinicalTrials.gov)	November 2006	25/9/2008	Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira	Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR)	Rheumatoid Arthritis	Drug: Humira (adalimumab)	Abbott	NULL	Terminated	18 Years	N/A	All	14	Phase 4	Puerto Rico
1053	NCT00396812 (ClinicalTrials.gov)	November 2006	6/11/2006	Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)	An Open Label, Single Arm, Single Center, Phase I/II Trial of Rituximab (a Monoclonal Antibody to CD20) for the Treatment of Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Terminated	18 Years	N/A	All	4	Phase 1/Phase 2	United States
1054	NCT00424346 (ClinicalTrials.gov)	November 2006	17/1/2007	Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis	A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) With Three Different Dose Regimens in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate Including 76-week and 96-week Extensions	Rheumatoid Arthritis	Drug: Canakinumab;Drug: Placebo	Novartis	NULL	Completed	18 Years	N/A	All	274	Phase 2	United States;Austria;Belgium;Canada;Germany;Spain;Finland
1055	NCT00072982 (ClinicalTrials.gov)	November 2006	13/11/2003	Treatment of Rheumatoid Arthritis With Marine and Botanical Oils	Treatment of Rheumatoid Arthritis With Marine and Botanical Oils	Rheumatoid Arthritis	Drug: fish oil;Drug: borage seed oil;Drug: combination fish oil and borage seed oil	National Center for Complementary and Integrative Health (NCCIH)	NULL	Active, not recruiting	18 Years	85 Years	Both	156	Phase 3	United States
1056	NCT00395577 (ClinicalTrials.gov)	November 2006	1/11/2006	A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702	A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate	Rheumatoid Arthritis	Drug: VX-702	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	75 Years	Both	120	Phase 2	Bulgaria;Croatia;Former Serbia and Montenegro;Poland;Russian Federation;Slovenia
1057	NCT00346216 (ClinicalTrials.gov)	October 4, 2006	28/6/2006	Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen	A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen	Arthritis, Rheumatoid	Drug: celecoxib;Drug: Ibuprofen;Drug: Naproxen	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	The Cleveland Clinic	Completed	18 Years	N/A	All	24081	Phase 4	United States;Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine
1058	NCT00399282 (ClinicalTrials.gov)	October 2006	13/11/2006	Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis	Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omega-3 and Vitamin E supplementation	Shahid Beheshti Medical University	NULL	Completed	16 Years	75 Years	Both	75	Phase 1	Iran, Islamic Republic of
1059	NCT00393146 (ClinicalTrials.gov)	October 2006	24/10/2006	A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis	A Randomized, Double Blind, Placebo Controlled Study to Investigate the Safety and Tolerability and Clinical Activity of 28 Days of Oral Repeat Dosing With GW856553 at 7.5mg BID in Subjects With Active Rheumatoid Arthritis on Stable Anti-rheumatic Therapy.	Arthritis, Rheumatoid	Drug: GW856553	GlaxoSmithKline	NULL	Completed	18 Years	N/A	Both	57	Phase 2	Romania;Russian Federation;Spain
1060	NCT00749645 (ClinicalTrials.gov)	October 2006	7/9/2008	Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients	Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients	Arthritis, Rheumatoid	Drug: FANG(30);Drug: Placebo	Juan C. Bertoglio, MD	Fondo Nacional de Desarrollo Científico y Tecnológico, Chile	Completed	18 Years	70 Years	Both	60	Phase 2	Chile
1061	NCT00488475 (ClinicalTrials.gov)	September 2006	18/6/2007	Observational Trial With Enbrel	A 1 Year Observational Study of the Use of Etanercept in Routine German Clinical Practice to Treat Rheumatoid Arthritis Patients: a Health Economic, Safety and Effectiveness Evaluation	Rheumatoid Arthritis	Drug: etanercept	Pfizer	NULL	Completed	18 Years	N/A	All	4945	N/A	Germany
1062	NCT00588393 (ClinicalTrials.gov)	September 2006	22/12/2007	FolateScan in Autoimmune Disease	Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases	Rheumatoid Arthritis;Osteoarthritis;Multiple Sclerosis;Crohn's Disease;Systemic Lupus Erythematosus	Drug: FolateScan (Technetium Tc 99mEC20)	Mayo Clinic	Endocyte	Completed	18 Years	N/A	Both	75	Phase 2	United States
1063	NCT01308255 (ClinicalTrials.gov)	September 2006	3/3/2011	Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)	A Multi-centre Randomised Double Blind Placebo Controlled Study Comparing Two Regimens of Combination Therapy in Early DMARD Naive Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Infliximab;Drug: Methylprednisolone;Drug: Methotrexate;Dietary Supplement: Folic acid	University of Leeds	NULL	Completed	18 Years	80 Years	All	112	Phase 4	United Kingdom
1064	NCT00361335 (ClinicalTrials.gov)	September 2006	4/8/2006	A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Golimumab;Drug: Methotrexate;Drug: Placebo	Centocor, Inc.	Schering-Plough	Completed	18 Years	N/A	All	643	Phase 3	United States;Argentina;Australia;Colombia;Germany;Hungary;Latvia;Lithuania;Malaysia;Malta;Mexico;New Zealand;Peru;Poland;Ukraine;Belgium;Russian Federation
1065	NCT01126541 (ClinicalTrials.gov)	September 2006	18/5/2010	SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy	A Comparative Study to Assess the Effect of Retreatment With 2 Doses of MabThera on Disease Activity Score in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to antiTNF-alfa Therapy.(SMART)	Rheumatoid Arthritis	Drug: rituximab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	224	Phase 3	France
1066	NCT00367211 (ClinicalTrials.gov)	September 2006	18/8/2006	Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.	A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.	Osteoarthritis;Rheumatoid Arthritis;Ankylosing Spondylitis	Drug: PN 200 tablets (500 mg naproxen and 20 mg omeprazole);Drug: Naproxen 500 mg tablets (PN 200 minus omeprazole)	POZEN	NULL	Completed	18 Years	N/A	Both	400	Phase 3	United States
1067	NCT01303874 (ClinicalTrials.gov)	September 2006	24/2/2011	Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)	A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis	Rheumatoid Arthritis;Inflammatory Arthritis	Drug: Etanercept (ETN);Drug: Placebo	University of Leeds	NULL	Completed	18 Years	80 Years	All	112	Phase 4	United Kingdom
1068	NCT00369473 (ClinicalTrials.gov)	September 2006	24/8/2006	Long-Term Assessment of Safety and Physical Function With AMG 108 in RA	A Long-Term Assessment of Safety and Physical Function With AMG 108 Subcutaneous Monthly Treatment in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: AMG 108	Amgen	NULL	Completed	18 Years	N/A	Both	690	Phase 2	Australia;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;United Kingdom;United States
1069	NCT00361634 (ClinicalTrials.gov)	September 2006	4/8/2006	Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis	DCE-MRI of the Wrist to Measure Short-Term Responses in Rheumatoid Arthritis Subjects Treated With Etanercept	Rheumatoid Arthritis	Drug: Etanercept	Amgen	NULL	Completed	18 Years	N/A	All	14	Phase 1	United States;United Kingdom
1070	NCT02006706 (ClinicalTrials.gov)	August 10, 2006	5/12/2013	A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy	An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate;Drug: methylprednisolone	Hoffmann-La Roche	NULL	Completed	18 Years	80 Years	All	15	Phase 3	Serbia
1071	NCT00326339 (ClinicalTrials.gov)	August 2006	12/5/2006	Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate	Rheumatoid Arthritis	Drug: R788;Drug: Placebo	Rigel Pharmaceuticals	NULL	Completed	18 Years	75 Years	Both	189	Phase 2	United States;Mexico
1072	NCT00369928 (ClinicalTrials.gov)	August 2006	29/8/2006	Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate	A Multicenter, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG-760564 in Adult Patients With RA Receiving Methotrexate	Rheumatoid Arthritis	Drug: PG -760564;Drug: Placebo dose	Procter and Gamble	NULL	Completed	18 Years	70 Years	All	254	Phase 2	United States;Czech Republic;Hungary;Netherlands;Poland;United Kingdom
1073	NCT01272908 (ClinicalTrials.gov)	July 18, 2006	7/1/2011	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)	Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)	Rheumatoid Arthritis	Drug: rituximab	Hoffmann-La Roche	NULL	Completed	18 Years	80 Years	All	120	Phase 3	Canada;Sweden
1074	NCT00369187 (ClinicalTrials.gov)	July 2006	25/8/2006	Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase		Rheumatoid Arthritis	Drug: large protein molecule	Halozyme Therapeutics	NULL	Completed	18 Years	N/A	Both	15	Phase 4	United States
1075	NCT00555542 (ClinicalTrials.gov)	July 2006	7/11/2007	An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis	B Cell Depletion Therapy in Rheumatoid Arthritis: An Analysis of Peripheral Blood T Cell Subsets	Rheumatoid Arthritis	Drug: rituximab	Chinese University of Hong Kong	NULL	Completed	21 Years	70 Years	Both	10	Phase 2	China
1076	NCT00445770 (ClinicalTrials.gov)	July 2006	8/3/2007	Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Multicenter, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Etanercept;Drug: Methotrexate	Pfizer	NULL	Completed	20 Years	75 Years	All	550	Phase 3	Japan
1077	NCT01685424 (ClinicalTrials.gov)	June 30, 2006	23/8/2012	Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)	Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis	Osteoarthritis;Rheumatoid Arthritis;Ankylosing Spondylitis;Gout;Arthritis	Drug: Etoricoxib	Organon and Co	NULL	Completed	N/A	N/A	All	79189		United States
1078	NCT00443950 (ClinicalTrials.gov)	June 2006	5/3/2007	Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Etanercept in Chinese Subjects With Active Rheumatoid Arthritis Receiving Methotrexate	Arthritis, Rheumatoid	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	Both	150	Phase 3	China
1079	NCT00280917 (ClinicalTrials.gov)	June 2006	23/1/2006	Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CF101	Can-Fite BioPharma	NULL	Completed	18 Years	75 Years	All	254	Phase 2	United States;Bulgaria;Israel;Poland;Romania;Serbia;Ukraine;Former Serbia and Montenegro
1080	NCT00439062 (ClinicalTrials.gov)	June 2006	20/2/2007	Treatment of Rheumatoid Arthritis With Roxithromycin	Treatment of Rheumatoid Arthritis With Roxithromycin	Rheumatoid Arthritis	Drug: Roxithromycin	Nazilli State Hospital	NULL	Completed	18 Years	70 Years	Both	100	Phase 4	Turkey
1081	NCT00424294 (ClinicalTrials.gov)	June 2006	18/1/2007	A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CP-195543 And Celecoxib Dual Therapy In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate	Arthritis, Rheumatoid	Drug: CP -195,543;Drug: celecoxib;Drug: Methotrexate	Pfizer	NULL	Terminated	18 Years	N/A	All	70	Phase 2	United States
1082	NCT00345748 (ClinicalTrials.gov)	June 2006	23/6/2006	A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate	A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	20 Years	N/A	Both	194	Phase 2	Japan
1083	NCT00497614 (ClinicalTrials.gov)	May 2006	4/7/2007	Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)	18F-FDG Positron Emission Tomography to Study the Response to Adalimumab in Rheumatoid Arthritis. A Monocentric Pilot Study	Rheumatoid Arthritis	Drug: adalimumab	University Hospital, Tours	NULL	Completed	18 Years	75 Years	Both	8	N/A	France
1084	NCT00380601 (ClinicalTrials.gov)	May 2006	25/9/2006	Phase?Open-label Study of MRA for Rheumatoid Arthritis(RA)	An Open-label, Phase? Study to Evaluate the Efficacy and Safety of MRA in Patients With RA	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	N/A	Both	20	Phase 3	Japan
1085	NCT00319917 (ClinicalTrials.gov)	April 2006	27/4/2006	A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients	FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients	Rheumatoid Arthritis	Drug: tacrolimus;Drug: placebo	Astellas Pharma Inc	NULL	Completed	20 Years	64 Years	Both	123	Phase 4	Japan
1086	NCT00303563 (ClinicalTrials.gov)	April 2006	16/3/2006	A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis	A Randomized, Double-blind Study to Compare the Effect of RO4402257 Monotherapy and Methotrexate Monotherapy on Disease Response in Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: P38 Inhibitor (4);Drug: Placebo	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	204	Phase 2	United States;Canada;Croatia;Czech Republic;France;Italy;Mexico;Romania;Serbia;South Africa;Spain;Taiwan;Former Serbia and Montenegro
1087	NCT00308282 (ClinicalTrials.gov)	March 28, 2006	28/3/2006	A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis	Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate	Arthritis, Rheumatoid	Drug: LY2127399;Drug: Placebo	Eli Lilly and Company	NULL	Completed	18 Years	75 Years	All	136	Phase 2	Romania
1088	NCT00293826 (ClinicalTrials.gov)	March 2006	17/2/2006	A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: AMG 108;Drug: Placebo	Amgen	NULL	Completed	18 Years	70 Years	Both	813	Phase 2	United States;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Slovakia;Spain;Sweden;United Kingdom;Puerto Rico
1089	NCT00394589 (ClinicalTrials.gov)	March 2006	31/10/2006	Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)	Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.	Rheumatoid Arthritis	Drug: Infliximab Control;Drug: Infliximab Increased Frequency;Drug: Infliximab Increased Dose	Merck Sharp & Dohme Corp.	Integrated Therapeutics Group	Terminated	18 Years	N/A	All	43	Phase 3	Austria;Belgium;Denmark;France;Germany;Netherlands;Sweden;Turkey
1090	NCT00286689 (ClinicalTrials.gov)	February 3, 2006	1/2/2006	Effects of Growth Hormone in Chronically Ill Children		Hurler Syndrome;Cerebral Palsy;Juvenile Rheumatoid Arthritis;Crohn Disease;HIV Infections	Drug: Growth Hormone;Procedure: Whole body Protein turnover;Procedure: DEXA scan	University of Texas Southwestern Medical Center	NULL	Withdrawn	3 Years	17 Years	All	0	N/A	United States
1091	NCT00502996 (ClinicalTrials.gov)	February 2006	17/7/2007	A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.	Multicenter Non-Comparative Expanded Access Program of to Assess Safety of Rituximab (Mab Anti Cd-20) in Patients With Rheumatoid Arthritis (Ser)	Rheumatoid Arthritis	Drug: Methotrexate;Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	246	Phase 3	Argentina;Brazil;Chile;Colombia;Ecuador;El Salvador;Mexico;Peru;Uruguay;Venezuela
1092	NCT00287794 (ClinicalTrials.gov)	February 2006	6/2/2006	Quality of Sleep in Patients With Rheumatoid Arthritis	Study on the Quality of Sleep in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: diazepam , melatonin	Kobe University	NULL	Recruiting	17 Years	N/A	Both	1000		Japan
1093	NCT00296257 (ClinicalTrials.gov)	February 2006	22/2/2006	Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114	A Phase 2, Multi-Centre, Randomised, Double Blind, Placebo Controlled Study Evaluating the Efficacy, Safety and Pharmacokinetics of Two Doses of a Candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg Once Daily), Administered in Combination With Ongoing Methotrexate Treatment in Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis (RA)	Drug: SMP-114	Dainippon Sumitomo Pharma Europe LTd.	NULL	Terminated	18 Years	N/A	Both	312	Phase 2	Czech Republic;Germany;Hungary;Netherlands;Poland;United Kingdom
1094	NCT00299546 (ClinicalTrials.gov)	February 2006	3/3/2006	A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)	Arthritis, Rheumatoid	Drug: Placebo;Biological: Golimumab 50 mg;Biological: Golimumab 100 mg	Centocor, Inc.	Schering-Plough	Completed	18 Years	N/A	All	461	Phase 3	United States;Australia;Austria;Canada;Finland;Germany;Netherlands;New Zealand;Spain;United Kingdom;France;Switzerland
1095	NCT00422383 (ClinicalTrials.gov)	February 2006	15/1/2007	A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)	A Randomized, Double-blind Study to Evaluate the Effect of Various Re-treatment Regimens of MabThera in Combination With Methotrexate on Treatment Response in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	378	Phase 3	Australia;Belgium;Brazil;Canada;China;Finland;France;Germany;Hungary;Italy;Netherlands;New Zealand;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;Switzerland;United States
1096	NCT00282308 (ClinicalTrials.gov)	January 23, 2006	24/1/2006	A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate	A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate	Rheumatoid Arthritis	Drug: Rituximab;Drug: Methotrexate;Drug: Methylprednisone;Biological: C. albicans;Biological: Tetanus toxoid adsorbed booster vaccine;Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: Keyhole limpet hemocyanin	Genentech, Inc.	NULL	Completed	18 Years	65 Years	All	103	Phase 2	United States
1097	NCT03496831 (ClinicalTrials.gov)	January 1, 2006	5/4/2018	Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs	Development of a Prediction Model for the Risk of Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs	Rheumatoid Arthritis;Spondyloarthritis;Psoriatic Arthritis	Drug: Biologic Agents	Simon Krabbe	University of Aarhus;Zealand University Hospital;University of Southern Denmark	Completed	18 Years	N/A	All	7500		NULL
1098	NCT00254293 (ClinicalTrials.gov)	January 2006	15/11/2005	Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)	A Study to Assess the Steady-State Trough Serum Concentration, Safety, and Immunogenicity of Abatacept (BMS-188667) Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Who Are Receiving Disease Modifying Ant-Rheumatic Drugs (DMARDs)	Rheumatoid Arthritis	Drug: Abatacept or Placebo (both as IV & SC Solution);Drug: Abatacept or Placebo (both as IV & SC solution);Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	87	Phase 1/Phase 2	United States
1099	NCT00264147 (ClinicalTrials.gov)	January 2006	9/12/2005	Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)	A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: etoricoxib;Drug: Comparator: placebo;Drug: Comparator: diclofenac	Organon and Co	NULL	Completed	18 Years	N/A	All	761	Phase 2	Canada;Colombia;Puerto Rico;Switzerland;United States
1100	NCT00266227 (ClinicalTrials.gov)	January 2006	14/12/2005	A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate	Rheumatoid Arthritis	Drug: placebo;Drug: rituximab;Drug: methotrexate;Drug: folate	Genentech, Inc.	NULL	Completed	18 Years	80 Years	All	559	Phase 3	United States
1101	NCT00422942 (ClinicalTrials.gov)	January 2006	15/1/2007	A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)	An Open-label, Exploratory Study of the Pharmacokinetic and Pharmacodynamic Activity of MabThera in Combination With Methotrexate in Synovial Tissue and in Peripheral Blood of Patients With Active Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: Methotrexate	Hoffmann-La Roche	NULL	Terminated	18 Years	80 Years	All	3	Phase 2	Netherlands;Spain
1102	NCT00299104 (ClinicalTrials.gov)	January 2006	2/3/2006	A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis	A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: folate;Drug: methotrexate;Drug: methylprednisolone;Drug: placebo;Drug: rituximab	Genentech, Inc.	Hoffmann-La Roche	Completed	18 Years	80 Years	All	755	Phase 3	United States
1103	NCT00724243 (ClinicalTrials.gov)	January 2006	25/7/2008	Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)	Remicade Treatment Registry in Rheumatoid Arthritis I	Rheumatoid Arthritis	Drug: Infliximab	Merck Sharp & Dohme Corp.	NULL	Completed	N/A	N/A	All	33	N/A	Slovakia
1104	NCT00379990 (ClinicalTrials.gov)	January 2006	21/9/2006	A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.	A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Synovial Thickness and Vascularity of 28 Days Repeat Dosing of GW274150 or 7.5mg Prednisolone in RA Subjects.	Arthritis, Rheumatoid	Drug: GW274150;Drug: Prednisolone;Other: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	N/A	Both	48	Phase 2	Serbia;United Kingdom
1105	NCT00234234 (ClinicalTrials.gov)	January 2006	5/10/2005	Predictors of the Response to Adalimumab in Rheumatoid Arthritis	Predictors of the Response to Adalimumab in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab	University Hospital, Rouen	NULL	Completed	18 Years	N/A	Both	200	Phase 4	France
1106	NCT00346294 (ClinicalTrials.gov)	January 2006	27/6/2006	An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis	An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept	Amgen	Immunex Corporation	Completed	18 Years	N/A	All	115	Phase 4	United States
1107	NCT00281294 (ClinicalTrials.gov)	December 2005	20/1/2006	A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis	A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Fontolizumab	PDL BioPharma, Inc.	NULL	Terminated	18 Years	N/A	Both	40	Phase 2	United States
1108	NCT00264550 (ClinicalTrials.gov)	December 2005	11/12/2005	An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy	A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Subjects With ActiveRheumatoid Arthritis Despite Methotrexate Therapy	Rheumatoid Arthritis	Drug: Golimumab 100 mg;Drug: Golimumab 50 mg;Drug: Methotrexate;Drug: Placebo injection;Drug: Placebo capsules	Centocor, Inc.	Schering-Plough	Completed	18 Years	N/A	All	444	Phase 3	United States;Argentina;Australia;Canada;Chile;Germany;Hungary;Korea, Republic of;Mexico;New Zealand;Poland;Taiwan;Brazil;India;Turkey
1109	NCT00264537 (ClinicalTrials.gov)	December 2005	11/12/2005	A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive	A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Placebo injections;Drug: Placebo capsules;Drug: Methotrexate capsules;Biological: Golimumab 50 mg injections;Biological: Golimumab 100 mg injections	Centocor, Inc.	Schering-Plough	Completed	18 Years	N/A	All	637	Phase 3	United States;Argentina;Australia;Austria;Belgium;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Ukraine;United Kingdom;Brazil;Mexico;Turkey
1110	NCT00642629 (ClinicalTrials.gov)	December 2005	20/3/2008	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes		Active, Moderate to Severe Rheumatoid Arthritis	Drug: STA 5326 mesylate;Drug: Placebo	Synta Pharmaceuticals Corp.	NULL	Completed	18 Years	N/A	Both	35	Phase 2	Netherlands
1111	NCT00256919 (ClinicalTrials.gov)	November 2005	21/11/2005	Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)	A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship	Arthritis, Rheumatoid	Drug: GW856553	GlaxoSmithKline	NULL	Completed	18 Years	N/A	Both	51	Phase 2	Bulgaria;Germany;Spain;Sweden;Ukraine
1112	NCT00380744 (ClinicalTrials.gov)	November 2005	22/9/2006	A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis	A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: LY2189102;Drug: placebo	Eli Lilly and Company	NULL	Completed	18 Years	75 Years	All	121	Phase 1/Phase 2	United States;Poland;Argentina;Hungary;Spain
1113	NCT00292422 (ClinicalTrials.gov)	November 2005	15/2/2006	Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis	A Randomized, Blinded, Placebo-Controlled, Multicenter, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD Therapy	Rheumatoid Arthritis	Drug: BG9924	Biogen Idec	NULL	Completed	18 Years	75 Years	Both	50	Phase 2	United States;Poland
1114	NCT00316771 (ClinicalTrials.gov)	November 2005	20/4/2006	A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy	A Randomized, Double-blind, Placebo-controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.	Rheumatoid Arthritis	Drug: P38 Inhibitor (4) 150mg;Drug: P38 Inhibitor (4) 25mg;Drug: P38 Inhibitor (4) 300mg;Drug: P38 Inhibitor (4) 50mg;Drug: P38 Inhibitor (4) 75mg;Drug: Placebo	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	374	Phase 2	South Africa;Spain;United Kingdom;United States;Australia;Brazil;Canada;Estonia;Germany;Greece;Ireland;Mexico;New Zealand;Poland
1115	NCT00162292 (ClinicalTrials.gov)	November 2005	9/9/2005	Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background	Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background	Rheumatoid Arthritis	Drug: BMS-582949 and Methotrexate	Bristol-Myers Squibb	NULL	Completed	18 Years	70 Years	Both	33	Phase 1	United States;Mexico
1116	NCT00320450 (ClinicalTrials.gov)	November 2005	28/4/2006	SB-681323 In Subjects With Rheumatoid Arthritis	A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: SB-681323	GlaxoSmithKline	NULL	Completed	18 Years	N/A	Both	78	Phase 2	Denmark;Germany;Hong Kong;Italy;Norway;Poland;Spain;Sweden;United Kingdom;Hungary
1117	NCT02720120 (ClinicalTrials.gov)	October 2005	22/3/2016	A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)	A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response	Rheumatoid Arthritis	Drug: Ocrelizumab;Drug: Placebo	Hoffmann-La Roche	NULL	Terminated	18 Years	80 Years	Both	175	Phase 1/Phase 2	Australia;Belgium;Canada;Netherlands;New Zealand;Russian Federation;Spain;United Kingdom
1118	NCT00299130 (ClinicalTrials.gov)	October 2005	3/3/2006	A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis	A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Folate;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Placebo;Drug: Rituximab	Genentech, Inc.	Hoffmann-La Roche	Completed	18 Years	80 Years	All	511	Phase 3	United States
1119	NCT00141102 (ClinicalTrials.gov)	October 2005	29/8/2005	Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis	Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events	Osteoarthritis;Arthritis, Rheumatoid	Drug: Celecoxib;Drug: Diclofenac + Omeprazole	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	NULL	Completed	18 Years	N/A	All	4484	Phase 4	Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czechia;Ecuador;Estonia;France;Germany;Greece;Guatemala;Hong Kong;India;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;Czech Republic;Former Serbia and Montenegro;Ireland
1120	NCT00241982 (ClinicalTrials.gov)	October 2005	18/10/2005	Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis	Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: long-circulating liposomal prednisolone	Radboud University	Utrecht University	Completed	18 Years	N/A	Both	22	Phase 2	Netherlands
1121	NCT00249041 (ClinicalTrials.gov)	October 2005	3/11/2005	Enbrel Liquid Immunogenicity Protocol	Open-label Study to Assess the Antibody Response to Etanercept Liquid in Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: 50 mg Etanercept;Drug: Enbrel liquid	Amgen	Immunex Corporation	Completed	18 Years	N/A	Both	447	Phase 3	United States;Canada
1122	NCT00720798 (ClinicalTrials.gov)	September 2005	22/7/2008	An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies	Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies	Rheumatoid Arthritis	Drug: Tocilizumab;Drug: Disease-modifying anti-rheumatic drugs;Drug: Non-steroidal anti-inflammatory drugs;Drug: Oral corticosteroids	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	2067	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom
1123	NCT00691028 (ClinicalTrials.gov)	September 2005	3/6/2008	Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis	Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TA-650 3 mg/kg;Drug: TA-650 6 mg/kg;Drug: TA-650 10 mg/kg	Mitsubishi Tanabe Pharma Corporation	NULL	Completed	20 Years	75 Years	All	327	Phase 3	NULL
1124	NCT00216177 (ClinicalTrials.gov)	September 2005	20/9/2005	Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis	Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks	Rheumatoid Arthritis	Drug: Infliximab;Drug: Adalimumab	Hvidovre University Hospital	University Hospital, Gentofte, Copenhagen	Recruiting	18 Years	80 Years	Both	112	Phase 4	Denmark
1125	NCT00721123 (ClinicalTrials.gov)	August 2005	22/7/2008	A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis	Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822	Rheumatoid Arthritis	Drug: Tocilizumab	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	538	Phase 3	Argentina;Australia;Austria;Brazil;Bulgaria;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Switzerland;Thailand;China
1126	NCT00508768 (ClinicalTrials.gov)	August 2005	27/7/2007	A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid Arthritis	A Randomized, Double-Blind, Parallel-Group, Pharmacokinetic Study of Oral SCIO-469 (90 mg qd and 30 mg Tid) in Female Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Oral SCIO-469 capsule	Scios, Inc.	NULL	Completed	18 Years	N/A	Female	16	Phase 1	NULL
1127	NCT00370435 (ClinicalTrials.gov)	August 2005	17/8/2006	Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)	An Open-label, Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of 90mg of GW274150 in Adult and Elderly RA Subjects.	Arthritis, Rheumatoid	Drug: GW274150	GlaxoSmithKline	NULL	Completed	50 Years	N/A	All	6	Phase 2	United Kingdom
1128	NCT00111410 (ClinicalTrials.gov)	August 2005	20/5/2005	Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)	A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Anakinra (r-metHuIL-1ra)	Amgen	NULL	Completed	18 Years	74 Years	Both		Phase 4	NULL
1129	NCT00243412 (ClinicalTrials.gov)	August 2005	21/10/2005	A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate	A Double-Blind, Randomized, Multicenter, Phase II Study of the Safety and Efficacy of Two Rituximab Regimens in Subjects With Moderate to Severe Active Rheumatoid Arthritis Receiving Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: folate;Drug: methotrexate;Drug: methylprednisolone;Drug: Placebo;Drug: Rituximab	Genentech, Inc.	NULL	Completed	18 Years	65 Years	All	42	Phase 2	United States
1130	NCT00141934 (ClinicalTrials.gov)	August 2005	31/8/2005	A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.	Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.	Rheumatoid Arthritis	Drug: AD 452	Sosei	NULL	Completed	18 Years	75 Years	Both	232	Phase 2	United States
1131	NCT00141830 (ClinicalTrials.gov)	August 2005	30/8/2005	Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy	Rheumatoid Arthritis	Drug: Methotrexate plus ERB-041 for 12 weeks;Drug: Placebo for 12 weeks	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	80 Years	All	159	Phase 2	United States;Canada;Hungary;Italy;Mexico;Spain
1132	NCT00122382 (ClinicalTrials.gov)	July 2005	19/7/2005	Remission and Joint Damage Progression in Early Rheumatoid Arthritis	A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: placebo;Drug: methotrexate	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	1052	Phase 3	United States;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;Austria;Ireland
1133	NCT00109408 (ClinicalTrials.gov)	July 2005	27/4/2005	A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis	A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Monotherapy Versus Methotrexate Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Methotrexate;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	673	Phase 3	United States;Argentina;Australia;Canada;China;Denmark;France;Israel;Italy;Lithuania;Mexico;Norway;Peru;Portugal;Serbia;Slovenia;South Africa;Spain;Croatia;Former Serbia and Montenegro
1134	NCT00503425 (ClinicalTrials.gov)	June 30, 2005	17/7/2007	A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.	An Open Label Study to Assess the Safety and Effect on Disease Activity of MabThera in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With DMARDs and/or One Anti-TNF Alpha Agent	Rheumatoid Arthritis	Drug: Rituximab [MabThera/Rituxan]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	215	Phase 3	Israel
1135	NCT00134693 (ClinicalTrials.gov)	June 21, 2005	24/8/2005	A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis	A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship	Arthritis, Rheumatoid	Drug: Prednisolone;Drug: SB-681323	GlaxoSmithKline	NULL	Completed	18 Years	N/A	All	77	Phase 2	Australia;France;Germany;Russian Federation;United Kingdom
1136	NCT00113308 (ClinicalTrials.gov)	June 2005	7/6/2005	COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis	A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: GW406381	GlaxoSmithKline	NULL	Completed	18 Years	N/A	All	2208	Phase 3	United States;Argentina;Austria;Belgium;Bulgaria;Canada;Chile;Costa Rica;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;Czech Republic;Estonia;Lithuania;Pakistan;Slovakia;Taiwan
1137	NCT00688103 (ClinicalTrials.gov)	June 2005	25/5/2008	Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan	Efficacy and Safety of Etanercept in Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan	Rheumatoid Arthritis	Drug: ETN Alone;Drug: ETN +MTX	Japan Biological Agent Study Integrated Consortium	NULL	Completed	18 Years	N/A	All	151	Phase 4	Japan
1138	NCT00160602 (ClinicalTrials.gov)	June 2005	8/9/2005	A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis	A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.	Rheumatoid Arthritis	Drug: Certolizumab Pegol	UCB Pharma	NULL	Completed	18 Years	N/A	All	590	Phase 3	United States;Bulgaria;Chile;Croatia;Czechia;Estonia;Israel;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Ukraine;Czech Republic;Former Serbia and Montenegro
1139	NCT00205478 (ClinicalTrials.gov)	June 2005	12/9/2005	Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702	A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: VX-702	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	75 Years	Both	300	Phase 2	Bulgaria;Croatia;Czech Republic;Former Serbia and Montenegro;Poland;Russian Federation;Slovakia;Slovenia;Ukraine
1140	NCT00233558 (ClinicalTrials.gov)	June 2005	13/9/2005	Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis	Multicentre, Randomised, Open Label Study Comparing a Scheduled Steroid Reduction Strategy” Versus a Free Steroid Reduction Strategy (Physician’s Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months	Rheumatoid Arthritis	Drug: adalimumab (up to 9 months exposure);Drug: methotrexate	Abbott	NULL	Terminated	18 Years	N/A	Both	160	Phase 4	United States
1141	NCT01270087 (ClinicalTrials.gov)	May 2005	4/1/2011	The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.	The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.	Rheumatoid Arthritis	Drug: Adalimumab	Skåne University Hospital	Abbott;The Swedish Research Council;The Swedish Rheumatism Ass;Crafoord Foundation	Completed	18 Years	N/A	Both	14	Phase 4	Sweden
1142	NCT00419809 (ClinicalTrials.gov)	May 2005	5/1/2007	SB-681323-Methotrexate Interaction Study	A Placebo Controlled Study to Evaluate the Safety and Tolerability of Repeat Doses of SB-681323 in Patients Receiving Methotrexate for Rheumatoid Arthritis.	Arthritis, Rheumatoid	Drug: SB-681323 oral tablets	GlaxoSmithKline	NULL	Completed	18 Years	75 Years	Both	18	Phase 1	Australia
1143	NCT00432484 (ClinicalTrials.gov)	May 2005	6/2/2007	Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis	Lingzhi (Ganoderma Lucidum) and Sen Miao San Supplementation in Rheumatoid Arthritis(RA): An Animal Model and A Phase I Study	Rheumatoid Arthritis	Drug: Lingzhi and Sen Miao San	Chinese University of Hong Kong	NULL	Completed	18 Years	N/A	Both	70	Phase 2	China
1144	NCT00115219 (ClinicalTrials.gov)	May 2005	21/6/2005	Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)	A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)	Rheumatoid Arthritis	Drug: Etanercept	Amgen	NULL	Completed	18 Years	N/A	Both	200	Phase 4	United States
1145	NCT00106522 (ClinicalTrials.gov)	May 2005	25/3/2005	A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy	A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Placebo;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	499	Phase 3	United States;Australia;Belgium;Canada;France;Germany;Iceland;Italy;Mexico;Netherlands;Puerto Rico;Sweden;Switzerland;United Kingdom
1146	NCT00124982 (ClinicalTrials.gov)	April 2005	30/6/2005	Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy	A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options	Rheumatoid Arthritis	Drug: Abatacept;Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD);Drug: Anti-Tumor Necrosing Factor (TNF) Therapy	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	1286	Phase 3	United States;Belgium;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;Canada
1147	NCT00106574 (ClinicalTrials.gov)	April 2005	25/3/2005	A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy	Rheumatoid Arthritis	Drug: Placebo;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	1220	Phase 3	United States;Argentina;Australia;Brazil;Canada;China;Costa Rica;Czech Republic;Finland;France;Germany;Hong Kong;Mexico;Panama;Russian Federation;South Africa;Spain;Sweden;Thailand
1148	NCT01745055 (ClinicalTrials.gov)	April 2005	4/12/2012	Co-Administration Of Methotrexate And CP-690,550	A Phase 1, Open Label Study Of The Pharmacokinetics Of Multiple Doses Of Oral CP-690,550 And Single Doses Of Oral Methotrexate In Rheumatoid Arthritis Subjects	Rheumatoid Arthritis	Drug: CP -690,550 (tofacitinib);Drug: Methotrexate (MTX)	Pfizer	NULL	Completed	18 Years	70 Years	All	12	Phase 1	United States
1149	NCT00144586 (ClinicalTrials.gov)	March 2005	2/9/2005	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA220JP or MRA221JP	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	75 Years	Both	42	Phase 3	NULL
1150	NCT00503503 (ClinicalTrials.gov)	March 2005	16/7/2007	Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan	Safety and Efficacy From Large Scale All Cases Surveillance for Etanercept in Japan	Rheumatoid Arthritis	Drug: Enbrel (etanercept)	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	11 Years	90 Years	Both			NULL
1151	NCT00124449 (ClinicalTrials.gov)	February 2005	30/6/2005	Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients	A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA	Arthritis, Rheumatoid	Drug: Abatacept;Drug: placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	75 Years	All	56	Phase 2	United States;Australia;Belgium;France;Germany;Italy;Mexico;Puerto Rico;Spain;United Kingdom
1152	NCT00152386 (ClinicalTrials.gov)	February 2005	7/9/2005	A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis	A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate	Rheumatoid Arthritis	Drug: Certolizumab pegol (CDP870)	UCB Pharma	NULL	Completed	18 Years	N/A	All	950	Phase 3	Croatia;Czechia;Israel;Latvia;Russian Federation;Ukraine;United States;Czech Republic;Argentina;Australia;Belgium;Bulgaria;Canada;Chile
1153	NCT00105976 (ClinicalTrials.gov)	February 2005	18/3/2005	Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)	A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: MM-093	Merrimack Pharmaceuticals	NULL	Completed	18 Years	80 Years	Both	260	Phase 2	United States
1154	NCT00144560 (ClinicalTrials.gov)	February 2005	2/9/2005	Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)	An Open-Label, Clinical Pharmacology Study to Investigate Drug-Drug Interaction in Patients With RA	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	75 Years	Both	31	N/A	NULL
1155	NCT00095147 (ClinicalTrials.gov)	February 2005	1/11/2004	Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis	A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB);Drug: Infliximab (INF) + MTX, DB;Drug: Placebo (PLA) + MTX, DB;Drug: PLA + MTX switched to ABA+ MTX, DB;Drug: ABA, open-label (OL)	Bristol-Myers Squibb	NULL	Completed	18 Years	75 Years	All	431	Phase 3	United States;Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland
1156	NCT00291928 (ClinicalTrials.gov)	February 2005	14/2/2006	HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II	A Double-blind, Randomized, Placebo Controlled, Dose Escalation, Multi-centerphase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20antibody, in Patients With Active Rheumatoid Arthritis Who Have Previously Failedone or More Disease Modifying Anti-rheumatic Drugs	Arthritis, Rheumatoid	Drug: Part A;Drug: Part B	GlaxoSmithKline	NULL	Completed	18 Years	N/A	Both	201	Phase 2	United States;Denmark;Finland;France;Hungary;Poland;United Kingdom
1157	NCT00106548 (ClinicalTrials.gov)	January 2005	25/3/2005	A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Placebo;Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	Both	623	Phase 3	Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;France;Germany;Hungary;Israel;Italy;Mexico;Singapore;Slovakia;Switzerland;Thailand;Spain
1158	NCT00147498 (ClinicalTrials.gov)	January 2005	2/9/2005	Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: CP -690,550;Other: Placebo	Pfizer	NULL	Completed	18 Years	70 Years	All	264	Phase 2	United States;Belgium;Brazil;Canada;Germany;Italy;Mexico;Slovakia;Spain;Austria
1159	NCT00365001 (ClinicalTrials.gov)	January 2005	15/8/2006	A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.	A Randomized, Open-label Study to Assess the Pharmacokinetics of Simvastatin and Methotrexate in Combination With Tocilizumab in Patients With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Methotrexate;Drug: Simvastatin	Hoffmann-La Roche	NULL	Completed	18 Years	75 Years	Both	23	Phase 1	United States;New Zealand
1160	NCT00132769 (ClinicalTrials.gov)	January 2005	2/8/2005	A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)	A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK-0873 in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MK-0873;Drug: Comparator: Placebo	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	65 Years	All	106	Phase 2	Belgium;Canada;Czech Republic;Finland;Germany;Italy;Norway;Spain;Switzerland
1161	NCT00123149 (ClinicalTrials.gov)	January 2005	19/7/2005	Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis	An Open-Label (OL) Extension Study to Assess Safety of PROCRIT (Epoetin Alfa) in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis (RA)	Anemia;Rheumatoid Arthritis	Drug: Epoetin alfa	Ortho Biotech Products, L.P.	NULL	Withdrawn	18 Years	99 Years	Both	0	Phase 2	NULL
1162	NCT00246168 (ClinicalTrials.gov)	January 2005	28/10/2005	ULTRACET (Tramadol Hydrochloride and Acetaminophen) for the Treatment of Rheumatoid Arthritis Pain.	ULTRACET (Tramadol Hydrochloride and Acetaminophen) add-on Therapy for the Treatment of the Pain of Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Study	Arthritis, Rheumatoid	Drug: tramadol hydrochloride + acetaminophen	Janssen Korea, Ltd., Korea	NULL	Completed	18 Years	79 Years	Both	277	Phase 4	NULL
1163	NCT00144573 (ClinicalTrials.gov)	January 2005	2/9/2005	Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment	An Open-Label, Clinical Pharmacology Study to Evaluate the Safety and PK of MRA in Patients With RA With Renal Impairment	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	75 Years	Both	14	N/A	NULL
1164	NCT00106535 (ClinicalTrials.gov)	January 2005	25/3/2005	A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)	A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: Placebo;Drug: Methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	1196	Phase 3	United States;Australia;Brazil;China;Denmark;Finland;France;Greece;Italy;Mexico;Norway;Poland;Puerto Rico;South Africa;Spain;Switzerland
1165	NCT00583557 (ClinicalTrials.gov)	January 2005	20/12/2007	A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01	A Multi-Center, Open-Label, Continuation Trial of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) Who Completed the Phase 2 Protocol LBRA01	Rheumatoid Arthritis	Drug: belimumab	Human Genome Sciences Inc.	NULL	Terminated	18 Years	N/A	All	155	Phase 2	United States;Poland
1166	NCT00854321 (ClinicalTrials.gov)	November 2004	2/3/2009	Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital	One Centre Follow-up Study on Safety and Efficacy	Rheumatoid Arthritis	Drug: rituximab;Drug: rituximab , observational study amon patients with active RA	Kuopio University Hospital	NULL	Completed	18 Years	N/A	Both	49	N/A	Finland
1167	NCT00170872 (ClinicalTrials.gov)	November 2004	9/9/2005	6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis	A 6 Week, Multicenter, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Lumiracoxib 200mg o.d. in Patients With Primary Knee Osteoarthritis or Rheumatoid Arthritis	Osteoarthritis;Rheumatoid Arthritis	Drug: Lumiracoxib	Novartis	NULL	Completed	18 Years	N/A	Both	135	Phase 3	NULL
1168	NCT00236028 (ClinicalTrials.gov)	November 2004	7/10/2005	A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis	A Randomized, Double-blind, Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared With Methotrexate Alone for the Treatment of Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Infliximab	Centocor, Inc.	NULL	Completed	18 Years	75 Years	Both	607	Phase 3	NULL
1169	NCT00195494 (ClinicalTrials.gov)	November 2004	13/9/2005	Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis	A 24-Month,Randomized,Double-Blind,Two-Period Study to Evaluate the Efficacy and Safety of the Combination of Etanercept and Methotrexate and Methotrexate Alone in Subjects With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Etanercept;Drug: Methotrexate;Drug: Placebo	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	All	542	Phase 4	United States
1170	NCT00747214 (ClinicalTrials.gov)	November 2004	3/9/2008	A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA	A Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to That of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects With RA	Rheumatoid Arthritis	Drug: CRx-102;Drug: Placebo;Drug: DMARD Therapy	Zalicus	NULL	Completed	18 Years	N/A	All	59	Phase 2	NULL
1171	NCT00379600 (ClinicalTrials.gov)	November 2004	21/9/2006	The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis	A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: rosiglitazone XR	GlaxoSmithKline	NULL	Completed	18 Years	N/A	Both	96	Phase 2	Lithuania;United Kingdom
1172	NCT01600521 (ClinicalTrials.gov)	November 2004	5/4/2012	A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications	A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications	Rheumatoid Arthritis	Drug: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs	University of Minnesota - Clinical and Translational Science Institute	NULL	Completed	18 Years	N/A	Both	1748	N/A	China
1173	NCT00094341 (ClinicalTrials.gov)	October 2004	16/10/2004	Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes	An Open-Label, Randomized, Crossover Study to Assess Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes	Rheumatoid Arthritis	Drug: Etanercept	Amgen	NULL	Completed	18 Years	N/A	Both	215	Phase 4	United States
1174	NCT00412256 (ClinicalTrials.gov)	September 2004	15/12/2006	Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)	Clinical Trial to Evaluate the Effect of Parenteral Supplementation With Omega-3-Fatty Acids in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Omegaven (10% fish-oil emulsion; Fresenius-Kabi)	Humanis Klinikum Niederosterreich	NULL	Completed	18 Years	N/A	Both	60	Phase 3	Austria
1175	NCT00831922 (ClinicalTrials.gov)	September 2004	28/1/2009	Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis	A Multicenter, Open Label, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis With Inadequate Response to at Least One Disease Modifying Anti Rheumatic Drugs (DMARD)	Rheumatoid Arthritis	Drug: masitinib (AB1010)	AB Science	NULL	Completed	18 Years	N/A	All	43	Phase 2	NULL
1176	NCT00831649 (ClinicalTrials.gov)	September 2004	27/1/2009	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201	A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201	Rheumatoid Arthritis	Drug: natalizumab	Biogen	Elan Pharmaceuticals	Terminated	18 Years	75 Years	Both		Phase 2	NULL
1177	NCT00117091 (ClinicalTrials.gov)	September 2004	30/6/2005	Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)	An Open-Label Multicentre Study of Anakinra (Kineret®) in Combination With DMARDS in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Anakinra (Kineret®)	Amgen	NULL	Completed	18 Years	N/A	Both		Phase 3	NULL
1178	NCT00146640 (ClinicalTrials.gov)	August 31, 2004	6/9/2005	Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis	A New Timed-Release Tablet Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis- A Randomized, Multi-Centre, Double-Blind, Active Controlled Study With Open Extension on the New Drug Only	Rheumatoid Arthritis	Drug: MR Prednisone;Drug: IR Prednisone;Drug: Placebo - MR Prednisone;Drug: Placebo - IR Prednisone	Merck KGaA, Darmstadt, Germany	NULL	Completed	18 Years	80 Years	All	288	Phase 3	Germany;Poland
1179	NCT00279734 (ClinicalTrials.gov)	August 2004	19/1/2006	Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers	An Exploratory Study to Evaluate the Effect of Abatacept (BMS-188667) on the Antibody Response Following Tetanus Toxoid and 23-Valent Pneumococcal Vaccinations in Healthy Subjects	Rheumatoid Arthritis	Drug: Tetanus + pnemococcal vaccines alone;Drug: Abatacept + vaccines;Drug: Abatacept + Vaccines	Bristol-Myers Squibb	NULL	Completed	18 Years	65 Years	Both	80	Phase 1	United States
1180	NCT00234897 (ClinicalTrials.gov)	August 2004	13/9/2005	Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis	Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)	Rheumatoid Arthritis	Drug: adalimumab	Abbott	NULL	Completed	18 Years	N/A	Both	1938	Phase 4	United States
1181	NCT00760864 (ClinicalTrials.gov)	August 2004	24/9/2008	Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: TAK-715 and methotrexate;Drug: Methotrexate	Takeda	NULL	Completed	18 Years	N/A	Both	432	Phase 2	NULL
1182	NCT00095498 (ClinicalTrials.gov)	August 2004	5/11/2004	Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis	A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: placebo;Drug: denosumab	Amgen	NULL	Completed	18 Years	N/A	All	227	Phase 2	United States
1183	NCT00696059 (ClinicalTrials.gov)	August 2004	9/6/2008	Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?	Can Bone Erosions Heal in Adalimumab (Humira) Treated Rheumatoid Arthritis Patients. An Imaging Study Using Computed Tomography and Magnetic Resonance Imaging.	Rheumatoid Arthritis;Arthritis;Joint Diseases	Drug: Adalimumab (Humira)	Hvidovre University Hospital	Abbott	Completed	18 Years	90 Years	Both	52	Phase 4	Denmark
1184	NCT00239382 (ClinicalTrials.gov)	July 1, 2004	13/10/2005	A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis	A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.	Arthritis, Rheumatoid	Drug: Meloxicam ampoule;Drug: Meloxicam tablet	Boehringer Ingelheim	NULL	Completed	18 Years	N/A	All	150	Phase 3	China
1185	NCT00236678 (ClinicalTrials.gov)	July 2004	7/10/2005	Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT	A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT? (Epoetin Alfa)	Anemia;Rheumatoid Arthritis	Drug: Epoetin alfa	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Ortho Biotech Products, L.P.	Terminated	18 Years	N/A	Both	29	Phase 2	NULL
1186	NCT00506896 (ClinicalTrials.gov)	July 2004	20/7/2007	Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients	Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study	Rheumatoid Arthritis	Drug: intraarticular injection	Federal University of São Paulo	NULL	Completed	18 Years	65 Years	Both	60	Phase 2	Brazil
1187	NCT00154336 (ClinicalTrials.gov)	July 2004	8/9/2005	A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.	3-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety & Tolerability of Imatinib 400 mg Daily in Combination With Methotrexate (MTX)Compared to MTX Alone in the Treatment of Rheumatoid Arthritis (RA).	Rheumatoid Arthritis	Drug: Imatinib;Drug: Methotrexate;Drug: Imatinib Placebo	Novartis Pharmaceuticals	NULL	Completed	18 Years	75 Years	All	50	Phase 2	Austria;Canada;Finland;United Kingdom
1188	NCT00089921 (ClinicalTrials.gov)	July 2004	17/8/2004	SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate	A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine	Arthritis, Rheumatoid	Drug: SCIO-469;Drug: Placebo	Scios, Inc.	NULL	Completed	18 Years	N/A	Both	302	Phase 2	United States
1189	NCT00144534 (ClinicalTrials.gov)	June 2004	2/9/2005	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP	Rheumatoid Arthritis	Drug: MRA (Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	75 Years	Both	115	Phase 3	NULL
1190	NCT00094562 (ClinicalTrials.gov)	June 2004	20/10/2004	A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss	AAFA™ Fish Oil Nutritional Supplementation to Maintain Body Weight in Patients With Disease-Related Weight Loss	Cancer;Cancer Cachexia;Chronic Obstructive Pulmonary Disease;Chronic Heart Failure;Rheumatoid Arthritis	Drug: Fish oil supplement	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	National Center for Complementary and Integrative Health (NCCIH)	Completed	18 Years	90 Years	All	25	Phase 2	United States
1191	NCT00273533 (ClinicalTrials.gov)	June 2004	6/1/2006	Ramipril in Rheumatoid Arthritis	Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Ramipril	University of Zurich	Sanofi	Completed	18 Years	60 Years	Both	13	Phase 2/Phase 3	Switzerland
1192	NCT00542022 (ClinicalTrials.gov)	June 2004	5/10/2007	Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)	A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0812 in Rheumatoid Arthritis Patients	Arthritis, Rheumatoid	Drug: MK0812 / Duration of Treatment: 12 Weeks;Drug: Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	65 Years	Both	149	Phase 2	NULL
1193	NCT02097745 (ClinicalTrials.gov)	June 2004	20/3/2014	A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies	An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies	Rheumatoid Arthritis	Drug: methotrexate;Drug: rituximab [MabThera/Rituxan]	Hoffmann-La Roche	Biogen	Completed	18 Years	80 Years	All	341	Phase 3	United States;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom
1194	NCT00252668 (ClinicalTrials.gov)	June 2004	9/11/2005	Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects	An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects	Rheumatoid Arthritis	Drug: Etanercept;Drug: Methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	Both	300	Phase 4	NULL
1195	NCT00244153 (ClinicalTrials.gov)	June 2004	25/10/2005	Intraarticular Opioids Vs Glucocorticosteroids in Gonarthritis	Intraarticular Application of Opioids Versus Glucocorticosteroids Versus Placebo in Rheumatoid Arthritis	Rheumatic Disease	Drug: intraarticular morphine;Drug: intraarticular dexamethasone	Charite University, Berlin, Germany	NULL	Recruiting	19 Years	N/A	Both	120	Phase 1/Phase 2	Germany
1196	NCT00110903 (ClinicalTrials.gov)	May 2004	16/5/2005	Treatment for Subjects With Active Rheumatoid Arthritis (RA)	Open-Label Study to Assess the Safety of Etanercept Liquid Administered Once Weekly in Subjects With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept Liquid	Amgen	NULL	Completed	18 Years	N/A	Both		Phase 3	NULL
1197	NCT00195403 (ClinicalTrials.gov)	May 2004	12/9/2005	A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA	A Drug Use Investigation of Enbrel for Post-Marketing Surveillance	Rheumatoid Arthritis	Drug: Etanercept	Pfizer	NULL	Completed	4 Years	N/A	All	1014	N/A	Korea, Republic of
1198	NCT00099554 (ClinicalTrials.gov)	May 2004	16/12/2004	Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)	A Phase 4, Open-Label, Single Arm, Observational Study Evaluating the Effectiveness and Safety of Enbrel® (Etanercept) 50 mg Once Weekly in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)	Rheumatoid Arthritis	Drug: Etanercept	Amgen	NULL	Completed	18 Years	N/A	Both	200	Phase 4	United States;Canada
1199	NCT00291915 (ClinicalTrials.gov)	May 2004	14/2/2006	Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis	Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis	Rheumatoid Arthritis;Arthritis	Drug: Adalimumab;Drug: Methotrexate	Goupe d'Etudes et de Recherche Clinique En Rhumatologie	NULL	Recruiting	18 Years	N/A	Both	80	Phase 4	France
1200	NCT00195338 (ClinicalTrials.gov)	May 2004	12/9/2005	Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg	A Post-Marketing Surveillance Looking At Safety And Adherence To Treatment Of Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg	Rheumatoid Arthritis	Drug: etanercept	Pfizer	Innovex, Inc	Completed	17 Years	N/A	All	25	N/A	Luxembourg
1201	NCT00083759 (ClinicalTrials.gov)	May 2004	1/6/2004	Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate	A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)	Rheumatoid Arthritis	Drug: natalizumab;Drug: placebo	Biogen	Elan Pharmaceuticals	Terminated	18 Years	75 Years	All	299	Phase 2	United States;Canada
1202	NCT00259610 (ClinicalTrials.gov)	May 2004	28/11/2005	Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)	Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)	Rheumatoid Arthritis	Drug: methotrexate;Drug: sulfasalazine;Drug: hydroxychloroquine;Drug: etanercept	University of Alabama at Birmingham	Amgen;Barr Laboratories;Pfizer	Completed	18 Years	N/A	All	755	Phase 4	United States
1203	NCT00280644 (ClinicalTrials.gov)	April 2004	19/1/2006	Leflunomide in Rheumatoid Arthritis	Efficacy of Leflunomide on Joint Inflammation and Destruction of Joint Integrity in Active Rheumatoid Arthritis (RA) Patients	Arthritis, Rheumatoid	Drug: Leflunomide	Sanofi	NULL	Completed	18 Years	75 Years	Both	60	Phase 4	Turkey
1204	NCT00144547 (ClinicalTrials.gov)	April 2004	2/9/2005	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	N/A	Both	241	Phase 3	NULL
1205	NCT00484809 (ClinicalTrials.gov)	March 2004	8/6/2007	Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children	A Post-Marketing Surveillance Looking at Safety of Enbrel (Etanercept) in Adults With Active Rheumatoid Arthritis (RA) and Children With Juvenile Rheumatoid Arthritis (JRA).	Rheumatoid Arthritis	Drug: Enbrel (Etanercept)	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	4 Years	N/A	Both	100		NULL
1206	NCT00468377 (ClinicalTrials.gov)	March 2004	30/4/2007	Safety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNFa Therapies	An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies	Arthritis, Rheumatoid	Drug: Rituximab	Hoffmann-La Roche	Genentech, Inc.	Active, not recruiting	18 Years	80 Years	Both	341	Phase 3	United States
1207	NCT00367965 (ClinicalTrials.gov)	February 2004	23/8/2006	Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis	The Effect of Eszopiclone 3 mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis	Insomnia;Arthritis, Rheumatoid	Drug: Eszopiclone;Drug: placebo	Sunovion	NULL	Completed	25 Years	64 Years	Both	153	Phase 3	United States
1208	NCT00224562 (ClinicalTrials.gov)	February 2004	14/9/2005	The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists	The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists	Rheumatoid Arthritis;Crohn's Disease;Ankylosing Spondylitis;Psoriasis	Drug: TNF-alpha antagonists	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	N/A	N/A	Both		N/A	France
1209	NCT00077870 (ClinicalTrials.gov)	February 2004	12/2/2004	A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis	A Randomized, Placebo-Controlled, Multicenter, Blinded Phase I/II Study of the Safety of Escalating Doses of Ocrelizumab (PRO70769) in Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate	Rheumatoid Arthritis	Drug: ocrelizumab	Genentech, Inc.	NULL	Completed	18 Years	80 Years	Both	237	Phase 1/Phase 2	United States
1210	NCT00679510 (ClinicalTrials.gov)	February 2004	15/5/2008	Rosuvastatin in Rheumatoid Arthritis (RORA)	Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: rosuvastatin;Drug: placebo	University of Dundee	NULL	Completed	40 Years	N/A	All	50	Phase 2/Phase 3	United Kingdom
1211	NCT00144521 (ClinicalTrials.gov)	February 2004	2/9/2005	Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)	A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA	Rheumatoid Arthritis	Drug: MRA(Tocilizumab);Drug: MRA placebo;Drug: MTX;Drug: MTX placebo	Chugai Pharmaceutical	NULL	Completed	20 Years	75 Years	Both	127	Phase 3	NULL
1212	NCT00157872 (ClinicalTrials.gov)	January 7, 2004	7/9/2005	A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)	A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 mg Once Daily Versus Naproxen Table 500 mg Twice Daily in the Treatment of Chinese Patient With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MK0966; rofecoxib;Drug: Comparator: naproxen tablet 500 mg	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	N/A	All	150	Phase 4	China
1213	NCT00076206 (ClinicalTrials.gov)	December 2003	15/1/2004	Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy	A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy	Rheumatoid Arthritis	Drug: CCI-779;Drug: Placebo	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Terminated	18 Years	75 Years	Both		Phase 2	United States
1214	NCT00071812 (ClinicalTrials.gov)	December 2003	31/10/2003	A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)	A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)	Arthritis, Rheumatoid	Drug: Placebo;Drug: Belimumab 1 mg/kg;Drug: Belimumab 4 mg/kg;Drug: Belimumab 10 mg/kg	Human Genome Sciences Inc.	NULL	Completed	18 Years	65 Years	All	283	Phase 2	United States
1215	NCT00234936 (ClinicalTrials.gov)	December 2003	16/9/2005	Quality of Life Study With Adalimumab in Rheumatoid Arthritis	Quality of Life Study With Adalimumab in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab;Drug: Methotrexate	Abbott	NULL	Completed	18 Years	N/A	Both	200	Phase 3	NULL
1216	NCT00095173 (ClinicalTrials.gov)	December 2003	1/11/2004	BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis	A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)	Juvenile Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	6 Years	17 Years	All	214	Phase 3	United States;Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland
1217	NCT00619905 (ClinicalTrials.gov)	December 2003	8/2/2008	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Cohort Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 (Anti-Interleukin-1Beta Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis (RA) Despite Ongoing Treatment With Methotrexate (MTX) 15 mg or More Weekly for at Least 3 Months.	Rheumatoid Arthritis	Drug: ACZ885	Novartis	NULL	Completed	18 Years	75 Years	Both	53	Phase 1/Phase 2	Germany;Netherlands;Switzerland
1218	NCT00207714 (ClinicalTrials.gov)	November 2003	13/9/2005	An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis	A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate	Rheumatoid Arthritis	Drug: Golimumab;Drug: MTX;Drug: Placebo;Drug: Infliximab	Centocor, Inc.	Centocor BV	Completed	18 Years	N/A	All	172	Phase 2	NULL
1219	NCT00162201 (ClinicalTrials.gov)	October 2003	9/9/2005	An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy	An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	16	Phase 1	United Kingdom
1220	NCT00221000 (ClinicalTrials.gov)	August 2003	13/9/2005	Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis	A Phase II, Multicenter, Randomized, Double-blind, Sham Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological Agents	Rheumatoid Arthritis	Drug: Methoxsalen;Procedure: Extracorporeal Photopheresis	Mallinckrodt	NULL	Completed	18 Years	N/A	Both	86	Phase 2	United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa
1221	NCT02184052 (ClinicalTrials.gov)	July 2003	3/7/2014	Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions	Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study	Arthritis, Rheumatoid	Drug: Meloxicam	Boehringer Ingelheim	NULL	Completed	N/A	N/A	Both	121	N/A	NULL
1222	NCT00235859 (ClinicalTrials.gov)	July 2003	7/10/2005	Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate	Rheumatoid Arthritis	Drug: adalimumab;Drug: methotrexate	Abbott	Eisai Limited	Completed	18 Years	N/A	Both	128	Phase 3	NULL
1223	NCT00195364 (ClinicalTrials.gov)	July 2003	13/9/2005	Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain	Long-Term Safety Study of Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain	Rheumatoid Arthritis;Inflammation	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	Both	93		Spain
1224	NCT00548834 (ClinicalTrials.gov)	June 2003	15/10/2007	Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis	Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD	Rheumatoid Arthritis	Drug: CDP870	UCB Pharma	NULL	Completed	18 Years	75 Years	Both	220	Phase 3	NULL
1225	NCT00074438 (ClinicalTrials.gov)	June 2003	12/12/2003	Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis	Randomized, Multifactorial, Double-blind, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Rituximab (MabThera®/Rituxan®) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: methotrexate;Drug: rituximab;Drug: corticosteroids;Drug: placebo	Genentech, Inc.	Roche Pharma AG	Completed	18 Years	80 Years	Both	465	Phase 2	United States
1226	NCT00396747 (ClinicalTrials.gov)	June 2003	6/11/2006	A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study	Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone	Rheumatoid Arthritis	Drug: Infliximab , methylprednisolone, methotrexate;Drug: Methotrexate;Drug: Methotrexate + Methylprednisolone;Drug: Methotrexate + Infliximab	Université Catholique de Louvain	NULL	Completed	18 Years	N/A	Both	45	Phase 4	Belgium
1227	NCT00317538 (ClinicalTrials.gov)	June 2003	21/4/2006	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept	Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept	Rheumatoid Arthritis	Drug: infliximab , etanercept	Centocor Ortho Biotech Services, L.L.C.	NULL	Completed	18 Years	N/A	Both	28	Phase 3	NULL
1228	NCT00062465 (ClinicalTrials.gov)	June 2003	5/6/2003	Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine	A 24-Week, Double Blind, Randomized Study to Determine the Effects of 24 Weeks of Dosing With Tripterygium Wilfordii Hook F (TwHF) or Sulfasalazine, in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TwHF	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	N/A	N/A	Both	157	Phase 2	United States
1229	NCT00213538 (ClinicalTrials.gov)	June 2003	13/9/2005	Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis	Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Response to anakinra associated with methotrexate	University Hospital, Rouen	NULL	Completed	18 Years	N/A	All	341	N/A	France
1230	NCT00245934 (ClinicalTrials.gov)	June 2003	26/10/2005	Study Evaluating Enbrel in Patients With Rheumatoid Arthritis	Observational Study With Enbrel in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Enbrel	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	Both	1500	N/A	NULL
1231	NCT00095342 (ClinicalTrials.gov)	May 2003	2/11/2004	Study Evaluating TMI-005 in Active Rheumatoid Arthritis	A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate	Rheumatoid Arthritis	Drug: TMI-005	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	75 Years	Both	390	Phase 2	United States;Canada
1232	NCT00468546 (ClinicalTrials.gov)	May 2003	30/4/2007	A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy	A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies	Rheumatoid Arthritis	Drug: MabThera /Rituxan;Drug: Methotrexate;Other: Placebo	Hoffmann-La Roche	Biogen	Completed	18 Years	80 Years	All	520	Phase 3	United States;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;United Kingdom
1233	NCT00563849 (ClinicalTrials.gov)	May 2003	21/11/2007	Leflunomide + Methotrexate in Rheumatoid Arthritis	An Open-Label, Multi-Center Study to Evaluation of Leflunomide Plus Methotexate for the Treatment of Rheumatoid Arthritis in DMARDs:(Disease-Modifying Antirheumatic Drug) na¿ve or Restart (Skip DMARDs More Than 4 Weeks) Subjects.	Rheumatoid Arthritis	Drug: Leflunomide	Sanofi	NULL	Completed	18 Years	75 Years	Both	74	Phase 4	Korea, Republic of
1234	NCT02214888 (ClinicalTrials.gov)	May 2003	12/8/2014	Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis	A 12 Week Double-blind, Randomized, Placebo-controlled Trial to Investigate Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets at Doses of 50 and 70 mg Administered Twice a Day in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD	Arthritis, Rheumatoid	Drug: BIRB 796 BS, low dose;Drug: BIRB 796 BS, high dose;Drug: Placebo	Boehringer Ingelheim	NULL	Terminated	18 Years	75 Years	Both	170	Phase 2	NULL
1235	NCT00213564 (ClinicalTrials.gov)	April 2003	13/9/2005	Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis	Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: response to infliximab associated with methotrexate	University Hospital, Rouen	NULL	Completed	18 Years	N/A	Both	40		France
1236	NCT00195377 (ClinicalTrials.gov)	April 2003	13/9/2005	Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain	Evaluating Safety and QoL in Patients Treated With Etanercept: an Open Multicenter Study	Arthritis, Psoriatic;Arthritis, Rheumatoid	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	4 Years	N/A	Both	1000		Spain
1237	NCT00144508 (ClinicalTrials.gov)	March 2003	2/9/2005	Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)	An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA	Rheumatoid Arthritis	Drug: MRA (Tocilizumab);Other: current treatment	Chugai Pharmaceutical	NULL	Completed	20 Years	N/A	Both	306	Phase 3	NULL
1238	NCT00908089 (ClinicalTrials.gov)	March 2003	22/5/2009	TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis	Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Trexan +Salazopyrin+Oxiklorin+prednisolone + infliximab;Drug: Trexan +Salazopyrin+Oxiklorin+prednisolone + placebo	Helsinki University	Seinajoki Central Hospital;Oulu University Hospital;Jyväskylä Central Hospital;Kuopio University Hospital;Satakunta Central Hospital;University of Turku;Rheumatism Foundation Hospital;Orton Invalid Foundation;South Karelia central hospital;Lappi Central Hospital;Central Hospital of Kanta-Hame	Active, not recruiting	18 Years	60 Years	Both	100	Phase 4	Finland
1239	NCT00356473 (ClinicalTrials.gov)	March 2003	25/7/2006	Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis	Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Atorvastatin	University of California, Los Angeles	NULL	Completed	18 Years	N/A	Both	20	Phase 4	NULL
1240	NCT00244556 (ClinicalTrials.gov)	March 2003	12/10/2005	Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy	A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy	Rheumatoid Arthritis	Drug: Methotrexate plus ENBREL or ENBREL alone	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	Both	300	Phase 4	NULL
1241	NCT00234845 (ClinicalTrials.gov)	March 2003	13/9/2005	Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis	A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: adalimumab;Drug: methotrexate	Abbott	NULL	Completed	18 Years	N/A	Both	148	Phase 3	United States
1242	NCT00650455 (ClinicalTrials.gov)	February 2003	28/3/2008	Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients	Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population	Arthritis, Rheumatoid	Drug: valdecoxib;Drug: naproxen;Drug: placebo	Pfizer	NULL	Completed	18 Years	N/A	Both	489	Phase 4	United States;Canada
1243	NCT00092742 (ClinicalTrials.gov)	February 2003	23/9/2004	Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)	A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: MK0663, etoricoxib;Drug: Comparator: Diclofenac sodium	Organon and Co	NULL	Completed	50 Years	N/A	All	4086	Phase 3	United States
1244	NCT00250445 (ClinicalTrials.gov)	January 2003	7/11/2005	A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)	A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis	Rheumatoid Arthritis,Osteoarthritis	Drug: MK0663, etoricoxib;Drug: Comparator: Diclofenac sodium	Organon and Co	NULL	Completed	50 Years	N/A	All	23498	Phase 3	NULL
1245	NCT00546533 (ClinicalTrials.gov)	January 2003	18/10/2007	Study Evaluating the Efficacy and Safety of Etanercept	Open-Label Evaluation Of The Efficacy And Safety Of Etanercept In Patients With Active Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	N/A	N/A	Both	40	Phase 4	NULL
1246	NCT00482417 (ClinicalTrials.gov)	December 2002	1/6/2007	Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)		Rheumatoid Arthritis	Drug: MK0359	Merck Sharp & Dohme Corp.	NULL	Completed	18 Years	65 Years	Both	11	Phase 2	NULL
1247	NCT00048568 (ClinicalTrials.gov)	December 2002	2/11/2002	A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Drug: Abatacept;Drug: Methotrexate;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	1250	Phase 3	United States
1248	NCT00433875 (ClinicalTrials.gov)	December 2002	8/2/2007	Phase 2 AMG 714 in Rheumatoid Arthritis	A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs	Rheumatoid Arthritis	Drug: AMG 714	Amgen	NULL	Completed	18 Years	N/A	Both	180	Phase 2	NULL
1249	NCT00048932 (ClinicalTrials.gov)	December 2002	11/11/2002	A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: Double-blind Abatacept;Drug: Double-blind Placebo;Drug: Open-label Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	1795	Phase 3	United States
1250	NCT00048581 (ClinicalTrials.gov)	December 2002	2/11/2002	Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.	A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy	Rheumatoid Arthritis	Drug: Abatacept;Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	738	Phase 3	United States
1251	NCT00764725 (ClinicalTrials.gov)	December 2002	1/10/2008	Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)	A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX	Rheumatoid Arthritis	Drug: conventional DMARD combination;Biological: MTX plus anti-TNF	Karolinska Institutet	NULL	Completed	18 Years	N/A	Both	487	Phase 4	NULL
1252	NCT00544154 (ClinicalTrials.gov)	October 2002	15/10/2007	Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis	Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate	Arthritis, Rheumatoid	Drug: CDP870	UCB Pharma	NULL	Completed	18 Years	75 Years	Both	247	Phase 3	NULL
1253	NCT00116727 (ClinicalTrials.gov)	October 2002	30/6/2005	Rheumatoid Arthritis DMARD Intervention and UtilizationStudy	Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2)	Rheumatoid Arthritis	Drug: ENBREL ®	Amgen	Immunex Corporation;Wyeth is now a wholly owned subsidiary of Pfizer	Completed	18 Years	N/A	Both	5103	N/A	United States
1254	NCT00946686 (ClinicalTrials.gov)	September 2002	24/7/2009	To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions	A Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions	Rheumatoid Arthritis;Psoriatic Arthritis	Drug: Leflunomide 20 mg Tablets (Geneva Pharmaceutical);Drug: Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)	Sandoz	NULL	Completed	18 Years	N/A	All	52	Phase 1	NULL
1255	NCT00121056 (ClinicalTrials.gov)	September 2002	30/6/2005	REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations	Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations (REKinDLE)	Rheumatoid Arthritis	Drug: Enbrel ®;Drug: Kineret ®	Amgen	NULL	Completed	18 Years	N/A	Both		N/A	NULL
1256	NCT00055133 (ClinicalTrials.gov)	September 2002	19/2/2003	A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis	A Phase 2 Open-Label Clinical Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Micellar Paclitaxel for Injection	Angiotech Pharmaceuticals	NULL	Completed	21 Years	70 Years	Both	50	Phase 2	United States
1257	NCT00042406 (ClinicalTrials.gov)	September 2002	29/7/2002	Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-alpha Blocker	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active RA Failing Treatment With Methotrexate and TNF-alpha Blocking Agents	Rheumatoid Arthritis	Drug: HuMax-CD4	Emergent Product Development Seattle LLC	NULL	Terminated	18 Years	N/A	Both	75	Phase 2/Phase 3	United States;Canada
1258	NCT00049751 (ClinicalTrials.gov)	September 2002	13/11/2002	Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis	A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Adalimumab	Abbott	NULL	Completed	18 Years	N/A	Both	3000	Phase 3	United States
1259	NCT02093026 (ClinicalTrials.gov)	August 2002	19/3/2014	Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)	An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Folic Acid	Hoffmann-La Roche	Genentech, Inc.	Completed	21 Years	N/A	All	465	Phase 2	United States;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Germany;Israel;Italy;Mexico;New Zealand;Poland;Spain;Sweden;United Kingdom
1260	NCT00111423 (ClinicalTrials.gov)	August 2002	20/5/2005	Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Pegsunercept (PEG sTNF-RI)	Amgen	NULL	Completed	18 Years	N/A	Both	216	Phase 2	NULL
1261	NCT00043732 (ClinicalTrials.gov)	July 2002	12/8/2002	Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients in Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: SCIO-469	Scios, Inc.	NULL	Completed	18 Years	N/A	Both	120	Phase 2	United States
1262	NCT00042068 (ClinicalTrials.gov)	June 2002	22/7/2002	A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis	A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Meloxicam	Boehringer Ingelheim	NULL	Completed	18 Years	80 Years	Both	1000	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Korea, Republic of;Russian Federation;Taiwan;Ukraine
1263	NCT00038298 (ClinicalTrials.gov)	April 2002	29/5/2002	A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Safety and Tolerability of AMG 719 in Subjects With Rheumatoid Arthritis Receiving Methothrexate	Rheumatoid Arthritis	Drug: Placebo;Drug: AMG 719;Drug: AGM 719;Drug: placebo to AMG 719	Amgen	NULL	Completed	18 Years	N/A	Both	53	Phase 2	United States
1264	NCT00034060 (ClinicalTrials.gov)	April 2002	19/4/2002	The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept	Suppression of the Growth Hormone/ Insulin-Like Growth Factor-1 (GH/IGF-1) Axis in Women With Rheumatoid Arthritis	Rheumatoid Arthritis;Healthy	Drug: Etanercept	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	N/A	N/A	Female	36	Phase 2	United States
1265	NCT00034203 (ClinicalTrials.gov)	April 2002	23/4/2002	Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.		Rheumatoid Arthritis	Drug: efalizumab	XOMA (US) LLC	NULL	Completed	18 Years	80 Years	Both		Phase 2	United States
1266	NCT00959439 (ClinicalTrials.gov)	March 2002	13/8/2009	Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)	A Comparative Bioavailability Study of Naproxen Delayed-Release Tablets, 375mg.	Rheumatoid Arthritis;Osteoarthritis	Drug: Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.);Drug: Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)	Sandoz	NULL	Completed	21 Years	50 Years	All	34	Phase 1	NULL
1267	NCT00036153 (ClinicalTrials.gov)	March 2002	8/5/2002	Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis	A Randomized, Double-Blind Study to Assess the Efficacy of Tacrolimus (Prograf®)+ Methotrexate Vs. Placebo + Methotrexate in the Treatment of Rheumatoid Arthritis in Patients With Partial Response to Methotrexate	Rheumatoid Arthritis	Drug: Tacrolimus (Prograf®);Drug: Methotrexate	Astellas Pharma Inc	Astellas Pharma US, Inc.	Completed	18 Years	N/A	Both	210	Phase 3	United States;Canada
1268	NCT00451971 (ClinicalTrials.gov)	March 2002	23/3/2007	Objective Study in Rheumatoid Arthritis	Objective Study in Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: LEFLUNOMIDE	Sanofi	NULL	Completed	18 Years	75 Years	Both	249	Phase 4	Australia
1269	NCT00048321 (ClinicalTrials.gov)	January 1, 2002	29/10/2002	ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis	ISIS 104838-CS7, A Double-Blind, Placebo-Controlled, Randomized Trial of the Safety, Efficacy and Pharmacokinetic Profile of ISIS 104838 (TNF-alpha Antisense Oligonucleotide) Subcutaneous Injections in Active Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: ISIS 104838	Ionis Pharmaceuticals, Inc.	NULL	Completed	18 Years	N/A	All	160	Phase 2	United States;Canada
1270	NCT00029042 (ClinicalTrials.gov)	January 2002	4/1/2002	Infliximab to Treat Children With Juvenile Rheumatoid Arthritis	A Randomized Double Blind Controlled Intra-Patient Dose Escalation Phase II Trial of Infliximab in Pediatric Patients With Refractory Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Infliximab	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Terminated	N/A	N/A	Both	48	Phase 2	United States
1271	NCT00246064 (ClinicalTrials.gov)	December 2001	28/10/2005	The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol	The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol. Tapering Methotrexate in Patients With Rheumatoid Arthritis Beginning Therapy With Infliximab	Arthritis, Rheumatoid	Drug: infliximab	Centocor Ortho Biotech Services, L.L.C.	NULL	Completed	18 Years	80 Years	Both	210	Phase 4	NULL
1272	NCT02180516 (ClinicalTrials.gov)	October 2001	1/7/2014	Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome	Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome	Arthritis, Rheumatoid	Drug: Meloxicam;Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac	Boehringer Ingelheim	NULL	Completed	N/A	N/A	Both	9984	N/A	NULL
1273	NCT00116714 (ClinicalTrials.gov)	October 2001	30/6/2005	Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy	Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 1)	Rheumatoid Arthritis	Drug: DMARD	Amgen	Immunex Corporation;Wyeth is now a wholly owned subsidiary of Pfizer	Completed	18 Years	N/A	Both	4968	N/A	United States
1274	NCT00036387 (ClinicalTrials.gov)	October 2001	9/5/2002	A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.	A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug Background Therapy.	Arthritis, Rheumatoid	Drug: Infliximab	Centocor, Inc.	NULL	Completed	18 Years	N/A	Both	347	Phase 3	United States
1275	NCT00035334 (ClinicalTrials.gov)	October 2001	2/5/2002	Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis	A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis	Secondary (AA) Amyloidosis;Rheumatoid Arthritis;Nephrotic Syndrome;Familial Mediterranean Syndrome;Kidney Diseases;Gastrointestinal Diseases	Drug: NC-503 (Anti-amyloidotic (AA) Agent)	Bellus Health Inc	FDA Office of Orphan Products Development	Completed	18 Years	N/A	Both	150	Phase 2/Phase 3	United States;Finland;France;Israel;Italy;Lithuania;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom
1276	NCT00036374 (ClinicalTrials.gov)	October 2001	9/5/2002	A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis	A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis	Rheumatoid Arthritis, Juvenile	Drug: Infliximab	Centocor, Inc.	NULL	Completed	4 Years	18 Years	Both	123	Phase 3	United States
1277	NCT00144651 (ClinicalTrials.gov)	August 2001	2/9/2005	Study of MRA in Patients With Rheumatoid Arthritis (RA)	An Open-label, Extension, Phase II Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Were Participated in Study MRA009JP	Rheumatoid Arthritis	Drug: MRA(Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	N/A	Both	135	Phase 2	NULL
1278	NCT00537667 (ClinicalTrials.gov)	August 2001	27/9/2007	The SPECTRA Study	A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: anakinra;Drug: anakinra and PEG sTNF-R1	Amgen	NULL	Terminated	18 Years	N/A	Both	22	Phase 2	NULL
1279	NCT00524160 (ClinicalTrials.gov)	July 2001	31/8/2007	A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis	Open-Label Study To Assess The Effect On Pain Control Of Durogesic (Fentanyl Transdermic Therapeutic System) Treatment In Subjects With Rheumatoid Arthritis Or Osteoarthritis Of The Knee Or Hip.	Arthritis;Osteoarthritis;Rheumatoid Arthritis	Drug: Fentanyl transdermal patch	Janssen Pharmaceutica N.V., Belgium	NULL	Completed	18 Years	N/A	Both	264	Phase 4	NULL
1280	NCT00078806 (ClinicalTrials.gov)	June 4, 2001	5/3/2004	Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis	A Phase 3 Safety and Efficacy Study of Etanercept In Children With Systemic Onset Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Etanercept;Drug: Placebo	Amgen	Immunex Corporation	Terminated	2 Years	18 Years	All	19	Phase 3	Canada;United States
1281	NCT02251210 (ClinicalTrials.gov)	May 2001	25/9/2014	Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis	Three Month, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multiple Dose-range Study of the Efficacy and Safety of BIIL 284 BS (5, 25 and 75 mg p.o. Once Daily) in Adult Patients With Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: BIIL 284 BS low dose;Drug: BIIL 284 BS medium dose;Drug: BIIL 284 BS high dose;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	18 Years	70 Years	Both	404	Phase 2	NULL
1282	NCT00037700 (ClinicalTrials.gov)	May 2001	20/5/2002	Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis		Rheumatoid Arthritis	Drug: anakinra;Drug: pegsunercept	Amgen	NULL	Completed	18 Years	N/A	Both		Phase 2	United States
1283	NCT02209779 (ClinicalTrials.gov)	May 2001	5/8/2014	Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis	A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD	Arthritis, Rheumatoid	Drug: BIBR 796 BS;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	18 Years	75 Years	Both	167	Phase 2	NULL
1284	NCT00014794 (ClinicalTrials.gov)	April 2001	11/4/2001	Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients	H215O Positron Emission Tomography (PET) in the Assessment of Synovial Blood Flow in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: 15-O labeled water	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	N/A	N/A	Both	10	Phase 1	United States
1285	NCT02693210 (ClinicalTrials.gov)	February 2001	23/2/2016	A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis	A Randomised, Double Dummy Controlled, Parallel Group Study of the Efficacy and Safety of MabThera (Rituximab) Alone or in Combination With Either Cyclophosphamide or Methotrexate, in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Cyclophosphamide;Drug: Methotrexate;Other: Placebo Cyclophosphamide;Other: Placebo Methotrexate;Other: Placebo Rituximab;Drug: Rituximab	Hoffmann-La Roche	NULL	Completed	21 Years	N/A	Both	161	Phase 2	Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
1286	NCT00579644 (ClinicalTrials.gov)	January 2001	18/12/2007	Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone	Treatment of Early Rheumatoid Arthritis: Minocycline in Combination With Methotrexate Versus Methotrexate Alone	Rheumatoid Arthritis	Drug: Combination of Minocycline and MTX or MTX alone;Drug: methotrexate	University of Nebraska	NULL	Completed	19 Years	75 Years	All	91	Phase 3	NULL
1287	NCT00034853 (ClinicalTrials.gov)	December 2000	2/5/2002	Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)	A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis	Arthritis, Juvenile Rheumatoid	Drug: meloxicam oral suspension;Drug: naproxen oral suspension	Boehringer Ingelheim	NULL	Completed	2 Years	17 Years	Both	180	Phase 3	United States;Brazil;Mexico;Ukraine;Argentina
1288	NCT00162266 (ClinicalTrials.gov)	October 2000	9/9/2005	Abatacept With Methotrexate- Phase IIB	A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate	Rheumatoid Arthritis	Drug: Abatacept (BMS-188667);Drug: Placebo	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	All	524	Phase 2	United States;Argentina;Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;South Africa;United Kingdom
1289	NCT00162279 (ClinicalTrials.gov)	October 2000	9/9/2005	The Study of Abatacept in Combination With Etanercept	A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	N/A	Both	141	Phase 2	United States
1290	NCT00393471 (ClinicalTrials.gov)	October 2000	26/10/2006	Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.	A Double-Blind Study Evaluating the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Comparison to Etanercept Alone or Methotrexate Alone in Rheumatoid Arthritis Patients.	Active Rheumatoid Arthritis	Drug: Etanercept	Wyeth is now a wholly owned subsidiary of Pfizer	NULL	Completed	18 Years	N/A	Male	615	Phase 3	Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Portugal;Romania;Spain;Sweden;United Kingdom
1291	NCT00006292 (ClinicalTrials.gov)	September 2000	23/9/2000	Infliximab for the Treatment of Early Rheumatoid Arthritis	Randomized Double Blind Active Treatment Controlled Trial of the Anti-TNF-Alpha Antibody Infliximab in Patients With Erosive Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Infliximab	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	N/A	N/A	Both	60	Phase 2	United States
1292	NCT00279747 (ClinicalTrials.gov)	September 2000	19/1/2006	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)	A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.	Arthritis, Juvenile Rheumatoid	Drug: meloxicam 0.25 mg/kg;Drug: meloxicam 0.125 mg/kg;Drug: naproxen 10 mg/kg	Boehringer Ingelheim	NULL	Completed	2 Years	16 Years	Both	226	Phase 3	Austria;Belgium;France;Germany;Italy;Russian Federation;United Kingdom
1293	NCT03781375 (ClinicalTrials.gov)	August 24, 2000	18/12/2018	Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis	A Phase III Double Blind Randomized Study Comparing Etanercept (Enbrel) Combined With Methotrexate vs Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Etanercept;Drug: Placebo to Etanerceot;Drug: Methotrexate	Amgen	NULL	Terminated	N/A	N/A	All	25	Phase 3	NULL
1294	NCT00037648 (ClinicalTrials.gov)	July 2000	17/5/2002	Juvenile Rheumatoid Arthritis	A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuIL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis	Juvenile Chronic Arthritis	Drug: Anakinra;Drug: Placebo	Amgen	NULL	Completed	2 Years	17 Years	Both	86	Phase 2	United States
1295	NCT00078793 (ClinicalTrials.gov)	June 2000	5/3/2004	Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis	Phase IV Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Enbrel ®	Amgen	Immunex Corporation	Completed	2 Years	18 Years	Both	600	Phase 4	United States;Canada
1296	NCT00138983 (ClinicalTrials.gov)	May 2000	29/8/2005	Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.	Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.	Rheumatoid Arthritis;Polymyalgia Rheumatica;Giant Cell Arteritis;Polymyositis;Wegener’s Granulomatosis	Drug: Alendronate versus alfacalcidol (1-alpha OH vitamin D)	UMC Utrecht	Dutch Health Care Insurance Board	Completed	18 Years	90 Years	Both	200	Phase 3	Netherlands
1297	NCT00132418 (ClinicalTrials.gov)	April 2000	19/8/2005	Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders	Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders	Rheumatoid Arthritis	Drug: Enbrel;Drug: Placebo	Amgen	Immunex Corporation	Completed	18 Years	N/A	Both	564	Phase 4	United States
1298	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States
1299	NCT00279760 (ClinicalTrials.gov)	January 2000	18/1/2006	Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis	A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Belatacept;Drug: Abatacept	Bristol-Myers Squibb	NULL	Completed	18 Years	65 Years	Both	210	Phase 1/Phase 2	United States;Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom
1300	NCT02247375 (ClinicalTrials.gov)	January 2000	19/9/2014	Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)	A Double-blind, Randomized, Three Parallel Group Placebo-controlled Study to Investigate Pharmacokinetics, Effect on Expression of CD11b/CD18 (Mac-1), as Well as Safety and Efficacy of Two Oral Doses of BIIL 284 BS (Dosage: 25 mg Daily, 150 mg Daily) in Patients With Rheumatoid Arthritis Over Two Weeks	Arthritis, Rheumatoid	Drug: Low dose of BIIL 284 BS tablets;Drug: High dose of BIIL 284 BS tablets;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	18 Years	65 Years	Both	26	Phase 1	NULL
1301	NCT00579878 (ClinicalTrials.gov)	December 1999	17/12/2007	Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis	Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Leflunomide;Drug: Methotrexate -Sulfasalazine-Hydroxychloroquine;Drug: Leflunomide -Sulfasalazine-Hydroxychloroquine	University of Nebraska	NULL	Completed	19 Years	80 Years	All	69	Phase 3	United States
1302	NCT00012506 (ClinicalTrials.gov)	October 1999	10/3/2001	The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis		Uveitis;Arthritis, Juvenile Rheumatoid	Drug: TNFR:Fc	National Eye Institute (NEI)	NULL	Recruiting	2 Years	18 Years	Both		Phase 3	United States
1303	NCT00000435 (ClinicalTrials.gov)	September 1999	21/1/2000	dnaJ Peptide for Relieving Rheumatoid Arthritis	A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: dnaJ peptide;Drug: None-placebo	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	18 Years	85 Years	Both	160	Phase 2	United States
1304	NCT00000401 (ClinicalTrials.gov)	July 1999	3/11/1999	Oral Collagen for Rheumatoid Arthritis	Open Label Multicenter Induction of CII Tolerance in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Oral bovine type II collagen	University of Tennessee	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	80 Years	Both	110	Phase 2	United States
1305	NCT00001862 (ClinicalTrials.gov)	February 1999	3/11/1999	TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis	The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis;Uveitis	Drug: Enbrel	National Eye Institute (NEI)	NULL	Completed	N/A	N/A	Both	15	Phase 2	United States
1306	NCT00209859 (ClinicalTrials.gov)	October 1998	16/9/2005	Methotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis	Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Intraarticular betamethasone;Drug: Cyclosporine/placebo-cyclosporine	Hvidovre University Hospital	NULL	Completed	18 Years	75 Years	Both	160	Phase 4	Denmark
1307	NCT00001677 (ClinicalTrials.gov)	June 1998	3/11/1999	Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy	Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy	Arthritis, Rheumatoid;Synovitis	Drug: Methotrexate;Drug: Fludarabine	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	N/A	N/A	Both	40	Phase 2	United States
1308	NCT00001614 (ClinicalTrials.gov)	July 1997	3/11/1999	The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis	The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis	Arthritis, Juvenile Rheumatoid;Uveitis	Drug: Chicken type II collagen	National Eye Institute (NEI)	NULL	Completed	N/A	N/A	Both	13	Phase 1	United States
1309	NCT03780959 (ClinicalTrials.gov)	May 1, 1997	18/12/2018	Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)	Safety, Population Pharmacokinetics, and Efficacy of Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) in Children With Juvenile Rheumatoid Arthritis	Juvenile Rheumatoid Arthritis	Drug: Etanercept;Drug: Placebo	Amgen	NULL	Completed	4 Years	18 Years	All	69	Phase 2/Phase 3	NULL
1310	NCT00269867 (ClinicalTrials.gov)	March 1997	22/12/2005	Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis	A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment	Rheumatoid Arthritis	Drug: Placebo;Drug: Infliximab 3 mg/kg;Drug: Infliximab 10 mg/kg	Centocor, Inc.	NULL	Completed	18 Years	75 Years	Both	428	Phase 3	NULL
1311	NCT00000395 (ClinicalTrials.gov)	September 1996	3/11/1999	Antifolate Effectiveness in Arthritis	Mechanisms of Antifolate Efficacy in Arthritis	Rheumatoid Arthritis;Adjuvant Arthritis	Drug: Methotrexate;Dietary Supplement: Folinic acid;Dietary Supplement: Folic acid	University of Alabama at Birmingham	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Office of Dietary Supplements (ODS)	Completed	18 Years	85 Years	Both	40	Phase 2	United States
1312	NCT00000429 (ClinicalTrials.gov)	June 1996	18/1/2000	Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis	Calcium Supplementation for Bone Mineralization in Juvenile Rheumatoid Arthritis (JRA)	Juvenile Rheumatoid Arthritis	Drug: Calcium carbonate	Children's Hospital Medical Center, Cincinnati	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	6 Years	18 Years	Both	192	Phase 2	United States
1313	NCT00004420 (ClinicalTrials.gov)	September 1994	18/10/1999	Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis		Juvenile Rheumatoid Arthritis	Drug: gamma-Linolenic acid	FDA Office of Orphan Products Development	University of Massachusetts, Worcester	Completed	1 Year	15 Years	Both	50	N/A	NULL

先頭へ